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It is universally accepted that all medicines have the potential to cause adverse
drug reactions (ADRs) during the course of their normal therapeutic use. Drug
safety surveillance during the post-marketing authorisation phase generates the
majority of drug safety data, even more so than the clinical trials during the drug
development process. Pharmacovigilance (PV), is based on the medical assessment
of ADRs or drug-related problems, collected within organised health programmes.
PV systems, by nature, are complex. The large number, fragmentation, and com-
plexity of existing PV systems, the equally large number of stakeholders within
such systems (i.e. pharmaceutical companies, government regulatory authorities,
national and international clinical regulatory bodies, healthcare workers, etc.), as
well as the significant number of dimensions along which the effectiveness and
efficiency could be influenced and also measured, adds to this complexity.
The primary goal of any PV system is to improve and protect patient safety by
enabling health care professionals to make more informed therapeutic decisions.
Achieving this goal is dependent on the successful communication of relevant ADR
information from the patient to the relevant PV authority. One such method of
communication is the spontaneous reporting of ADRs, which is widely regarded
as the cornerstone of data generation in PV during post-marketing authorisation
safety surveillance.
Currently, spontaneous reporting systems (SRSs) are faced with problems such
as under-reporting and the communication of incomplete, unrepresentative, and
uncontrolled data. The lack of standardisation and interoperability among these
systems results in a reduced capability to detect and characterise new adverse drug
interactions and ADRs.
The primary obstacle to achieving interoperability between SRSs is the fundamental
difference in the purpose of the existing SRSs. Stakeholders in the PV system
operate SRSs with different goals and perspectives such as maintaining regulatory
compliance, mitigating financial risk, and for the protection and promotion of
patient safety in public health programmes.
ii
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The aim of this study is to contribute towards the interoperability of SRSs in the PV
landscape through the development of a novel maturity model with a sociotechnical
system focus. The aim of the model is to promote and improve interoperability
by addressing the degree of integration of systems involved, provide guidance on
which system components need to be improved, as well as provide a means for
measuring interoperability progress across the community of SRSs in the global
PV landscape.
A multidisciplinary literature review covering PV, capability maturity models, in-
teroperability, and sociotechnical systems served as a theoretical foundation for
the development of the model. The development of the model followed an adap-
tation of the 8-phase procedural model for developing maturity models, proposed
by Becker et al. (2009).
A comparison of 18 existing maturity models in the fields of: (i) PV; (ii) eHealth;
(iii) eHealth/interoperability; (iv) interoperability; and (v) IT infrastructure, was
conducted. The model is made up of three domains, seven subdomains, and thirty
dimensions which were identified as a result of the preceding literature review and
comparison of existing models.
Through a combination of verification and validation processes involving subject
matter experts, the maturity model was refined. The resulting maturity model
was implemented in a case study within a national regulatory authority context,
to determine the generalisability and empirical validity of the model. The model
was deemed a useful, unique, and valuable contribution to organisations operating




Oor die algemeen word dit aanvaar dat alle medisyne die potensiaal het om
negatiewe geneesmiddelreaksies te veroorsaak tydens hul normale terapeutiese
gebruik. Dwelmveiligheidswaarneming tydens die na-bemarkingsmagtigingsfase
genereer die meerderheid van dwelmveiligheidsdata, selfs meer as die kliniese proewe
tydens die dwelmontwikkelingsproses. Pharmacovigilance (PV ), is gebaseer op
die mediese evaluering van geneesmiddelreaksies of dwelmverwante probleme, wat
binne georganiseerde gesondheidsprogramme ingesamel word.
PV -stelsels is inherent kompleks. Die groot aantal, fragmentasie en kompleksiteit
van bestaande PV -stelsels, die ewe groot aantal belanghebbendes binne hierdie
stelsels (d.w.s. farmaseutiese maatskappye, staatsregulerende owerhede, nasionale
en internasionale kliniese reguleringsliggame, gesondheidswerkers, ens.), sowel as
die beduidende aantal dimensies waarlangs die effektiwiteit en doeltreffendheid
bëınvloed kan word en ook gemeet word, dra by tot hierdie kompleksiteit.
Die primêre doel van enige PV -stelsel is om pasiëntveiligheid te verbeter en te
beskerm deur gesondheidsorgwerkers in staat te stel om meer ingeligte terapeutiese
besluite te neem. Die bereiking van hierdie doelwit is afhanklik van die suksesvolle
kommunikasie van relevante geneesmiddelreaksie-inligting van die pasiënt na die
betrokke PV -owerheid. Een sodanige kommunikasiemetode is die spontane rap-
portering van geneesmiddelreaksies, wat algemeen beskou word as die hoeksteen
van data-opwekking in PV tydens die veiligheidswaarneming na bemarking.
Tans word spontane rapporteringstelsels (SRSe) gekonfronteer met probleme soos
onder-rapportering en die kommunikasie van onvolledige, nie-verteenwoordigende
en onbeheerde data. Die gebrek aan standardisering en interoperabiliteit tussen
hierdie stelsels lei tot ’n verminderde vermoë om nuwe geneesmiddelsinteraksies en
geneesmiddelreaksies na te spoor en te karakteriseer.
Die primêre struikelblok vir die bereiking van interoperabiliteit tussen SRSe is die
fundamentele verskil in die doel van die bestaande SRSe. Belanghebbendes in die
PV -stelsel bedryf SRSe met verskillende doelwitte en perspektiewe, insluitende:
die handhawing van regulatoriese vereistes; die vermindering van finansiële risiko;
iv
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en die beskerming en bevordering van pasiëntveiligheid in openbare gesondheid-
sorgprogramme.
Die doel van hierdie studie is om by te dra tot die interoperabiliteit van SRSe in
die PV -landskap deur die ontwikkeling van ’n nuwe en oorspronklike volwassen-
heidsmodel met ’n sosiotegniese stelselfokus. Die doel van die model is om inter-
operabiliteit te bevorder en te verbeter deur die mate van integrasie van betrokke
stelsels aan te spreek, leiding te gee oor watter stelselkomponente verbeter moet
word, asook om die interoperabiliteitsprogressies in die wêreldwye gemeenskap van
SRSe te meet.
’n Multidissiplinêre literatuuroorsig oor PV, volwassenheidsmodelle, interoperabiliteit
en sosiotegniese-stelsels het gedien as ’n teoretiese grondslag vir die ontwikkeling
van die model. Die ontwikkeling van die model het gevolg op ’n aanpassing van die
8-fase prosedure model vir die ontwikkeling van volwassenheidsmodelle, voorgestel
deur Becker et al. (2009).
’n Vergelyking van 18 bestaande volwassenheidsmodelle in die velde van: (i)
PV ; (ii) eHealth; (iii) eHealth/interoperabiliteit; (iv) interoperabiliteit; en (v)
IT-infrastruktuur, is uitgevoer. Die model bestaan uit drie domeine, sewe sub-
domeine en dertig dimensies wat gëıdentifiseer is as gevolg van die voorafgaande
literatuuroorsig en vergelyking van bestaande modelle.
Die volwassenheidsmodel is deur ’n kombinasie van verifiërings- en valideringspros-
esse, waar vakkundiges betrokke was, verfyn. Om die veralgemeenbaarheid en em-
piriese geldigheid van die model te bepaal, is die gevolglike volwassenheidsmodel in
’n gevallestudie, binne die nasionale konteks van ’n regulerende owerheid, gëımple-
menteer. Die gestelde doel van die model is bereik en die model word geag as ’n
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In this chapter, the context within which the research problem exists, as well as the aims and
objectives of the research are summarised. The research approach, methodology, and scope
demarcation are specified. The structure of the dissertation is laid out, and a list of research
outputs produced from this dissertation is provided.
1.1 Background
It is universally accepted that all medicines have the potential to cause adverse drug reactions
(ADRs) during the course of their normal therapeutic use (Belton et al., 1997). The terms
ADR and ‘side effect’ are often confused for one another, or used interchangeably. A side effect
is defined as being any unintended, usually predictable, effect of a pharmaceutical product,
which may or may not result in harm, occurring at a normal therapeutic dosage. An ADR is
different in that it is a noxious1 and unintended response to a pharmaceutical product (World
Health Organization, 2006).
Figure 1.1 relates the terms medication error, ADR, and adverse drug event (ADE). Medication
errors are those which occur during prescribing, transcribing, dispensing, administering, adher-
ence, or monitoring a pharmaceutical product. Medication errors may or may not result in the
patient being harmed. An ADE can be any negative or harmful occurrence that takes place
during the course of treatment, which may or may not be associated with a pharmaceutical
product (World Health Organization, 2006). Figure 1.1 shows that all ADRs are a type of
ADE but not vice versa. Figure 1.2 is a cause-and-effect diagram showing the various factors
which may contribute to an ADE.
The World Health Organization (WHO) (2006) defines pharmacovigilance (PV) as “the sci-
ence and activities relating to the detection, assessment, understanding and prevention of








(dark grey area only)
Figure 1.1: The relationship between medication errors, adverse drug events, and adverse drug
reactions (Nebeker et al., 2004).
adverse effects or any other possible drug-related problems”. PV, often referred to more sim-
ply as patient safety, is based on the medical assessment of ADEs or drug-related problems,
collected within organised health programmes. Within these programmes it is vital to be able
to consistently identify the nature of events, their severity, their likelihood of occurrence and
to assess causality with the suspected drug(s) or medicine(s). The primary goal of any PV
system is to improve and protect the safety of the patient by enabling health care profession-
als (HCPs) to make more informed therapeutic decisions. The successful operation of a PV
system is dependent on the successful communication of relevant ADR information from the
patient experiencing the ADR to the relevant PV authority, so that the necessary action can
be taken to prevent medicine related problems and reduce morbidity and mortality associated
with ADRs.
ADR information can be communicated via multiple reporting methods, throughout the entire
pharmaceutical drug development life cycle. The majority of ADR information is generated
during the post-marketing authorisation phase of the drug life cycle (Figure 3.1). This is when
a pharmaceutical company has performed all of the necessary clinical trials and safety studies
for a product which they are developing with the intention of marketing within the jurisdiction
of a regulatory authority (RA). Once marketing authorisation has been granted and a product
enters the market, the number of patients consuming that product increases exponentially, and
with that comes an increase in unexpected ADRs. Information pertaining to these ADRs is
captured and communicated via a spontaneous reporting system (SRS), this is a system where
the ADR information can be reported in an unsolicited, or voluntary manner, either by a health




























































1.1.1 The global PV landscape
The international PV landscape is difficult to characterise due to the large number and variety
of stakeholders, and the number of fragmented PV systems in various countries. A simplified
view of the current landscape of global PV activities can be seen in Figure 1.3. The World
Health Organisation (WHO) established the Uppsala Monitoring Centre (the UMC)1 in 1978
to co-ordinate the programme for international drug monitoring. The UMC, under leadership
of the WHO, communicates information between its member countries and the pharmaceutical
industry, regarding the benefits and risks of medicines that are used in their public healthcare
programmes.
The UMC manages and maintains a SRS which is comprised of several data management
tools and methods, these tools and methods are discussed in detail in Section 4.4. The
UMC is the custodian of an Individual Case Safety Reports2 (ICSRs) database called VigiBase.
The ICSRs in VigiBase are submitted by national PV centres or RAs via reporting gateway
applications such as the UMC’s VigiFlow. Some RAs have developed their own reporting
gateway applications, for example, the two largest RAs in the world, namely the United States
Food and Drug Administration (FDA) and the European Medicines Agency (EMA), shown in
Figure 1.3, make use of the FDA Adverse Events Reporting System (FAERS)(Li et al., 2015)
and EudraVigilance (Pacurariu et al., 2015), respectively. These ICSRs are analysed with the
objective of drawing quantitative conclusions from the input data. The UMC is faced with
negotiating and persuading policy makers and regulators, particularly those in resource-limited
and middle- to low-income countries to give pharmacovigilance the necessary attention and
resources to strengthen the global system.
Supporting organisations such as the International Society of Pharmacovigilance (ISoP), as well
as academia, and standards development organisations (SDOs), participate in the development
of PV practices as well as training and education with respect to PV around the world. Figure
1.3 does not delineate a clear hierarchy, protocol of interaction, or division of responsibility
amongst the various stakeholders, this is indicative of the lack of such high-level coordination
within the global PV landscape.
1Stylised as ‘the UMC’, by the organisation itself.
2An ICSR is a document which includes an identifiable patient, an identifiable reporter (HCP), as well as
a drug and a suspected ADR relating to the drug. An ICSR can contain multiple drugs and suspected ADRs,


























































1.1.2 Challenges in the PV landscape
The most widespread challenge facing PV is the high level of under-reporting of ADRs (Batel
Marques et al., 2016; Graham et al., 2012; Hazell & Shakir, 2006; Koutkias & Jaulent, 2015;
Lester et al., 2013), typically attributed to a lack of knowledge, time and incentive (DalPan,
2014; Hasford et al., 2002), which eludes to the lack of standardised reporting protocols and
methodologies. Multiple sources have been identified which point to the need for a standard-
ised SRS (Barnett, 2015; Field, 2017; Graham et al., 2012; Richesson et al., 2008; Shiffman
et al., 2003; Wong et al., 2015). Problems such as under-reporting and the communica-
tion of incomplete, unrepresentative, and uncontrolled data prove to be significant barriers to
detecting and characterising new adverse drug interactions and ADRs (Banerjee et al., 2013).
A survey conducted by Stergiopoulos et al. (2016) found that hospitals with the necessary
infrastructure for ADR reporting were only reporting 12% of ADRs to the respective PV
centres. ADRs due to incorrect treatment plans resulted in the fourth to sixth leading cause
of death in hospitalised US patients in 1994 according to a study by Lazarou et al. (1998).
The total cost of drug related morbidity and mortality for the year 2000 in the USA was
estimated at $177 billion (Ernst & Grizzle, 2001). According to the National Health Service
of the United Kingdom, ADRs resulted in approximately 250 000 hospital admissions yearly,
costing the health system £466 million yearly (World Health Organization, 2008).
The Strengthening Pharmaceutical Systems (SPS) Program (2011) report offers an interesting
view of the socio-technical aspect of PV systems, the report highlights the reluctance of HCPs,
particularly in low- and middle-income countries (LMIC) to report ADRs as they feel that in
doing so, it reflects poorly on their ability to provide care of an adequate standard. Socio-
economic barriers include the lack of financial incentive for HCPs to report ADRs to national
PV centres (Bhagavathula et al., 2016).
1.2 Problem statement
PV systems, by nature, are complex. The large number, fragmentation, and complexity of
existing PV systems, the equally large number of stakeholders within such systems (i.e. phar-
maceutical companies, government regulatory bodies, national and international clinical regu-
latory bodies, healthcare workers, etc.), as well as the significant number of dimensions along





Spontaneous reporting of ADRs is the cornerstone of data generation in the post-marketing
authorisation phase of PV activities. Furthermore, the lack of a standardised reporting protocol
across the various PV systems hinders efforts to coherently manage PV on a global scale.
The primary obstacle to standardising and achieving interoperability between SRSs globally
is the fundamental difference in purpose of the existing SRSs. The three main role players
at the global level of pharmacovigilance are the UMC1, the various MAHs, and the RAs
representing governments around the world, a characterisation of the interaction between these
three role players is shown in Figure 1.3. Each of these three role players has its own goals
and perspectives when conducting PV:
1. The UMC: To successfully integrate PV data from all WHO member countries and to
perform statistical analysis and continuous monitoring of the global PV landscape.
2. MAHs: To achieve and maintain regulatory compliance, mitigation of financial and
market risks, as well as being able to make informed marketing decisions.
3. RAs: To protect and promote patient safety within their public health programs and
thus alleviate pressure on their health system.
With this fundamental difference in the purpose of the existing SRSs in mind, it is important
to note that the strength of the global PV system lies in the integration of various national and
private sector PV systems. While the UMC offers substantial support to the WHO member
countries, many of the developing member countries lack the capacity and capability to take
full advantage of the services offered by the UMC.
1.3 Research gap
It is evident from the lack of available literature on pharmacovigilance from an engineering and
systems perspective, that there is considerable potential for these disciplines to contribute to
the PV body of knowledge. The vast majority of published literature relating to PV comes from
a clinical perspective, typically that of health care clinicians, health care scientists, epidemiol-
ogists, and statisticians. Preliminary research results, presented in this chapter, indicate the
need for a solution that would contribute and improve the interoperability of spontaneous re-
porting systems in PV. Although various maturity models and maturity assessment frameworks
exist in the fields of eHealth, Interoperability, and IT Infrastructure, as discussed in Chapter
6; a maturity model based on the concept of the capability maturity model (CMM) has not
1The UMC is the operational unit having responsibility for the direct implementation of the WHO Pro-




been comprehensively considered in the field of pharmacovigilance and the interoperability of
spontaneous reporting systems.
In order to determine the research gap, and simultaneously the uniqueness of this research a
customised search protocol was developed and employed across various literature databases.
The search protocol differed slightly depending on the literature database but the same basic
logic was applied during each search. The search involved the use of boolean and proximity
operators to find literature which met the search criteria. The following four terms were
combined in various search queries and executed in the Scopus database, Web of Science
database, Taylor and Francis database, and Google Scholar database:
 Pharmacovigilance OR “drug safety” OR “patient safety”,
 “Spontaneous reporting system”,
 “Sociotechnical system”, and
 “Capability maturity model”.
Table 1.1: Structured search protocol results.





pharmacovigilance AND ("socio technical system" OR 
"capability maturity model")
0 0 0 56
pharmacovigilance AND "capability maturity model" 0 0 0 28
pharmacovigilance AND "socio technical system" 0 0 0 38
pharmacovigilance AND "socio technical system" AND 
"capability maturity model"
0 0 0 0
(pharmacovigilance OR "drug safety") AND ("socio 
technical system" OR "capability maturity model")
4 0 1 105
("drug safety" OR "patient safety") AND ("socio technical 
system" OR "capability maturity model")
34 13 25 1170
(pharmacovigilance OR "drug safety" OR "patient safety") 
AND "socio technical system" AND "capability maturity 
model"
0 0 0 7
(pharmacovigilance OR "drug safety") AND "socio 
technical system"
3 0 1 75
(pharmacovigilance OR "drug safety") AND "capability 
maturity model"
1 0 0 40
"spontaneous reporting system" AND "capability 
maturity model"
0 0 0 0
"spontaneous reporting system" AND pharmacovigilance 
AND ( "socio technical system" OR "capability maturity 
model" )
0 0 0 1
"spontaneous reporting system" AND ("socio technical 
system" OR "capability maturity model")




1.4 Aim and objectives
The combined result of these searches were eight documents, seven of which were academic
journal articles addressing patient safety from an ergonomics perspective, mostly regarding
the design of hospitals, as well as one PhD dissertation from Imperial College, London. The
PhD dissertation focuses on the development of clinical trials by improving evidence-based
risk-benefit decision-making of medicines for children (Mt-Isa, 2011). After investigating the
results of the structured search protocol, a conclusion was reached that no capability maturity
model for spontaneous reporting systems in PV exists. To the best knowledge of the author
at the time of conducting this research there is no PVR-CMM (Pharmacovigilance Reporting
Capability Maturity Model) equivalent in existence.
1.4 Aim and objectives
This dissertation seeks to contribute to the global PV landscape by achieving the research aim
and supporting research objectives outlined below.
1.4.1 Aim
The aim of this research is to contribute towards the interoperability of SRSs in the PV
landscape through the development of a maturity model with a sociotechnical system focus.
The maturity model should be useful and of value to RAs, by providing guidance on how to
manage and develop their SRSs towards interoperability.
1.4.2 Objectives
It is envisaged that the objectives which will collectively contribute towards achieving the above
stated aim are:
1. To conduct a literature review on the structure of the PV landscape and to define
concepts and paradigms from this literature relevant to this study.
2. To evaluate the value of interoperability in the global PV reporting system through a
comprehensive and system-based evaluation of the effects of the lack of such interoper-
ability on PV/health outcomes.
3. To identify through a comparative analysis of PV systems, the main elements that such
an interoperable system would need to comprise of.




5. To conduct a literature review on maturity models with a specific focus on the scientific
and design considerations of maturity models; and define concepts and paradigms from
this literature that are relevant to this study.
6. To conduct a literature review on sociotechnical systems, with a specific focus on the
associated theory, and to characterise the PV system as a sociotechnical system.
7. To define the design requirements for a PV reporting capability maturity model.
7.1. To verify the design requirements by engaging subject matter experts.
8. To search for an existing model which satisfies the design requirements.
9. To develop a maturity model for PV reporting activities, rooted in sociotechnical system
theory, if such a model does not exist.
9.1. To streamline and refine the maturity model by engaging subject matter experts,
with a focus on including an industry perspective, so as to verify that the maturity
model is suitable for implementation in a real world setting.
10. To design and execute a case study in which the maturity model will be implemented by
a key role player in the PV landscape.
10.1. To analyse the findings and results of the case study.
11. To validate the model by determining whether the model can achieve its stated aims, as
well as the extent of the models generalisability.
1.5 Scope demarcation
There exist multiple channels via which the reporting of ADRs can take place. This research
focuses on the spontaneous reporting of ADRs during the post-marketing phase of the phar-
maceutical product life cycle. Spontaneous reporting is considered the cornerstone of data
generation in PV (Pal et al., 2013). A functioning spontaneous reporting system is consid-
ered one of the minimum requirements by the WHO, for countries conducting PV activities
(World Health Organization, 2010). To improve PV on a global level, the interoperability of
SRSs is paramount, the demonstrable benefits of interoperability can be found in Chapter 3.
This dissertation culminates with the presentation of a maturity model which can be used to
assess the capability and interoperability maturity of SRSs. Improved PV outcomes rely on
the statistical analysis of data. At present, the availability, accuracy, and format of the PV




bound by application to one context; but rather considers PV across a spectrum of contexts
from resource-limited to world leading PV systems such as that of the European Union. This
research is not bound by application to one role player in the global PV system; but rather
takes a general approach to studying PV in a global context.
1.6 Document structure
The structure of this research was designed to guide the reader from understanding the back-
ground and context of the real-world problem, to understanding the underlying theory on which
the model development is based, before the model that has been developed is finally presented.
A brief description of the contents of each chapter can be found below.
Chapter 1: Introduction
In this chapter, the context within which the research problem exists, as well as the aims and
objectives of the research are summarised. The research methodology and document structure
are also described.
Chapter 2: Research methodology
In this chapter, the research philosophy is discussed, as well as the research approach and
strategy. The chapter concludes with a discussion on the relevant research tools and techniques
which are employed in this dissertation.
Chapter 3: Contextualisation
This chapter focuses on understanding the global PV landscape, what is meant by a standard-
ised spontaneous reporting system, the challenges and barriers which affect the spontaneous
reporting of ADRs, and an analysis of the effects of the lack of a standardised global PV
reporting system. This chapter concludes with a discussion focussing on the extent to which
standardisation could alleviate these PV challenges.
Chapter 4: Reporting of adverse drug reactions
This chapter describes the flow of information through the PV system, the key role players
in the system, as well as the communication channels between the key role players in the
PV system. The different methods for reporting ADRs are discussed and the current best
practices are described. A comparison between methods currently in use by three selected
countries is made and a comparative analysis is performed, outlining their respective differences
and discrepancies. The introduction of the Electronic Health Record (EHR) as a disruptive
technological innovation is discussed and a new approach, involving the use of maturity models,




Chapter 5: Maturity models and interoperability
In this chapter the concept of a maturity model (MM) is explored and defined within the
context of this study. The history of MMs as well as their various types and purposes is
explored. The concept of interoperability is also discussed, with a particular focus on the
interoperability of health information technologies (HITs) in the eHealth field. The chapter
concludes with a discussion on the need to take a sociotechnical approach to introducing MMs
within an eHealth context.
Chapter 6: A sociotechnical system perspective
Taking into consideration the difficulty associated with implementing standardised health infor-
mation technologies (HITs) into large, complex systems, the notion of sociotechnical systems
was investigated. The pharmacovigilance system was described as a sociotechnical system to
gain an improved understanding of how best to design and implement HITs in these complex
systems. Through the conceptualisation of the PV system as a sociotechnical system, the
PVR-CMM development process was more cognizant of social, cultural, and political factors,
rather than focussing solely on the technological factors.
Chapter 7: Development of the Pharmacovigilance Reporting Capability Maturity
Model
This chapter deals with the creation of a model based on the CMM which can be used by
governments or any entity wishing to conduct PV activities to measure and assess their PV
capabilities so as to guide them towards reaching ICH E2B(R3) compliance. Thus, contributing
maximally to PV on a global scale, while also receiving maximum value from the services offered
by the UMC.
Chapter 8: Verification and model refinement
This chapter focusses on the verification and validation strategy, in the development of the
second generation of the PVR-CMM. The subtle, yet significant difference between verification
and validation is discussed; thereafter, the verification and validation strategy of the PVR-
CMM is detailed. The tools and methods involved in this strategy are described, as well as the
outcomes and results yielded through the application of these tools and methods. A deviation
to the verification strategy is discussed and executed, resulting in more well founded verification
outcomes.
Chapter 9: Case study implementation and external validation
This chapter introduces the second generation PVR-CMM, the resulting iteration of the ma-
turity model after the refinements, based on the SME feedback in the previous chapter, were




V2 is implemented in a real-world setting. The outcomes of the validation process are com-
municated and the overall acceptance of the PVR-CMM V2 by it’s intended target audience
is established. By extent to which the PVR-CMM is generalisable is determined by its ability
to achieve it’s stated aims.
Chapter 10: Conclusion
The final chapter contains an overview of the research presented in this dissertation, as well as
confirmation that the research objectives, as stated in Section 1.4.2, have been achieved. The






During the execution of this research a number of research outputs were produced:
Journal Publication:
A journal article titled “An investigation into the value of a standardised global pharmacovig-
ilance reporting system” was published in the South African Journal of Industrial Engineering
November 2017 Vol 28(3) Special Edition, pp 78-88. The contents of the paper were also
presented at the 28th annual conference of the Southern African Institute for Industrial Engi-
neering (SAIIE), held from 25-27 October 2017 in Vanderbijlpark, South Africa.
Available online: http://dx.doi.org/10.7166/28-3-1841.
International Conference Proceedings:
An international conference proceeding titled “Sociotechnical considerations for Health Infor-
mation Technology design and implementation in complex and adaptive health systems” was
presented at the 27th annual conference of the International Association for Management of
Technology (IAMOT), held from 22 - 26 April 2018 at Aston Business School in Birmingham,
United Kingdom, and was published in the conference proceedings.
1.8 Chapter 1: Conclusion
In this chapter the research was introduced through a summary of the real-world problem that
PV is faced with. The problem statement, research aim, objectives, and scope demarcation
were specified. The research approach, methodology, and the structure of the dissertation
was laid out. Finally, a list of research outputs produced from this dissertation was provided.
Following Chapter 1, Chapters 3 and 4 will involve an in depth review of the appropriate
literature to further understand the challenges facing PV as well as the intricacies of ADR





In this chapter, the research aims and objectives are linked to the research methodology. The
relevant research philosophy will be discussed, as well as the suitable research approach and
methodologies that were adopted to fulfil the research aims and objectives. The research
strategy, as well as the research tools and techniques which were employed in this study are
justified by showing their practical applicability to the study.
2.1 Research philosophy
In order for a researcher to effectively approach the subject under investigation, it is necessary to
adopt the appropriate research strategy. In order to identify the appropriate research strategy,
the three components of the research paradigm must be considered. The three components
of the research paradigm are the ontology, epistemology and axiology.
Ontology is concerned with the way researchers perceive reality. According to the ontological
assumption, there are two means of producing valid knowledge, either objectively or sub-
jectively. If one considers an ontological continuum, the ends of the continuum would be
objectivism and subjectivism respectively. In an objective reality, the world exists and can be
studied as it is by applying natural science methods to understand social reality, in a value free
way (Bryman & Bell, 2015). In a subjective reality, the world exists but is studied differently
by different people, where access to reality is only through social constructs (Bryman & Bell,
2015).
Saunders et al. (2009) state that epistemology considers what constitutes acceptable knowl-
edge in a field of study. There exist three primary epistemological positions, namely, positivism,
interpretivism, and pragmatism. Positivism involves the deductive or inductive research ap-
proach within an objective ontological paradigm. Interpretivism involves an inductive research




positions, the pragmatic epistemological position is one which recognises the need to take a
pluralistic approach to deriving knowledge.
In this study, the pragmatic philosophical position is adopted. By taking a pragmatic ap-
proach the researcher can employ a mixed methodology approach including both qualitative
and quantitative methods, including different cycles of deductive and inductive research ap-
proaches. Sale et al. (2002) suggest that combining research methods in this way is useful in
some instances, for example in healthcare, where the complexity of the phenomena involved
requires data from a large number of perspectives.
2.2 Research approach
This study is primarily non-empirical in nature and employs qualitative research methods such
as literature reviews and model development based on secondary data. An empirical component
of the research methodology is introduced along with the case study which is conducted as
part of the research. The research conducted in this dissertation is exploratory in nature; this
is partially due to the fact that a significant amount of research was required to more clearly
define the problem. The purpose of exploratory research is to explore the research objectives
and not necessarily to offer a conclusive solution to an existing problem. It is not uncommon
for a researcher, conducting exploratory research, to change the direction of the research as a
result of new insights (Saunders et al., 2009). In fact, flexibility and adaptability to change
can be considered an advantage of exploratory research (Stebbins, 2001).
Given that this research is primarily non-empirical, appropriate research methods must be
selected for the acquisition of secondary data. Literature reviews complement exploratory
research as they allow for the development of an inductive argument from the ‘general’ to
the ‘specific’. Unlike deductive arguments, inductive reasoning results in the formulation of
hypotheses and theories which provide support for the truth of a conclusion, but do not
necessarily guarantee the conclusion (Arthur, 1994).
2.3 Research strategy
Various research strategies exist, before selecting the appropriate research strategy the re-
searcher must consider the type of research being conducted, either exploratory, descriptive,
or explanatory. In the case of this research, the strategy is devised to support the exploratory
nature of this study. For this study, a mixed methods strategy was devised. The benefit of
a mixed method strategy is that it allows the researcher to address an exploratory research




and quantitative methods, the researcher has the benefit of multiple world views or paradigms
to make better inferences.
In terms of research methodology, a combination of literature review, theory building, model
development, and model verification and validation are used in this research endeavour. The
overarching research approach that is followed is based on the ‘seven step model’ from On-
wuegbuzie et al.’s (2012) “Qualitative analysis techniques for the review of the literature”.
The research approach is depicted in Figure 2.1 and is divided into three phases, namely: (i)
exploration; (ii) interpretation and development; and (iii) communication.
The exploration phase includes Chapters 1 and 3, which make use of literature reviews to
provide the necessary background to understanding the research problem, represented by steps
1 and 2 in Figure 2.1. Steps 3, 4, and 5 in Figure 2.1 results in a multidisciplinary literature
review which produces outcomes from various domains, namely Chapters 4, 5 and 6; covering
PV, capability maturity models; interoperability, and sociotechnical systems respectively.
Chapter 4 investigates the current workings of the global PV system, including the various
role players and current best practices for the communication of ICSRs. The identified best
practices, together with a thorough understanding of the reporting of ADRs, lead to the
investigation of capability maturity models and interoperability in Chapter 5, and sociotechnical
systems in Chapter 6.
In the interpretation phase (steps 6 and 7 in Figure 2.1), Chapters 3, 4, 5 and 6 serve as a
theoretical foundation for the development of the model in Chapter 7. The outcome of this
multidisciplinary literature review allows for the problem statement to be more focussed, in
Section 7.3. The development of the model follows an adaptation of the 8 phase procedural
model for developing maturity models, proposed by Becker et al. (2009).
The two step verification strategy, as described in Chapter 8, involves the selection and en-
gagement of subject matter experts based on a selection criteria. The subject matter experts
validate the model’s face and construct validity via the completion of various questionnaires.
By incorporating SME perspectives, the methodological rigour is strengthened due to the tri-
angulation of the literature review findings, with inductive reasoning of the author, as well as
industry perspectives gathered from a number of SMEs with diverse skill-sets and roles within
the pharmaceutical industry. Further detail on the specific verification methodology that is
applied, is provided in Section 8.3. Iterative refinements of the model are made, as illustrated
by the cyclical relationship between steps 6 and 7 in Figure 2.1.
Upon completion of the verification activities, the final iteration of the PVR-CMM, namely
the PVR-CMM V2, is deemed ready for implementation in a real world setting. Steps 8




V2 is implemented within an organisation that is external to the development, verification,
and refinement processes, of the interpretation and development phase. Step 8 involves the
execution of a case study to determine the extent of the PVR-CMM V2’s empirical validity.
Empirical validity is indicated by ability of the model to achieve the stated aims, from the
perspective of the end-user, as well as the extent to which a maturity model is generalisable





















































2.4 Research tools and techniques
Research tools and techniques are procedures used to obtain and analyse data.
2.4.1 Self-completion questionnaires
Much like a structured interview, a self-completion questionnaire is one of the main tools used
for gathering data using a social survey design (Bryman & Bell, 2015). The use of a self-
completion questionnaire in this research, as opposed to structured interviews, was selected
as the primary verification technique due to the numerous advantages when comparing the
two techniques. Self-completion questionnaires can be constructed to have fewer open ended
questions, since closed questions are typically easier to answer. Closed questions are typically
easier to understand and therefore reduce the risk that the respondent will fail to understand the
question, or inadvertently leave a question unanswered. The shorter nature of questionnaires
can also reduce the risk of respondent fatigue. Bryman & Bell (2015) list additional advantages
of questionnaires including the rate at which they can be distributed, the absence of interviewer
effects and social desirability bias, the lack of interviewer variability, as well as convenience
for the respondents. Interviewer effects such as age, ethnicity, and gender, could result in a
change of the respondents’ behaviour. Social desirability bias is the tendency for people to
act in a socially desirable way when an interviewer is present. The negative effects of social
desirability bias are well documented (Fisher, 1993).
There are, however, some limitations to the use of self-completion questionnaires. Without
the presence of an interviewer the respondent cannot be prompted when experiencing difficulty
in answering a question. In addition, respondents cannot be probed by the interviewer to
provide additional information when answering questions (Bryman & Bell, 2015). These two
disadvantages could result in a greater risk of missing data. In order to avoid this, the self-
completion questionnaire must be designed in such a way that it makes answering easy for the
respondents.
2.4.2 Case study
Chapter 8 indicates that a well regarded method of ascertaining a maturity model’s validity
is to deploy the model in a case study with an organisation which is independent from the
maturity model’s development and testing activities. By implementing the maturity model
in such a way, the extent of the model’s generalisability can be determined (De Bruin et al.,
2005). It is worth noting that in the context of this research and the case study described, the
PVR-CMM V2 is not taken through a full implementation cycle. It is acceptable practice to
not take a maturity models through it’s full implementation cycle in a research context, due
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to the lengthy time horizon associated with a full implementation cycle. This characteristic of
maturity model development research is demonstrated in a number of doctoral dissertations
involving the development of maturity models (Essmann, 2009; Van Dyk, 2013).
The aim of the case study is to determine whether or not the PVR-CMM V2 can indeed achieve
it’s stated aims. As stated in Section 7.3, the aims of the PVR-CMM V2 are to promote and
improve interoperability by addressing the degree of integration of systems involved, to provide
guidance on which system components need to be improved, as well as to provide a means for
measuring interoperability progress across the community of SRSs in the global PV landscape.
Once an appropriate participating organisation has been identified, the organisation would
be contacted and a proposal would be made. If the prospective participating organisation
was to accept the proposal, an assessment of their organisation’s capability and interoperabil-
ity maturity would be conducted. After conducting the maturity assessment, the researcher
would analyse the results of the assessment and develop a set of practical recommendations
with regard to the dimensions that require improvement. These practical recommendations
would be delivered to the organisation, along with a validation questionnaire. The validation
questionnaire is discussed in detail in Section 9.5.
2.5 Chapter 2: Conclusion
In this chapter, the research methodology was introduced. The research philosophy was de-
scribed and the pragmatic position adopted was justified. The research approach and strategy
were laid out, wherein the relevant research methods were discussed. Finally, the research tools







This chapter focuses on understanding the global PV landscape, what is meant by an interop-
erable spontaneous reporting system, the challenges and barriers which affect the spontaneous
reporting of ADRs, and an analysis of the effects of the lack of standardisation across the
global PV reporting system. This chapter concludes with a discussion focussing on the extent
to which standardisation and interoperability could alleviate these PV challenges.
The majority of this chapter has been published in the Southern African Journal of Industrial
Engineering (SAJIE), in an article titled “An investigation into the value of a standardised
global pharmacovigilance reporting system” in November 2017, Vol 28(3) Special Edition, pp
78-88.
3.1 Pharmacovigilance
The terms pharmaceutical drug, therapeutic drug, drug, medicine, and medicinal product
are used interchangeably in this dissertation document. A medicinal product as defined by
the European Medicines Agency is “any substance or combination of substances presented
as having properties for treating or preventing disease in human beings; or any substance or
combination of substances which may be used in or administered to human beings either with a
view to restoring, correcting or modifying physiological functions by exerting a pharmacological,
immunological or metabolic action, or to making a medical diagnosis” (European Medicines
Agency, 2004).
The pharmacodynamics of these drugs on a molecular level are numerous and intricate; and it
is resource intensive and difficult to fully characterise the interactions of a drug in vitro. The
reality is that no therapeutic drug is inherently safe, each treatment situation is unique, and




The Thalidomide disaster of the late 1950’s raised concerns around the world with regard to
the safety of medicines and the associated dangers of ADRs to public health. In the United
Kingdom a medication containing thalidomide was prescribed to pregnant women to treat
the symptoms of morning sickness which are associated with the early stages of pregnancy.
Initially the drug brought symptomatic relief, however in the months and years that followed,
thousands of babies were born with congenital deformities (phocomelia) after in utero exposure
to the seemingly safe drug. There was a considerable time delay before the causal relationship
between thalidomide and phocomelia was identified (World Health Organization, 2002).
It was only in 1968, that the World Health Organisation (WHO) established an International
Drug Monitoring Programme (IDMP), with 10 member countries, in direct response to this
disaster. The objectives of the IDMP comprised of collecting, processing, analysing and dis-
seminating information pertaining to the safety of medicinal substances. This was the birth of
PV.
Considerable research has been conducted in the field of pharmacovigilance since the 1970’s,
with increasing research outputs generated every year. The majority of the research is generated
by and pertains to the North American and European regions.
There is an increasing trend in research into PV activities in developing countries. These
countries typically have the more complex and disease burden public health systems, thereby
exposing barriers and challenges faced more commonly by developing countries. Olsson et al.
(2010) investigates some of these challenges and provides useful information for the progress
of this proposed research. Developing countries stand to benefit significantly from the collab-
orative global PV effort, through the leverage of pooled resources and knowledge.
Multiple sources have been identified which point to the need for a standardised reporting
system, such as (Barnett, 2015; Field, 2017; Graham et al., 2012; Richesson et al., 2008;
Shiffman et al., 2003; Wong et al., 2015). Preliminary findings highlight that the dissemination
of knowledge and education of the public are important drivers of ADR reporting adherence.
If patients have not been adequately informed, or fail to understand the intended outcomes
of their treatment plans, they will be less likely to report any adverse experiences they might
have with that treatment plan.
3.2 The process of drug development and approval
To understand how PV reporting methods vary, according to the stage of the drug develop-
ment process, it is necessary to understand the process of drug development and marketing
authorisation. The drug development and approval process according to the Food and Drug
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Administration (FDA) of the United States is shown in Figure 3.1. The process of develop-
ment and approval for new medicines and therapeutic drugs is lengthy and well established.
For a medicine or therapeutic drug to gain approval from clinical regulatory bodies and re-
ceive marketing authorisation it must meet stringent requirements and pass multiple stages of
pre-clinical and clinical trials. Upon completion of these trials, the regulatory body conducts a
comprehensive review of the drug in question, with the aim of assessing the potential benefits
and harms of the drug.
Once the drug has been approved and marketing authorisation has been granted, the drug may
be marketed within the jurisdiction governed by the relevant regulatory body. When the drug
is marketed on a global scale the number of patients using the drug can be in the order of
millions. This presents an opportunity for a robust global PV system to receive large amounts
of data from new patient groups through the spontaneous reporting of ADRs. With a large
and multi-ethnic population consuming medications the identification of new drug interactions
is made more feasible. Different ethnic groups could respond differently to certain medications
due to the effects of Single Nucleotide Polymorphisms (SNPs) which are slight variations in
their DNA (Maggo et al., 2016). The consumption of a medication across a large population
would also elude to the effects of consuming the medication at varying doses. For a global PV
system to be able to draw quantitative conclusions from the data a standard reporting protocol
must be established. Currently, problems such as under-reporting and the communication of
incomplete, unrepresentative, and uncontrolled data prove to be significant barriers to detecting


































Data management is a key principle of pharmacovigilance. Sources of data include non-
clinical and clinical trials, scientific literature, pharmacoepidemiologic studies, and spontaneous
reporting systems. PV reporting systems primarily rely on the generation and detection of
signals. A signal is the communication of an ADR or ADE made by a patient, manufacturer or
HCP to the appropriate PV centre. The unsolicited reporting, or spontaneous reporting of such
ADRs, is the cornerstone of data generation in post-marketing drug safety and surveillance.
However, research suggests that spontaneous reporting is not a sufficiently comprehensive
method of generating the data that is needed to make quantitative conclusions about the
safety of medicines in the long term (Layton & Shakir, 2015; Ndagije et al., 2015; Pal et al.,
2013).
There are three primary methods of reporting ADRs and drug safety information, these are
Spontaneous Reporting (SR) and two active surveillance methods, Cohort Event Monitoring
(CEM) and Targeted Spontaneous Reporting (TSR). In addition to the three methods of
reporting, one can also make a broad distinction between a ’pull’ and ’push’ approach to
reporting. Further discussion surrounding this, and the three methods reporting methods can
be found in Chapter 4.
3.3.1 Spontaneous Reporting
Spontaneous reporting during the post-marketing phase generates the majority of drug safety
data, even more so than the clinical trials during the drug development process (Lester et al.,
2013). Lester et al. (2013), found that between 52% and 55% of drug label changes were
as a result of spontaneous reporting; thereby demonstrating the significance of spontaneous
reporting in PV activities. Spontaneous reporting involves the unsolicited generation of a signal
by an HCP or a patient relating to the suspicion of an ADR. This method is advantageous
over active surveillance methods in that it incurs little to no administrative costs, it covers a
large population of potential reporters, as well as a large profile of drugs, and it allows for the
monitoring of a medicine throughout its entire life cycle.
3.3.2 Cohort Event Monitoring
Cohort Event Monitoring (CEM) involves the prospective study of the ADRs associated with a
specific drug within a small group of patientsa cohort. The primary benefit of CEM is realised
when used to observe the effects of a new medicine in the early stages of post-marketing




safety, CEM takes the approach of focussing on a specific medication for the time before and
during the control period.
3.3.3 Targeted Spontaneous Reporting
Targeted Spontaneous Reporting (TSR) is a methodology which is similar to spontaneous
reporting but involves well defined patient groups; where healthcare professionals are on the
lookout for specific ADRs (Pal et al., 2013). TSR is an active method of surveillance in a
well-defined population group whereas spontaneous reporting is a passive method of surveil-
lance used within an undefined population (Mehta et al., 2014). Being an active surveillance
method TSR is therefore more resource intensive when compared to spontaneous reporting,
TSR however, produces reporting data of a higher standard. TSR methods have shown strong
potential in low- and middle-income countries for the monitoring of drug safety over extended
periods of time in populations with specific disease burdens, such as HIV and TB (Pal et al.,
2015).
3.4 Standardisation for interoperability
Standardisation is a principle tool used in quality improvement initiatives which focusses on
cost reduction and the identification and elimination of inefficiencies within systems (Blind
& Mangelsdorf, 2016). The concept of standardisation is broad and spans multiple domains
(Xie et al., 2016). The standardisation of a system must be performed by subject matter
experts from each of the various domains included in the system; as well as a wide variety of
stakeholders who have a vested interest in the system.
Interoperability is defined by the Healthcare Information and Management Systems Society
(HIMSS) (2013) as the ability of different information technology systems and software ap-
plications to communicate, exchange data, and use the information that has been exchanged.
Interoperability enables different health information systems to work together across organisa-
tional boundaries to advance the quality of healthcare and improve the efficiency of healthcare
delivery.
This chapter aims to drawn a connection between the potential benefits of standardisation
for interoperability of reporting systems and the challenges brought about by the fragmented
nature of the current global PV context. A review of literature on ADR reporting shows that
the traditional method of spontaneous reporting is not effective and is met with a variety of
problems such as poor data quality, and insufficient data capturing due to the under-reporting
of ADRs by HCPs and patients alike.
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3.4.1 Effects of a lack of interoperability
A brief summary of all issues related to the lack of interoperability are presented here. The
likely impact of standardisation on the various stages of the PV reporting system will be
discussed in the following Sections 3.5 and 3.6. The most wide spread challenge facing PV
is a high level of under-reporting (Batel Marques et al., 2016; Graham et al., 2012; Hazell
& Shakir, 2006; Koutkias & Jaulent, 2015; Lester et al., 2013), typically attributed to a lack
of knowledge, time and incentive (DalPan, 2014; Graham et al., 2012; Hasford et al., 2002),
which eludes to the lack of standardised reporting protocols and methodologies. PV is also
faced with socio-cultural challenges, such as the existence of a culture of fear surrounding the
reporting or ADRs due to a fear of undue disciplinary action taken against HCPs (Hasford
et al., 2002; Kim et al., 2010; Suku et al., 2015).
The literature also highlights the urgent need for educational awareness of PV activities and
the simplification of the ADR reporting process to improve public participation (Bhagavathula
et al., 2016; Layton & Shakir, 2015; Sevene et al., 2008; Stergiopoulos et al., 2016). Ac-
countability among all stakeholders in a health system is important for the overall successful
functioning of the system. A systematic review of ADR reporting systems by Bailey et al.
(2016) found a high degree of variability, with 1782 distinct data elements having been identi-
fied across 108 systems; thus, showing the need for ADR report forms to consist of standardised
terminology and a comprehensive set of unique data elements.
3.4.2 What is meant by an interoperable reporting system
Given the scope of this research, an interoperable reporting system is envisioned to comprise
of the following characteristics:
 A global system wherein an ADR is reported once, with data of high quality to facilitate
causality analysis;
 A transparent system where data is accessible by all stakeholders, this includes public
health programs (PHPs), regulatory authorities (RAs), manufacturers, HCPs, patients,
and the public at large;
 A system which ensures the confidentiality of patients;
 A system which reduces fragmentation and duplication of data and resources;
 A system which improves resource utilization in resource limited contexts;
 A system which reduces administrative pressure, allowing HCPs to direct their attention




 A system which enables HCPs to make more informed therapeutic decisions and improve
patient safety.
The objectives of this system would be:
 To reduce the frequency and severity of ADRs by widening the scope of pharmacovigi-
lance on a global level;
 To improve causality analysis and risk assessment, allowing HCPs to make more informed
therapeutic decisions;
 Enabling quantitative conclusions to be made regarding the safety of medicines over long
term use; and
 To improve the communication of drug safety information between HCPs and patients.
3.5 Analysis of the effects of the lack of an interoperable global
PV reporting system
ADRs are a significant cause of morbidity, mortality and increasing costs for PHPs (Nazer
et al., 2013). By facilitating the communication and collation of comprehensive ADR data,
the objectives of PV reporting can be achieved. These objectives include the characterisation
of known reactions, to measure risk, to identify new reactions by the detection of signals,
to characterise drug interactions, to identify risk factors such as age, gender, dosage etc.; to
assess safety in various patient groups (pregnancy, elderly, paediatric, etc.), and to detect and
measure the inefficacy of medicines.
Data pooling has a direct effect on the accuracy of ADR frequency estimation. By not pooling
data from across the international landscape, we lessen the rate of detection of rare but
clinically significant ADRs (Olsson, 1998), specifically those which occur with low incidence
rate but can pose a significant threat to public and patient safety. By pooling data, these
silent but serious ADRs can be more readily detected.
Patel et al. (2017), found that the mean preventable ADRs leading to hospitalisation was
45.11%, with the primary suspects being cardiovascular system drugs (28.1%), non steroidal
anti-inflammatory drugs (NSAIDs) (16.1%), nervous system drugs (16.9%) and musculoskele-
tal drugs (16.1%). Inappropriate drug selection due to a misdiagnosis, toxic drug serum levels,
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Under-reporting x       
Partnerships x x x x x x x 
Culture and 
transparency 
x x x x x x x 
Public 
participation 
x     x x 
Quality reports 
of ADR reports 
 x x x    
Text-mining  x x x    
Lack of data x x x x    
Causality analysis   x x    
Proactive vs 
reactive systems 
x     x  
Lack of PV 
centres 
 x   x x x 
Insufficient 
resources 
x x x x x x x 
Lack of reporter 
feedback 
    x   
Clinical trials  x x x    
Country specific 
factors 
x x x x x x x 
 
Potential for standardization to alleviate PV challenge 
High Low 
Figure 3.2: Breakdown of challenges facing different stages of the PV system. Adapted from
Lamprecht et al. (2017).
There exist a multitude of complex challenges which hinder PV activities, Figure 3.2 shows the
Lamprecht et al. (2017) breakdown of the challenges and which part of the PV system they
are associated with. The colour grading scale shows the extent to which a standardised ADR
reporting system would alleviate the respective challenges and has been added to the matrix
as part of this research on the value of standardising ADR reporting. The colour gradings are
motivated in the subsections below.
It is important to consider the limitations of spontaneous reporting systems. Due to the
unsolicited nature of spontaneous reporting, problems such as under-reporting, the inability to
derive incidence and prevalence rates due to the lack of denominator data, and the potential





Under-reporting is widely regarded as the most prominent challenge across the PV landscape.
This issue has been brought to the fore by various journal publications, such as (Alvarez-
Requejo et al., 1998; Bäckström et al., 2004; Bhagavathula et al., 2016; Hazell & Shakir,
2006; Moride et al., 1997; Neubert et al., 2013).
A systematic review performed by Hazell & Shakir (2006), provided evidence of widespread
under-reporting across 12 countries, stating that the rate of under-reporting was as high as
94%. The notion of under-reporting in the literature has often been attributed to the knowl-
edge, attitudes and practices (Bhagavathula et al., 2016) of HCPs. Common concerns and
barriers to reporting of HCPs have been identified, these include lack of knowledge of the
functioning of a PV system, lack of incentive to report ADRs, lack of time, and interestingly, a
fear of blame (Kim et al., 2010). HCPs, particularly in low income countries have been found
to show a reluctance in reporting ADRs as they believe it reflects poorly on their professional
ability to treat their patients (Graham et al., 2012). An interoperable and standardised re-
porting system would assist in reinstating confidence in both HCPs and patients by ensuring
confidentiality of submitted reports.
Through standardisation of the PV reporting system and associated protocols, PV in general
will become easier and more manageable to include in all undergraduate training curricula of
HCPs. The concept of a minimum requirement report is worth further investigation. This
form would seek to capture the most important characteristics of the ADR, the medication,
and the patient. If a more detailed follow up report must be filed, the HCP and the patient
would be notified accordingly. HCPs often cite a lack of time as a primary reason for not filling
out ADR reports, a minimum requirement form would be less time consuming to complete and
could therefore improve under-reporting rates.
A further improvement would be the use of a feedback mechanism to provide the HCP and
patient with acknowledgement of receipt of the ADR report. The provision of feedback to
reporters of ADRs would almost certainly increase the overall rate of spontaneous reporting
among HCPs and patients alike. This feedback could comprise of a simple acknowledgement
of receipt or could provide information to the reporter regarding an appropriate course of action
to take in order to treat the symptoms of the ADR which are experienced by the patient.
3.5.2 Culture and transparency
There exists a need for a change in culture and transparency surrounding ADR reporting
(Chruscicki et al., 2016). There is a misconception among many healthcare practitioners,
particularly those in low- and middle-income countries (Bhagavathula et al., 2016; World
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Health Organization, 2006), that PV is not the responsibility of a public health program, but
rather that of the pharmaceutical industry itself. Transparency is improving in PV systems
around the globe with some countries such as Canada and the Netherlands making their
spontaneous reporting databases freely accessible by the public (Molokhia et al., 2009). It
is important to understand the distinction between transparency and confidentiality, and how
they do not necessarily contradict one another.
Transparency of the system would enable all stakeholders to interact with the system and
extract all the ADR data that pertains to their role in the PV system. Confidentiality of
patient information can be achieved by not disclosing information to unauthorised parties. In
the PV context, there are certain elements of an ADR report which should be disclosed to all
stakeholders, but also some which contain sensitive information about the patient. By ensuring
the anonymity of patients, when sharing their ADR report data, they can have confidence that
the data which they generate will not be used against them by any third-party entities.
Interoperability as a product of standardisation would improve transparency of the system and
improve accessibility of up-to-date information regarding the safety of medicines. Improving
accessibility to the latest information would allow for patients to have a greater degree of
confidence in their PHP. Accountability can be improved through improving the knowledge,
attitudes and practices of HCPs during their undergraduate training. When HCPs understand
that the responsibility of PV is shared across all stakeholders in the health system, they will
be able to report ADRs with confidence that their actions will not result in undue disciplinary
action taken against them.
3.5.3 Public participation
Patient-centricity is a key aspect of an effective PV system. Through fostering an environment
wherein, the patient is well informed and confident, public participation is likely to improve.
PHPs need to provide accurate and transparent information to the public to gain public trust,
a notable example of this would be with national immunization programs. For the public to
cooperate with a national program for immunization, the risks and benefits of the program
must be adequately communicated.
An electronic web-based form should be made available to all members of the health system,
and could be available in all languages to improve ease of use. The use of a feedback mechanism
to provide HCPs and patients with acknowledgement of receipt of their ADR report would likely
improve levels of reporting. People will be more likely to participate in the system when they
are made to feel valued by the system. Giving the patient a platform to make their voice heard




encouragement of patient reporting would increase the rate of overall spontaneous reporting
and would likely enable earlier detection of unexpected ADRs (Jarernsiripornkul et al., 2017).
3.5.4 Lack of data
The development of a standardised and interoperable ADR spontaneous reporting framework
would directly support the WHO’s efforts to manage PV activities on a global scale. An
effective ADR spontaneous reporting system would allow for the early detection of ADRs in the
post-marketing phase. Incidence rates of the ADRs could be established, and the identification
and characterisation of novel drug interactions could take place. Bailey et al. (2016), found a
high degree of variability among the 108 reporting systems in their study, they also point to
the lack of standardised data elements in reporting forms, having identified 1782 distinct data
elements, which were mapped to 33 reporting concepts. A standardised reporting form would
comprise of a comprehensive list of unique data elements, thereby prompting the extraction of
all demographically and clinically relevant data relating to the patient and the ADR.
This reduction in the number of data elements can be achieved through the use of standard-
ised terminology. The two principal medical terminology directories are the MedDRA (Medical
Dictionary for Regulatory Activities) and the WHO-ART (World Health Organisation Adverse
Reactions Terminology) dictionaries. Discrepancies between MedDRA and WHO-ART con-
tribute to the problem of data quality. An interoperable spontaneous reporting system would
allow for improved causality analysis through the pooling of uniform data, extracted from
various databases using standardised terminologies.
3.5.5 Proactive vs. reactive system
The unsolicited nature of spontaneous reporting makes it a reactive system. With 55% of all
drug label changes in the United States since 2010 being in direct response to spontaneous
reporting of ADRs (Lester et al., 2013) it is clear to see that an improved reporting system
can benefit the proactive drug safety activities such as drug labelling and package inserts.
By improving efficiency in ADR reporting, drug safety labels will reflect the latest safety
information, thereby allowing HCPs to make more informed therapeutic decisions.
3.5.6 Lack of PV centres and insufficient resources
Healthcare systems are unique to the countries in which they function. PV activities, par-
ticularly in low- and middle-income countries (LMIC) are often considered ’nice to have’ and
take second place to efforts focussed primarily on improving access to medicines (Olsson et al.,
2015). Given the variety and complexity of public healthcare programmes around the world,
the UMC faces considerable challenges and difficulties in attempting to co-ordinate the IDMP.
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A study by (Olsson et al., 2010), found that only 41% of the countries studied had any form
of budget allocated to PV.
The lack of standardisation and interoperability results in reporting systems receiving reports
with incomplete or insufficient data, thereby placing stress on the system and diverting re-
sources such as time, people and money, away from other more important activities (DalPan,
2014). Accurately quantifying the cost of health care is difficult enough on a national public
health program level, assessing the costs associated with ADRs on a global level is even more
challenging. However, research has been conducted to expose the reasons for these costs as
well as to give estimates of the costs incurred by PHPs.
Costs associated with ADRs are attributed to the extended lengths of hospitalisation, the
costs of treating illnesses caused by ADRs and the cost of avoiding ADRs. The majority of
the literature on the pharmacoeconomic aspects of ADRs focus primarily on costs due to the
hospitalisation of patients due to ADRs. A 1998 study found that complications brought on
from ADRs account for the fourth to sixth leading cause of death in hospitalised patients in the
United States of America (Lazarou et al., 1998). Total hospital costs associated with ADRs in
the US have been estimated to be between $30 billion and as high as $130 billion annually.
By pooling resources among PHPs and drug manufacturers, a mechanism could be established
to facilitate the follow-up of minimum requirement reports that have been received, as required.
If sufficient minimum requirement reports, at an aggregate level, generate a signal which eludes
to the presence of an unexpected ADR, then the appropriate resources can be allocated for a
more thorough investigation into the safety of a specific medicine, such as a CEM initiative.
3.6 The potential impact of interoperability
Pharmacovigilance activities contribute to the prevention of unnecessary patient harm, im-
proved clinical practices, and support research and education activities. Patient safety remains
the central focus among all PV activities; with the end goal of assisting HCPs in making
more informed therapeutic decisions for their patients. In order to identify and characterise
evidence-based causal relationships between ADRs and their suspected medicines, standardised
data must be communicated efficiently and effectively along all stages of the PV system.
An effective, interoperable ADR spontaneous reporting system, would allow for the early detec-
tion of ADRs in the post-marketing phase. Incidence rates of the ADRs could be established,
and the identification and characterisation of novel drug interactions could take place. PV ac-
tivities contribute to the prevention of unnecessary patient harm, improved clinical practices,
and support research and education activities. The advantages of spontaneous reporting over




less labour intensive when compared to an active surveillance approach. Spontaneous reporting
is administratively simpler and allows for continuous passive monitoring of medicinal products.
The development of an interoperable ADR spontaneous reporting framework would directly
support the WHO’s efforts to manage PV activities on a global scale. If regional differences
are insuperable or a universal solution found to be infeasible, the sharing of best practices,
together with the leveraging of PV capacity and capability through collaboration and partner-
ship must be considered. Governments and their respective regulatory bodies need to provide
political mandate to the relevant role players, together with supporting legislation and standard
operating procedures (SOPs) to improve awareness of and adherence to good PV practices
across all levels of their public health programs (PHPs).
A collaborative global effort is needed to fast track PV development around the world. It is
those countries that do not have the necessary facilities, expertise and resources for PV that
need them the most (World Health Organization, 2006). Developing countries often have the
highest disease burden on their PHPs. The strength of global PV lies in the integration of
various national PV systems. Although efforts may have been made to standardise parts of the
PV system, the focus must shift to the diffusion and successful adoption and implementation
of those standards.
3.7 Chapter 2: Conclusion
This chapter described the global PV landscape, what is meant by an interoperable sponta-
neous reporting system, the challenges and barriers which affect the spontaneous reporting
of ADRs, and an analysis of the effects of the lack of interoperability across the global PV
reporting system. The chapter concludes with a discussion focussing on the extent to which




Reporting of adverse drug reactions
This chapter describes the flow of information through the PV system, the key role players
in the system, as well as the communication channels between the key role players in the PV
system. The different methods for reporting ADRs are discussed and the current best practices
are described. A comparison between methods currently in use by 3 selected countries is made
and a comparative analysis is performed, outlining their respective differences and discrepan-
cies. The introduction of the Electronic Health Record (EHR) as a disruptive technological
innovation is discussed and a new approach to addressing the challenges of under-reporting
is introduced. The concept of maturity models are introduced as a means of addressing the
challenges facing ADR reporting, regulatory compliance, and general population health and
safety within the PV context.
4.1 Introduction
The effective use of a strong PV system ensures continuous worldwide safety and efficacy
monitoring. For effective PV to take place we need to ensure that all key role players contribute
to PV reporting and the effective communication of information.
4.1.1 Who are the respective role players?
The PV framework relating people, functions, structures, and expected outcomes and impacts
can be seen in Figure 4.1. Generally the reporting of an ADR begins with a patient who ex-
periences the ADR and culminates in the relevant information being effectively communicated
to a national PV centre as well as the Uppsala Monitoring Centre, where it can be analysed
and where the outcome of this analysis can be taken into consideration for the necessary
decision-making processes. The final step in improving patient safety is in disseminating the
information back down the chain of communication towards the patient. It is important to
distinguish between a reporter and a sender. A reporter is someone who reports the facts
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Prevented Medicine-Related Problems        Reduced Morbidity and Mortality
PEOPLE FUNCTIONS STRUCTURES
Figure 4.1: The pharmacovigilance framework relating people, functions, structures, and ex-
pected outcomes and impacts (Strengthening Pharmaceutical Systems (SPS) Program, 2011).
related to an ADR, this is usually the patient themselves or a HCP in consultation with the
patient. A sender is simply a secondary source of reporting who transmits the information
from one role play to another, for example a Marketing Authorisation Holder1 (MAH) and the
regulatory authority. The role players involved in the reporting of ADRs are described below.
1. Patients/Consumers: Generally the process of reporting an ADR is initiated by the
patient who has experienced the ADR. In countries which restrict the reporting of ADRs
to HCPs only (i.e. where patients are not permitted to report ADRs to PV authorities
directly), the report is made up of an interpretation of the description originally provided
by the patient, together with some objective measurements. The patient communicates
with his or her HCP and thus the initiation of a spontaneous ADR report occurs. In
this case the responsibility rests with the HCP to ensure that the report is transmitted
to the necessary PV authority. Most countries had restricted the reporting of ADRs to
PV authorities to HCPs, only since the 2000’s did it become more common to allow for
patients to report directly to PV authorities (Herxheimer et al., 2010). Inácio et al. (2017)
performed a systematic review of literature on patient reporting wherein the advantages
1A Marketing Authorisation Holder is a person or entity who has received the right to market and sell a




and limitations of patient reporting were summarised. Key advantages include the faster
accumulation of information which complements the information received from HCPs,
as well as more detailed information found in the patient reports. The limitations of
patient reporting include patients questioning the validity of their judgement on ADRs,
as well as a low level of awareness among patients of the availability of patient reporting.
Inácio et al. (2017) concluded that “patient reporting of ADRs provides new information
and perspective in a way otherwise unavailable”.
In 2012 the European Union PV system underwent major regulatory reform, with the
introduction of the legal right for citizens to report suspected ADRs directly to national
PV centres (Borg et al., 2011; Steurbaut & Hanssens, 2014). According to the 2016
annual report of the European Medicines Agency (2016a), 2015 saw an increase of 30%
in patient reporting with 48 782 patient reports, compared to the 37 797 reports in
2014. The United Kingdom has allowed patient reporting of ADRs since 2005, however
a study by Avery et al. (2011) found that in 2011 only 8,5% of patients were aware of
the possibility of reporting.
2. Health Care Professional: The responsibility to report ADRs traditionally rested with
physicians, however in recent years there has been a trend in which the responsibility
to report ADRs is shared among all HCPs including doctors, pharmacists, nurses, other
healthcare workers and carers. It is well known that the success of any spontaneous
reporting system depends on the active engagement of reporters. By restricting reporting
to only physicians it was thought that the reports would contain data of higher quality.
A review of ADR reports by Hornbuckle et al. (1999) argues that by allowing reporting
by different HCPs across the healthcare setting, different kinds of drug related problems
would be uncovered. Wherever medicines are being consumed, in which ever health
setting including public and private hospitals, doctors practices, nursing homes, clinics,
pharmacies etc., there should be an awareness of ADR reporting and the capacity to
report these events to the necessary PV authorities. By inviting all HCPs to report
ADRs, a full spectrum of the complications associated with medicines can be achieved
(Hornbuckle et al., 1999). After the consultation with the patient, the HCP will examine
the possible causes of the ADR. Possible causes include (the Uppsala Monitoring Centre,
2018e):
 The possibility of a misdiagnosis,
 Interactions with other medications, foods or substances,
 Non-adherence to the dosing instructions of the medication, or
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 The source or quality of the medication (falsified or sub-standard, out of specifica-
tion medication).
The HCP initiates the formal process of reporting the ADR to their regional or national
PV centre, this is the first step towards the creation of an Individual Case Safety Report
(ICSR). An ICSR is compiled at the national PV centre, where the necessary information
can be solicited from the HCP and the patient experiencing the ADR. This process can
involve multiple back and forth communications between all three role players.
3. Hospitals and Academia: The role of Hospitals and Academia in the reporting process
is somewhat limited in that HCPs report directly to the national PV centre. The primary
role of the hospital in the reporting of ADRs is to provide the HCPs operating within it,
the necessary knowledge and tools to report ADRs. This role is often delivered through a
drug and therapeutics committee (DTC). The American Society of Hospital Pharmacists
provides the following definition for a DTC: “The committee that evaluates the clinical
use of medicines, develops policies for managing pharmaceutical use and administration,
and manages the formulary system1” (American Society of Health-System Pharmacists,
2008). A DTC is formally organised group of HCPs which can include medical specialists,
clinical pharmacologists, pharmacists and epidemiologists. The existence and opreation
of a DTC is considered one of the WHO’s 22 prerequisites for a functioning PV system
(World Health Organization, 2010). The primary function of the DTC is, among other
things, to manage ADRs and medication errors, thereby decreasing the amount of ADRs
occurring. The benefits of a properly functioning hospital DTC include increased staff
and patient awareness of ADR reporting, as well as improved quality of patient care and
health outcomes. A DTC should have an appropriate plan in place to address problems
associated with ADRs including regular monitoring, assessment, reporting, and preven-
tion. DTCs contribute to drug quality assurance through facilitating communication
among all the various role players in the health facility as well as through communication
with manufacturers and regulatory authorities.
4. Regional and national PV centres (National competent authorities): Every mem-
ber state of the WHO’s programme for International Drug Monitoring must set up a
national PV centre which has the necessary designated staff, stable funding, clear man-
dates, and well defined structures and roles. These national PV centres must also ensure
the existence of a national ADR reporting form, as well as a national database which
supports the management of the ADR reports (Maigetter et al., 2015).




It is at the regional or national level that spontaneous reports of ADRs are collated and
aggregated together to be subjected to various analyses. The national PV centres of
member countries of the PIDM are encouraged to submit ICSRs to the UMC’s VigiBase
as early as possible or at least on a quarterly basis (the Uppsala Monitoring Centre,
2018e).
Regulatory authority : Regulatory authorities (RAs) are government structures which
are responsible for the scientific evaluation, supervision and safety monitoring of phar-
maceutical products in their area of jurisdiction. In South Africa this is performed by the
South African Health Products Regulatory Authority (SAHPRA) which evolved from and
is based on the Medicines Countrol Council (MCC). Undoubtedly the most recognisable
role players in the the PV landscape from the perspective of the general public would be
the United States Food and Drug Administration (FDA) and its European counter-part
the European Medicines Agency (EMA). These are the two largest pharmaceutical reg-
ulatory bodies in the world. RAs operate in terms of the laws and regulations prescribed
to them by their respective Departments of Health. In South Africa this is the Medicines
and Related Substances Act, 1965 (Act 101 of 1965). It is worth noting that both the
FDA and EMA have their own electronic ADR processing and management systems. The
FDA provides those within its jurisdiction to report ADRs via the FAERS (FDA Adverse
Event Reporting System), this system makes use of standards which enable interoper-
ability of information with the VigiBase database. Similarly the EMA, on behalf of the
EU, provides its inhabitants with the EudraVigilance system, which operates within the
European Economic Area (EEA). EudraVigilance also supports the standards in use by
the UMC’s VigiBase.
Pharmacovigilance Risk Assessment Committee (PRAC): The European Medicines
Agency (EMA) has a specialised team which is mandated to perform PV risk manage-
ment related tasks, the Pharmacovigilance Risk Assessment Committee. The PRAC is
responsible for the design and evaluation of post-authorisation safety studies, as well as
PV auditing in the EU.
5. The World Health Organisation: The Quality Assurance and Safety: Medicines team
of the WHO operates within the Department of Essential Drugs and Medicines Policy,
under the cluster of WHO Health Technology and Pharmaceuticals. The goal of the
team is to ensure equity of access to essential drugs, drug quality and safety, and the
rational use of drugs.
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Uppsala Monitoring Centre (UMC): The UMC is the organisation charged with the
management of an international database of ADR reports received from the national
PV centres of countries belonging to the Programme for International Drug Monitoring
(PIDM). The UMC actively promotes the international use of the Individual Case Safety
Report (ICSR) standard exchange format, the International Conference on Harmonization
E2B (ICH E2B) (Lindquist, 2008). The UMC has developed a set of software tools and
methods for the communication of PV data. The software tools and methods which
facilitate the management of PV data, are collectively referred to as the “Vigi tools and
methods”1.
6. MAHs and Pharmaceutical Industry: MAHs and manufacturers are subjected to dif-
ferent rules and regulations depending on the country which they are marketing their
medicines in. Generally the MAHs are required to operate and maintain a spontaneous
reporting system, however, these often differ from the national PV centre’s reporting
systems. The MAH must follow the guidelines set by the government that is regulating
its operations. For example the European Medicines Agency, of the European Parlia-
ment. In countries where patient reporting is permitted but the PV centre is not part
of a regulatory body, the exchange of patient report information with pharmaceutical
companies must be carefully considered.
7. Media: The media plays an important role in alerting the public whenever an acute
problem with a medication arises. It is for this reason that a good relationship must be
maintained between those in charge of PV activities and journalists. Pharmacovigilance
data is understood differently by HCPs compared to consumers. For this reason, to
create successful communication with the public, the type of information, level of detail
and the communication channel used, must all be carefully considered.
8. Professional Groups: Professional medical and pharmaceutical groups should seek to
reinforce that patient reporting by no means replaces the need for reporting by HCPs.
These groups and organisations must encourage their members to take initiative and
continue to increase the number of reported ADRs.
1The tools include VigiBase, VigiLyze, VigiAccess, and VigiFlow; while the methods include vigiGrade,
vigiMatch, vigiPoint, vigiTrace, and vigiRank (the Uppsala Monitoring Centre, 2018b). These tools and methods




4.1.2 The flow of information
The successful operation of a PV system is dependent on the successful communication of
relevant ADR information from the patient experiencing the ADR to the relevant PV authority,
so that the necessary action can be taken, in a timely manner, so as to prevent medicine
related problems and reduce morbidity and mortality associated with ADRs. Reporting or the
detection of ADRs and subsequent generation of ADR data is therefore a critical function
in the PV system (see Figure 4.1). The communication channels used during the reporting
of ADRs is depicted in Figure 4.2, while the types of interaction amongst the various role
players in PV reporting is characterised in Table 4.1. As is evident, there exist a multitude of
communication channels which are involved during the reporting of ADRs.
In the event of a patient experiencing an ADR from the consumption of a medicine, the
reporting process can be initiated in one of two ways, by consulting with a relevant HCP
(typically a doctor, a pharmacist or a nurse) or, depending on where the patient lives and the
severity of the ADR, direct patient reporting to a regional or national PV centre. The patient
and their HCP discuss the ADR and investigate possible causes of the ADR. These causes can
include a misdiagnosis, an interaction between the prescribed medicine and another medicine
or food substance, an error relating to the administration of the medicine or failure to adhere
to the dosing and scheduling instructions of the medicine, or the possibility of the medicine
being counterfeit or of sub-standard quality. A decision is reached by the patient and the HCP
in terms of how to proceed with the treatment of the ADR (feedback), this could include a
change in medication, a change in dosage or a change in frequency. This decision is often
reached through the collaborative decision-making efforts of multiple healthcare professionals
(see cell B2, in Table 4.1), each with unique knowledge bases, across multiple healthcare
disciplines. At this point, in an ideal situation, regardless of the severity, duration or outcome
of the ADR, the HCP would initiate a spontaneous report of the ADR to the relevant PV
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Figure 4.2: A schematic representation of the communication channels used during the report-
ing of ADRs.
Row A in Table 4.1 shows the different interactions that take place between the patient and the
other role players in PV. A study by Saleh et al. (2018) found that 44 countries allow for direct
patient reporting of ADRs to national PV centres (see cell A5, in Table 4.1). This is largely due
to the launch of the eReporting module of the UMC’s VigiFlow system1 in 2014, which is free
to use for all member countries of the WHO IMDP (the Uppsala Monitoring Centre, 2018c).
Many of the most prominent pharmaceutical companies or MAHs have their own proprietary
systems (see cell A6, in Table 4.1) for capturing data on ADRs experienced by their customers.
The reason that these systems differ to the system in use by the country in which the MAH
markets their products is that the MAH operates in multiple countries and is subject to different
laws and regulations. MAHs and national PV centres have different interests when it comes
to collecting information on ADRs, national PV centres aim to protect and promote public
health, while MAHs seek to gain an improved understanding of the marketability of their
pharmaceutical products. It is important to note that member countries of the WHO PIDM
1A web-based ICSR management system.
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do require all MAHs operating within their jurisdiction to submit all ADR reports that they
might receive to the relevant PV authority, which in most cases is the national PV centre. For
the purpose of this research, we will consider that any ADR reporting performed via an MAH’s
proprietary system is supplementary to the reports of ADRs which are transmitted between the
reporters and the national PV centres.
In some cases, the HCP will be a member of, or interact with, a Drug and Therapeutics
Committee (DTC) within the healthcare facility in which they operate (see cell B3, in Table
4.1). The DTC might provide initial feedback to the HCP in terms of how to proceed with
treating the patient. The DTC would have somebody responsible for PV activities and would
be able to provide support to HCPs when it comes to initiating the ADR report to the regional
or national PV centre. The DTC will also keep a record of all the ADRs occurring within
the healthcare facility and can adjust the facility’s formulary as necessary if required. If a
regional PV centre exists, then the HCP will initiate the ADR report to the regional PV centre
via the healthcare facility DTC. If no DTC or regional PV centre exists, then the HCP will
report the ADR directly to the national PV centre. Depending on the country in question
and the availability of resources for PV activities, the reporting of ADRs to this point (the
National ICSR database) can occur via a number of formats such as paper-based forms,
facsimiles, e-mail, telephonic, text messaging, online forms, patient record systems, or mobile
applications. Nigeria for example makes use of the PRASCOR system (Pharmacovigilance
Rapid Alert System for Consumer Reporting), a short code service for consumers to alert
the National Agency for Food and Drug Administration and Control (NAFDAC) of safety or
quality issues via SMS. When a reporter makes use of this system, the national PV centre in
Nigeria phones the reporter to provide feedback and if necessary request additional information
pertaining to the ADR (The Nigerian National Agency for Food and Drug Administration and
Control, 2018).
In the case of the European Union, one could consider the national PV centre of the EU
member states as regional PV centres which operate under the guidance of the European
Union’s regulatory authority, the EMA. Similarly in the United States the regional PV centres
within each of the states fall under the jurisdiction of the FDA.
The majority of the challenges in PV which were discussed in Chapter 3 are generally contained
within the PV system in the stages leading up to the generation of an Individual Case Safety
Report (ICSR), after which the system for the transmission of ADR information is largely
standardised. These challenges include under-reporting due to poor knowledge, attitude and
practices (Bhagavathula et al., 2016); and a lack of financial incentive (Kim et al., 2010).
Further challenges include poor culture and transparency in PV, low public participation, in-




Figure 4.3 shows what can be considered as the ‘ideal’ pathway for the reporting of ADRs.
Reporting is initiated upon consultation between the patient experiencing the ADR and their
HCP. In an ideal situation the patient would be able to report the ADR directly to the national
PV centre via a direct patient reporting mechanism. A study by Saleh et al. (2018) found that
44 countries of the WHO PIDM allow for direct patient reporting. The benefits of direct patient
reporting are frequently discussed in literature, with the consensus that direct patient reporting
of ADRs yields more detailed information about how the ADR affects a patient’s quality of life.
Direct patient reporting has also been identified as an important tool for assessing the effects
of a pharmaceutical product throughout its entire life cycle, as evidence has shown that most
HCPs are reluctant to report ADRs from medicines which have existed on the market for a
number of years prior to the ADR taking place (Agarwal et al., 2013).
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Health Care Professional














Figure 4.3: A schematic representation of the ‘ideal’ communication channels used during the
reporting of ADRs.
In Figure 4.3 the information moves in a linear fashion from the patient to the HCP (Flow
1, in Figure 4.3), the DTC (Flow 2, in Figure 4.3), a regional PV centre (Flow 3, in Figure
4.3), and finally a national PV centre (Flow 4, in Figure 4.3). It is at the national PV centre
where the information is translated from one of several types of reporting media (paper-based
form, fax, telephone, etc.) into a standardised electronic format known as an Individual Case
Safety Report (ICSR) (see Section 4.3). Member countries of the PIDM can make use of the
UMC’s VigiFlow software to capture the data and compile an ICSR. The compilation of an
ICSR can consist of multiple instances of data entry, this might be necessary in the case that
the national PV centre solicits additional information from either the patient or the HCP in
order to compile a more comprehensive ICSR. Once the ICSR has been formalised the national
PV centre sends the ICSR to the MAH and the UMC simultaneously (see cells E6 and E7, in
Table 4.1)(Flows 5 and 6, in Figure 4.3).
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In terms of the MAHs communication with other role players, their proprietary systems could
provide some initial feedback to patients and HCPs who make use of their system. The
only role player which the MAH directly communicates with in terms of ADR reporting is the
national PV centre of the country within which it is marketing its products. The MAH is legally
obligated to submit all received spontaneous reports to the national PV centre, as well as to
provide the national PV centre with all of the necessary documentation regarding the product
which it is marketing. In the EU, according to European Medicines Agency (2010), MAHs are
legally required to provide the national PV centres with a Pharmacovigilance System Master
File (PSMF), a technical document which according to Article 1(28e) (European Medicines
Agency, 2004) is defined as:
“A detailed description of the pharmacovigilance system used by the marketing
authorisation holder with respect to one or more authorised medicinal products.”
The PSMF contains sections on the organisational structure of the MAH, the sites where PV
activities take place, descriptions of the delegated PV activities, procedural documentation,
and data handling and database functionality. Furthermore, MAHs can be requested at any
point in time to perform post authorisation safety studies (PASS) to monitor the risk-benefit
profile of their products over their entire life cycle. The findings of the PASSs are then made
available to national PV centres via periodic safety update reports (PSURs) (see cell F5, in
Table 4.1).
Once the ICSR has been submitted to the UMC’s VigiBase, the information is analysed, the
outputs of which are made accessible to national PV centres and MAHs around the world (see
cells G5 and G6, in Table 4.1). Member countries of the PIDM pay a subscription fee for the
use of the UMC’s services, this fee is calculated using the World Bank Atlas method1. MAHs
are also required to pay a subscription fee for the use of the UMC’s services. The components
and functionality of the UMC’s Vigi Tools and Methods are discussed in detail in Section 4.4.
Figure 4.4 shows the communication channels used during the reporting of ADRs according
to the minimum requirements for a functional national PV system as described by the WHO
(World Health Organization, 2010). The minimum requirements include:
1. A national PV centre with designated staff (at least one full time), stable basic funding,
clear mandates, well defined structures and roles, and collaboration with the WHO
Programme for International Drug Monitoring.
1The World Bank’s official estimates of the size of economies are based on GNI converted to current U.S.
dollars using the World Bank Atlas method. The Atlas method smoothes exchange rate fluctuations by using




2. The existence of a national spontaneous reporting system with a national Individual
Case Safety Report (ICSR) form, i.e. an ADR reporting form.
3. A national database or system for collating and managing ADR reports.
4. A national ADR or PV advisory committee able to provide technical assistance on
causality assessment, risk assessment, case investigation and, where necessary, crisis
management including crisis communication.
5. A clear communication strategy for routine communication and crisis communication.
Note that no direct patient reporting is available in this context.
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Figure 4.4: A schematic representation of the communication channels used during the report-
ing of ADRs in a resource limited context. Note: No patient reporting allowed.
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Figure 4.5: A schematic representation of the communication channels used during the report-
ing of ADRs in a resource limited context which allows for patient reporting.
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Figure 4.5 shows the communication channels used during the reporting of ADRs in resource
limited contexts, but with the addition of direct patient reporting. The short code service
PRASCOR, used in Nigeria, is a good example of how the use of mobile technology can address
some of the challenges relating to insufficient resources. In this instance a patient or HCP sends
a free SMS message via a mobile telephone to a short code number, in this case 20543; the
message must include the name of a medication and a suspected ADR. The reporter receives
an automated response acknowledging receipt and providing some guidance on which steps to
follow next (The Nigerian National Agency for Food and Drug Administration and Control,
2018). The national PV centre then contacts the reporter and solicits more information from
them and their HCP to compile a suitably completed ICSR.
4.2 Types of reporting
The concept of ADR reporting was introduced in Chapter 3. Three methods of PV report-
ing were described and differentiated by the solicited or unsolicited nature of the monitoring
method. In summary, Spontaneous Reporting (SR) is by definition the unsolicited reporting of
ADRs, whereas the methods of Cohort Event Monitoring (CEM) and Targeted Spontaneous
Reporting (TSR) involved the soliciting of ADR information from specific groups of patients.
In this section the different types of monitoring methods and their objectives are discussed.
Hill (2014) gives the following different objectives of PV monitoring systems:
 To establish a functional reporting system to monitor the safety of all medicines marketed
within a country. This is a minimum requirement set by the WHO for a functional
national PV system.
 To learn more about the benefit/risk profile of new medicines, specifically during the
early post-marketing authorisation phase.
 To learn more about the ADR profile associated with a specific medicine in a given
population.
 To estimate the incidence of a known ADR to a specific medicine in a given population.
 To utilise electronic health records and health registries to identify emerging drug safety
concerns.
These objectives of reporting can be attributed to each of the five methods described by Tanaka
(2015), shown in Figure 4.6. Moving from left to right along the Figure 4.6 it is shown that
which each reporting method, the level of suspicion decreases while the amount of information
increases simultaneously. The unsolicited nature of a spontaneously reported ADR implies a
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certain level of suspicion in that the reporter suspects an ADR and acts upon this suspicion.
On the opposite end of the spectrum there is no level of suspicion because the data already
exists in the electronic health record and is available for continuous analysis. On the other
hand, the level of information increases as you move across the spectrum, both in terms of
quality of information and quantity of information. This will be elaborated on in the following
discussion.
4.2.1 Push and pull methods in data flows
In data flow systems the notion of push and pull models is well known. Within each of
these models there exists an active component and a passive component. A push model is
data driven, with the sender of information actively pushing information towards the receiver.
While in a pull model, the active component would be the receiver requesting the information
from the sender, in this instance the receiver is in control over what information is received.
4.2.1.1 Push methods
In this section the first four reporting methods in Figure 4.6 are discussed. These four methods
can be considered push PV methods in that the ADR information must be sought and accu-
mulated before being pushed through the system towards the ICSR document that is compiled
by the national PV centre.
A spontaneous reporting system involves the unsolicited, voluntary submission of ADR reports
to a national PV centre and is considered a cornerstone of a national PV system according to
the WHO minimum requirements as outlined in Section 4.1.2. The reporter in a spontaneous
reporting system can be a healthcare professional, a pharmaceutical manufacturer, or a patient.
A spontaneous reporting system allows for the reporting of all suspected ADRs and enables
a national PV centre to develop a profile of ADRs that are experienced with locally used
medicines.
Intensified ADR reporting can be seen as an extension to spontaneous reporting but is used
specifically to learn more about the benefit/risk profile of new medicines, during the early
post-marketing authorisation phase. An example of an intensified ADR reporting method
is the Black Triangle Scheme used in the United Kingdom. A black triangle (H) printed
on the label of a medicinal product means that the product is being monitored more inten-
sively. Medicines under additional monitoring could include those with new active ingredients,





















Figure 4.6: The five reporting methods and change in levels of suspicion and information
(Tanaka, 2015).
Targeted Spontaneous Reporting (TSR) is a methodology which is similar to spontaneous
reporting but involves well defined patient groups. TSR is an active method of surveillance
in a well-defined population group whereas spontaneous reporting is a passive method of
surveillance used within an undefined population (Mehta et al., 2014). TSR is useful when the
objective of the monitoring is to learn more about the ADR profile associated with a specific
medicine in a given population, or to estimate the incidence of a known ADR to a specific
medicine in a given population.
Hill (2014) defines Cohort Event Monitoring as “a prospective, longitudinal, observational,
cohort study of adverse events associated with one or more monitored medicines.” The primary
benefit of CEM is realised when used to observe the effects of a new medicine in the early
stages of post-marketing authorisation (Pal et al., 2013). Although all PV monitoring methods
focus on patient safety, CEM takes the approach of focussing on a specific medication for the
time before and during the control period.
4.2.1.2 Pull method: Electronic health record mining
In contrast to the push methods of ADR reporting, the use of Electronic Health Records
(EHRs) would result in a pull-based system. EHRs allow for the passive surveillance of drug
safety concerns through the mining of information that exists within the EHR. An EHR is
a single electronic document which contains a comprehensive and exhaustive record of all
routinely collected, longitudinal health related data for a given patient. When information on
this scale is available, the opportunity for automated data mining techniques are indisputable.
EHRs can consist of aggregations of data across multiple organisations, this concept is known
as record-linkage. Medical records from hospitals and HCPs, pharmacy and drug dispensary
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registries, and health insurance claims could potentially contribute towards the rich data set
of an EHR. Rigorous methods to systematically evaluate this data, to better understand the
benefit-risk profiles of new and existing medications, are rapidly becoming a priority in the PV
practices of many countries.
Currently the two largest initiatives for using EHRs as a data source for computerised data min-
ing and signal detection are the FDA’s Sentinel Initiative and the “Exploring and Understanding
Adverse Drug Reactions by integrative mining of clinical records and biomedical knowledge”
(EU-ADR) initiative (Patadia et al., 2015). The EMA’s EU-ADR project uses eight European
population-based administrative and healthcare databases from the UK, Netherlands, Germany,
Italy, and Denmark (Pacurariu et al., 2015). The data in the EU-ADR project is representa-
tive of approximately 20 million patients, with drug exposure data sourced from prescription
and dispensing data according to the Anatomical Therapeutic Chemical (ATC) Classification
System. The ATC system classifies pharmaceutical products in a hierarchy with five levels, an
example of the ATC classification for metformin, the most frequently prescribed drug for the
treatment of type 2 diabetes, is shown in Table 4.2. Prescriptions with the same ATC codes
can be grouped together and prescription start dates and end dates are used to determine
concomitant drug use.
Table 4.2: ATC classification for metformin. (WHO Collaborating Centre for Drug Statistics
Methodology, 2018)
A
Alimentary tract and metabolism
(1st level, anatomical main group)
A10
Drugs used in diabetes
(2nd level, therapeutic subgroup)
A10B
Blood glucose lowering drugs, excl. insulins
(3rd level, pharmacological subgroup)
A10BA
Biguanides
(4th level, chemical subgroup)
A10BA02
metformin
(5th level, chemical substance)
The primary limitation of EHR mining is that the data in EHRs is not collected for the purpose
of PV activities such as signal detection. For this reason attention must be given to finding
the appropriate signal detection methods that can be applied to EHRs so as to ‘find the needle
in the haystack’ as it were.
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4.3 The Individual Case Safety Report
Once the spontaneous reporting process has been initiated, as discussed in Section 4.1.2, the
national PV centre compiles a standardised electronic document known as an Individual Case
Safety Report (ICSR). The ICSR can be updated to include all information referring to a
specific ADR generated by the patient and HCP alike. The ICSR is a primary source of data
in PV. Due to various international and national laws and regulations, the information within
ICSRs needs to be transmitted (International Council for Harmonisation, 2001):
 from identifiable reporters to RAs, national PV centres, and MAHs,
 between RAs,
 between MAHs and the RAs of the jurisdictions within which they operate,
 within RAs or MAHs, and
 from national PV centres to the WHO Collaborating Centre for International Drug Mon-
itoring, the UMC.
 

















Figure 4.7: Minimum requirements for a valid ICSR per the UMC guidelines.
The minimum required information for a valid ICSR is shown in Figure 4.7. According to the
UMC and the ICH E2B standard, the minimum required information for a valid ICSR is:
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1. One identifiable patient1,
2. One identifiable reporter,
3. One reaction/event, and
4. One suspected drug.
The minimun administrative information that is needed to correctly identify and process a
report in the UMC’s VigiBase is:
1. Sender’s unique case identification number,
2. Worldwide unique case identification number,
3. Sender identifier, and
4. Date of receipt of most recent information.
The personal information of the patient and the reporter must under no circumstances be sent
to VigiBase as this information is confidential.
4.3.1 The new ICH E2B(R3) standard
Successful electronic transmission of information relies on the definition of standard data el-
ements. The International Council for Harmonisation of Technical Requirements for Phar-
maceuticals for Human Use (ICH) published a guideline “Data Elements for Transmission of
Individual Case Safety Reports” in 1997. The guideline was proposed to address challenges
faced by the large number of participants in a world-wide exchange of information. The ICH
sought to bring together regulatory authorities and the pharmaceutical industry to harmonise
scientific and technical aspects of pharmaceutical regulation. In 2005 the implementation of
the electronic submission of ICSRs (ICH E2B(R2)) became wipespread in the ICH regions,
being Japan, the European Economic Area, and the United States of America. ICH E2B(R3)
was initiated in 2006 when the ICH Steering Committee took the decision to collaborate with
multiple international Standards Development Organisations (SDOs) in an effort to achieve
greater interoperability across the global health and regulatory systems. The project was named
the Joint Initiative on SDO Global Health Informatics Standardization and involved, among
others, the International Organisation for Standards (ISO), Health Level 7 (HL7), and the
European Committee for Standardization (CEN)(European Medicines Agency, 2016b).
1There exist several data elements which can be considered sufficient to define an identifiable patient or
reporter, these include initials, age, sex, address, qualifications etc. Additional rules for the required ’minimal
information’ might be enforced at the regional PV centre level.
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By 2011 multiple additional SDOs had joined the joint initiative, including the Clinical Data In-
terchange Standards Consortium (CDISC), the International Health Terminology Standards De-
velopment Organisation (IHTSDO), and Global Standards One (GS1). The new ICH E2B(R3)
standard was published in 2011 (ISO/HL7 27953-2:2011 , HL7).
An ICSR that is in compliance with the ICH E2B(R3) standard is developed using eXtensible
Markup Language (XML) encoding syntax, a programming language that is both human-
readable and machine-readable. RAs are advised to enforce the use of the ICH E2B(R3)
format for electronically capturing and transmitting ICSRs by MAHs. According to European
Medicines Agency (2016b) and the FDA Centre for Drug Evaluation and Research (2014) the
ICH E2B(R3) format for electronically capturing and transmitting ICSRs is currently in use
in Japan, the European Union, and the United States of America. The benefits of the new
ICSR standard include a general improvement of the ICSR format due to almost 10 years
of operational experience, additional data elements which increases the quality of the ICSR,
alignment with the ISO Identification of Medicinal Products (IDMP) standards, improved
interoperability with global health and regulatory systems, as well as improved harmonisation
of data formats in use beyond the ICH region.
4.3.2 The structure of an ICSR
Figure 4.8 is a relational diagram showing the components of an ICSR. The ICSR is made
up of two primary sections, section A on the left hand side depicted in yellow is concerned
with administrative and identification information. Section B on the right hand side, contains
information on the case. The code sets, terminologies and vocabularies used to populate
an ICSR can be found in the Medical Dictionary for Regulatory Activities (MeDRA) and the
WHODrug Dictionary.
Compatibility between the ICH E2B(R2) and the new ICH E2B(R3) formats must be ensured,
for both forward compatibility and backward compatibility. Compatibility means that different
PV systems which interact on the basis of either ICH E2B(R2) or ICH E2B(R3) can support
the electronic exchange of PV data.
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Figure 4.8: The ICH E2B(R3) ICSR structure. (ISO/HL7 27953-2:2011 , HL7)
4.4 WHO solution: the Uppsala Monitoring Centre and their
software tools and methods
The UMC has developed a set of software tools and methods for the communication of PV
data. The software tools and methods which facilitate the management of PV data, are
collectively referred to as the “Vigi tools and methods”1. The tools include VigiBase, VigiLyze,
VigiAccess, and VigiFlow; while the methods include vigiGrade, vigiMatch, vigiPoint, vigiTrace,
and vigiRank (the Uppsala Monitoring Centre, 2018b). A brief description of each of these
tools and methods is provided below:
 VigiBase: The UMC’s global ICSR database. Developed in 1968, VigiBase is the largest
database of its kind in the world, with over 20 million reports of suspected ADRs of
medical products (the Uppsala Monitoring Centre, 2018f). Data in VigiBase is encoded
according to certain terminology code sets, such as MedDRA and WHODrug, the original
terminology used for coding ADRs was WHO-ART, until it was replaced by MedDRA
in 2008. The hierarchical structure of the MedDRA code set can be seen in Figure 4.9.
VigiBase accepts ICSR data from over 110 member countries of the WHO Programme,
representing over 90% of the world’s population. According to the 2016 UMC Annual
1The vigi methods (vigiRank, vigiMatch, vigiGrade, vigiPoint, and vigiTrace) are stylised by the UMC, with
a lower-case ‘v’, while the vigi tools are stylised with an upper-case ‘v’.
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Figure 4.9: The five levels to the MedDRA hierarchy. (MedDRA, 2018).
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Report, 11.5% of the ICSRs in VigiBase come from low- and middle-income countries
(the Uppsala Monitoring Centre, 2016).
 VigiSearch: A powerful search tool which can be used to find individual case safety
reports (ICSRs) collected in VigiBase from all participating countries. Replaced by Vig-
iLyze in July 2013.
 VigiMine: A statistical tool within VigiSearch with vast statistical material calculated
for all Drug-ADR pairs available in VigiBase. The main features include the dispro-
portionality measure (IC value) stratified in different ways and useful filter capabilities.
Replaced by VigiLyze in July 2013.
 VigiLyze: A web-based resource that provides a quick and clear overview of VigiBase
data in tabular and graphical formats. VigiLyze takes advantage of the well structured
nature of the data within VigiBase to provide search and analysis functions. Due to the
well-known problem of under-reporting, free access to VigiLyze is given to all national PV
centres, the aim of this is to allow countries with low numbers of ICSRs to complement
their data with the global database.
 VigiAccess: Online resource for the general public to gain access to VigiBase data.
VigiAccess searches the VigiBase database for ADR data relating to a pharmaceutical
product that the user has specified in the VigiAccess search. The user provides the
tradename of the drug as it would appear on the product packaging. The search returns
the name of the product together with the active ingredient of the product. The total
number of records retrieved is shown together with the distribution of the reports in terms
of: ADRs, geographical distribution, age group distribution, patient sex distribution, and
ADR reports per year. The summary statistics that VigiAccess provides are formatted
in a way that protects patient confidentiality and individual country data.
 VigiFlow: A web-based ICSR management system. VigiFlow is available for use by
national PV centres of countries belonging to the WHO Programme for International
Drug Monitoring, the UMC does however charge a license fee for the use of VigiFlow,
this fee is determined by the World Bank Atlas method. As of October 2017 there are
over 70 countries which make use of VigiFlow (the Uppsala Monitoring Centre, 2017).
Through its compliance with the new ICH E2B(R3) standard, VigiFlow supports the
collection, processing and sharing of ICSRs to facilitate effective data analysis. Data
transmitted via VigiFlow is structured with WHODrug and MedDRA codes to ensure
compatibility. VigiFlow ensures that ICSR data can be imported and exported in a
harmonised format through the use of XML-files, these files can be easily exchanged with
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external stakeholders such as national PV centres and pharmaceutical companies, while
being stored in VigiBase. Due to the web-based nature of VigiFlow all that is required
for its effective use is a suitable computer and internet access, thus eliminating the need
for local installations, back-ups or maintenance. Unfortunately VigiFlow provides no off-
line functionality. VigiFlow encrypts the data and ensures that the information is only
accessible by authorised parties. Although VigiFlow is strongly recommended to national
PV centres as a means of submitting ICSRs to VigiBase, it is not mandatory for reporting
to VigiBase. According to the 2015 Annual Report by the UMC, 74 national PV centres
make use of VigiFlow as their ICSR management system, with a total of 480 485 ICSRs
having been submitted to VigiBase from the VigiFlow system (the Uppsala Monitoring
Centre, 2016). In October 2017 a new version of VigiFlow was released (the Uppsala
Monitoring Centre, 2017). The update supports the recording of causality assessment
results, and now includes options for WHO-UMC causality, WHO AEFI (Adverse event
following immunization) causality, and Naranjo methods1. As of October 2017 the
default medical terminology in use is MedDRA, those countries which still use WHO-
ART (WHO Adverse Reaction Terminology) will be assisted by the UMC to convert
their data to be MedDRA compliant.
 vigiRank: Predictive model that ranks PV safety signals according to multiple aspects
of strength of evidence. vigiRank was implemented in the UMC signal detection process
in 2014 (the Uppsala Monitoring Centre, 2018d).
 vigiMatch: Probabilistic record-matching method to detect unexpectedly similar pairs
of records in a database. The vigiMatch algorithm was included in the VigiLyze tool in
November of 2017 (the Uppsala Monitoring Centre, 2018a). The algorithm calculates a
match score for a pair of ICSRs, if the match score exceeds a certain threshold then the
ICSRs are flagged as suspected duplicates. If suspected duplicates of ICSRs exist, then
only the ICSR with the highest vigiGrade completeness score is included in calculations.
 vigiGrade: Multidimensional measure of data quality in PV (completeness, relevance,
consistency, etc.). vigiGrade assigns each ICSR with a completeness score, this is
achieved by selecting critical data entry fields and giving them a score; these individual
scores can then be weighted and combined to produce a total score for the ISCR, the
maximum score is 1.0 (the Uppsala Monitoring Centre, 2018d).
1The Naranjo Algorithm, or Adverse Drug Reaction Probability Scale, is a method by which to assess
whether there is a causal relationship between an identified untoward clinical event and a drug using a simple
questionnaire to assign probability scores (Naranjo et al., 1981).
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 vigiPoint: An algorithm to pinpoint the key features of a subset of database records
in contrast to a broader set. These features include, but are not limited to age, sex,
co-reported drugs, and adverse reactions.
 vigiTrace: Suite of analytics methods for the analysis of longitudinal event history
data, including chronographs for statistical graphical overviews and the calibrated self-
controlled cohort design for temporal screening.






Figure 4.10: The flow of information pertaining to ICSRs through the use of the UMC’s
software environment.
Figure 4.10 shows how the national PV centres of participatory countries submit ICSRs via
VigiFlow to the UMCs VigiBase, these national PV centres can also explore VigiBase data
through the VigiLyze interface. Marketing authorisation holders can access the data within
VigiBase by making use of the VigiAccess interface. MAHs are subjected to varying laws and
regulations around the world, and it is for this reason that they are obligated to submit any
PV data they receive to the national PV centre of the country within which they are marketing
their pharmaceutical products.
4.5 Case studies: What is the current situation?
According to the 2016 annual report by the UMC, by June 2016 the total number of ICSRs
received into the VigiBase database was 13 208 000, representing an increase of 18% from the
previous year (the Uppsala Monitoring Centre, 2016). 11.5% of the ICSRs in VigiBase were
received from low- and middle-income countries (LMICs), an increase of 32% from 2015.
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Figure 4.11 shows the country distribution for ICSRs received by VigiBase during 2016. Cur-
rently 75% of the PIDM countries adhere to ICH E2B standard, most will be focussing their
efforts on transitioning from the ICH E2B(R2) to the new ICH E2B(R3) standard.
Figure 4.11: Country distribution for ICSRs received by VigiBase during 2016 (the Uppsala
Monitoring Centre, 2016).
While Figure 4.12 shows countries distributed according to time elapsed since last submis-
sion of ICSRs to VigiBase, as of June 2016.
Figure 4.12: Countries distributed according to time elapsed since last submission of ICSRs to
VigiBase, as of June 2016 (the Uppsala Monitoring Centre, 2016).
4.5.1 High income countries: Pharmacovigilance in the European Union and
the United Kingdom
The EU pharmacovigilance system is supported by a regulatory network consisting of National
Competent Authorities (NCAs), the EMA, the European Commission (EC) and a set of legal
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frameworks. The legislation found in the European Medicines Agency (2010) aims to strike
a balance between two objectives, namely the free movement of pharmaceutical products in
the EEA, and the simultaneous protection of public health throughout the EU. There are two
mechanisms by which pharmaceutical companies can obtain marketing authorisation, the first
being through a decentralised process involving individual Member States, or by a centralised
process involving the EMA. If a product is centrally authorised it is referred to as a Centrally
Authorised Product (CAP) and may be marketed anywhere within the EU, similarly if a product
obtains authorisation from a Member State NCA then the product is referred to as a Nationally
Authorised Product (NAP)(Santoro et al., 2017). During pre-marketing drug development,
the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) assesses the risks and
benefits of all products seeking marketing authorisation to determine their quality, safety,
and efficacy. The Co-ordination Group for Mutual Recognition and Decentralised procedures -
Human (CMDh) is the chief decision-making body when pharmaceutical products are marketed
in the EU through the decentralised process.
In the EEA, patients and HCPs can submit reports of suspected ADRs to their respective NCAs
or the MAH of the drug in question. The reports are then submitted to EudraVigilance, a
centralised database of ADR reports in the EU which is maintained by the EMA. Transparency
is a priority in the EU PV system and as such the general public can access annonymised
data from EudraVigilance through a website. The number of ICSRs submitted spontaneously
for CAPs can also be seen by the general public. The EudraVigilance system is compliant
with the ICH E2B(R2) standard, as is currently being enhanced to comply with the new ICH
E2B(R3) standard for ICSRs. The EMA also requires all MAHs to submit information on all
their authorised medicines, as well as the PV system master file, which must be compliant with
standards for the identification of medicinal products. NCAs are responsible for the collection
of all reported ADRs, and must appoint at least one qualified person for pharmacovigilance
(QPPV).
We now consider ADR reporting in the United Kingdom. PV in the UK is conducted by the
Medicines and Healthcare products Regulatory Agency (MRHA). The UK established its PV
system with the introduction of the Yellow Card Scheme in 1964. In the 1960’s ADR reporting
via the Yellow Card Scheme was restricted to physicians and dentists only, with other HCPs
being allowed to report since the 1990’s, and direct patient reporting being introduced in 2005.
This meant that patient reporting in the UK was permissible 5 years prior to the European
Medicines Agency (2010) which introduced patient reporting throughout the EU. While MAHs
are legally obligated to report all reports of suspected ADRs to the MHRA database, HCPs are
not legally but professionally obligated to report ADRs and serious ADRs, with encouragement
to report all suspected ADRs associated with medicines on the Black Triangle Scheme (H) list.
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In 2005, the MHRA launched the “Yellow Card App” for smartphones, an additional reporting
method for patients to make use of, along with telephone reporting and paper-based reporting
via the mail. In 2015, the MHRA received 40 000 ADR reports, an increase on previous years
which it attributes to the improved patient reporting channels and general promotion and
awareness of ADR reporting conducted by decentralised MRHA sites throughout the country
(Kaeding et al., 2017). The MHRA must submit all serious ADR cases to the EMA within 15
days of receiving them.
4.5.2 Middle income countries: Pharmacovigilance in South Africa
South Africa is faced with the large burden that is one of the highest co-morbidity rates of HIV
and TB infections in the world. The high prevalence of infectious diseases, together the use of
medicines and therapies of ever-increasing complexity, necessitates a strong pharmacovigilance
system to reduce morbidity, mortality and the associated costs (Terblanche et al., 2017).
PV activities in South Africa are coordinated by the Medical Controls Council (MCC), under
the Medicines and Related Substances Control Act of 19651. South Africa was the first African
country to become a full member of the WHO PIDM having joined in 1992 and established the
National Adverse Drug Event Monitoring Center (NADEMC) in 1987 through collaboration
with the University of Cape Town. The MCC also established a WHO collaborating centre in
1995 for regional training in drug policy in the School of Pharmacy at the University of the
Western Cape. Although legal provisions for PV activities are available, there is no national
PV policy in South Africa (Mehta et al., 2014). NADEMC was instrumental in setting up the
adverse events following immunization (AEFI) targeted spontaneous reporting (TSR) system
for the expanded programme for immunization (EPI) in 1998. In 2003 provincial TSR sys-
tems were established for the monitoring of ADRs associated with the roll-out of the national
antiretroviral (ARV) treatment program (Mehta et al., 2017).
South Africa is currently undergoing a transition process in that the MCC is being replaced by
the South African Health Products Regulatory Authority (SAHPRA). With this transition it
is envisioned that a strengthening of PV activities and legislation will be achieved. Currently,
the reporting of suspected ADRs to the NADEMC by industry and HCPs is voluntary but the
regulations in the Medicines and Related Substances Control Amendment Act require MAHs to
report all received reports of ADRs within 15 days of initial receipt. This reporting is performed
via telephone, facsimile, or regular mail. Direct patient reporting is not currently supported
in South Africa and in the event of a patient reporting to a MAH, the MAH is obliged to
encourage the patient to consult with their HCP and complete the reporting process with their
1Medicines and Related Substances Control Act 101 of 1965 after amendment by the Medicines and Related
Substances Control Amendment Act (Act 90 of 1997)
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assistance. The current ADR form in use in South Africa is not ICH E2B(R3) compliant,
however it is worth noting that with the current change in PV stewardship (the introduction of
SAHPRA), this could change in the near future. Representatives from the MCC were invited
to Osaka Japan in November 2016 to observe the assembly of several members of the ICH
with regards to discussions surrounding the implementation guideline for the new ICH E2B(R3)
standard for ICSRs (The International Council for Harmonisation, 2016). Up to 2015, South
Africa had contributed 28 609 case report forms to the WHO PIDM database. Under-reporting
of ADRs and the multiple contributing factors to under-reporting were discussed in Chapter 3.
Substantial evidence of internationally widespread under-reporting is present in the literature.
A South African study performed by Terblanche et al. (2017) showed that awareness of ADR
reporting among HCPs in a South African district hospital was only 18.9%, however 96.2%
agreed that ADR reporting was necessary with 89.4% indicating that ADR reporting is their
professional obligation. The study found that only 12.1% of HCPs in the district hospital
had ever reported an ADR. To improve HCP’s knowledge, attitudes and perspectives on ADR
reporting, and thereby strengthen spontaneous reporting; appropriate education and training
of HCPs is crucial.
According to the Strengthening Pharmaceutical Systems (SPS) Program (2011) assessment
of PV systems in sub-Saharan Africa (SSA), South Africa has the strongest pharmaceutical
industry, accounting for 70% of the the pharmaceutical market, in SSA. The report concludes
that although encouraging trends are seen in the South African pharmaceutical industry with
development in terms of structure, staff and SOPs, there remain considerable challenges in
ADR reporting, data collation, risk evaluation and decision-making. The report highlights the
low level of awareness on reporting regulations, guidelines and ADR forms. The current PV
strategy in SA seeks to augment passive surveillance systems such as spontaneous reporting of
ADRs, with active surveillance approaches. The primary drawback of spontaneous reporting
systems is their inability to quantify ADR incidence or to identify risk factors, for this reason,
the MCC has chosen to take a mixed approach to PV in SA (Mehta et al., 2017).
4.5.3 Low income countries: Pharmacovigilance in Burkina Faso
According to the UMC, Burkina Faso first established its PV system in 2005 (the Uppsala
Monitoring Centre, 2011). Subsequently, in 2010 Burkina Faso became an official member of
the WHO PIDM. An event which contributed significantly to the development of PV activities
in Burkina Faso was the roll-out of the meningococcal A conjugate vaccine MenAfriVac in
2010 (Ouandaogo et al., 2012). Before 2008 PV activities were limited to mass vaccination
campaigns. However, in 2008 under supervision from WHO representatives, PV protocol was
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established within the Ministry of Health, the “Direction Gnrale de la Pharmacie, du mdica-
ment et des laboratoires, Sant, Mdicament BF, Laboratoire” (DGPML), in preparation for the
roll-out of MenAfriVac. The objectives of the protocol included the detection and identifica-
tion of all serious AEFIs, thereby enabling the appropriate action to be taken and corrective
measures to be put in place (Compaore, 2010). The protocol was presented to the WHO
Global Advisory Committee on Vaccine Safety (GACVS) in Geneva in 2009. The surveillance
of the MenAfriVac roll-out was performed through two systems, a targeted spontaneous
reporting system, with the intention to find potentially serious AEFIs; as well as a passive
spontaneous reporting system for the identification of any potential AEFIs. Burkina Faso ben-
efited greatly from this Vaccination Programme as it allowed for the NRA to develop capacity
and the relevant functionality to manage PV activities in other public health programmes.
A study by Kabore et al. (2013) conducted an analysis of the PV system in Burkina Faso
with the use of the USAID Indicator-based PV Assessment Tool (IPAT). The study found that
the two areas which scored the least were the ‘policy, law, and regulation’ and the ‘signal
generation and data management’ categories. The PV system in Burkina Faso failed to meet
the requirements of 7 out of a total of 22 core indicators. The 7 indicators which were not
met are:
1. Specific references to PV in the national medicines legislation.
2. Availability of a Question-Answer service on the safety of medicines.
3. Existence of national PV guidelines.
4. Existence of patients’ safety standard operating procedures.
5. Existence of a platform of coordination across all PV stakeholders.
6. Existence of a form for reporting suspected defective product quality.
7. Existence of a form for reporting suspected treatment failure.
Additionally, 3 of the 5 largest hospitals in Burkina Faso failed to meet two indicators: the
existence of a PV unit or DTC, and the existence of a bulletin on the safety of medicines.
Encouraging findings from the assessment included membership of the UMC, allowing the
use of the ICH E2B compliant ICSR form through the web-based portal VigiFlow. Kabore
et al. (2013) found that at the time of their study, VigiBase has received 1986 suspected ADR
reports from Burkina Faso, this is largely attributed to the targeted spontaneous reporting
initiative for the MenAfriVac vaccination programme.
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According to the minimum requirements for a functional national PV system as described by
the WHO (World Health Organization, 2010), Burkina Faso’s’ PV system is considered non-
functional as it does not meet the 22 core indicators of a functional PV system. Due to the
low ratio of physicians and pharmacists to patients in 2012, 1:21 320 and 1:82 656 respectively
(Burkina Faso Ministre de la Sant, 2012), it is clearly a necessity to ensure that ADR reporting
in Burkina Faso can be achieved in a streamlined and timely manner, so as to not increase
the already heavy workload of HCPs. The formation of hospital DTCs should have a positive
influence on ADR reporting rates, with little to no extra resources required as the constituent
members of a DTC are all present within a hospital in any event.
4.5.4 Key differences between the three presented cases
The strength of the EU’s PV system lies not only in the availability of resources but in the
extensive and exemplary set of laws and regulations set out by the EC and EMA. PV systems
in LMICs are typically not predicated on solid legal and regulatory foundations, as well as being
mostly under-funded and suffering from a lack of suitably trained professional staff.
If LMICs are to bridge the gap between their current situation and achieving the functionality
of a PV system such as the EU PV system, technological innovations must be embraced
wherever possible. Nigerias’ PRASCOR system is a good example of how to increase patient
involvement and alleviate the workload of HCPs.
Collaboration between NCAs and with organisations such as the WHO PIDM should be encour-
aged so as to maintain adherence to current best practices and improved SOPs. To facilitate
this exchange of information, a concerted effort must be made by NCAs to comply with the
ICH E2B(R3) standard.
4.6 Resource availability and resource efficiency
Developing countries, the LMICs, have the highest disease burdens and are therefore the largest
consumers of critical medicines, particularly vaccines. Yet, in 2016 only 11.5% of the ICSRs
in VigiBase were received from LMICs. One of the largest challenges facing the global PV
landscape is the matter of resource availability and resource efficiency. It is undeniable that
the most disadvantaged countries, the LMICs, are those which stand to benefit the most
from global PV initiatives. It is therefore the socially just and moral imperative that the
international community provides the necessary resources required to have a functional global
PV network. The development of strong drug safety legislation in the EU, in particular the
European Medicines Agency (2010), has led to significant improvements in coordination and
data collection. This legislation also allows for the EMA to charge fees to pharmaceutical
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companies which market their products in the European Economic Area (EEA); the proceeds
from which are used to strengthen PV systems.
4.7 Towards interoperability
After considering differences and similarities in the way in which high income-, middle income-,
and low income-countries conduct PV it is clear that finding a solution to the global harmoni-
sation of PV is not as straightforward as employing standardised technologies. The discussion
must take into consideration a number of other factors, including the different goals and per-
spectives of the multiple different stakeholders conducting PV, as well as understanding and
categorising challenges and obstacles to harmonisation in terms of organisational, behavioural,
operational, technical, and economic factors. These goals and perspectives are discussed in
more detail in Chapter 7.
After considering the challenges in PV as described in Chapter 3 and understanding how PV
systems function in terms of generating data, capturing data, and presenting data (discussed
here in Chapter 4 and seen in Figure 4.13) it becomes clear that the majority of the challenges
faced in PV are found in the activities leading up to the creation of the ICSR document.
For these reasons it is clear that there is considerable value in the potential creation of a
Capability Maturity Model-like tool (CMM) with a behavioural science focal point, to assist
with conceptualizing intervention and interaction strategies so as to achieve interoperability
across multiple systems. This CMM-like tool could be used by governments or any entity
wishing to conduct PV activities to measure and assess their PV capabilities so as to guide
them towards reaching ICH E2B(R3) compliance. Thus, contributing maximally to PV on a
global scale, while also receiving maximum value from the services offered by the UMC.
4.7.1 Targeting the ICSR: A common goal
As shown in Section 4.3 the electronic submission of ICSRs is outlined by the newly developed
ICH E2B(R3) message standard. The standard was developed for the expedited exchange of
Data Generation Data Capture Data Presentation




safety information between systems subjected to various national and international rules and
regulations. The exchange of patient safety information has been extensively covered in this
chapter. As the ever increasing demand for world-wide data exchange continues, there has
been a shift from paper-based systems to the electronic transmission of ICSRs using the ICH
E2B(R3) standard.
Adding to the complexities already faced in the PV landscape, patient safety messages must
be transmitted throughout the product life-cycle. It is clear that harmonisation is of vital
importance when it comes to avoiding difficulties in reconciling ICSRs on a global level, which
the World Health Organisation seeks to achieve. The ICSR described in Section 4.3 is the
culmination of efforts to standardise reporting in PV. The recently developed ICSR standard,
the ICH E2B(R3) is a testament that standardised solutions do exist in practice but the
challenge standing in the way of worldwide system interoperability lies not in developing these
standards, but rather in the adoption and implementation of these standards.
4.7.2 Differing goals and perspectives in PV and strategic alignment
The different goals of the three primary role players (the UMC, MAHs and RAs) who conduct
PV activities and stand to gain value from this research were outlined in Section 1.2. Due to
these differing goals and perspectives, it is important to create a tool which can be of value
to each of these role players, as we know that the cooperation and interaction between these
role players is critical to the overall success of the global PV system.
4.7.3 A maturity model approach to guide organisations to interoperability
and ICH E2B(R3) compliance
Given the barriers to the adoption and implementation of the ICH E2B(R3) standard, as
well as the different goals and perspectives of the major PV role players, a solution must
be developed which caters to the different needs and priorities of the end-users. Maturity
models are valuable in helping organisations understand their current position and capabilities,
as well as offering guidance through strategically linked continuous improvement processes. In
short, maturity models are tools birthed from the field of total quality management and help
organisations transition from an ‘As-is’ state to a ‘To-be’ state. A maturity model will result
in the identification of the relevant domains and sub-domains for PV system interoperability
as well as enable each of the various PV role players to measure the maturity of the various
components of their PV systems, offering guidance on which actions to take in order to reach
a greater level of maturity. Further discussion relating to maturity models and interoperability
can be found in Chapter 5.
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4.8 Chapter 3: Conclusion
This chapter described the key role players in the global PV system, as well as the communica-
tion channels between the key role players and the flow of information through the PV system.
The different methods for reporting ADRs were discussed and the current best practices were
described. A comparison between methods currently in use by three selected countries was
made and their respective differences and discrepancies were discussed. A new approach to
addressing the challenges of under-reporting was introduced. The concept of maturity models
was introduced as a means of addressing the challenges facing ADR reporting within the PV
context and the value of taking a sociotechnical systems perspective during the development




Maturity models and interoperability
In this chapter the concept of a maturity model (MM) is explored and defined within the
context of this study. The history of MMs as well as their various types and purposes is
explored. The concept of interoperability is also discussed, with a particular focus on the
interoperability of health information technologies (HITs) in the eHealth field. The chapter
concludes with a discussion on the need to take a sociotechnical approach to introducing MMs
within an eHealth context.
5.1 Background
In recent years, through the combination of an ever increasingly competitive environment,
innovation, and the rate of change in technology, there has been an increase in the introduction
of new systems, business processes, markets, and enterprise integration approaches. As this
trend increases, many enterprises and organisations are faced with the complex task of keeping
up to date. Information and operational technologies are exhibiting ever shortening life-cycles
and disruptive innovation is continually putting pressure on enterprises and organisations to
adapt to change or suffer the consequences.
Along with these changes, it is important for an organisation to be able to manage the interac-
tion of their systems and processes, as well as to be able to monitor progress and measure how
well they are adapting to these changes. Equally important for an enterprise or organisation
is to have an understanding of the effects of poor interaction between systems and processes
which could ultimately impact interoperability, safety, reliability, efficiency, and effectiveness.
Maturity models have been proposed as a solution to many of these problems. A maturity
model is a tool which can assist organisations in tackling problems and challenges in a logical,
structured manner. Maturity models in their most basic form, provide an organisation with a
benchmark against which their capabilities can be measured, as well as providing a roadmap
to guide improvement initiatives when moving forward.
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5.1.1 Early maturity models
Maturity models as we know them today owe their origin to the fast growing body of knowledge
which was first applied by Nolan (1973) of Harvard University in 1973. The model he published
was a staged maturity model for growth in IT organisations. The development of the Capability
Maturity Model® (CMM) followed, in the 1980’s, by the Software Engineering Institute (SEI)
at Carnegie Mellon University in Pittsburgh, Pennsylvania. The CMM was requested by the US
Department of Defence and included organisational best practices for software development
(Pöppelbuß & Röglinger, 2011).
The five maturity levels that are associated with the business areas and processes of the CMM
were introduced in 1991 as a continuation of the work done in the 1980’s. It was after the
introduction of these five maturity levels that the principles and concepts of process maturity
began to be applied more generically, to non-software processes (Caralli et al., 2012). In 2002
the SEI published an update to the CMM framework, the CMMI® (Capability Maturity Model
Integration), to integrate and standardise the separate models of the CMM. In 2018, the CMMI
Institute released the CMMI® Developement V2.0 which was “designed to meet the challenges
of the changing global business landscape, and drive business performance through building
and benchmarking key capabilities” (CMMI Institute, 2018).
5.2 Maturity models
A maturity model is typically made up of a set of characteristics, indicators, attributes, or pat-
terns1 that represent progression and achievement in a particular domain or discipline (Caralli
et al., 2012). Maturity models allow organisations to evaluate their practices and processes
against an established benchmark. In doing so, organisations are able to measure their ‘as-
is’ capability and then make use of the model to drive improvement and control progress
(Röglinger et al., 2012).
Maturity models typically comprise various maturity levels, usually three to six. A maturity
level is a set of distinguishable attributes which relate to their respective level and domain.
A domain could be a business process, system component, or an organisation; the maturity
level of the domain is identified where the attributes described most accurately represent the
current state of the domain.
Caralli et al. (2012) state that for a MM to be considered effective and impactful, the ‘measur-
able transitions’ between levels should be based on empirical data that has been validated in
practice. Each level in the model must be validated as being more ‘mature’ than the previous




level, against best practices. In other words, that which constitutes ‘maturity’ must be well
characterised and validated.
Caralli et al. (2012) also state that an effective MM must provide the following uses:
 a place to start;
 the benefit of a community’s experience and knowledge;
 a common language and a shared vision;
 a way to define what improvement and ‘maturity’ means for an organisation;
 a framework for prioritising actions; and
 a roadmap for return on investment (ROI) for increased maturity.
Some authors have criticised MMs for oversimplifying reality and have stated that MMs too
often lack empirical foundation (De Bruin et al., 2005). Furthermore, Pöppelbuß & Röglinger
(2011) pose that MMs have the tendency to neglect the potential existence of multiple equally
advantageous paths to maturity. King & Kraemer (1984) warned those developing MMs to
not focus solely on a sequence of levels toward a predefined ‘end state’, but rather to focus on
the factors which drive evolution and change in the organisation in question. These criticisms
have resulted in efforts being made to categorise MMs according to their application, this is
discussed in more detail throughout the remainder of this chapter.
5.3 Maturity
The concept of maturity is mostly associated with the study of human psychology. A person’s
maturity can be defined as the ability to respond to the environment in an appropriate manner.
Maturity models draw a connection between the concept of maturity from a human psychology
perspective and organisational maturity via what is commonly referred to as ‘organisational
learning’ (Van Dyk, 2013).
5.3.1 Organisational learning
Organisational learning is the act of growing in terms of maturity. The nature of maturity
models implies that maturity is to some extent measureable across different states or levels.
Maturity is not only about the current state, it also implies the transitioning from some initial
state to a more advanced state. One of the primary aims of a maturity model is to assess the
current state and to facilitate the transition across multiple states towards some predefined
perfected end-state (Fraser et al., 2002).
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5.3.1.1 Organisational entity under consideration
Van Dyk (2013) identified three organisational entities which are typically measured through
the use of a maturity model. The three entities within an organisational context are:
 Process maturity which refers to the extent to which a process is defined, managed,
measured, controlled, and effective. The focus is on activities and work practices, with
efficiency almost always being the underlying goal of process maturity;
 Object or technology maturity which refers to the extent to which a particular object
or technology reaches a predefined level of sophistication; and
 People or culture maturity which relates to the extent to which the workforce can
create knowledge and enhance proficiency.
5.3.2 Capability and maturity
The terms ‘capability’ and ‘maturity’ are often used interchangeably in literature. This can
cause a great deal of confusion when discussing different types of maturity models. Capability is
associated with specific business processes or a practice area within an organisation. Whereas,
Van Looy et al. (2011) describe maturity as “the degree to which an organisation has explicitly
and consistently deployed processes, according to the business objectives”.
5.3.2.1 Capability levels and maturity levels
Capability levels are applied on a per process basis; whereas organisational maturity levels can
be defined as a set of profiles for these processes (Paulk & Konrad, 1994). According to the
CMMI Institute (2018) the maturity level or capability level of an organisation provides a way
to characterise its capability and performance. Organisations should focus their improvement
efforts on a prioritised and manageable number of practice areas at a time. Continuous im-
provement is something which all organisations should seek to embed in their culture. Maturity
models assist organisations with linking their business objectives to the improvement goals they
seek to achieve. By placing the focus of the organisation on achieving its business objectives
with the help of a MM, performance results typically occur naturally and endure for longer.
A comparison between capability levels and maturity levels by the CMMI Institute (2018) is




Table 5.1: Capability levels vs. Maturity levels as described by the CMMI Institute (2018).
Capability levels Maturity levels
0 Incomplete
Incomplete approach to meeting the intent of
the Practice Area.




Ad hoc and unknown
Work may or may not get completed.
1 Initial
Initial approach to meeting the intent of the
Practice Area.
Not a complete set of practices to meeting the
full intent of the Practice Area.
Addresses performance issues.
1 Initial
Ad hoc and unknown
Work gets completed but is often delayed and
over budget.
2 Managed
Subsumes level 1 practices.
Simple, but complete set of practices that ad-
dress the full intent of the Practice Area.
Does not require the use of organisational as-
sets.
Identifies and monitors progress towards
project performance and objectives.
2 Managed
Unpredictable and reactive.
Projects are planned, performed, measured,
and controlled.
3 Defined
Builds on level 2 practices.
Uses organisational standards and tailoring to
address project and work characteristics.
Projects use and contribute to organisational
assets.
Focus on achieving both project and organ-
isational peformance objectives.
3 Defined
Proactive, rather than reactive.
Organisation-wide standards provide guidance
across projects, programs, and portfolios.
4 Quantitatively managed
Builds on level 3 practices.
Uses statistical and other quantitative tech-
niques to understand performance variation
and detect, refine, or predict the area of fo-
cus to achieve quality and process performance
objectives.
Identifies and understands variation, and
predicts and improves the ability to achieve
quality and process performance objectives.
4 Quantitatively managed
Measured and controlled.
Organisation is data-driven with quantitative
performance improvement objectives that are
predictable and align to meet the needs of in-
ternal and external stakeholders.
5 Optimizing
Builds on level 4 practices.
Uses statistical and other quantitative tech-
niques to optimise performance and improve-




Organisation is focused on continuous improve-
ment and is built to pivot and respond to oppor-
tunity and change. The organisation’s stability
provides a platform for agility and innovation.
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5.4 Types of maturity models
According to Caralli et al. (2012) maturity models can be categorised as one of the following
three types: progression models, capability models, or hybrid models.
Progression models represent simple, often linear progression of a practice, characteristic or
attribute. The movement up the maturity levels correlates to the progression of the attribute’s
maturity. The levels describe higher states of achievement or evolution; they are typically
agreed upon by the users, or industry experts. An example of a maturity progression model












Here, the lower levels could be considered primitive, while the higher levels could be char-
acterised as tool-enabled. Regardless of these characterisations it is important to note that
progress does not necessarily equate to maturity.
The CMMI® as an example of a capability maturity model can be seen in table 5.1. Capability
maturity models are more complex by nature than progression models, in that they are used
to measure organisational capability around a set of characteristics, attributes, or processes.
CMMs go beyond simply measuring the ability to perform a task, they also measure the extent
to which capabilities are embedded into the organisational culture. This is the reason that
CMMs describe the different states of organisational maturity relative to process maturity, as
seen in table 5.1. The higher the degree of institutionalisation, the more stable those processes
are, which equates to processes that are repeatable, consistent, and resilient during times of
stress (Caralli et al., 2012). The CMM framework developed by the SEI at Carnegie Mellon
University has been used successfully in many cases and has also been built upon to provide
more specialised frameworks such as the CMMI and the CERT-RMM (Computer Emergency
Response Team - Resilience Management Model).
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Hybrid models can be simply described as being a combination of progression models and
capability maturity models, by combining the features of both types, hybrid models allow for
the measurement of evolution as seen with progression models but with the added ability to
measure capability, albeit not with the same level of rigor that the CMM allows for. Hybrid
maturity models will have domains much like those of the other model types. However, the
maturity levels of hybrid models will typically consist of defined sets of characteristics and
outcomes, as well as capability considerations. The content of the model will be attributes,
characteristics and processes which represent progression, and capability, as opposed to just
one or the other.
The benefits of using hybrid models include ease of use, easy measurement of core competencies
and an approximation of capability.The primary drawback of using a hybrid model is that the
same level of rigor when measuring capability can not be achieved as when the CMM is used.
5.4.1 Descriptive, prescriptive, and comparative models
Pöppelbuß & Röglinger (2011), Becker et al. (2009) and De Bruin et al. (2005) differentiate
MMs by categorising them according to their application. The following three categories are
described: descriptive models, prescriptive models, and comparative models.
Descriptive models provide an organisation with a diagnostic tool, with which it can perform
internal, external, and longitudinal benchmarking. Prescriptive models typically draw from
historical data to enable an organisation to develop a road-map for improvement measures
(De Bruin et al., 2005). Pöppelbuß & Röglinger (2011) describes the third type of model as
being comparative. Comparative models allow for benchmarking to be performed by organ-
isations with similar practices and process across different industries and regions. De Bruin
et al. (2005) likens each of these three models to different phases of an evolutionary life cycle.
Descriptive models have value when seeking to attain a deep understanding of the ‘as-is’ state,
which after multiple instantiations, evolves to become a prescriptive model. Finally the model
can be considered comparative when it has matured to the point that it can be applied in a
wide range of organisations and across multiple industries.
5.5 Essential components of a maturity model
Although various MMs can differ significantly in type or purpose, most MMs conform to a
set of basic structural components. It is important to understand this structure as it provides
the user with important linkages between the objectives, assessments, and best practices; as
well as between the current capabilities and the improvement roadmap, linking business goals,
standards, and so forth. In this section, the relevant terminology as it relates to this study
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will be defined. Unfortunately there is a significant amount of confusion and incorrect use of
terminology in the literature (Van Dyk, 2013).
Levels
Levels represent the transitional states in the maturity model. Depending on the purpose of
the model and the domain in question, a level could represent an expression of capability or
some other attribute which can be measured by the model. These levels have been discussed
in more detail in Section 5.3.2.1.
Domains and attributes
A domain is a group of attributes which are collectively considered as an area of importance
for the subject matter and intent of the model (Caralli et al., 2012). Van Dyk (2013) provides
a suitable definition of a domain which can be used for the purpose of this study: “A domain is
a sphere of activity, concern, or function and represents an angle from which to view the use,
consequences and implications of the entity under consideration”. According to the CMMI
Institute (2018) the CMMI® Development V2.0 refers to domains as ‘practice areas’, where
they formerly referred to domains as ‘process areas’. The reason for this change was to
emphasise that CMMI® Development V2.0 is a collection of best practices, rather than just a
set of processes to be implemented.
Attributes represent the core content of the model grouped together by domain and level
(Caralli et al., 2012). Attributes are typically based on processes, observed- and best practices,
and standards.
Diagnostic methods
A useful maturity model must include some mechanism for assessment, measurement, gap
identification, or benchmarking.
Improvement roadmaps
As previously stated, most maturity models tend to serve two purposes, a descriptive role for
the purpose of benchmarking, followed by a prescriptive role for the purpose of outlining an
improvement initiative moving forwards. This cycle can be likened to the classic plan-do-check-
act cycle.
5.6 Interoperability
The Healthcare Information and Management Systems Society (2017) defines interoperability
within a healthcare context as “the ability of different information technology systems and




exchanged”. HIT interoperability can be further broken down into four levels: foundational,
structural, semantic, and process.
Foundational interoperability involves data exchange between two information technology sys-
tems where the system receiving the data does not necessarily possess the ability to interpret
the data. Structural interoperability involves the use of data exchange standards, or standard
message formats (the ICSR discussed in Chapter 4 is an example of this). The use of these
data exchange standards ensures that when there is uniform movement of health data from
one system to another, the clinical or operational purpose and meaning of the data is preserved
and unaltered. Semantic interoperability is the highest level of interoperability, this is achieved
when two or more IT systems can exchange information and make sense of that information
(Healthcare Information and Management Systems Society, 2017). Process interoperability
refers to the coordination of business processes at an organisational level. Process interoper-
ability is achieved when human beings share a common understanding of the business processes
(Soceanu et al., 2013).
According to Gottschalk (2009), interoperability results as a product of standardisation in four
dimensions: technology, syntax, semantics, and pragmatics. Technology standards concern
the technologies involved which make up the system, together with networking protocols and
security protocols. Syntax standardisation refers to the agreement on the structure and lan-
guage of the messages exchanged between the various heterogenous applications across the
network. With reference to the preceding discussion of levels of HIT interoperability, syntax
standardisation enables structural interoperability. Semantic standardisation enables semantic
interoperability of HITs. Finally, pragmatic standardisation refers to agreements on protocols
and practices which are prompted by specific messages.
Hammond et al. (2010) provide four axioms of interoperability for health information systems:
1. Data should be entered only once and should be available for multiple purposes, that is,
they should be ‘reusable.’
2. Interoperability requires the cooperation of a group of stakeholders to ensure the applica-
tion of consistent rules across technical domains. It must also be done with sensitivity to
legal, ethical, and societal requirements, including security, privacy, and confidentiality.
3. A single global set of data elements with attributes must become the building blocks of
all such systems. Precise and unambiguous definitions of items are mandatory.
4. There will be diverse health information systems, not just one or even several – it is
critical to achieve interoperability among all of them.
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The potential impact of interoperability should not only be considered in terms of the current
state of the healthcare delivery system. The potential future benefits of interoperability could
be truly significant, especially when one considers the impact that interoperability could have
on easing the load on health information exchanges imposed by the development of future
healthcare technologies such as EHRs (Brailer, 2005). There are typically two schools of
thought when considering interoperability and its association with the attempted introduction
of a new interoperable system. The first suggests that interoperability should precede the
development of the system itself, that is to say that the ability to share information should
be designed into the system from the onset of development. The second school of thought is
that interoperability follows naturally after widespread adoption of stand-alone systems, as a
result of the natural evolution of standards.
5.6.1 Interoperability and EHRs
The most widely covered topic in literature when it comes to eHealth and interoperability is the
EHR (Erturkmen et al., 2011). The primary limitation of EHR mining for pharmacovigilance
data is that the data in EHRs is not collected for the purpose of PV activities such as signal
detection. Erturkmen et al. (2011) suggest the use of EHRs to improve post-marketing safety
activities on a proactive basis. The ability to mine EHRs for data will constitute a partial
solution to the largest problem facing spontaneous reporting systems, underreporting. Func-
tional and semantic interoperability would enable secondary use of EHR data in an efficient
and effective way to reinforce post-marketing safety studies. Interoperability means that phar-
maceutical companies and regulatory authorities can cooperate during post-marketing safety
studies even though the data exists in heterogeneous, distributed EHR systems.
Successful integration of EHR data will directly improve post-marketing safety activities by
allowing automated ADE detection tools to screen hospital EHRs, thereby eliminating the
need for manual screening of patient medical records and thus easing the burden on HCPs.
Extraction of relevant data directly into an ICSR reduces errors associated with the double
entry of data, as well as reducing lead times when transmitting ADE data to regulatory au-
thorities. Along with these benefits, the use of interoperable EHRs would significantly improve
on current ADE detection capabilities by allowing the monitoring of multiple, distributed,
heterogeneous EHR systems (Erturkmen et al., 2011). EHRs also facilitate the monitoring
of patients over extended periods of time and thus contribute to improved monitoring of a





Brailer (2005) provides reasons as to why achieving interoperability within an eHealth context
could be challenging. The study likens the introduction of EHRs to that of the fax machine, the
last to install an interoperable EHR benefits significantly from the prior investment of everyone
else, while the first to install incurs most of the costs. The overall aim of interoperability
is to provide benefits across a wide range of stakeholders. Unfortunately, along the path to
interoperability, some stakeholders are bound to lose due to the disruption of long-standing
industry practices. Furthermore, early adopters experience what is known as the first-mover
disadvantage1.
To date, the largest project involving EHRs in post-marketing safety studies has been the
SALUS project also known as the “Scalable, Standard based Interoperability Framework for
Sustainable Proactive Post Market Safety Studies” (Erturkmen et al., 2011). The project
budget was ¿5.077 million and its main objective was to provide a comprehensive solution to
enable the secondary use of the already available EHR data in the patient care domain, for
clinical research purposes. SALUS particularly aimed to strengthen the spontaneous reporting
process by automating ADE detection across disparate EHR systems. Hammond et al.’s (2010)
third axiom of interoperability was a focal point of the SALUS project’s efforts, with harmonised
ontologies acting as a common denominator for the exchange of clinical data (Erturkmen et al.,
2011). It is important to note that the operationalisation of the solution offered by the SALUS
project in any given context will be dependent on the large-scale roll-out of EHRs in the
context.
Erturkmen et al. (2011) discusses the five main challenges faced when seeking semantic in-
teroperability among heterogeneous knowledge sources in the healthcare domain. These five
challenges are: (i) context-awareness: the ability to identify context-specific components from
various knowledge sources relevant to the clinical problem at hand; (ii) modularity : the ability
to reuse relevant components from various knowledge sources; (iii) profile and policy manage-
ment: the ability to treat internal policies or profiles distinctively; (iv) correspondence expres-
siveness: the ability to relate heterogeneous knowledge, within or between changing contexts;
and (v) dealing with inconsistencies: patching or tolerating discrepancies, incompatibilities,
and inconsistencies, within or between contexts.
1“The mechanisms that benefit the first-mover may be counterbalanced by various disadvantages. These
first-mover disadvantages are, in effect, advantages enjoyed by late-mover firms. Late-movers may benefit from:
(1) the ability to ’free-ride’ on first-mover investments, (2) resolution of technological and market uncertainty,
(3) technological discontinuities that provide ’gate-ways’ for new entry, and (4) various types of ’incumbent
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5.6.2 Interoperability and maturity models
A maturity model which aims to promote and improve interoperability should seek to address
the degree of integration of systems involved, provide guidance on which system components
need to be improved, as well as provide a means for measuring interoperability progress in a
community. Interoperability can be complex when dealing with multiple large systems, it can
also be difficult to define because while interoperability can be measured to some extent, it is
not a entity in and of itself. Interoperability can be measured by assessing how diverse entities
interact and work together across technical, social, political, and organisational boundaries.
Gottschalk (2009) proposed a maturity model for e-Government interoperability. Gottschalk
(2009) considered the nine constraints laid out by Scholl & Klischewski (2007) that influence
government integration and interoperability. In this research it is useful to consider seven of
these constraints, with the constitutional and jurisdictional constraints being excluded from
further discussion. The seven constraints considered are as follows (Gottschalk, 2009):
1. Collaborative constraints: Organisations differ in terms of readiness and capability
for collaboration and interoperability. Organisational leadership style will influence the
organisation’s degree of willingness for and acceptance of potential interoperability.
2. Organisational constraints: Without the standardisation of processes, systems, and
policies, achieving interoperability could prove to be exceedingly difficult.
3. Informational constraints: Organisations may be unwilling to share certain types of
information. Difference in opinion as to what constitutes transactional, strategic, or
organisational information could result in resistance to the sharing of information. Quality
issues could also arise as a result of heterogeneous systems built upon differing data and
quality standards.
4. Managerial constraints: Interoperability becomes more difficult to achieve as the num-
ber of organisations involved increases. Organisations may also have in-congruent inter-
ests, needs, and perspectives.
5. Cost constraints: Although information sharing initiatives and interoperability are typi-
cally associated with a reduction in cost, interoperability between multiple organisations
could be limited to the lowest common denominator in terms of availability of funds.
6. Technological constraints: Similar to the cost constraint, interoperability between
multiple organisations could be limited to the lowest common denominator in terms of
technological capability. Although, with the increase in heterogeneous health informa-
tion systems across the world, interoperability could arise as a product of the increased































Figure 5.1: Maturity levels for interoperability in e-Government. Adapted from Gottschalk
(2009).
7. Performance constraints: The overall system performance in terms of responsiveness
decreases with the higher number of interoperating system participants.
Together with these constraints Gottschalk (2009) provides a set of maturity levels for the
interoperability of e-Government. The levels, shown in Figure 5.1, are defined in such a way
that they focus on semantic interoperability and organisational interoperability. Organisational
interoperability is defined as the extent to which organisations using different work practices
are able to communicate (Gottschalk, 2009).
Level 1 - Computer interoperability
At this level interoperability is achieved when the appropriate hardware and software systems
allow for semantic information sharing. Semantic interoperability refers to the ability to directly
exchange messages, as well as meaningful, context-specific data between two or more IT
systems.
Level 2 - Process interoperability
At this level work processes are aligned between organisations so as to achieve interoperability.
It is important to consider that work processes are adopted by the organisation as well as the
person carrying out the work process.
Level 3 - Knowledge interoperability
Electronic work processes deal with information but knowledge work is handled by employees
in collaborating organisations. Gottschalk (2009) proposes that knowledge sharing is critical to
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the maintenance of good relationships between organisations and plays a vital role in resolving
issues relating to incompatibilities across a network of information systems.
Level 4 - Value interoperability
A value network is an organisational value creation configuration similar to the more frequently
studied value chain. A value network generates value through the efficient connection of
subscribers to the network. Interoperability at this levels is concerned with interactions between
primary activities in different value configurations that exist in the healthcare industry.
Level 5 - Goal interoperability
Gottschalk (2009) states that the role of IT functions is to support and influence organisational
strategy. At this level of interoperability, organisations have no competing goals, which is often
the case in the lower levels of the model.
The model proposed by Gottschalk (2009) includes a cautionary statement that the optimal
level of interoperability is not necessarily the highest level in their maturity model. From a
cost perspective it is important to consider the cost of transacting between systems and the
volume of transactions. If the volume of transactions is low or the cost of transacting high,
it may be wasteful to seek comprehensive strategic alignment (goal interoperability) between
interoperating organisations. An example of an interoperability maturity model in the HIT field
is the one that was proposed by van Velsen et al. (2016) and deals with interoperability in an
eHealth context. van Velsen et al.’s (2016) proposed maturity model for the interoperability
of eHealth systems, can be seen in Figure 5.2. It is intended to guide the development of an
interoperable eHealth infrastructure.
Although maturity models exist for enterprise interoperability and e-Government interoper-
ability, the case of eHealth poses a unique set of challenges which differentiates it from the
former cases. In an eHealth context there are different actors such as patients and healthcare
professionals who interact and form part of different organisations such as medical institutions,
commercial companies, or government bodies, each of these organisations having distinct pro-
tocols, information needs and information systems. Stroetmann (2014) defines interoperability
in eHealth as “facilitating and safeguarding the exchange, understanding, and acting on pa-
tient and other health information and knowledge among linguistically and culturally dispersed
medical professionals, patients, and other actors within and across healthcare systems in a
collaborative manner”.
The levels of interoperability in van Velsen et al.’s (2016) maturity model are discussed below
and take into consideration interoperability from a technical point of view, its implications for
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Level 0 - System as a silo
Technical. An eHealth application consisting of a single technology, not connected to any
other application.
Procedural. This application does not change the nature of the task that it is supposed to
serve, and does not necessitate the redesign of any protocols or medical procedures.
Standardisation. No standardisation is required as a single eHealth application does not require
the means to communicate with other technologies.
Level 1 - Peer-to-peer systems
Technical. Two applications directly linked to one another for simple data exchange.
Procedural. The transfer of data occurs in a context where the parties involved have made
simple agreements about a working procedure.
Standardisation. Both systems should take into consideration agreements on how to exchange
data as well as the format of the data. Data handling before and after transmission is left to
the discretion of each of the system’s users/developers.
Level 2 - Distributed systems
Technical. Linking of eHealth applications to achieve a common objective. Server architecture
is used in such a way so as to allow multiple applications to communicate with each other via
a central service. At first, the different applications are provided under control of one supplier
(distributed, organisation-bound). The next step is to cross the organisational boundary and
to link applications of different suppliers for achieving a common objective (distributed, inter-
organisational).
Procedural. At this level of interoperability, the streamlining of protocols and organisational
procedures is a necessity. The interoperable infrastructure should support the varying protocols
and working routines of the actors across the different organisations, as much as possible. For
working procedures that are non-conclusive or contradictory, a new, shared procedure must be
found as a solution and incorporated into the interoperable infrastructure.
Standardisation. At this level it is important to consider how data is exchanged between or-
ganisations with special attention to data safety, security, and privacy standards. Standards
development organisations such as HL7 have produced extensive resources for health informa-





Level 3 - Integrated systems
Technical. At this level of interoperability, applications from different suppliers that serve a
common goal are linked, but the applications do not need to have common objectives. The
infrastructure is developed to offer interoperability to a selected set of eHealth suppliers either
on a national level (integrated, national) or on an international level (integrated, international).
The set of suppliers may shrink and expand over time but it is never intended to be ‘open for
all’.
Procedural. At this level of interoperability it becomes difficult to streamline procedures as the
possibilities that eHealth technologies offer become paramount. No protocols or organisational
policies exist to guide such widespread exchange of data. Instead, this level of interoperability
should encourage the discovery of new use cases and allow applications to play a supportive
role, which may lead to the adaptation of existing protocols. This provides a useful means of
re-assessing how healthcare is organised.
Standardisation. Standardisation at this level does not differ significantly from the previous
level. The same standards and terminologies are used to facilitate the smooth exchange of
data among the applications in the eHealth infrastructure.
Level 4 - Universal interoperability
Technical. At this level of interoperability the infrastructure allows for applications to connect
and disconnect freely, making use of data exchanges without having to serve a common goal,
and also while spanning multiple countries.
Procedural. Similarly to the case in Level 3, this kind of interoperability allows for supporting
existing work procedures and protocols as well as for many new use cases. The availability of
data at this level of interoperability provides ample opportunity for data mining and possibly
the introduction of new insights and use cases.
Standardisation. Standardisation at this level does not differ significantly from the previous
level. The same standards and terminologies are used to facilitate the smooth exchange of
data among the applications in the eHealth infrastructure.
van Velsen et al.’s (2016) maturity model shows how an eHealth application can evolve from
a stand-alone entity to a part of a universal network for eHealth. The model can be used for
benchmarking a set of applications or infrastructures with regard to their level of interoper-
ability, or as a roadmap for developing interoperable eHealth infrastructure.
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5.7 The need for a sociotechnical approach
Both Gottschalk (2009) and van Velsen et al. (2016) concluded that in order to achieve inter-
organisational interoperability one must consider the appropriate sociotechnical characteristics
of the organisations involved. For interoperability to be achieved between various heteroge-
neous information systems, it is clear that some organisations will have to adapt their technical
and organisational processes to accommodate the standardisation initiatives. Challenges re-
lating to interoperability from a technical perspective are more easily understood, however,
it is perhaps of greater importance to understand the challenges brought about from an or-
ganisational perspective. Interoperability can result in the creation of new work processes,
the mobilisation of limited resources, and the management of inter-organisational relationships
(Pardo & Tayi, 2007). These changes are products of specific social interactions such as group
decision-making, trust building, and conflict resolution. These dimensions form part of the
greater discussion on sociotechnical systems, which is discussed in detail in Chapter 6. Chap-
ter 6 provides an argument for the adoption of a sociotechnical systems design approaches to
improve the design, implementation, and adoption of HITs which seek to assist in promoting
safer, better healthcare. The need to incorporate the social sciences in the improvement of
health information systems (HIS) has been widely acknowledged in literature, however, it has
not yet been realised through the application of conventional system design methods in the
context of PV (Braithwaite et al., 2009).
5.8 Chapter 4: Conclusion
In this chapter the concept of an MM was explored and defined within the context of this
study. The history of MMs as well as their various types and purposes was discussed. The
concept of interoperability was discussed, with a particular focus on the interoperability of
HITs in the eHealth field. The chapter concludes with a discussion on the need to include a




A sociotechnical system perspective
Taking into consideration the difficulty associated with implementing standardised HITs into
large, complex systems, the notion of a sociotechnical system is investigated in this chapter.
The need for a sociotechnical approach to studying HITs in complex adaptive health systems
is explained and motivated. A comparison is drawn between a generic sociotechnical system
and the PV system across multiple levels of analysis, in an attempt to better understand how
sociotechnical systems design methods can lead to systems which are more acceptable by- and
provide better value to all stakeholders of the system.
The contents of this chapter form part of the conference proceedings titled “Sociotechnical
considerations for HIT design and implementation in complex and adaptive health systems”
which was presented at the 27th annual conference of the International Association for Man-
agement of Technology (IAMOT), held from 22 - 26 April 2018 at Aston Business School in
Birmingham, United Kingdom.
“If we want safer, higher-quality care, we will need to have redesigned systems of
care, including the use of information technology to support clinical and adminis-
trative processes” (Corrigan et al., 2005).
6.1 Introduction
The activities relating to PV form part of what is essentially an extended health system-wide
quality management system (Santoro et al., 2017) that contributes towards patient safety.
Patient safety relies on data systems and data systems rely on data standards. Traditional
approaches to introduce information and communications technology (ICT) into complex sys-
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Figure 6.1: A conceptual diagram of a four-level health system.
6.1.1 Level of analysis
The activities relating to PV can be associated with different levels of a health system. The
functions of a PV system are carried out by different people, in different physical environments,
working under different organisational structures, with different responsibilities, across these
different levels of the healthcare system. The scope of this research revolves around the first
stage of the PV system that is, the reporting of ADRs, and the subsequent propagation of the
generated signal to the VigiBase system of the World Health Organisation. With this in mind,
the four levels in Figure 6.1 will be explained briefly:
1. Operational level: From an engineering perspective, the operational level of a system is
the level at which decisions relating to the day to day activities of an organisation are
made. Spontaneous reporting of suspected ADRs is the cornerstone of pharmacovigilance
in that it generates the largest amount of data. It is at the operational level where the
HCPs and patients have a direct interaction with the HIT system. At this level the nature
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of healthcare work and the individual characteristics of the HCPs, such as knowledge
base, skill level, training and education, attitudes, beliefs, and physical capabilities have
the largest influence on the success or failure of the system.
2. Facility level: The facility level encompasses the operational level. The facility within
which the HCP works will have a number of intrinsic characteristics, such as the physical
environment and layout, the organisational structure, embedded human-system inter-
faces, communication and coordination practices, as well as local work procedures.
3. National level: All facility level activities are governed and coordinated at the national
level. Each country conducting PV activities will do so according to different healthcare
policies, laws and regulations. Decisions made at this level have a trickle down effect
onto the facility and operational levels, affecting the overall safety, quality, and efficiency
of these parts of the larger system. The PV data generated at the preceding levels is
collated and analysed internally by NCAs before transmitting the signals to the VigiBase
system.
4. Global level: At the global level there are a number of external environmental forces
influencing the system, such as technological innovations, economic pressures, political
climate, and public awareness. The global level is unique in the context of a PV sys-
tem in that participatory countries submit their domestic PV data to the World Health
Organisation for the benefit of the entire worlds population.
Based on these descriptions of the levels of the healthcare system, it becomes clear that
the outcome of patient care is produced through the interaction of multiple intricate and
fragmented subsystems. This view of a health system highlights the need to educate HCPs
across all levels and make them aware of their functioning in the greater system (Hartman
et al., 2017).
6.2 Introduction to systems engineering and sociotechnical sys-
tems
A system is a purposeful collection of inter-related components that work together to achieve
a common objective. A system may include software, mechanical, electrical and electronic
hardware (Sommerville, 2004). People, and the respective organisations to which they belong,
are responsible for the systems entire development life cycle, including its operation and own-
ership. The properties of these systems are most often inextricably inter-mingled, which can
lead to high degrees of complexity. The behaviour of complex systems is often very difficult
to predict. This represents the largest challenge that is faced by organisations which seek to
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develop, leverage, and control complex systems to improve their operations and activities. In
the case of PV this relates to the introduction of health information technologies to support
the functioning of SRSs and improve interoperability across the global PV system.
Systems Engineering is an interdisciplinary field of engineering which comprises the body of
knowledge concerned with the design and management of complex systems throughout a
system’s life cycle. In the early years of systems engineering the general consensus was to
take a technocentric1 approach to systems development, this approach has been challenged
by the introduction of a relatively new body of knowledge known as Sociotechnical Systems
Engineering (STSE). A sociotechnical system (STS) is one which includes technical systems
but also operational processes and people who use and interact with the technical system.
STSE places more importance on a user-centred approach; one which focusses more so on job
satisfaction and the needs of the end user. The use and value of sociotechnical systems design
methods is discussed in more detail in Section 6.2.2. As with systems engineering and its focus
on the end user, the activities related to PV are patient centred. It can be argued that every
actor involved in the PV system is an end user in that every actor extracts value from, and
interacts with, the system in a different way. A sociotechnical approach to studying systems
places special attention on the interactions and interdependencies of the system components,
not only on the components themselves.
6.2.1 The sociotechnical nature of healthcare work
Health information technologies (HITs) such as EHRs, computer physician order entry, and
clinical decision support systems are those which leverage computer systems to improve safety
and quality of care, while assisting in cost reduction and improved efficiencies. Difficulties faced
by those using these HITs have been widely described as being ‘organisational issues’ (Berg,
1999). When designing information technology solutions for health systems it is important to
acknowledge that health care work has an inherent ‘ad hoc’ and ‘Byzantine’2 nature; and that
many attempts to use IT initiatives in a health care context have failed due to incompatibility
between organisational issues and the structured, standardised and rational nature of IT systems
(Berg, 1999).
A common challenge in implementing HITs is to move from the drawing board to successful
implementation. HITs are too often bound to the specific context within which they have been
developed (Berg, 1999). When designing a new HIT system, it is clear that a sociotechnical
1Technocentrism is a value system rooted in classical science, technology, conventional economic thinking,
and in the human control over nature.
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design approach can hold significant value, the nature of healthcare work is inherently messy
and is the goal of protecting the health of a patient is often realised through a collaborative
effort between many HCPs across multiple healthcare disciplines. With the introduction of
a new technical system, one must be sensitive to the fact that the system will become so
intertwined with the work environment in which it exists, and that each change in IT will have
widespread consequences for that work practice (Berg et al., 1998).
Sociotechnical approaches focus on the nature of health care work and working with information
technologies as a social process. Patients have varying needs and present various problems to
the healthcare professionals seeking to care for them. Standard organisational solutions never
wholly fit a patients individual problem.
Studies in cognition show that what we traditionally conceive as individual thinking processes
are in fact heavily influenced by the social and physical contexts within which these think-
ing processes take place (Hutchins, 1995). With new technologies enabling new forms of
communication between health care workers, the relations between those communicating are
invariably affected. When communication between health care workers becomes more efficient,
the delivery and quality of patient care is improved.
6.2.2 Sociotechnical systems design
STSE is an approach to systems design which considers human, social, and organisational
factors with equal importance to that of technical factors (Baxter & Sommerville, 2011).
Adopting a sociotechnical approach to systems development results in systems which are more
acceptable to end users and deliver better value in the organisations within which they exist. A
sociotechnical approach to organisational change, such as in the case of implementing new ICTs
in healthcare systems, focusses on two key activities, those being sensitisation and awareness,
and active engagement of all relevant stakeholders (Berg et al., 1998).
The aim of taking a sociotechnical approach to system design and the implementation of new
technologies in a healthcare environment should seek to improve the traditional way of carrying
out the primary care process. The largest challenge and simultaneous largest opportunity with
regard to this is to find a synergy between the formal tools of information technology and the
sociotechnical nature of healthcare work.
Technological innovation can be seen as a social process in which organisations are deeply
affected (Baxter & Sommerville, 2011). Insights from the social sciences are becoming in-
creasingly recognised within the field of health informatics and information systems in general.
Information systems require human interaction and input, resulting in both elements of the
system affecting each other. To understand these affects, the interrelation between technology
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and the social context of its use must be studied accordingly. Taking a sociotechnical approach
to systems design aims to accomplish exactly that. Sociotechnical approaches seek to under-
stand the way in which information technologies are developed and implemented, as well as
how these systems become a part of social practices. In the simplest way, sociotechnical ap-
proaches seek to strike a balance between the social, environmental, and technical elements of
a system so as to develop users skills and to improve job satisfaction and working relationships
(Berg et al., 2003).
Technological development cannot be seen as a merely technical linear process. Upon uncov-
ering how the introduction of new technologies impact the work setting in which they have
been implemented, one can investigate the feasibility of the social roles that are inscribed in
the system for the working environment.
The process of developing the technology is of paramount importance. A sociotechnical ap-
proach to the development process favours the central role of the user, however, involving the
user is not often as easy as it might seem. The design approach should embrace the non-
linear nature of technology development and allow for iterative and incremental improvement
to be made in the system. Instead of aiming to design the perfect system before implemen-
tation, the design approach must allow for more flexibility, involving the stitching together of
partially integrated systems which would better satisfy the information needs of a complex
organisation (Monteiro et al., 2003). Sociotechnical systems exhibit emergent properties, in
that some of the properties of the system only emerge after it has gone into use and cannot
be predicted in advance (Baxter & Sommerville, 2011). This is true of all systems but in
particular sociotechnical systems because of the complexity of the interactions between parts
of the system.
From a sociotechnical perspective, design is about finding the synergy between specific charac-
teristics of healthcare work, and the potential benefits of ICT. It is about designing interactions
not from the view of the technology but from the users that work with that technology, and
the practices in which it will become embedded (Berg et al., 2003). The emphasis should be
on guiding and nurturing the natural properties of sociotechnical systems rather than imposing
top-down instructions and hierarchical structures from people who do not actually work at the
operational level (Braithwaite et al., 2009).
As stated previously, the activities relating to PV occur at different organisational levels
throughout the health system. Most systems engineering approaches to improve PV fall short
of their goals, by merely focussing on the lower levels of the of the system. Although it is clearly
important to focus on the point of patient care, one must not forget to consider the multitude
of other influential factors at higher organisational levels. The STS design approach allows
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for more cognisance of failures originating from different levels of the system. Active failures
are characterised as being those resulting from the decision of an individual, in the context
of PV this could be an incorrect dosage delivery, choice of drug, or route of administration.
These types of failures are typically found in, and constrained within, the lower levels such
as the operational level. Latent failures are those which manifest as a culmination of small
inefficiencies and flaws in the higher levels of the system, flaws and inefficiencies which have
a trickle down effect on the lower levels. In terms of PV this could be the effects of national
policies and the way in which these policies are implemented on an operational level. Another
example of a latent failure is the inadequate education and training of HCPs with regard to
PV activities.
Figure 6.2 shows the layers that make up a typical sociotechnical system. When comparing
this figure with the discussion on the levels of analysis in Section 6.1.1, one can see how the













Figure 6.2: Layers of a sociotechnical system stack.
6.3 Pharmacovigilance as a sociotechnical system
Considering the sociotechnical nature of healthcare work as discussed in Section 6.2.1, one can
classify the PV system as a sociotechnical system. Sociotechnical systems include IT systems
and the social and organisational environment in which these systems are used.
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Badham et al. (2000) defines five characteristics of open sociotechnical systems:
1. Systems should have interdependent parts;
2. Systems should adapt to and pursue goals in external environments;
3. Systems have an internal environment comprising separate but interdependent technical
and social subsystems;
4. Systems have equifinality. In other words, system goals can be achieved by more than one
means. This implies that there are design choices to be made during system development;
and
5. System performance relies on the joint optimisation of the technical and social subsys-
tems.
PV can be classified as an open sociotechnical system according to the five characteristics
defined by Badham et al. (2000). Healthcare professionals interact with hardware and software
infrastructure, recording, storing, and sharing data through the use of a human computer
interface. These actions coupled with the multidisciplinary nature of communication and work
flows in healthcare, influence internal organisational policies and culture, while adapting to
ever changing external environments such as rules and regulations (Sittig & Singh, 2010).
The aim of this chapter is to provide an argument for the adoption of a sociotechnical systems
design approaches to improve the design, implementation, and adoption of HITs which seek
to assist in promoting safer, better healthcare. In the case of PV, this would involve the HITs
which are designed to support the processes relating to the spontaneous reporting of ADRs, and
improved interoperability of SRSs. As mentioned in Section 5.7, the need to incorporate the
social sciences in the improvement of health information systems has been widely acknowledged
in literature, however, it has not yet been realised through the application of conventional
system design methods in the context of PV (Braithwaite et al., 2009).
Individual users from different small work groups (GPs, nurses, pharmacists, etc.) in the PV
system, will inevitably interact with these HITs in different ways. Certain features of the HITs
will be appropriated by some but rejected by others, this relates to the common uncertainty
between HCPs regarding where their individual responsibilities begin and end within the system.
To understand how technology changes the work practices of HCPs, an investigation into
what HCPs understand about the technology, and how they use technology in their daily work
practices, should be conducted. An important consideration that is often overlooked is to study
not only the adoption of new technology but also its rejection. This must be carried out with
the use of qualitative research methods during the implementation and evaluation stages of
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the project life-cycle. Ethnographic1 studies, after the implementation of HITs such as those
supporting the spontaneous reporting of ADRs by HCPs, must be carried out to understand
how they perform their work functions in situ2 (Petrakaki et al., 2010).
Research by Cho et al. (2008) shows how the adoption of HIT in a hospital resulted in a
redistribution of professional responsibility as well as a redistribution of labour as people tried
to inscribe their interests into the technology. The research further showed that physicians
were reluctant to adopt the new paperless information system as they believed it would project
extra administrative duties onto themselves, which they had previously informally displaced to
nurses. Nurses on the other hand embraced the technological change process as they felt they
would have increased control over the monitoring of their patients. This is an example of how
different users experience the adoption process differently, which can have varying influence
on the design, development and use of the systems.
Studies on human factors and ergonomics relating to patient safety carried out by Safren &
Chapanis (1960) found that the majority of medication errors were largely due to work system
factors such as failure to follow required protocols and procedures, as well as verbal or written
communication problems. The medication errors were categorised as: (i) wrong patient; (ii)
wrong dosage; (iii) extra unordered medication; (iv) omitted medication administration; (v)
wrong medication; (vi) wrong timing of medication administration; and (vii) incorrect route of
administration.
HCPs work more efficiently when allowed to perform work in an autonomous manner, rather
than being directed, micromanaged and controlled through a hierarchical structure. A bottom-
up strategy is urgently needed to counter the traditionally top-down approaches which only
result in modest improvements that are typically difficult to sustain. Healthcare reformation
must be championed by clinicians themselves, too often politicians and bureaucrats seek to
effect change by decree, when in reality, clinical practice is shaped by the social and behavioural
aspects of HCPs (Berg, 1999). The collective values and behaviours of the individuals which
make up a complex system comprise the culture of the system. Supporting the natural processes
by which these individuals interact and cooperate, rather than constantly trying to reorganise
them, is the key to changing the culture of the system.
Activities relating to PV can be considered a natural hub in the network of healthcare practices;
which, pervasively3 influences the practices and attitudes of HCPs who regard the work as being
1Ethnographic research is a qualitative method where researchers observe and/or interact with a study’s
participants in their real-life environment.
2In situ is a Latin phrase that translates literally to“on site” or “in position”.
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out of their scope of responsibilities. This negative association by a few opinion leaders in the
network can have a disproportional influence on the attitudes of other colleagues with regard
to patient safety.
6.3.1 Failures in sociotechnical systems:
Large complex systems fail not because of technical inadequacy, but rather because they do
not recognise the social and organisational complexity of the environment in which they are
implemented (Whitney & Daniels, 2013). Baxter & Sommerville (2011) describe common
reasons behind the failure of sociotechnical systems including inconsistent terminology, levels
of abstraction, conflicting value systems, lack of agreed success criteria, and multidisciplinary
work environments.
Changing contexts-of-use, means that the judgement on what constitutes a failure changes,
as the effectiveness of the system in supporting work changes. Different stakeholders will
interpret the same behaviour in different ways because of different interpretations of ‘the
problem’. Therefore, the successful operation of a system for one set of stakeholders will
inevitably mean ‘failure’ for another set of stakeholders. This results in a conflict inevitability,
as it can become increasingly difficult to establish a set of requirements where stakeholder
conflicts are all resolved. As is the case with SRSs belonging to the various role-players in the
global PV landscape, these conflicts are represented by the different perspectives and goals
of the various SRSs, as discussed in Section 1.2. Another contributing factor to the conflict
inevitability is that groups of stakeholders in organisations are often in perennial1 conflict (e.g.
managers and clinicians in a hospital).
Decision-making within a system depends on the power held at some time by a stakeholder
group (Markard et al., 2016). Examples of this decision-making power in the PV context
includes the setting of regulations by RAs, as well as the design and development of HITs
to support SRS interoperability by system developers. There exists a plethora of intricate
power relations within a sociotechnical system due to the large number of stakeholders and
the overlapping nature of system boundaries.
6.3.2 Challenges in PV related to failures of sociotechnical systems
Healthcare outcomes are produced through the collaborative interactions between people,
equipment, tools, documents, and organisational routines (Berg, 1999). Managers and HCPs
too often blame the failure of newly implemented technologies on the technical properties
(Miller & Sim, 2017; Poon et al., 2017). While technical flaws can certainly result in many
1lasting or existing for a long or apparently infinite time; enduring or continually recurring.
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problems, it is often the sociotechnical interactions between the new HIT and the existing
social and technical systems that lead to undesirable outcomes of HIT implementation. A
common misconception is that computerisation inherently improves reliability, but what is of-
ten overlooked are the contributions of HCPs clinical judgement, communication within small
work groups, and teamwork to patient safety (Baker et al., 2006).
The most common reasons behind system failure in medical informatics are not attributed to
hardware or software problems; but rather that systems are built upon incorrect assumptions
(Hyysalo et al., 2003), or that they incorporate inaccurate characterisation of medical work, or
failure to see the implementation process as an organisational change process (Van der Meijden
et al., 2003). The organisational change process associated with STSs is further discussed in
Section 6.5.1.
The chances of system failure can be significantly reduced if, throughout the system devel-
opment, evaluation studies are performed. By making use of qualitative research methods to
gain an understanding of user experiences, complaints and change in working relations; or-
ganisational learning can be increased, facilitating the organisational change process (Kaplan,
1997).
The failures associated with STSs have been discussed in Sections 6.2.2 and 6.3.1. Rather
than aiming to design a perfect system, the design process must be flexible enough, to allow for
small errors to be addressed through incremental improvements. By taking the sociotechnical
system perspective and using the higher levels of the sociotechnical stack to identify and trap
failures, adverse consequences become limited. The goal should be to contain failures within
technical systems and not allow the failure to propagate across the sociotechnical system,
resulting in failure.
6.4 The problem with standardisation in sociotechnical systems
When considering the process of standardisation in sociotechnical systems it is crucial to
understand the balance between system adaptability to local work practices on a low level of
abstraction against the interoperability of the system on a higher level of abstraction (Harrison
et al., 2007).
Different countries have, for multiple reasons such as economic or cultural, different approaches
to work organisation. This is why traditional systems development methods have not been
fruitful in providing a global solution to the management of healthcare information. Countries
and, in the context of SRSs, organisations, typically adapt these methods to suit their particular
needs (Baxter & Sommerville, 2011), as described in the problem statement in Section 1.2.
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It would however, be nonsensical to ignore those elements of the system which lend them-
selves to standardisation. The primary care processes which are employed by HCPs are not
necessarily suitable for standardisation because every patient requires a unique combination of
care approaches. The extent to which the standardisation of these elements is value adding, is
an important consideration, and will result in a system which can alleviate the HCP of some
of their duties and ease their cognitive load, thus allowing them to perform the primary care
processes more efficiently.
6.5 Organisational change in sociotechnical systems
The implementation of new technology in an organisation is in essence a process of organisa-
tional change. For this process to be successful a number of criteria must be met, including
a high level of commitment and focus from the users as well as the management of the
organisation.
There is a definite need to transition away from the static pre- and post-implementation impacts
or notions of discrete change which currently dominate studies in healthcare (Hendy et al.,
2005, 2007). Previous attempts to change healthcare practices involving education, persuasion
and mandating through hierarchical structure have largely failed due to strong opposing forces
such as clinical autonomy and an inability to overcome individual and regional variations in
practice. In the case of PV, systems designers should embrace the natural properties of complex
systems and empower, engage, and support HCPs in their efforts to promote better and safer
patient care. By involving HCPs in the development of HITs which support their work function
as well as improve SRS interoperability, organisational learning1 is increased.
6.5.1 STS transition theory and the reconfiguration pathway
Geels & Schot (2007) are thought leaders in the field of sociotechnical transition pathways.
They developed a typology of four sociotechnical transition pathways: (i) transformation; (ii)
reconfiguration; (iii) technological substitution; and (iv) de-alignment and re-alignment. The
four transition pathways clarify the relationship between three structural levels (the multi-level
perspective (MLP)) and the role of agency2. The MLP is made up of the ‘landscape level’,
the ‘regime level’, and the ‘niche level’, which can be seen on the left side of Figure 6.3, along
the y-axis.
1Organisational learning is the process of creating, retaining, and transferring knowledge within an organi-
sation.
2In social science, agency is the capacity of individuals to act independently and to make their own free
choices. By contrast, structure is those factors of influence (such as social class, religion, gender, ethnicity,
ability, customs, etc.) that determine or limit an agent and his or her decisions (Barker, 2003).
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Figure 6.3: Reconfiguration pathway. Geels & Schot (2007).
The reconfiguration pathway seen in Figure 6.3 has been identified as the most appropriate of
the four pathways to aid in the understanding of the sociotechnical transition that is brought
about through the design and implementation of HITs in the context of PV. The landscape
level exerts pressure onto the regime level in an exogenous1 manner, here the regime level is
the PV system within a health system. There are political, regulatory, technological, and social
forces which are external to the inner-workings of the PV system that create pressure at the
regime level. In addition to pressure from the landscape level, the niche level is the micro-
level where new technological innovations emerge. These niche-level innovations, whether
technological or social, accumulate and can destabilise the system, resulting in the origination
of a sociotechnical transition. It is important to understand that these change process are
influenced by complex interactions between various system components, and across all levels
of the sociotechnical system (Geels & Schot, 2007).
Sociotechnical transitions invariably result in a shift in work roles and responsibilities. More
often than not, the shift in work tasks is from those who inherited extra work tasks, from people
who considered themselves to be in a position of power in the organisational hierarchy, back
to the appropriate people. For example, GPs often delegate the administrative duties of their
work practices to the nurses, when in fact, the responsibility to perform those administrative
duties is that of the GPs themselves.
1Having an external cause or origin.
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6.5.2 Capacity building to guide the process of change in sociotechnical sys-
tems
According to the work of Berg (1999), HIT interventions that embed pre-fixed sequences of
steps in a care process, or that only allow for certain modes of data input would perish amidst
the contingencies and pragmatic needs that characterise healthcare work. New competencies
for healthcare workers must be established so that higher levels of complexity in work tasks
can be established. In other words, the doctors of the future will need to be trained to use
emerging technologies whilst understanding the sociotechnical dynamics which undermine their
work. Additionally, new HIT initiatives must be developed according to sociotechnical systems
design methods. Further theory which supports the study of change and transitions in STSs, is
that of Potter & Brough (2004). An adaptation of Potter & Brough’s (2004) capacity building
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Figure 6.4: Capacity building pyramid. Adapted from (Potter & Brough, 2004).
In developing these new competencies the adapted capacity building pyramid in Figure 6.4,
must be considered. Tools and skills are more technical and are easier to change over shorter
periods of time, when compared to staff and infrastructure; and structures, systems, and roles;
this is partly attributed to the fact that these elements of the system lend themselves to the
process of standardisation. Performance capacity is, to a large extent, governed by the tools
which HCPs are afforded to make use of. These tools in the context of PV can be understood
as being the hardware and software elements of the system. Personal capacity is governed by
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the skills that the HCPs are equipped with. The bottom two levels of the capacity pyramid
are more socio-cultural and are more resistant to change, requiring more effort and more time
to change.
When designing, developing, and implementing HITs, to support HCPs work processes and
SRS interoperability; the adapted capacity building pyramid shows how the higher levels of the
pyramid require the appropriate capacity in the lower levels, in order to be most effective.
6.6 Chapter 5: Conclusion
Chapter 6 involved discussion on the notion of sociotechnical systems. The activities relating
to PV were organised into levels according to the four level health system model. The PV
system was described as a sociotechnical system to gain an improved understanding of how
best to design and implement HITs in these complex and adaptive health systems. From the
findings presented in this chapter we show that HIT innovations can never be fully achieved
with technological advances alone. The research dismisses the notion that problems regarding
HIT implementations can be solved simply with more or better HIT. The introduction of HIT
in sociotechnical systems inevitably leads to organisational change. This organisational change
must be strategically guided, thus presenting an opportunity for the development of a maturity








This chapter deals with the development of a model, based on the concept of a CMM, which
can be used by RAs, or similar entities which might own or operate a SRS, to measure,
assess, and improve their PV capabilities in terms of various domains and dimensions so as to
guide them towards reaching ICH E2B(R3) compliance. The ultimate aim being to contribute
towards improving the interoperability of SRSs on a global scale, while also optimally leveraging
the value that can be derived from the services offered by the UMC.
7.1 Introduction
The development of the Pharmacovigilance Reporting Capability Maturity Model (PVR-CMM)
builds on the literature reviews that have been presented in the preceding chapters. Before
presenting the development of the PVR-CMM, the most salient inputs to the development of
the model are briefly summarised.
The first step towards developing the PVR-CMM is to gain an understanding of the global PV
landscape, what is meant by an interoperable spontaneous reporting system, the challenges
and barriers which affect the spontaneous reporting of ADRs, and the effects of the lack of an
interoperable global PV reporting system, as outlined in Chapter 3. From this, the extent to
which interoperability could alleviate these PV challenges was established.
Chapter 4 involved characterising the global PV system by identifying the role players, their
responsibilities, and the communication channels between them. This stage of the research
also identifies and elaborates on best practices for the reporting of ADRs (the ICH E2B(R3)
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standard for electronic ICSR transmission) as well as the solutions and services offered by the
UMC. By understanding the roles and responsibilities of the various role players, the PVR-CMM
is developed with the three perspectives described in Section 7.3 in mind.
The use of maturity models as assessment and improvement guidance tools is investigated
in the following step in the research. One application of MMs, as demonstrated in Chapter
5, is to provide guidance towards interoperability. By comparing various MMs and maturity
assessment frameworks in an eHealth context, it has been determined that MMs can also
feasibly be used for this purpose within the PV landscape.
Taking into consideration the difficulty associated with implementing standardised HITs into
large, complex systems, the notion of STSs is investigated in Chapter 6. The PV system was
described as an STS to gain an improved understanding of how best to design and implement
HITs in these complex systems. Through the conceptualisation of the PV system as an STS,
the PVR-CMM development process is more cognisant of social, cultural, and political factors,
rather than focusing solely on the technological factors.
7.2 Maturity model development strategy
Becker et al. (2009) put forward a procedural model to facilitate the development of MMs; the
procedure consists of eight phases. This procedure has been adapted for the purpose of this
study. A comparison of Becker et al.’s (2009) procedural model and the phases of development
of the PVR-CMM can be found in Table 7.1. The phases of the PVR-CMM development have
been aligned with the eight phases of Becker et al.’s (2009) procedural model. It is important
to note that phase 5 has been added to the PVR-CMM development, covered in Chapter 8,
while phases 6 through 8 are covered in Chapter 9. The reason for this uncoupling is to allow
for Chapter 7 to focus on the model development, while Chapter 8 focuses on the verification
of the model to determine whether or not it is suitable for implementation in a case study
(Chapter 9), thus allowing for the validation and overall acceptance or rejection of the PVR-




7.3 Phase 1: Revisiting the problem definition
Table 7.1: The PVR-CMM seven phases of development compared to Becker et al.’s (2009)
eight phase procedural model.
Becker et al.’s 8 phase MM development strategy PVR-CMM phases of development Chapter section
1. Problem definition 1. Problem definition 7.3
2. Comparison of existing maturity models 2. Determination of design requirements 7.4
3. Determination of development strategy 3. Comparison of existing maturity models 7.5
4. Iterative maturity model development 4. Iterative maturity model development 7.6 to 8.7
5. Conception of transfer media 5. Verification 8.1
6. Implementation of transfer media 6. Conception of transfer media 9.2.1
7. Evaluation 7. Implementation and validation 9.3 to 9.5
8. Acceptance/Rejection of maturity model 8. Acceptance/Rejection of maturity model 9.5.2.1
The eight phases are executed in Sections 7.3 to 9.5.2.1. The presentation of the final model
and the supporting practical recommendations are found in Chapter 9, in Sections 9.2 and 9.4
respectively.
7.3 Phase 1: Revisiting the problem definition
Chapters 3 and 4 discuss the various challenges associated with the spontaneous reporting
of ADRs, as well as how SRSs operate and the best practices associated with spontaneous
reporting. Spontaneous reporting of ADRs is the cornerstone of data generation in the post-
marketing authorisation phase of PV activities. Figure 7.1 depicts how the ICSR is created via
collaboration between the ICSR informer and the ICSR creator, typically the patient and/or
consumer and an HCP respectively. The creation of the ICSR is usually performed via an HIT
application at the operational level. The ICSR is then sent to the primary receiver, which in
most cases is the appropriate RA or NCA, which then transmits the ICSR to the appropriate
secondary receiver, such as the MAH, which manufactured the drug, or the UMC’s VigiBase.
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Figure 7.1: ICH E2B(R3) ICSR data flow. Adapted from the International Council for Har-
monisation of Technical Requirements for Pharmaceuticals for Human Use (2016).
Figure 7.2 is a conceptual model of a health information system from a patient safety per-
spective. At the operational level, HCPs interact with HITs in the form of clinical applications
which capture patient safety data in multiple forms. Figure 7.2 displays the three stages of
data flow on the left hand side (data capture, data storage and aggregation, and data presen-
tation), on the y-axis to the right of the figure, the four levels of the health system are shown,
accompanied by the scale of interoperability standards which relate to the three stages of data
flow across the various levels of the system.
Data captured via clinical applications, are stored within patient care systems. These patient
care systems in combination with data from other sources form the basis of data aggregation
for analysis. Population-based analyses can be conducted internally by an organisation such
as an RA or healthcare facility, or externally, such as in the case of the UMC’s Vigi tools and
methods. Ultimately, the outcomes of such population-based analyses are disseminated back
to the patients, HCPs, or any entity which plays a role in the patient safety system, such as
MAHs or RAs.
Standardised solutions in the form of various HIT initiatives are available; it is the failure
in adoption and implementation of these solutions that is hindering worldwide PV system
interoperability, as discussed in Chapter 6. This failure in adoption and implementation of
HITs across the various PV systems hinders efforts to coherently manage PV on a global scale.
The primary obstacle to achieving interoperability between SRSs globally is the fundamental
difference in purpose of the existing SRSs. This difference in purpose is a result of the differing
perspectives of the three main role players at the global level of PV, the UMC, the various
MAHs, and the RAs representing governments around the world, discussed in Sections 1.2
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and 4.7.2. The strength of the global PV system lies in the integration of various national
and industry PV systems. While the UMC offers substantial support to the WHO member
countries, as discussed in Section 4.4, many of the developing member countries lack the
capacity and capability to take full advantage of the services offered by the UMC.
Maturity models, as discussed in Chapter 5, are primarily used to assess system capabilities and
to guide strategically linked continuous improvement processes. Chapter 6 highlights one of
the main issues facing HIT designers and implementation teams, i.e. the challenge of bringing
together people, policies, and technology. This chapter therefore deals with the development
of a model, based on the concept of a CMM, which can be used by MAHs, RAs, or any entity
that owns or operates an SRS to measure and assess their PV capabilities; thereby improving
ADR reporting or data generation, which is the cornerstone of all PV systems.
The benefits associated with interoperability in the context of PV are incontrovertible. Inter-
operability is a solution to the risks associated with health information becoming considered
a proprietary asset held within stand-alone information systems (Brailer, 2005). As discussed
in Chapter 3, fragmentation of PV systems when it comes to collecting and processing ADR
reports, leads to errors, loss of information, duplication, lack of coordination, amongst other
problems. In the context of an SRS, the question is whether interoperability will emerge as
a result of wide-spread adoption of stand-alone systems; or whether a new system should be
designed with interoperability standards at the core. When all the necessary stakeholders in
PV are collecting ADR information independently of each other but are legally required to
share that information with each other, interoperability should emerge as there are demonstra-
ble benefits in terms of costs and ease of sharing information associated with interoperability
(Gottschalk, 2009).
Thus, the specific problem that will be addressed by the developed model is the lack of
interoperability among SRSs globally. This will be addressed by developing a maturity model,
based on the CMM. The aim of which, will be to promote and improve interoperability by
addressing the degree of integration of systems involved, providing guidance on which system
components need to be improved, as well as providing a means for measuring interoperability




















































































































































































































































Figure 7.2: A conceptual model of a health information system from a patient safety perspective. Adapted from (Erickson et al., 2003)
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7.4 Phase 2: Determination of design requirements
To aid in the development of the PVR-CMM, the necessary design requirements for such
a model must be defined. The design requirements are developed from the findings and
conclusions of the preceding literature review chapters, as well as with the use of Pöppelbuß
& Röglinger’s (2011) work on the development of maturity models. Based on a systematic
review of a large number of maturity model development strategies, Pöppelbuß & Röglinger
(2011) summarise the most pertinent design considerations to adhere to for the design and
development of descriptive maturity models. Van Dyk (2013) divide these design considerations
into two groups: firstly design considerations in terms of methodology; and secondly, design
considerations related to design requirements. This grouping of the design considerations is
well suited to this research as a number of the design considerations relating to methodology
have already been acknowledged via the use of the MM development procedural model of
Becker et al. (2009), which was discussed in Section 7.2. The ten basic design considerations
of Pöppelbuß & Röglinger (2011), as grouped according to Van Dyk (2013), and the design
requirements which are derived from these considerations, are as follows:
Design considerations related to design requirements:
1. Application domain
The first design consideration refers to the application domain of the maturity model that is to
be developed. In this case, the maturity model’s application domain is the spontaneous report-
ing of adverse drug reactions in pharmacovigilance. This informs the first design requirement
(DR).
DR1: The PVR-CMM can describe all activities relating to the spontaneous re-
porting of an ADR within PV.
2. Purpose of use
Along with the application domain, the maturity model’s purpose of use must be clearly defined.
Pöppelbuß & Röglinger (2011) list three types of maturity models, which were discussed in
Section 5.4.1. The PVR-CMM will initially act as a descriptive maturity model, used to assess
an organisation’s spontaneous reporting capability, and then as a prescriptive maturity model
in that the model will provide guidance to the organisation on how to increase their maturity
across various dimensions. In the case of the PVR-CMM, the purpose of use is described in
Section 7.3, and is encapsulated in the following two DRs:
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DR2: The PVR-CMM enables the assessment of the maturity of an organisation’s
spontaneous reporting capabilities.
DR3: The PVR-CMM can be used to guide improvement initiatives.
3. Target audience
The target group refers to the group of people who apply the maturity model, as well as the
organisation which they represent, in that the results of the maturity assessment pertain to
various other constituents of an organisation (De Bruin et al., 2005). In the case of the PVR-
CMM, the target audience is any organisation which owns or operates a spontaneous reporting
system for the management of ADR reports. Following discussions with a number of leading
global experts in PV, it was decided that the PVR-CMM should be targeted towards regulatory
authorities primarily, especially those in developing countries1. The PVR-CMM should also be
designed in such a way that it can be easily understood by the person or persons who will
use it in carrying out a maturity assessment. A well constructed maturity model should seek
to emulate a reference model in that it should characterise and structure its components in a
comprehensive manner which enables non-specialist users to make sense of, and make use of
the model (Organization for the Advancement of Structured Information Standards, 2006).
DR4: The PVR-CMM is designed for the intended use by a specified target audi-
ence.
DR5: The PVR-CMM can be used for educational purposes and can be used to
explain various aspects of the spontaneous reporting of ADRs to anyone with little
to no background in PV.
DR6: The PVR-CMM is presented in an easy to understand manner and can be
used by organisations to reach a common understanding of the system and the
associated standards.
In the case of DRs 12 and 13, these DRs resulted as a response to subject matter feed-
back received during verification activities conducted at the later stage of the research. This
verification process is described in Section 8.5.
DR12: The PVR-CMM can be used by stakeholders from various disciplines in
PV to assess the spontaneous reporting of ADRs at the level in which they are
engaged.
1These discussion were held at the ISoP-ASoP Mid-Year Symposium & Training Course, held in Nairobi,
Kenya, between 6 - 8 May 2019.
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4. Class of entities under investigation
Maturity models can refer to various classes of entities. Mettler & Rohner (2009) suggest that
typical classes are people, processes, or other objects from a specific application domain. This,
together with design considerations 7 and 8, listed below, yield the following two DRs. Design
considerations 7 and 8 are discussed further in the section on design considerations relating to
methodology.
DR7: The PVR-CMM provides a set of domains, subdomains, and dimensions
which characterise all aspects of spontaneous reporting of ADRs in PV.
DR8: The PVR-CMM is designed with sociotechnical systems theory in mind
and therefore does not focus solely on the technical components of spontaneous
reporting systems.
5. Maturity, maturity levels and maturation paths
The goal, according to De Bruin et al. (2005), when developing the capability statements of a
maturity model, is to attain a set of statements which are mutually exclusive and collectively
exhaustive. Mutual exclusivity is when no two statements are the same; and for the set to
be collectively exhaustive, at least of one of the statements must be considered true for each
dimension. These principles yield the following three DRs:
DR9: The capability statements of the PVR-CMM are mutually exclusive.
DR10: The capability statements of the PVR-CMM are collectively exhaustive.
DR11: The capability statements and maturity levels accumulate, with each level
and statement encompassing the preceding lower levels and statements.
6. Available levels of granularity of maturation
Both, Pöppelbuß & Röglinger (2011) and De Bruin et al. (2005), refer to the need for maturity
models to be structured in layers according to different levels of granularity of maturation.
When a maturity model is structured hierarchically in such a way, it allows for an organisation
to make comparisons of maturity levels at a high level of abstraction, such as a domain level;
or, to compare maturity at a lower level of abstraction, allowing for more specific improvement
areas to be identified, such as within a dimension level. These various levels of granularity allow
for the communication of information which may better suit stakeholders which are external to
the organisation, for example shareholders and executive bodies; or internal stakeholders such
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as different departments or functional units. As stated previously, DRs 12 and 13 were added
as a response to subject matter feedback received during verification activities conducted at a
later stage of the research. This verification process is described in Section 8.5.
DR13: The descriptions of the capability statements clearly relate to and discrim-
inate between maturity levels.
Design considerations related to methodology:
The following design considerations from the work of Pöppelbuß & Röglinger (2011) are not
explicitly linked to the DRs discussed above, but rather, innately incorporated into the method-
ology of this dissertation, as well as the design and development strategy of the PVR-CMM in
this chapter, as summarised in Table 7.1.
7. Definition of central constructs
Design consideration 7 is addressed in Chapters 3, 4, 5, and 6.
8. Underpinning foundations with respect to evolution and change
Design consideration 8 is also addressed in Chapters 5, and 6.
9. Differentiation from related maturity models
This design consideration forms part of the development strategy as described in Section 7.2,
as well as being an integral step in Becker et al.’s (2009) procedural model, shown in Table 7.1.
18 maturity assessment frameworks and models, from various application fields, are compared
in Section 7.2.
10. Design process and extent of verification and empirical validation
Pöppelbuß & Röglinger (2011) build on the work of Benbasat et al. (1984), and King &
Kraemer (1984) when addressing the extent of empirical validation of maturity models. As
part of the development process it is necessary to document to what extent the maturity
model under development has been subjected to verification and validation processes. These
verification and validation processes can be performed by means of interviews with subject
matter experts, questionnaires, case studies, focus groups, and workshops, in an attempt to
improve the maturity model’s intended usage and performance.
The development of the PVR-CMM included multiple verification and validation processes. The
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7.5 Phase 3: Comparison of existing maturity models
In keeping with the MM development procedure of Becker et al. (2009), the next phase is
to make a comparison of existing maturity models and frameworks. This comparison is made
in order to ensure that a strong foundation of literature is considered, as well as to ascertain
whether or not a model or framework already exists which satisfies the DRs stated in Section
7.4. A body of literature surrounding the interoperability of information systems as well as
health information systems specifically was studied. A literature review performed by Carvalho
et al. (2016) found a wealth of maturity models focussing on healthcare information systems
and technologies. From this research, a collection of 18 MMs and frameworks were identified. A
comparison of these 18 models and frameworks assisted with the selection and characterization
of the 30 dimensions included in the PVR-CMM. The 18 models and frameworks summarised
in Table 7.2 are grouped together by their application field. The application fields are: (i) PV;
(ii) eHealth; (iii) eHealth/interoperability; (iv) interoperability; and (v) IT infrastructure.
Other models and frameworks which could contribute significantly to the development of the
PVR-CMM include Leon et al.’s (2012) framework for assessing the health system challenges
to scaling up mobile Health (mHealth) in South Africa which proposes four key domains: (i)
government stewardship; (ii) organisational/behavioural; (iii) technological; and (iv) financial.
Similarly, Tanriverdi & Iacono (1999) suggest that the primary barriers to eHealth innovation
diffusion can be categorised as behavioural, technical, economical, and organisational barriers.
Sittig & Singh (2010) introduces an 8-dimensional model to assist in understanding the chal-
lenges inherent in studying HIT. The model will be built upon for the design, development,
implementation, use, and evaluation of HIT within complex adaptive healthcare systems. The
8 interdependent dimensions are as follows: (i) hardware and software; (ii) clinical content;
(iii) human computer interface; (iv) people; (v) work-flow and communication; (vi) inter-
nal organisational features; (vii) external rules and regulations; and (viii) measurement and
monitoring.
Of the four models and frameworks within the application field of PV, none are developed
following a well regarded reference model, with only one being based on the concept of a
maturity model. The SCOPE best practice guide however, does not include an assessment tool.
Of the remaining three models and frameworks, two can be used as assessment tools, namely
the WHO Data Collection Tool, and the Indicator Based Pharmacovigilance Assessment Tool.
The last of the models and frameworks in the PV application field, is the Pharmacogovernance
and Modes of Engagement Tool. This last tool however, is not based on the concept of a
maturity model, nor is it used as an assessment tool.
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Although none of the models or frameworks considered in this study were able to satisfy all of
the DRs in Section 7.4, the findings from the literature study, in particular with regard to the
four models and frameworks in the application field of PV, yielded valuable insights to guide
the development of the PVR-CMM. It is evident that HIT designers and implementation teams
are tasked with the challenge of bringing together policies, people, and technology; as well as
the stakeholders which personify these domains, policy makers, HCPs, and IT developers. User
participation must be at the heart of STS design, with users being an integral part throughout
the systems development life cycle. Sensitisation and awareness of stakeholders across the
system to the value of a sociotechnical approach is essential; as is constructive engagement
in terms of involving a multidisciplinary team of developers, engineers and healthcare practi-
tioners throughout the entire SDLC and integrating STS design approaches into the change















































ADR IT system funtionality: Collect, Record, Report in E2B, Received ADR data analysis  
ADR system maturity level: Basic, Well developed, Advanced
n/a n/a
SCOPE team of the Agency 
for Medicinal Products and 
Medical Devices of Croatia 
(HALMED)
(SCOPE, 2018)
WHO Data Collection Tool - 
Module 11: Pharmacovigilance
PV n/a n/a
Legal Underpinnings, Directives, Organisation and Structure, Internal Procedures, Huamn and Other Resources, Records and 
Results, Availability of Information.
Yes n/a
World Health Organization 
Technical Cooperation for 










Policy, Law, Regulation (Governing structures, Norms, Policy Instruments, Practices, Institutional authority), Accountability and 
Transparency, Participation and Representation, Equity and Inclusiveness (Distribution of resources for PV), Ethics (Policy), 
Effectiveness and Efficiency (System integration and communication), Responsiveness (Risk communication), Intelligence and 
Information (e-Reporting technology, Risk communication), Stakeholder communication (Pooled resources, Network 
mobilisation, Communication network).
n/a n/a










Components: (Policy, Law, and Regulation), (Systems, Structures, and Stakeholder Coordination), (Signal Generation and Data 










Electronic Healthcare Maturity 
Model (eHMM)
eHealth 7 n/a Entities, Department, Infrastructure. n/a n/a Quintegra Solutions Limited (Sharma, 2008)






New Data Sources, Complexity, Data Literacy, Data Timeliness. Yes EMRAM Health Catalyst
(Sanders et al., 
2013)







Man, Machine, Material, Method, Money. Yes CMM
Liezl van Dyk, Stellenbosch 
University
(Van Dyk, 2013)






Elements: Focus on Users, Management, Process and Infrastructure, Resources, Education. 
















Governance: Leadership and Governance, Strategy and Value Management. 
Solutions: IEHI, Healthcare Service Delivery, Healthcare Information and Knowledge, Public Health and Healthcare Management 
and Administration. 
Foundations and Enablers: Infrastructure, Standards and Interoperability, IT Process Management, (Legislation, Polic and 
Compliance), Workforce, Adoption Mechanism, Technological and Innovation Trends. 
Maturity levels: 1 Initial, 2 Ad-hoc, 3 Defined, 4 Managed, 5 Optimised.
Yes CMM












Layers of Interoperability: Legal and Regulatory (legal and regulatory constraints), Policy (collaboration agreeements), Care 
Process (alignment of care processes), Information (defining of coding of information), Applications (integrated healthcare 
systems), IT Infrastructure (communication protocols). 
Implementation levels: Strategic, Tactical, Operational. 
Cross-cutting issues: (Standards and Profiles, Certification), (Security, Privacy, Governance).
n/a n/a














Perspectives: Technical, Procedures, Standardisation. 
Maturity levels: Level 0 (System as silo), Level 1 (Peer-to-peer), Level 2 (Distributed Organisation-bound/Distributed Inter-





Lex van Velsen, 
Telemedicine Cluster 
Roessingh Research and 
Development Enschede, the 
Netherlands
(van Velsen et al., 
2016)
























































































Domains: Leadership and Governance, Human Resources, Technology. 
Subdomains 
Maturity levels: 1 Nascent, 2 Emerging, 3 Established, 4 Institutionalised, 5 Optimised.
Yes CMM
MEASURE Evaluation and 























Maturity levels for 







Constraints: Constitutional/legal, Jurisdictional, Collaborative, Organisational, Informational, Managerial, Cost, Technological, 
Performance. 

















Interoperability Categories: Organisational (Economic/Regulatory Policy, Business Objectives, Business Procedures), Informational 
(Business Context, Semantic Understanding), Technical (Syntactic Interoperability, Network Interoperability, Basic Connectivity). 
Cross-cutting Issues: Configuration and Evolution, Operation and Performance, Security and Safety. 
Maturity levels: 0 None, 1 Initial, 2 Managed, 3 Defined, 4 Quanititatively managed, 5 Optimising.
Yes CMM













Domains: Infrastructure Management, Knowledge, Infrastructure Provisioning, Service Management, Solution Driver, Ecosystem 
Relationship, Management Focus, Organisation, Agility, Pricing Scheme, Business Interface, Utilisation, Automation and Process 
Management. 
Maturity levels: 1 Basic, 2 Controlled, 3 Standardised, 4 Optimised, 5 Innovative.
Yes CMM
Ferry Haris, University of 
Twente
(Haris, 2010)








Key Capabilities: Common Applications and Services, Infrastructure Hardware Platforms, Network Devices and Services, IT 
Security and Information Governance, Infrastructure Patterns and Practices, End User Devices, Infrastructure Governance, 
Business Alignment, Procurement, People and Skills, Value Management; Principles, Standards, Procedures and Guidelines. 
Maturity levels: 1 Basic, 2 Controlled, 3 Standardised, 4 Optimised, 5 Innovative.
Yes CMM
Andy Savvides, NHS 
Connecting for Health
(Savvides, 2011)




















7.6 Phases 4 and 5: Iterative maturity model development and verification
7.6 Phases 4 and 5: Iterative maturity model development and
verification
Phases 4 and 5 in Becker et al.’s (2009) procedural model, shown in Table 7.1, are “Iterative
maturity model development” and “verification”, respectively. In this section the first gener-
ation of the PVR-CMM is developed, thereafter in Chapter 8, the PVR-CMM is subjected to
verification processes in order to ascertain which aspects of the maturity model might require
improvement, resulting in the second iteration of the PVR-CMM. For the first generation, the
domains, subdomains, and dimensions have been selected from the findings of the preced-
ing literature review chapters as well as from existing maturity models which are discussed
in Section 7.5. The PVR-CMM is developed in such a way that it aims to be easily under-
stood at a high level, with the details of capability maturity and interoperability maturity of
the dimensions being addressed as the user delves deeper into the model. The PVR-CMM is
comprised of three domains which include seven subdomains and 30 dimensions. As discussed
in Chapter 5, research suggests that interoperability results as a product of standardisation in
four domains: technology, syntax1, semantics2, and pragmatics3.
The PVR-CMM is structured with sociotechnical system engineering principles in mind, that is
to say, placing equal importance on the social, political and environmental (workplace) factors
(Baxter & Sommerville, 2011). The domains are organised accordingly into three categories:
Organisational (pragmatic), Informational (syntax and semantic), and Technical. These three
domains lend themselves to the discussion of capability maturity as well as interoperability,
and are consistent with the findings of the literature review in Table 7.2.
The PVR-CMM further breaks down these three domains and provides subdomains. The
subdomains within the organisational domain characterise the pragmatic aspects of interoper-
ability in PV. The informational subdomains characterise the semantics of interoperability, and
the technical subdomains emphasise the syntax or format of the information being exchanged
between systems. PV systems involve complex interactions between healthcare profession-
als, computer hardware and software, as well as the physical work environment within which
they operate, all the while being exposed to external pressures from ever changing political,
technological, cultural and social factors.
1Syntax standardisation refers to the agreement on the structure and language of the message exchanged
by heterogenous applications across a network.
2Semantic standardisation refers to the extension of syntactic standardisation, that is to say the meaning
of the messages are mutually understood.




7. DEVELOPMENT OF THE PHARMACOVIGILANCE REPORTING CAPABILITY
MATURITY MODEL
The PVR-CMM is developed for a target audience with a presumably good understanding of
the concept of interoperability, as well as familiarity with spontaneous reporting systems, and
general process improvement concepts such as the PDCA cycle. Users of the PVR-CMM with
this level of understanding should be expected to derive value from the PVR-CMM by being
able to adapt and refine the model to suit their organisation’s individual needs. Ultimately,
the PVR-CMM is developed for use by RAs, MAHs, and any other organisation involved in the
ownership or operation of an SRS.
7.6.1 PVR-CMM domains and subdomains
The Interoperability Framework by National E-Health Transition Authority Ltd (2012), and the
Smart Grid Interoperability Maturity Model prepared by The GridWise Architecture Council
(2011) considered interoperability goals from three perspectives, Organisational, Informational,
and Technical. The PVR-CMM further breaks down these three domains and provides seven
subdomains, shown in Figure 7.3. The subdomains within the organisational domain, coloured
blue in Figure 7.3, characterise the pragmatic aspects of interoperability in PV. The informa-
tional subdomains, coloured green in Figure 7.3, characterise the semantics of interoperability,
and the technical subdomain, coloured yellow in Figure 7.3, emphasise the syntax or format






















Figure 7.3: The seven subdomains of the PVR-CMM.
7.6.2 PVR-CMM dimensions
The 30 dimensions included in the PVR-CMM will be listed below and motivation for their
inclusion in the model will be provided. The contextual definition for each of these dimensions
is included in the PVR-CMM itself, in the fourth column.
1. Organisational (Pragmatics)
(a) Leadership and governance
i. Law, regulation and policy
This dimension serves as acknowledgement of the existence of the appropriate
legal provisions that mandate and guide all PV related activities. From an
interoperability perspective it is necessary to have a common understanding of
legislation relating to the exchange of information and the associated security
and privacy issues. Legislation and regulatory guidelines must be compatible
and define the boundaries of interoperability between two ICT systems.
ii. Governance structures and commitment
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Governance structures are those consisting of the highest executive manage-
ment of the organisation. The governance structure should enable management
to ensure the organisations compliance with the relevant legislation. Gover-
nance impacts change management, regulatory compliance, and also directs
the progress of evolving policies and procedures towards interoperability.
iii. Business continuity and responsiveness
Certain PV processes are critical and the appropriate business continuity plans
should be developed in a risk-based manner. These processes include collec-
tion, processing, management, and timely transmission of ICSRs. Back-up
systems allowing exchange of critical information within an organisation, be-
tween organisations, or between the MAH and the RA.
iv. Data ethics/ownership
Data ethics addresses the moral dimension of data management. This includes
ensuring adherence to ethical principles throughout data generation, recording,
curation, processing, dissemination, sharing, and use. With the aim of inter-
operability being the sharing of data, it is important to stipulate the ownership
of the data and to protect and uphold the interests of the owner.
v. Monitoring of performance and effectiveness
The organisation should clearly define performance indicators which can be
used to continuously monitor the performance of PV activities. Monitoring of
performance will include activities such as reviews, audits, compliance moni-
toring, and inspections. Good PV practices have been defined by the European
Medicines Agency and can serve as a set of quality requirements for the various
PV activities. Corrective and preventative measures can be implemented as a
means of addressing performance shortcomings.
vi. Transparency and accountability
Transparency instils trust and confidence in the organisation and their system
by the public. Accountability refers to the organisation taking responsibility
for its actions. Both transparency and accountability are exercised in a PV
context through the clear communication of post authorisation safety studies
(PASSs) and patient safety update reports (PSURs) by the MAH.
vii. Partnerships
Patient safety and PV activities must be considered when forming and manag-
ing partnerships. In the case where multiple partner organisations make use of
the same PV system, each partner must ensure that the PV system functions
to meet their individual regulatory compliance needs.
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viii. Stakeholder communication
Provisions for timely and effective communication of patient safety information
or safety concerns to the relevant stakeholders (consumers, HCPs, MAH, RAs,
etc.), be it within an organisation or between organisations. This also applies
to communication between MAHs and their respective RAs. Coordination and
cooperation between the various parties involved in communicating patient
safety information, as well as the management of communication tools and
channels should seek to improve access to information by those in need of the
information.
ix. Organisational strategy alignment
It is important that the organisation has a shared understanding of the PV
operating model across all levels of the organisation as well as a common
understanding of the role of the organisation within the global patient safety
system. Different functional units of an organisation, such as manufacturing,
sales and marketing, and quality control, may have contradicting goals and
incentive structures, which do not focus on patient safety.
x. Building a culture of safety
By developing and maintaining a system of shared actions, values, and beliefs,
the safety culture will permeate throughout the organisation. A strong culture
of safety can help shape the way in which the organisation views PV, from
that of a collection of compliance and risk mitigation activities, to a means
of developing a set of standard business procedures which yield a competitive
advantage.
xi. Organisational change management
Change management processes need to be established to guide the adoption
of newly identified best practices and updated work procedures. Change man-
agement is critical when dealing with an ever-changing business environment
and the constant introduction of new technologies.
(b) Finance and economics
i. Financial management
A dedicated budget for PV-related activities is crucial. Procedures must be
in place to ensure correct spending of funds in the public sector. A proactive
approach to investing in innovative technologies must be adopted, e.g. the
case of the electronic health record (EHR).
ii. Financial resource mobilisation
123
Stellenbosch University https://scholar.sun.ac.za
7. DEVELOPMENT OF THE PHARMACOVIGILANCE REPORTING CAPABILITY
MATURITY MODEL
Activities relating to the acquisition of new financial resources for the organi-
sation, are vital to guarantee the continued availability of financial resources.
These financial resources could include grants, investments from the private
sector, or monetary donations from international aid organisations.
(c) Business objectives
i. Regulatory compliance
Organisational policies and processes must always be cognisant of, and remain
compliant with, regulatory compliance policies. In order to maintain regulatory
compliance, awareness of the applicable legislation and regulations is critical
across all stakeholders in the PV system.
ii. Resource efficiency and business sustainability
Business sustainability in this context refers to the organisations ability to con-
tinually control the costs and benefits of interoperability while sustaining the
overall quality and performance of their spontaneous reporting system. Achiev-
ing efficient utilisation of resources is to exploit system inputs to maximise
system outputs, while minimising wasted resources.
iii. Data management
Data management refers to the set of procedures and policies which govern
the management of data within the SRS. This includes how data are captured,
collected, stored, transmitted and processed.
(d) Human resources
i. Human resources policy
This dimension serves as acknowledgement of the existence of the necessary
policies which specify roles and responsibilities for PV in the organisation. Ev-
ery organisation is legally required to designate a qualified person for PV, this
person is tasked with overseeing all PV related activities within the organisa-
tion.
ii. Human resources capacity
This refers to the availability of personnel with the relevant and required char-
acteristics, attributes, and capabilities to perform the specified PV roles. PV
is a responsibility that is shared across functional business units within an or-
ganisation and therefore requires personnel across all stages of the system life
cycle.
iii. Human resources capacity development
Awareness, education, and training initiatives aimed at the development of a
strong PV culture within the organisation. An organised activity with clear
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learning outcomes that aims to impart knowledge and skills, shape attitudes,
and develop specific competencies and capabilities in personnel.
2. Informational (Syntax and semantics)
(a) Business procedures
i. Data capture
Methods of capturing data associated with suspected ADRs and the technolo-
gies involved. The WHO states that an ADR reporting form is one of the
minimum requirements for a functioning spontaneous reporting system.
ii. Data storage and aggregation
The WHO states that an ADR report database is one of the minimum re-
quirements for a functioning spontaneous reporting system. The methods of
aggregating data for statistical analysis, as well as methods for duplicate de-
tection are important when considering the spontaneous reporting system.
iii. Workflows
Workflows detail the sequential steps taken when performing business processes
and typically involve standard operating procedures (SOPs).
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iv. Data presentation/transmission
The format in which the ICSR is transmitted from the sender to the receiver.
Currently the best practice is the ICH E2B(R3) standard for the electronic
transmission of ICSRs with backwards/forwards compatibility.
(b) IT standards
i. Data standards
To achieve syntactic interoperability the ICT systems which seek to interoper-
ate must make use of specified data formats and communication protocols.
ii. Information content
The data encoded in an ICSR must collectively represent information that is
interpreted in the same way by the ICSR sender and receiver.
iii. Data protection, privacy, and security standards
Information shared by consumers and HCPs has associated rights attributed
to the consumers and HCPs, these rights must be protected and respected.
iv. Information exchange and interoperability standards
For interoperability to occur, the interacting ICT systems must agree on the




ICT hardware refers to the physical hardware necessary for the effective and
efficient operation of a spontaneous reporting system.
ii. Network
The network refers to the existence of the appropriate IT infrastructure to
enable the transmission of ICSRs over a local area network (LAN) or a wide
area network (WAN).
iii. Development and maintenance
This dimension refers to the development and maintenance of technologies and
standards to ensure optimal performance of the spontaneous reporting system.
It is important to note that maintenance involves different activities at the
local and global levels.
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7.6.3 Maturity
The PVR-CMM makes use of two maturity scales, relating to capability maturity and interop-
erability maturity respectively. It is believed that by providing two scales according to which
maturity can be measured, the PVR-CMM user will better understand how the two perspec-
tives interact with each other. The capability levels are defined in the PVR-CMM exactly as
those in the original CMM, developed by the CMMI Institute (2018), the CMMI definitions are
provided in Table 5.1. As discussed in Chapter 5, the term capability is associated with specific
business processes or a practice area within an organisation; while maturity is described as the
degree to which an organisation has explicitly and consistently deployed processes, according
to their business objectives. In terms of organisational interoperability, the PVR-CMM was de-
veloped using a combination of the levels proposed by Gottschalk (2009) and van Velsen et al.
(2016), as described in Section 5.6.2. These interoperability maturity levels are summarised in
Table 7.3.
Table 7.3: Interoperability maturity levels for the PVR-CMM
Interoperability ma-
turity level
Description of interoperability maturity level
Level 1:
System as silo
Single technology. No standardisation.
Technical and semantic issues are solved.
Level 2:
Peer-to-peer
Two systems linked for simple exchange of data.















Systems can connect and disconnect freely and exchange data
without serving a common goal.
7.7 The PVR-CMM V1
This chapter has described the activities leading up to the development of the first iteration of
the pharmacovigilance reporting capability maturity model (PVR-CMM). Together, the DRs
defined in Section 7.4, as well as the model components described in Sections 7.6.1 and 7.6.3,
seek to elucidate the model’s structure. The high-level structure of the PVR-CMM is depicted
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in Figure 7.4 and is justified and motivated in Section 7.6. The first generation PVR-CMM
(PVR-CMM V1) is presented in its entirety in Appendix A. With reference to the high-level
structure of the PVR-CMM in Figure 7.4, the first three columns from the left indicate the
groupings of the dimensions into their respective domains and subdomains. Beginning with
the organisational domain, the 30 dimensions are listed according to their subdomains, along
with their contextual definitions. Moving from left to right, the capability maturity statements
and the interoperability maturity statements are provided in pairs, according to their level of
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Figure 7.4: The high-level structure of the PVR-CMM.
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7.8 Chapter 6: Conclusion
This chapter focussed on the development of the PVR-CMM V1. The problem statement was
revisited and the target audience for the PVR-CMM was specified. The design requirements for
the PVR-CMM were listed and a comparison was drawn between 18 models and frameworks
from a variety of application fields within a healthcare context. The findings of this comparison
assisted with the selection and determination of the PVR-CMM structure in terms of domains,
subdomains, and dimensions. The three domains, seven subdomains, and 30 dimensions were
listed and a motivation for their inclusion was provided. The two maturity scales, capability
maturity, and interoperability maturity were discussed and motivated. The chapter concludes
with a description of the first generation of the PVR-CMM, namely the PVR-CMM V1, as well
as a graphical representation of the model’s high-level structure. Following the development
and population of the model, Chapter 8 will address the verification of the model’s constructs




Verification and model refinement
In this chapter the PVR-CMM V1 is subjected to verification in order to determine the model’s
relevance and the veracity of it’s constitution. The subtle, yet significant difference between
verification and validation is discussed; thereafter, the verification and validation strategy of
the PVR-CMM is detailed. The tools and methods involved in this strategy are described, as
well as the outcomes and results yielded through the application of these tools and methods. A
deviation to the verification strategy is discussed and executed, resulting in more well founded
verification outcomes.
8.1 Introduction
Following the development of the PVR-CMM V1, the constructs and contents of the model
must be tested for relevance and rigour (De Bruin et al., 2005). The verification phase of
the PVR-CMM development is completed in the remainder of this chapter, followed by the
incremental improvement or refinement of the model based on the outcomes and feedback
received from the verification activities. The final version of the PVR-CMM is presented in
Section 9.2.
The fourth and seventh phases of Becker et al.’s (2009) procedural model are “iterative ma-
turity model development” and “evaluation”, respectively. In the PVR-CMM phases of devel-
opment, shown alongside Becker et al.’s procedural model in Table 7.1, there is an additional
“verification” phase. This is because the verification process will inform the model refinement,
thereby making up the iterative nature of the PVR-CMM development. Here, it is important
to distinguish between verification and validation.
Some of the feedback received from SMEs in this chapter, was incorporated into the develop-




8. VERIFICATION AND MODEL REFINEMENT
8.2 Verification versus validation
In general, verification is concerned with the design and methods employed in research, whereas
validation is concerned with measuring the outcome of the research. For the purpose of this
research, the validation of the PVR-CMM can only be executed once the model has been
subject to the necessary verification processes. Verification and validation are two separate
procedural actions, that together, can be used to ascertain whether or not a product or system
meets the required standards and specifications. In the literature surrounding maturity model
development and testing, the two terms, along with the concepts of internal and external
validation are often used interchangeably. For the purpose of this research, these terms and
concepts will be defined here. The IEEE Standards Coordinating Committee’s (1990) defini-
tions of verification and validation are deliberately contrasting, so as to remove any uncertainty
when using the terms.
Verification is defined as:
“The process of evaluating a system or component to determine whether the
products of a given development phase satisfy the conditions imposed at the start
of that phase.” (IEEE Standards Coordinating Committee, 1990)
Whereas, validation is defined as:
“The process of evaluating a system or component during or at the end of the
development process to determine whether it satisfies specified requirements.”
(IEEE Standards Coordinating Committee, 1990)
Validity is concerned with the integrity of the conclusions that are generated from a piece of
research and is often considered an important criterion of research (Bryman & Bell, 2015).
The validation of the PVR-CMM V2, the iteration of the PVR-CMM which is the product of
the verification and refinement process, will be conducted in Chapter 9.
8.3 Verification and validation strategy
In the case of this research, the aim of the verification process is to engage with subject matter
experts (SMEs) from a diversity of backgrounds, such as those in regulatory capacities, as well
as in the pharmaceutical industry, in order to determine the accuracy, applicability, integrity,
and value of the PVR-CMM and it’s development in this study.
Following the initial verification of the PVR-CMM, discussed in Section 8.5, the author recog-
nised a potential limitation in the verification activities leading up to that point. The initial
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verification, although valuable and encouraging, engaged only SMEs from pharmaceutical or-
ganisations, thereby failing to obtain inputs from SMEs that are experienced in a regulatory
capacity. To address this, a second round of verification activities was executed. This time
engaging with a more diverse (in terms of their role in the pharmaceutical industry), yet more
focussed (in terms of their involvement in SRSs and their knowledge thereof) cohort of subject
matter experts. This deviation in the verification strategy is described in Section 8.5.5 and
the remainder of this chapter, thereafter. Figure 8.1 shows the strength of the verification
and validation strategy in this study. With the addition of subject matter expert input, as well
as the provision of the SME’s industry (or regulatory) perspectives, the development of the
PVR-CMM V2 benefits from the research method known as triangulation. Triangulation is
described in the research methodology section in Chapter 1.
The final methodological design consideration stated in Section 7.4 is the extent of empirical
validation. For the purpose of this research, and in the search for true objectivity, the PVR-
CMM must be subjected to validation by an entity which is not involved in the development
and verification activities. De Bruin et al. (2005) state that the issue of generalisability of
maturity models can only be addressed if the maturity model in question is deployed to an
entity that is external to the the development and verification of the maturity model. For this
reason, the PVR-CMM must be tested in a real-world setting, with an organisation that has
not been involved in the model’s development or verification.
8.3.1 Verification criteria
For the PVR-CMM verification processes described in Sections 8.5 and 8.6, the subject matter
experts are provided with questions which collectively seek to determine whether or not the
PVR-CMM holds up to the criteria, developed by Van Dyk (2013):
 The PVR-CMM is clear: it is easily understood and implemented,
 The PVR-CMM is useful: it reflects the important dimensions of the management of
an SRS,
 The PVR-CMM is reliable: it allows for continuous assessment over time by different
stakeholders,
 The PVR-CMM is valid: it is a true measure of what it purports to measure, and,
 The PVR-CMM is practical: it can be implemented in a timely manner, to inform the
continuous improvement processes and guide decision-making.
The specific questions and verification methods are described in detail in Sections 8.5 and 8.6.
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Figure 8.1: The use of triangulation in this study to improve the development of the PVR-
CMM, resulting in the PVR-CMM V2.
8.4 Verification and validation instruments and methods
An instrument, in the context of verification and validation testing, is a measurement device
which a researcher can make use of to engage with research participants, to acquire feedback
and answers to specific questions pertaining to their research topic. When selecting an in-
strument such as this, one must consider the type of feedback that is being sought, as well
as the applicability and usability of the instrument. Here, the usability of the instrument is
defined as being the ease with which the researcher can administer it, the ease with which the
instrument can be interpreted by the participant, as well as how easily the resultant informa-
tion can be interpreted by the researcher. The self-completion questionnaire, the instrument
of choice in this research, makes use of a five point Likert scale1 consisting of a symmetric
agree-disagree scale which the respondents could select to represent their attitude towards a
series of questions.
8.4.1 Questionnaire respondents
A number of SMEs were contacted and asked to assist with the verification of the PVR-
CMM via the self-completion questionnaires. For the purpose of this research, a number of
1A scale used to represent people’s attitudes to a topic.
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factors were considered when identifying SMEs. These factors include: (i) the role of the SME
within their organisation, their occupation, or the relevance of their experience; (ii) academic
qualifications; (iii) the depth of their experience, or number of years in the pharmaceutical
industry; and (iv) the SME’s affiliation (MAH/regulatory/academia etc.) and geographical
region. Table 8.1 summarises the characterisation of the 14 SMEs who participated in this
research.
This list of SMEs was expanded to include the addition of SMEs number 5 through 14, who
were identified in response to the concerns raised in Section 8.5.5.
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Table 8.1: Characterisation of the SMEs who were involved in the verification and validation
of the PVR-CMM.

















































African Union Development Agency
(AUDA-NEPAD) NEPAD Agency.
BPharm. 18







1WHO African Collaborating Centre
for Pharmacovigilance, 2Ghana Min-
istry of Health, 3International Society
of Pharmacovigilance.
BSc, MSc, PhD. 10






















2International Society of Phar-
macovigilance, 3World Health
Organisation.
BSc, MSc, PhD. 41
8.5 First verification of the PVR-CMM V1
Verification can be measured in many ways. For the purpose of this research, a number of
SMEs were requested to verify that the PVR-CMM stood up to predetermined verification
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criteria that addressed the face validity and construct validity of the PVR-CMM (Bryman &
Bell, 2015). This was achieved by providing each subject matter expert with a brief summary
of the research methodology leading up to the development of the PVR-CMM, a copy of the
PVR-CMM itself, as well as a self-completion questionnaire. For the first verification of the
PVR-CMM V1, SMEs one to four1 were engaged.
8.5.1 Verification questions: First verification
Together with the self-completion questionnaire, which can be found in Appendix B.2, the
SMEs received a ‘pre-reading document’ which summarised the relevant literature findings and
development process of the PVR-CMM. The pre-reading document can be found in Appendix
B.1. The detailed responses to the self-completion questionnaires can be found in Appendix
B.3. For ethical reasons and to protect the privacy of the SMEs and ensure confidentiality of
their responses, the personal information has been redacted from this dissertation.
The questions, shown in Table 8.2, were designed to test the overall construct validity of the
PVR-CMM, and to assess whether or not the design objectives have been achieved. De Bruin
et al. (2005) state that construct validity is made up of face validity and content validity. In
order to test that the theoretical basis upon which the model has been developed is sound, these
two measures of validity must be determined, before the maturity model may be considered
ready for implementation. Face validity is a measure of how well the DRs have been translated
and achieved in the model and content validity is a measure of the extent to which the literature
review covered the subject area, as well as the breadth of the literature review.
The self-completion questionnaire consists of 19 questions. The first five questions address
details pertaining to the SME/respondent, specifically to their relevant experience. To test for
content validity, the SMEs were asked a high level question relating to the research methodology
(limited to the development of the PVR-CMM only), represented by question 2.1, as well as
two questions to determine whether two of the literature review findings are valid, represented
by questions 3.1 and 3.2. To test for face validity, the SMEs were asked to what extent they
1SME number one is employed as a pharmacovigilance officer, with a diploma in pharmaceutical man-
agement and has been working in the pharmaceutical industry for 20 years. SME number two has 20 years of
experience and is the senior manager of application development and support, for the ‘Global Pharmacovigilance
Information Management Services (GPVIMS)’ of a top ten ranked independent multinational pharmaceutical
and biotechnology company (ranked by revenue). SME number two was a faculty member for the ‘EMA Eu-
draVigilance Information Day’ in June 2017, which focussed on the ICH E2B (R3) Implementation Working
Group. SME number three has five years of experience and is a medical advisor for a multinational pharma-
ceutical company, holding a medical degree as well as a postgraduate diploma in pharmaceutical science. SME
number four is a medical doctor with a masters degree in public health, and has four years of experience in the
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agreed that the PVR-CMM met the DRs defined in Chapter 7, these questions are numbered
4.1 through 4.11.
8.5.2 Subject matter expert feedback: First verification
From the 14 questions relating to the research methodology, the literature review findings,
and the PVR-CMM, a maximum possible score of 70 per SME, or 20 per question, can
be achieved using a 5 point Likert scale1. Table 8.2 summarises the results of the self-
completion questionnaire and highlights any questions to which the respondents might have
selected ‘unsure’, ‘disagree’, or ‘strongly disagree’, corresponding with values of 3, 2, and 1,
respectively. The questions to which the SMEs responded with ‘strongly disagree’, ‘disagree’,
or ‘unsure’, are discussed in Section 8.5.3.
Table 8.2: A summary of the SME responses, highlighting questions to which the SMEs
responded with ‘unsure’, ‘disagree’, or ‘strongly disagree’.
SME 1 SME 2 SME 3 SME 4
Methodology 2.1 To what extent do you agree that the PVR-CMM has the 
potential to achieve the stated aim of the study?
4 4 4 4 80%
3.1 To what extent do you agree with the finding that the ICH E2B 
standard is the current best practice for reporting ADRs?
4 5 4 4 85%
3.2 To what extent do you agree that the ICH E2B (R3) standard 
would support harmonization and interoperability of 
spontaneous reporting systems?
4 5 4 4 85%
DR1 4.1 The PVR-CMM can describe all activities relating to the 
spontaneous reporting of an ADR within PV.
4 5 4 4 85%
DR2 4.2 The PVR-CMM enables the assessment of the maturity of an 
organisation's spontaneous reporting capabilities.
5 5 4 4 90%
DR3 4.3 The PVR-CMM can be used to guide improvement initiatives. 5 5 4 4 90%
DR4 4.4 The PVR-CMM is designed for the intended use by a specified 
target audience.
4 4 4 4 80%
DR5 4.5 The PVR-CMM can be used for educational purposes and can be 
used to explain various aspects of the spontaneous reporting of 
ADRs to anyone with little to no background in PV.
3 3 4 3 65%
DR6 4.6 The PVR-CMM is presented in an easy to understand manner and 
can be used by organisations to reach a common understanding 
of the system and the associated standards.
4 4 4 4 80%
DR7 4.7 The PVR-CMM provides a set of domains, subdomains, and 
dimensions which characterise all aspects of spontaneous 
reporting of ADRs in PV.
4 4 4 4 80%
DR8 4.8 The PVR-CMM is designed with STS theory in mind and therefore 
does not focus solely on the technical components of 
spontaneous reporting systems.
4 5 4 4 85%
DR9 4.9 The capability statements of the PVR-CMM are mutually 
exclusive.
3 3 4 4 70%
DR10 4.10 The capability statements of the PVR-CMM are collectively 
exhaustive.
3 4 4 3 70%
DR11 4.11 The capability statements and maturity levels accumulate, with 
each level and statement encompassing the preceding lower 
levels and statements.
4 4 4 3 75%































1The Likert scale in the questionnaire, found in Appendix B.2, was adjusted to a 5 point scale, for the sake
of consistency with the subsequent use of the 5 point Likert scale.
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8.5.3 Points of interest: First verification
As shown in Table 8.2, none of the SMEs responded with ‘strongly disagree’ or ‘disagree’
to any of the questions. However, several responses of ‘unsure’ were provided, as shown by
the highlighted cells. Three of the SMEs responded with ‘unsure’ to question 4.5, while two
responded with ‘unsure’ to question 4.9 and question 4.10. Finally, one SME responded with
‘unsure’ to question 4.11. In this section, these responses will be further discussed, taking
into consideration any additional comments provided by the SMEs on the self-completion
questionnaire responses discussed in Section 8.5.4.
Question 4.5: The PVR-CMM could be used for educational purposes to explain the
various aspects of spontaneous reporting to anyone with little or no background in
pharmacovigilance.
SMEs one, two and four, were ‘unsure’ whether the PVR-CMM could be used for educational
purposes to explain the various aspects of spontaneous reporting to anyone with little or no
background in pharmacovigilance. To address this concern, an appendix labelled ‘Appendix 1’,
will be added to the PVR-CMM in Section 9.2 (Note that ‘Appendix 1’ will form part of the
PVR-CMM documentation and should not be confused with Appendices A, B and C of this
dissertation). Appendix 1 will contain a summary of spontaneous reporting, with the aim of
providing the PVR-CMM user with a foundational understanding of a spontaneous reporting
system as well as what is meant by an interoperable system and what the associated objectives
of such a system are.
Question 4.9: The capability and interoperability statements are mutually exclusive.
SMEs one and two were ‘unsure’ whether the capability and interoperability statements are
mutually exclusive. SMEs three and four agreed that the capability and interoperability state-
ments are mutually exclusive.
Question 4.10: The capability and interoperability statements are collectively exhaus-
tive.
SMEs one and four were ‘unsure’ whether the capability and interoperability statements are
collectively exhaustive. SMEs two and three agreed that the capability and interoperability
statements are collectively exhaustive.
Question 4.11: The capability statements and maturity levels accumulate while en-
compassing the preceding statements and maturity levels.
SME four was ‘unsure’ whether the capability statements and maturity levels accumulate
while encompassing the preceding statements and maturity levels. The remaining SMEs all
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agreed that the capability statements and maturity levels accumulate while encompassing the
preceding statements and maturity levels.
Regarding questions 4.9, 4.10 and 4.11, it should be acknowledged that the ‘unsure’ response
from some of the SMEs could be due to their presumably limited previous exposure to the
concept of CMMs, given their qualifications as stated in Table 8.1. In addition to this, a
disadvantage of the self-completion questionnaire, is that the respondent cannot be prompted
when experiencing difficulty in understanding or answering a question due to the absence of the
interviewer. This may have been a contributing factor in these responses. Given that it would
be impractical to ask an SME to verify 300 capability statements, the DRs seek to ensure that
the capability statements are designed in such a way that they adhere to the basic principles
of maturity model capability statements. In other words, by providing the SMEs with the
DRs themselves, the SMEs can then verify the capability statements’ adherence to the DRs,
by considering a smaller sample size drawn from the total of 300 capability statements. To
improve the subsequent iteration of the PVR-CMM, an additional DR was added, in response
to the last three questions in the initial verification questionnaire. As discussed in Section 7.4,
the additional DR is DR13: The descriptions of the capability statements clearly relate to and
discriminate between maturity levels.
8.5.4 Additional comments from the first verification of the PVR-CMM
The following statements were made in response to the first verification of the PVR-CMM V1:
“The aim of the study is to contribute towards the harmonisation of spontaneous
reporting systems in the PV landscape. I think the use of the two maturity scales in
the model will well define an organisation’s capability maturity with regard to PV.
How this contributes to harmonisation, I’m not 100% sure, but this is certainly a
great first step. Follow up actions would be required by an organisation to initiate
that harmonisation.”
The latter portion of this comment raises a valid concern; that, without implementation and
repeated use of the PVR-CMM, the model may not “contribute to harmonisation”. The
“follow up actions” which the comment refers to are indeed the repeated use of the PVR-
CMM to make maturity assessments which highlight areas for improvement, thereby guiding
the organisation towards harmonisation. The challenge with verifying this aspect of the PVR-
CMM is that without a real-world implementation of the model, it would be impossible to
determine the extent of the model’s empirical validity. To determine the validity of the PVR-
CMM, a case study was conducted at a later stage of this research, following the completion
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of the verification activities described in this chapter. The case study is presented in Chapter
9 of this dissertation.
“Well thought out and put together. The only reason I haven’t strongly agreed
with [some of] the [statements in the questionnaire] is because of the length of
time it would take me to go through each dimension and scale. Nevertheless,
impressive in the time I have. Well done.”
This comment raises the concern that the PVR-CMM V1 does not meet the practical veri-
fication criterion described in Section 8.3.1. The PVR-CMM should allow for timely imple-
mentation, to inform the continuous improvement processes and guide decision-making. To
address this, it is worthwhile considering a reduction in the number of dimensions included in
the PVR-CMM. An additional proposed solution would be to change the physical layout of the
PVR-CMM, so as to make the PVR-CMM more use-friendly, thereby reducing the probability
of user error or fatigue. These two activities are subsequently addressed in Sections 8.6 and
9.2.
“[The] guidelines aim to improve interoperability and harmonisation and I agree
that the R3 has achieved this end, however we also need to be cognisant regarding
the teething issues in implementation of the R2 vs R3? This includes compliance,
system upgrades etc.”
This comment provides insight into one of the primary concerns held by the MAHs; that is,
how to guide the implementation of the new ICH E2B (R3) standard in a sustainable and
efficient manner, so as to minimise the negative effects associated with inevitable “teething
issues”. As discussed at length in Chapter 5, this represents the rationale behind the use of
many maturity models and frameworks. This comment could potentially be a result of the
SME’s unfamiliarity with the concept of maturity models.
“It is a good concept to apply the CMM to PV activities. The author has developed
a clear framework of the processes and levels of maturity. There is good literature
review in terms of applicable CMM models in the healthcare domain. I agree that
more streamlined and standardised PV activities [are] required, and that the E2B
R3 aims to address the standardisation and interoperability within the EU. How-
ever, this remains a challenge even within an EU context, system changes, training,
updating SOP’s etc. which means more resources [required]/cost to company in
the short and medium term. How would the [PVR-CMM] address efficiency and
cost effectiveness? Another point would be a consideration of looking at region
specific needs versus global. How do global challenges specifically translate into
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African context? Would the same infrastructure globally, be applicable relevant or
available in a local African context?”
The latter part of this comment highlights some of the apparent limitations of the PVR-
CMM. It is widely accepted that the strength of a good maturity model lies in it’s ability
to be generalised to various applications within a defined domain (De Bruin et al., 2005;
Pöppelbuß & Röglinger, 2011). By challenging the applicability of the PVR-CMM in an
African context, the SME has simultaneously highlighted the need to test the PVR-CMM in a
real-world implementation, as well as to engage with SMEs from other stakeholder groups such
as National Regulatory Authorities. An additional DR was added in Section 7.4 in response
to the two statements made above. The DR is DR12: The PVR-CMM can be used by
stakeholders from various disciplines in PV to assess the spontaneous reporting of ADRs at
the level in which they are engaged. This DR requirement recognises the various stakeholders
that operate in different functions and capacities in a spontaneous reporting system, such as
those involved in system infrastructure, training, and development of SOPs, etc.
This last comment, together with the other feedback received, resulted in the decision to
subject the PVR-CMM to further verification testing, in order to increase the level of rigour in
the PVR-CMM development, and the overall robustness of the final PVR-CMM.
8.5.5 Acknowledgement of limitations in verification process
Upon completion of the first verification of the PVR-CMM V1, a number of potential limita-
tions in the verification process were identified. The three most notable limitations include:
1. A lack of diversity in the cohort of SMEs that were engaged to verify the PVR-CMM
V1,
2. The difficulty associated with verifying the model content, such as the dimensions in-
cluded and the capability statements, due to the large number of dimensions and state-
ments and the time required to review them, and
3. Uncertainty regarding the generalisability of the PVR-CMM V1, and therefore the overall
validity of the PVR-CMM V1, due to the lack of implementation of the model via an
illustrative case study; with special reference to the model’s validity in an African context.
The first and second limitations of the PVR-CMM V1 verification mentioned here, are ad-
dressed in the remainder of this chapter through more rigorous verification activities. The
third limitation is addressed in Chapter 9.
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8.5.5.1 Identifying a more diverse yet focused cohort of SMEs
To address the first potential weakness of the PVR-CMM V1, a larger quantity of SMEs
with more diverse backgrounds had to be identified. To achieve this, the author attended
a three day symposium and training event which brought together subject matter experts in
PV from around the world to discuss PV in Africa. The event, hosted by the International
Society of Pharmacovigilance (ISoP), together with the African Society of Pharmacovigilance
(ASoP), was titled “Pharmacovigilance in Africa, beyond Spontaneous Reports”. The event
was the first of this kind organised in Africa, presented in Nairobi, Kenya; and addressed the
specific needs and interests of people working in the field of PV either in regulatory authorities,
pharmaceutical companies, in academia, hospitals or community settings. Amidst the various
challenges associated with PV in Africa, the symposium and training event was focused on
improving different components of safety regulatory systems and practices.
The faculty contributing to the symposium consisted of international and national experts
in PV, representing government, academia, and industry. Given the specific focus of the
symposium and the quality of the faculty members involved in the presentations and workshops,
the symposium presented a unique opportunity to engage with experts to further verify and
validate the PVR-CMM. Table 8.1 includes the details associated with the SMEs which were
identified at the symposium, these additional SMEs are numbered from 5 through 14. It is
important to recognise the diversity in the affiliations attributed to each of these SMEs as it was
a priority to identify SMEs which represented not only MAHs but also RAs and the WHO. The
newly identified cohort of SMEs represented various organisations and institutions including,
but not limited to, two in academia, two WHO representatives, two representatives with
considerable regulatory and policy experience from a top ten ranked independent multinational
pharmaceutical and biotechnology company (Company ‘B’; ranked by revenue), as well as
three representatives from NRAs of African countries.
8.6 Second verification of PVR-CMM V1
The aim of the second verification of the PVR-CMM V1 was to engage with a larger cohort of
SMEs to address the concerns raised in Sections 8.5.4 and 8.5.5. In Section 8.5.4, one of the
SMEs drew attention to the fact that the PVR-CMM could be faced with challenges during
implementation given the scale of the maturity model, more specifically the 300 capability
statements associated with the 30 dimensions. To address this, the 30 dimensions of the
PVR-CMM are subjected to a further round of verification with the purpose of determining
which dimensions, if any, can potentially be removed from the PVR-CMM in order to simplify
the model and improve its usability.
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A further concern raised in Section 8.5.4, was that the first verification of the PVR-CMM V1
DRs, involved only SMEs from the MAH background. To address this, the SMEs identified
at the ISoP-ASoP Mid Year Symposium in Nairobi, which represent a much more diverse
cohort of SMEs, were requested to review the DRs of the PVR-CMM V1, and to propose any
additional DRs that they considered to be worth including.
8.6.1 Verification questions: Second verification
Similarly to the first verification process, the questions presented to the SMEs in the second ver-
ification process aim to strengthen the PVR-CMM by addressing the face validity and content
validity. To support the face validity, the SMEs numbered 5 through 12, were presented with
the complete list of 13 DRs, with the addition of DR12 and DR13, as defined in Section 7.4.
The SMEs were asked from their perspective whether or not the list of DRs was comprehensive,
and which DRs should be added to strengthen the PVR-CMM in the subsequent iteration of
development. In support of the content validity of the PVR-CMM, the complete set of 30
dimensions were presented to the SMEs, along with their respective contextual definitions and
justification for inclusion. The SMEs were asked to what extent they agreed with the inclusion
of the various dimensions in the PVR-CMM, in an effort to ascertain which dimensions, if any,
could perhaps be removed from the PVR-CMM in the next iteration of development. The
SMEs were also provided with a pre-reading document which provided them with an overview
of the research leading to the development of the PVR-CMM.
During the symposium described in Section 8.5.5.1, every effort was made to engage with the
SMEs in a face to face manner, this proved beneficial in that a significant amount of positive
feedback and encouragement was received in response to the research overview, aims, and
objectives. This feedback during personal communication, although undocumented, reaffirmed
the value and necessity of the research, especially in the context of capacity building for PV
in Africa. These face to face conversations also allowed the SMEs to ask any questions with
regard to completing the second verification questionnaire. Due to the short duration of the
symposium, the SMEs were provided with the questionnaires in the form of a hard copy and
well as via email, which included an online version of the questionnaire.
8.6.2 Subject matter expert feedback: Second verification
Overall, the feedback from the second verification process was positive. The feedback will
be discussed in two parts, relating to the two sections of the questionnaire. In response to
the section addressing the comprehensiveness of the DRs, five of the responses shared the
same sentiment, that the list of DRs was comprehensive. The remaining three SMEs provided
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comments which required more reflection and response. The following statements were made
by the eight SMEs1:
“I think the design requirements are comprehensive enough.”
“The above list of offers a robust range of requirements.”
“All aspects are covered.”
“None that immediately come to mind. I know ethics has been mentioned but
this, in my opinion, holds the key to enhancing Patient Safety across the world
and across all institutions and stakeholders.”
“It is comprehensive, but [there is] a need to look at support systems for sustain-
ability.”
While all five of the above statements agree that the list of DRs in Section 7.4 is comprehensive,
the fifth comment specifies a need to “look at support systems for sustainability”. While this
is a valid recommendation, the concept of sustainability is one typically associated with the
use of maturity models to solve problems by developing capacity and increasing organisational
maturity in a sustainable way, as conveyed in Chapter 5. Section 6.3 acknowledges the challenge
associated with sustainability when implementing HIT solutions in health systems. The PVR-
CMM also includes dimension 1.3.2 which refers to business sustainability practices in PV.
“Capability to be versatile and be used for Active Safety Surveillance; Utility and
capability for reporting Serious Adverse Events for investigational medicinal prod-
ucts used in clinical trials.”
The contextualisation of this research is presented in Chapter 3. This research focusses on the
post-marketing authorisation phase and the collection of safety data via spontaneous reporting
of ADRs. In Section 3.2, the drug development process is described, indicating that clinical
trials form part of the pre-marketing authorisation activities. Additionally, in Section 3.3, a
distinction is made between active surveillance methods and passive surveillance methods,
with spontaneous reporting being part of the latter. With that in mind, the SMEs comments
regarding versatility for active safety surveillance and utility during clinical trials should be
considered for possible inclusion in future iterations of the PVR-CMM, but at present, remain
beyond the scope of this research .
1Note that the order in which these statements are presented in the dissertation does not necessarily
correspond to the order in which the SMEs are listed in Table 8.1
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“I don’t seem to feel a sense of patient perspective or involvement in the design.
Also the Ministry of Health as a stakeholder could be beneficial as an implementer
of the many recommendations. I was also wondering if media (social, print, radio,
TV, etc) could be incorporated in one of the areas as administrative or data or IT
concern.”
The role of the patient, although perhaps difficult to identify in the context of the PVR-
CMM assessment tool, has been described at length in Section 4.1.1 as well as in the level
of analysis of PV as a sociotechnical system in Section 6.1.1. The concept of direct patient
reporting is discussed throughout Chapter 4 and is addressed in the data capture dimension
(dimension 2.1.1) of the PVR-CMM. In terms of the role of media, this has also been discussed
in Section 4.1.1 and forms part of the PVR-CMM in dimension 1.4.3, human resources capacity
development.
“Not sure how the matrix will tackle some of the key barriers to reporting cases.”
While the PVR-CMM is not developed with the primary intention of alleviating key barriers to
reporting, every effort was made in studying the key barriers to reporting. Identifying the key
barriers to reporting is the fourth research objective in this dissertation, as stated in Section
1.4.2. The design and development is cognisant of many of the key barriers to reporting,
as discussed in Chapters 1, 3, and 4, with additional attention given to the sociotechnical
challenges of introducing HITs to health systems in Chapter 6. The PVR-CMM does include
a number of dimensions which seeks to address challenges relating to HCP knowledge and
training, as well as the technologies used in reporting cases.
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Law, Regulation, and Policy 5 5 5 5 4 5 5 5 39 97,5% 5,0 5,0
Governance structures and commitment 5 5 4 5 5 4 5 5 38 95,0% 5,0 5,0
Business Continuity and Responsiveness 5 4 5 5 5 4 5 5 38 95,0% 5,0 5,0
Data ethics/Ownership 5 5 5 5 5 4 3 5 37 92,5% 5,0 5,0
Monitoring of performance and effectiveness 5 4 5 5 4 3 4 5 35 87,5% 5,0 4,5
Transparency and accountability 5 5 5 5 5 4 5 5 39 97,5% 5,0 5,0
Partnerships 5 5 5 5 3 5 4 5 37 92,5% 5,0 5,0
Stakeholder communication 4 5 5 5 4 4 5 5 37 92,5% 5,0 5,0
Organisational Strategy alignment 4 5 5 5 4 3 4 5 35 87,5% 5,0 4,5
Building a culture of Safety 5 5 5 5 5 4 4 5 38 95,0% 5,0 5,0
Organisational change management 4 5 5 5 4 4 5 5 37 92,5% 5,0 5,0
Financial management 5 5 5 5 4 4 5 4 37 92,5% 5,0 5,0
Financial resource mobilisation 4 5 5 5 3 4 5 4 35 87,5% 5,0 4,5
Regulatory Compliance 5 5 5 5 5 5 5 4 39 97,5% 5,0 5,0
Resource efficiency and business sustainability 5 5 5 5 4 4 4 5 37 92,5% 5,0 5,0
Data management 4 5 5 5 4 5 3 5 36 90,0% 5,0 5,0
Human resources policy 5 5 5 5 4 5 5 5 39 97,5% 5,0 5,0
Human resources capacity 5 5 5 5 4 5 5 5 39 97,5% 5,0 5,0
Human resources capacity development 4 5 5 5 5 5 5 5 39 97,5% 5,0 5,0
Data Capture 5 4 4 5 5 5 4 5 37 92,5% 5,0 5,0
Data Storage and Aggregation 5 5 4 5 5 4 4 5 37 92,5% 5,0 5,0
Workflows 5 5 5 5 4 4 5 5 38 95,0% 5,0 5,0
Data Presentation/Transmission 5 5 5 5 4 4 3 5 36 90,0% 5,0 5,0
Data Standards 5 5 5 5 4 3 5 5 37 92,5% 5,0 5,0
Information content 5 5 5 5 5 3 5 5 38 95,0% 5,0 5,0
Data protection, privacy, and security standards 5 5 5 5 5 3 5 5 38 95,0% 5,0 5,0
Information exchange and interoperability standards 5 5 5 5 5 4 5 5 39 97,5% 5,0 5,0
ICT Hardware 5 5 5 5 4 3 5 4 36 90,0% 5,0 5,0
Network 5 5 5 5 4 4 5 4 37 92,5% 5,0 5,0
Development and Maintenance 5 5 5 5 3 4 5 4 36 90,0% 5,0 5,0
Regarding the second section of the questionnaire, the SMEs were asked to what extent they
agreed with the inclusion of each of the 30 dimensions in the PVR-CMM. Table 8.3 shows
the responses from the eight SMEs numbered from SME five through twelve. The responses
highlighted in red are those which represent a response of ‘unsure’. Given that none of the 30
dimensions received more than one ‘unsure’ response, it was clear that all 30 of the dimensions
should remain part of the PVR-CMM.
In addition to the results summarised in Table 8.3, the eight SMEs made the following com-
ments:
“IT infrastructure should not be for PV only but integrated to daily operations at
patient care level.”
“Very well thought out approach - I like it.”
“Consider possibility of hosting the database in the ”cloud” and new emerging
options in ICT; also consider options of building the IT system as opposed to
contracting or buying the software off the shelf.”
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Both the first, and second parts of this comment are suggesting the type of incremental
improvements and use cases that are associated with the use of maturity models. By using the
PVR-CMM it is envisioned that an organisation would increase it’s data storage capabilities to
the extent that new technologies, such as cloud-based storage and computing, are adopted.
With regard to the second part of this comment, the case study in Chapter 9, considers the
scenario where an organisation would use the PVR-CMM to develop its internal capabilities
to the extent that it does not rely on ‘off the shelf’ software, this is specifically addressed in
Section 9.4.
“Some items on data seems to me would fit better in IT infrastructure or IT
standards rather than business procedure or business objectives. I felt some of the
dimension better suited other subdomains. For example, data presentation and
transmission rather seem well suited for IT standards or infrastructure.”
In response to this comment, it is important to consider the difference between business
procedures and IT standards. Data presentation and data transmission are included in the
business procedures because these are representative of what type of activities an organisation
needs to execute to achieve their business objectives and remain within regulatory compliance.
In terms of communicating PC data, whether by a regulator or an MAH, the key business
procedures involved revolve around the receiving, capturing, storing, and sending of data. IT
standards include documented, agreed upon, and repeatable ways of carrying out business
procedures to improve their efficiency and effectiveness. The role of IT standards in the PVR-
CMM is to support the execution of the associated business procedures.
“Suggest hierarchical control analysis to demonstrate relations of different stake-
holders and who is in control at different levels. It is difficult to judge whether this
model with assess PV system maturity without testing it on a few examples.”
Hierarchical control analysis would be a valuable analysis to carry out. However, within the
context of this study, performing such an analysis remains beyond the scope of what is prac-
tically achievable, given the significant amount of time such an analysis would require. More
on this suggestion is discussed in the future work section of this dissertation, found in Section
10.5.
8.7 Verification conclusion
Overall, positive feedback was received from all twelve of the SMEs. The results from the
first verification, although positive, were deemed incomplete due to the lack of regulatory
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representation among the SMEs. To address this, a second round of verification was performed,
engaging a larger cohort of SMEs with more varied attributes. The results of the second
verification, while resulting in minor refinements, corroborate the results of the first verification,
indicating that the PVR-CMM V2 is verified and ready for implementation in a real-world
setting. Additional comments from the SMEs included that the model was “impressive, well
thought out and put together”(Appendix B.3.2), and that it is “a good concept to apply the
CMM to PV activities”(Appendix B.3.3). Collectively, the results from the first and second
verification activities indicate that the PVR-CMM V2 has the potential to achieve the aim and
objectives which were stated in Sections 7.3 and 7.4. Comments relating to applicability of
the model in region specific contexts, and more specifically the translation of problems from
a global level to an African context, serve as inputs for the design and execution of the case
study in Chapter 9.
8.8 Chapter 8: Conclusion
Following the population of the PVR-CMM V1, in Chapter 7, this chapter focussed on a
verification and validation strategy, with the goal of ensuring the PVR-CMM’s suitability for
implementation in a real world setting. The PVR-CMM V1 was subjected to two verification
processes, by engaging with subject matter experts and focussing on the design requirements
and model components that made up the PVR-CMM V1. The feedback of the SMEs was





Case study implementation and
external validation
In this chapter the final version of the PVR-CMM, namely the PVR-CMM V2, is presented.
The conception of transfer media is described, and the layout of the PVR-CMM V2 assessment
tool is shown. The PVR-CMM V2 is subsequently implemented in a case study to determine the
extent of empirical validity. The case study design, participating organisation, execution, and
results, are discussed accordingly. Accompanying the results of the PVR-CMM V2 assessment
results, are practical recommendations which seek to assist the participating organisation in
improving their maturity across various dimensions. Finally, the PVR-CMM V2 is subjected to
a validation activity, whereby the participating organisation is asked to validate the outcomes
of the assessment against the PVR-CMM V2’s stated aims; as well as the applicability of the
PVR-CMM, and the overall acceptance of the PVR-CMM V2.
9.1 Introduction
This chapter discusses the case study which was executed using the second generation PVR-
CMM, which was developed and refined in Chapters 7 and 8. The purpose of these chapters
was to develop and refine the PVR-CMM by subjecting it to multiple rounds of verification,
through the engagement of numerous SMEs. Once the model had been verified and refined,
the next logical step was to apply the model in a maturity assessment case study.
Given the lengthy time horizon associated with the implementation of maturity models and
maturity assessment frameworks, the PVR-CMM was not taken through a complete cycle of
implementation. A complete cycle of implementation could require anywhere between one and
two years to execute. For the purpose of this dissertation, the maturity model would be used
to make an assessment of the organisation’s maturity, followed by the development of practical
recommendations which seek to guide the organisation towards a more mature overall state.
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9.2 The PVR-CMM V2
Following the discussion of the SME feedback from the verification activities in Chapter 8, the
final iteration of the PVR-CMM is presented in this chapter. The sixth phase in the PVR-
CMM phases of development shown in Table 7.1, is the conception of transfer material. The
conception of transfer refers to the method of transferring a maturity model to an organisation
which seeks to use the maturity model to make a maturity assessment. In the case of the
PVR-CMM V2, the conception of transfer media involved the transformation of the theoretical
components and constructs of the model, together with the outcomes of the various phases
of development and verification of the PVR-CMM, into a tangible and practicable assessment
tool.
9.2.1 Conception of transfer media
The PVR-CMM V2 was constructed in Microsoft Excel (2016) as a workbook comprising 39
sheets. The 39 sheets are divided into three groups: (i) four introductory sheets; (ii) thirty
sheets which capture the assessment data; and (iii) five sheets which display the results of
the assessment. The complete PVR-CMM V2 is included in Appendix C.2, and a summary is
presented via Figures 9.1 to 9.6.
The overall goal during the conception of transfer media is to create an assessment tool which
facilitates the assessment procedure by improving the accessibility and usability of the PVR-
CMM. The design and layout of the PVR-CMM V2 is intended to reduce user fatigue by
keeping a consistent layout, allowing for simplified navigation throughout the assessment tool.
The presentation of the PVR-CMM V2 in a staged manner is in response to the concerns
raised by SMEs relating to the large number of dimensions and statements and the time
required to review them. The inclusion of the four introductory sheets also serves to improve
the users’ knowledge and understanding of concepts such as spontaneous reporting systems,
maturity models, and interoperability. This was deemed a necessary addition to the PVR-CMM
V2 after considering the feedback from SMEs, particularly the feedback discussed in Section
8.5.3. To ensure that the users of the PVR-CMM V2 are fully conversant in the spontaneous
reporting of ADRs, an appendix, namely Appendix 1 of the PVR-CMM was developed (found
in Appendix C.1). This appendix is added to the PVR-CMM to address the question of
whether the PVR-CMM can be used for educational purposes to explain the various aspects of
spontaneous reporting to anyone with little or no background in pharmacovigilance. Appendix
1 is made up primarily from the contents of Chapters 3 and 4 and is therefore repetitive in the
context of this thesis.
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The landing page of the PVR-CMM V2 is the introduction sheet, shown in Figure 9.1. The
introduction includes the aim and intended use of the assessment tool, as well as some back-
ground information relating to the development of the PVR-CMM. A disclaimer is included in
the introduction so as to assist the user in understanding the intended use of the assessment
tool, as well as to notify the user that the model may have to be tailored slightly to fit the
needs of the individual or the organisation that is conducting the maturity assessment.
Figure 9.2 shows an overview of the PVR-CMM V2. The 30 dimensions are presented and
grouped according to their respective domains and subdomains. By providing a high-level
overview of the PVR-CMM V2 in such a way, the user is informed of the model’s content and
scope. This presents the user with an indication of what information might be required from
the organisation, when conducting a maturity assessment.
Figure 9.3 shows the general maturity levels that are used in the PVR-CMM V2. This page in
the assessment tool provides the user with definitions associated with the concepts of capability
and interoperability. The generic maturity levels of both the capability and interoperability
scales are provided so as to familiarise the user with the progression of maturity as well as to
indicate how the maturity levels accumulate, in accordance with DR11, as stated in Section
7.4.
The user of the PVR-CMM V2 is provided with a set of instructions pertaining to the maturity
assessment process, as shown in Figure 9.4. The instructions also inform the user how to
navigate through the assessment tool by clicking the appropriate links. Below the instructions
in Figure 9.4, is the profile page of the PVR-CMM V2. This profile section allows the user to
capture information pertaining to the assessment which is being conducted. Information such
as, the date, identification of the individual conducting the assessment, as well as information
relating to the nature of the assessment, whether is it determined internally or externally, and
within which department of which organisation. Upon completing the profile data entry, the
user will begin the assessment by clicking the link at the bottom of the page.
Figure 9.5 shows the first dimension of the PVR-CMM V2. The layout of this page is consistent
with the remaining 29 dimensions. The user is shown which dimension is being assessed,
together with the contextual definition of the dimension and the respective sets of capability
and interoperability statements. Once the user has read all of the necessary information, they
can select from the drop-down list, the level description which most accurately describes the
maturity of the dimension in question. Once the appropriate level description has been selected,
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The results page of the PVR-CMM V2 is shown in Figure 9.6. This page is automatically
updated as the user progresses through the maturity assessment. The results are grouped
according to the structure of the PVR-CMM as shown in the overview page, in Figure 9.2.
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Please direct any feedback regarding this tool to: Results
16497457@sun.ac.za
©Stellenbosch University, 2018
MJ Schurer, L Louw, L Bam, IH de Kock
The Pharmacovigilance Reporting Capability Maturity Model (PVR-CMM) is a maturity assessment tool which was developed to assist
organisations which own or operate a spontaneous reporting system for pharmacovigilance. The aim of the model is to promote and improve
interoperability by addressing the degree of integration of systems involved, providing guidance on which system components need to be
improved, as well as providing a means for measuring interoperability progress accross the community of spontaneous reporting systems in the
global pharmacovigilance landscape.
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
INTRODUCTION
Spontaneous reporting of adverse drug reactions is widely considered to be the cornerstone of data generation in pharmacovigilance.
Pharmacovigilance systems, by nature, are complex. Spontaneous reporting systems are faced with problems such as under-reporting and the
communication of incomplete, unrepresentative, and uncontrolled data. The lack of standardisation and interoperability among these systems
results in a reduced capability to detect and characterise new adverse drug interactions and reactions. 
Maturity models assist organisations with linking their business objectives to the improvement goals they seek to achieve. By using this maturity
assessment tool, an organisation can:
  -  Identify their current maturity level
  -  Identify a desired maturity level
  -  Benchmark and/or compare their capability maturity against a community of similar organisations 
  -  Identify specific dimensions where potential improvement can be made
  -  Develop a roadmap or plan to grow the organisations maturity to the desired level
The development of the PVR-CMM was the culmination of an extensive multidisciplinary literature review covering aspects of pharmacovigilance,
sociotechnical systems, interoperability, and maturity models. Through multiple validation processes with subject matter experts, the PVR-CMM
has demonstrated value to organisations which own or operate a spontaneous reporting system.
Disclaimer: The PVR-CMM was developed with the intention of being used in conjunction with other PV related statutes, guidelines and
documents. The contents of the PVR-CMM should be considered as general guidelines which can be adapted to suit the individual needs of any
country or organisation managing a spontaneous reporting system for pharmacovigilance, while incorporating current best practices and
achieving and maintaining regulatory compliance. The PVR-CMM lends support to other pharmacovigilance tools such as the WHO Global
Benchmarking Tool and the Indicatior Based Pharmacovigilance Assessment Tool.
It is intended that the user of the PVR-CMM has a sufficient understanding of their organisations pharmacovigilance system so that the necessary
adaptations and refinements to the tool can be made to fit the organisation's individual needs. The PVR-CMM has been developed to allow for
enough generality to be widely applicable to organisations in pharmacovigilance, but also with enough specificity that it is possible to identify
potential areas of weakness and strength. It was deemed necessary to simplify certain complex realities, at the sacrifice of accuracy in some cases,
however, the best effort was made to avoid a too generic, vague, or too detailed and too complex approach. Although the covered topics are
necessarily complex, simplicity in order to improve readability and applicability was paramount, with the intention of developing a tool which can
be used to better understand the situation and define focused, specific strategies for improvement.
Finally, the PVR-CMM should by no means be considered perfect or even complete, it is expected that with feedback from users the model can be
continuously improved, making it a better, more accurate tool. To send feedback, please see the note at the bottom of this page.
Figure 9.1: The landing page and introduction of the PVR-CMM V2 assessment tool.
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Domain 1: Organisational Domain 2: Informational
Subdomain 1: Leadership and Governance Subdomain 1: Business Procedures
1.1.1 Law, Regulation, and Policy 2.1.1 Data Capture
1.1.2 Governance structures and commitment 2.1.2 Data Storage and Aggregation
1.1.3 Business Continuity and Responsiveness 2.1.3 Workflows
1.1.4 Data ethics/Ownership 2.1.4 Data Presentation/Transmission
1.1.5 Monitoring of performance and effectiveness
1.1.6 Transparency and accountability Subdomain 2: IT Standards
1.1.7 Partnerships 2.2.1 Data Standards
1.1.8 Stakeholder communication 2.2.2 Information content
1.1.9 Organisational Strategy alignment 2.2.3 Data protection, privacy, and security standards
1.1.10 Building a culture of Safety 2.2.4 Information exchange and interoperability standards
1.1.11 Organisational change management
Subdomain 2: Finance and Economics Domain 3: Technical
1.2.1 Financial management
1.2.2 Financial resource mobilisation Subdomain 1: IT Infrastructure
3.1.1 ICT Hardware
Subdomain 3: Business Objectives 3.1.2 Network
1.3.1 Regulatory Compliance 3.1.3 Development and Maintenance
1.3.2 Resource efficiency and business sustainability
1.3.3 Data management
Subdomain 4: Human Resources
1.4.1 Human resources policy
1.4.2 Human resources capacity
1.4.3 Human resources capacity development
Please direct any feedback regarding this tool to: Results
16497457@sun.ac.za
©Stellenbosch University, 2018
MJ Schurer, L Louw, L Bam, IH de Kock
Research suggests that interoperability results as a product of standardisation in four domains: technology, syntax, semantics, and pragmatics.
The PVR-CMM is structured with sociotechnical system engineering principles in mind, that is to say, placing equal importance on the social,
political, and environmental (workplace) factors. For these reasons, the 30 dimensions of the PVR-CMM (as seen below) are catagorised into 3
domains: Organisational (pragmatic), Informational (syntax and semantic), and Technical; as well as several subdomains.
The 30 dimensions which make up the PVR-CMM were selected from literature and have been subjected to multiple validation processes
whereby subject matter experts from various pharmacovigilance organisations judged their inclusion in the model as critical to the success of a
spontaneous reporting system in the global pharmacovigilance landscape. Explicitly, the 30 dimensions are:
The overall maturity level of the system being assessed is
represented by the collective maturity levels of these 30
dimensions. The results section of this tool will provide an overview
of the maturity levels, as well as some graphical representations of
the maturity levels across the various domains and subdomains.
MATURITY LEVELS
OVERVIEW
The PVR-CMM is developed in such a way that it aims to be easily understood at a high level, with the details of capability maturity and
interoperability maturity of the dimensions being addressed as the user delves deeper into the model.
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
Figure 9.2: The overview page of the PVR-CMM V2 assessment tool.
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Builds on level 3. Uses statistical and other quantitative techniques to understand performance 
variation and detect, refine, or predict the area of focus to achieve quality and performance 
objectives.
Single technology. No standardisation.
Technical and semantic issues are solved.
Two systems linked for simple exchange of data.
Work processes are linked.
Linking of homogenous systems for a common objective.
Knowledge is shared.
Linking of heterogenous systems for a common goal.
Benefits shared.
Systems can connect and disconnect freely and exchange data without serving a common goal.
DESCRIPTION
The interoperability maturity scale used in the PVR-CMM is based on the work of Gottschalk (2009) and van Velsen et al.  (2016):
Builds on level 4. Uses statistical and other quantitative techniques to optimise performance and 
improvement to achieve quality and process performance objectives.
CAPABILITY MATURITY
DESCRIPTION
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
Initial approach to meeting the intent of the practice area.
Subsumes level 1. A simple, but complete set of practices that address the full intent of the practice 
area.
The PVR-CMM makes use of two maturity scales, relating to capability maturity and interoperability maturity respectively. Capability is 
associated with specific business processes or a practice area within an organisation. Whereas, maturity is the degree to which an organisation
has explicitly and consistently deployed processes, according to the business objectives. Interoperability can be defined as "the ability of
different information technology systems and software applications to communicate, exchange data, and use information that has been
exchanged".
Builds on level 2. Uses organisational standards and tailoring to address project and work 
characteristics.
The capability maturity levels that are used in the PVR-CMM are exactly the same as those originally developed by the well known CMMI
Institute (2018):
Figure 9.3: The maturity levels of the PVR-CMM V2 assessment tool.
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Respondent details:       (All fields marked * MUST be completed)
©Stellenbosch University, 2018




Internal or External assessment: *
Department: *
Name of respondent: *
Role or position: *
PROFILE
Date of assessment: *
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
INSTRUCTIONS
9)  When all of the dimensions have been assessed the top right corner of the screen will display "RESULTS", click here.
5)  Click the drop-down list in the red outlined cell to select the level which you have identified
6)  The number of the level and the description of the level will update accordingly
4)  Identify which level description most accurately describes the maturity of the dimension in question
10)  The results will be summarised and graphical representation of the results can be found using the appropriate links on the results page
(Please note that the level descriptions are based on generic situations, so “perfect matches” to your specific reality will be rare. )
7)  Click on the green arrow in the top right corner of the window to navigate to the next dimension
8)  Repeat steps 3 - 7 until all of the dimensions have been assessed
1)  Complete the user profile form by clicking the link at the bottom of this page labelled "PROFILE"
2)  When the profile form is complete, click the link at the bottom labelled "BEGIN ASSESSMENT"
3)  Read the dimension definition and the maturity statements for both the capability maturity and the interoperability maturity  scales


















LEVEL NAME LEVEL NAME
1 Initial 1 System as silo
2 Managed 2 Peer-to-peer





5 Optimizing 5 Universal
©Stellenbosch University, 2018
MJ Schurer, L Louw, L Bam, IH de Kock Results
D1.1.1 Law, Regulation, and Policy
The existence of the appropriate legal provisions that mandate and guide all PV related activities. Legal requirements and guidelines applicable to all National Competent Authorities/Regulatory Authorities and Marketing 
Authorisation Holders, regarding the collection, data management and reporting of suspected adverse drug reactions associated with medicinal products for human use. From an interoperability perspective it is necessary 
to have a common understanding of legislation relating to the exchange of information and the associated security and privacy issues. Legislation and regulatory guidelines must be compatible and define the boundaries of 
interoperability between two ICT systems.
SYSTEM AS SILO
All legislation and policies relating to patient safety are well defined, 
implemented, and actively reviewed and updated by a wide range of 
stakeholders.
Regulations are tailored to support patient safety activities and policies 
are developed to ensure compliance.
Policies are developed to understand performance variation and detect, 
refine, or predict the area of focus to achieve quality and process 
performance objectives associated with patient safety.
Simple agreements between two homogenous systems are agreed upon to 
address simple business processes which are shared.
Peer-to-peer.
Legislation is fully distributed across all organisations/role players within 
the jurisdiction of the National Regulatory Authority.
Linking of systems for a common objective.
National legislation is fully integrated and aligned with international 
legislation.
Policies are harmonised between organisations to share benefits and 
achieve value interoperability.
National legislation is fully integrated and aligned with international 
legislation. Legislation is continuously updated and improved upon and 
contributes to the development of the international legislative landscape.
CAPABILITY MATURITY LEVEL
Select the level with the most accurate 
description
DESCRIPTION
Some regulations are policies have been developed and implemented, but 
in an unstructured manner, lacking consistency.
Legislation has been developed to address patient safety, with a simple 
but complete set of regulations to support the legislation.
INTEROPERABILITY MATURITY 
LEVEL
Select the level with the most accurate 
description
DESCRIPTION
No formal legislation or policies. Any existing policies are localised to the 
individual system setting.
No standardisation.
Figure 9.5: The first of the 30 dimensions included in the PVR-CMM V2 assessment tool.
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Organisation:
Assessment date:
Subdomain 1: Leadership and Governance Capability Level Score Interoperability Level Score
1.1.1 Law, Regulation, and Policy Initial 1 System as silo 1
1.1.2 Governance structures and commitment Initial 1 System as silo 1
1.1.3 Business Continuity and Responsiveness Initial 1 System as silo 1
1.1.4 Data ethics/Ownership Initial 1 System as silo 1
1.1.5 Monitoring of performance and effectiveness Initial 1 System as silo 1
1.1.6 Transparency and accountability Initial 1 System as silo 1
1.1.7 Partnerships Initial 1 System as silo 1
1.1.8 Stakeholder communication Initial 1 System as silo 1
1.1.9 Organisational Strategy alignment Initial 1 System as silo 1
1.1.10 Building a culture of Safety Initial 1 System as silo 1
1.1.11 Organisational change management Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 2: Finance and Economics Capability Level Score Interoperability Level Score
1.2.1 Financial management Initial 1 System as silo 1
1.2.2 Financial resource mobilisation Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 3: Business Objectives Capability Level Score Interoperability Level Score
1.3.1 Regulatory Compliance Initial 1 System as silo 1
1.3.2 Resource efficiency and business sustainability Initial 1 System as silo 1
1.3.3 Data management Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 4: Human Resources Capability Level Score Interoperability Level Score
1.4.1 Human resources policy Initial 1 System as silo 1
1.4.2 Human resources capacity Initial 1 System as silo 1
1.4.3 Human resources capacity development Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Subdomain 1: Business Procedures Capability Level Score Interoperability Level Score
2.1.1 Data Capture Initial 1 System as silo 1
2.1.2 Data Storage and Aggregation Initial 1 System as silo 1
2.1.3 Workflows Initial 1 System as silo 1
2.1.4 Data Presentation/Transmission Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 2: IT Standards Capability Level Score Interoperability Level Score
2.2.1 Data Standards Initial 1 System as silo 1
2.2.2 Information content Initial 1 System as silo 1
2.2.3 Data protection, privacy, and security standards Initial 1 System as silo 1
2.2.4 Information exchange and interoperability standards Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Subdomain 1: IT Infrastructure Capability Level Score Interoperability Level Score
3.1.1 ICT Hardware Initial 1 System as silo 1
3.1.2 Network Initial 1 System as silo 1
3.1.3 Development and Maintenance Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Maturity Assessment Results
Domain 1: Organisational
Domain 2: Informational (Syntax and Semantics)
Domain 3: Technical
The following results pertain to:
Figure 9.6: The results page of the PVR-CMM V2 assessment tool.
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9.3 Case study: Implementation of the PVR-CMM V2
This section, together with Section 9.5, represent phase 7 of the PVR-CMM phases of devel-
opment in Table 7.2; that is, implementation and validation. Upon completion of the transfer
media, following the two verification activities, the PVR-CMM V2 is deemed ready for imple-
mentation in a real-world setting. To implement the PVR-CMM V2 in a case study, the design
of the case study must be determined, a suitable participating organisation must be identified,
and the validity of the maturity assessment outcomes must be ascertained to determine the
generalisability of the maturity model.
Following the feedback received from SMEs during the second round of verification, discussed
in Section 8.6, as well as discussions held with SMEs 13 and 141, it was decided that the PVR-
CMM should be developed and implemented primarily within an African regulatory context.
With this in mind, an appropriate participating regulatory authority had to be identified.
9.3.1 Case study participating organisation
For this case study, a prominent National Pharmaceutical Regulatory Authority within the
Southern African Development Community (SADC) was approached. The regulatory authority
has been conducting PV activities for over 40 years, having been among the first African
countries to join the WHO IDMP, in the early 1990’s. The regulatory authority coordinates
the national pharmacovigilance programme, which includes 3 national PV centres, as well as
a national ADR monitoring unit which was created in the late 1980’s. In 2015, the regulatory
authority reported spontaneous reporting rates of approximately 62 reports/million capita. The
vigilance and post-marketing surveillance working group of the RA is tasked with establishing
a regimen of vigilance for the collection and evaluation of information relevant to the benefit
to risk balance of medicines and medical devices on the market within it’s jurisdiction. As well
as, the continuous monitoring of the safety profiles of these products and taking appropriate
action where necessary.
Given the scale of a case study of this nature, as well as the limited number of national
regulatory authorities within a reasonable geographical proximity, it was deemed that one
thorough case study would suffice to demonstrate the applicability and value of the PVR-
CMM.
A letter of request for the case study was sent to the regulatory authority, which can be found
in Section C.3, of Appendix C. The letter serves to inform the organisation of the purpose of
the case study. It also communicates the time and materials that are necessary to conduct the
case study. Upon receipt of the letter, the organisation invited the researcher to present the
1Conversations occurring during the ISoP-ASoP symposium in Nairobi, Kenya.
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findings of this dissertation as well as a proposal presentation to various representatives of the
organisation’s executive body. Upon delivering this presentation the director granted approval
for the commencement of the case study.
9.3.2 Case study execution
The case study was conducted over a period of five days at the location of the national regula-
tory authority and comprised a series of contact sessions with the appropriate members of the
organisation. In total, four sessions of 3 hours were conducted, resulting in one complete as-
sessment of the organisation’s maturity. Each session involved at least 3 people, the facilitator,
as well as two members of the regulatory authority. During the maturity assessment, relevant
members of the vigilance unit were invited to provide information pertaining to dimensions
which they were more directly involved in. Throughout the sessions, three members of the
organisation were exposed to the entire maturity assessment process, including all 30 dimen-
sions of the PVR-CMM. These three representatives, henceforth referred to as participants 1,
2, and 3; included two medicines control officers (P1 and P2), as well as the deputy director
of the pharmacovigilance unit (P3).
If at any point during the maturity assessment process, the participants were in a state of
disagreement as to which maturity level to ascribe to a particular dimension, a note was
made and the final decision was left to the discretion of P3, given P3’s seniority within the
organisation. Throughout the assessment, the evidence provided in support of each capability
maturity level and interoperability maturity level selected, was recorded. For the protection of
the regulatory authority’s identity, this detailed information is not included in the dissertation.
Upon completion of the maturity assessment, the results are discussed and practical recom-
mendations are developed in Section 9.4.
9.4 Case study results and practical recommendations
The results of the maturity assessment, as generated by the PVR-CMM V2, are displayed in
Table 9.1, as well as in various radar charts in Figures 9.7 to 9.11. Following Table 9.1, the
discussion of the results will be structured according to the radar charts as well as the following
criteria:
1. Dimensions which score a maturity level below the average capability maturity or inter-
operability maturity score;
2. Dimensions which score the lowest combined capability maturity and interoperability
maturity scores, in other words, the weakest dimensions;
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3. Dimensions with the greatest absolute difference between capability maturity and inter-
operability maturity;
4. Subdomains with the lowest average capability maturity;
5. Subdomains with the lowest average interoperability maturity; and
6. Subdomains with the greatest absolute difference between average capability maturity
and average interoperability maturity.
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Table 9.1: Case study maturity assessment results.
Organisation:
Assessment date:
Subdomain 1: Leadership and Governance Capability Level Score Interoperability Level Score
1.1.1 Law, Regulation, and Policy Managed 2 System as silo 1
1.1.2 Governance structures and commitment Quantitatively Managed 4 Distributed 3
1.1.3 Business Continuity and Responsiveness Initial 1 System as silo 1
1.1.4 Data ethics/Ownership Defined 3 Peer-to-peer 2
1.1.5 Monitoring of performance and effectiveness Defined 3 Peer-to-peer 2
1.1.6 Transparency and accountability Managed 2 Peer-to-peer 2
1.1.7 Partnerships Managed 2 Peer-to-peer 2
1.1.8 Stakeholder communication Managed 2 Peer-to-peer 2
1.1.9 Organisational Strategy alignment Managed 2 Peer-to-peer 2
1.1.10 Building a culture of Safety Defined 3 Peer-to-peer 2
1.1.11 Organisational change management Defined 3 Peer-to-peer 2
Subdomain Score: 2,45 Subdomain Score: 1,91
Subdomain 2: Finance and Economics Capability Level Score Interoperability Level Score
1.2.1 Financial management Quantitatively Managed 4 System as silo 1
1.2.2 Financial resource mobilisation Managed 2 System as silo 1
Subdomain Score: 3,00 Subdomain Score: 1,00
Subdomain 3: Business Objectives Capability Level Score Interoperability Level Score
1.3.1 Regulatory Compliance Quantitatively Managed 4 Integrated 4
1.3.2 Resource efficiency and business sustainability Defined 3 Integrated 4
1.3.3 Data management Defined 3 Peer-to-peer 2
Subdomain Score: 3,33 Subdomain Score: 3,33
Subdomain 4: Human Resources Capability Level Score Interoperability Level Score
1.4.1 Human resources policy Quantitatively Managed 4 System as silo 1
1.4.2 Human resources capacity Defined 3 Peer-to-peer 2
1.4.3 Human resources capacity development Quantitatively Managed 4 System as silo 1
Subdomain Score: 3,67 Subdomain Score: 1,33
Domain Score: 3,11 Domain Score: 1,89
Subdomain 1: Business Procedures Capability Level Score Interoperability Level Score
2.1.1 Data Capture Managed 2 Peer-to-peer 2
2.1.2 Data Storage and Aggregation Managed 2 Peer-to-peer 2
2.1.3 Workflows Defined 3 System as silo 1
2.1.4 Data Presentation/Transmission Quantitatively Managed 4 Universal 5
Subdomain Score: 2,75 Subdomain Score: 2,50
Subdomain 2: IT Standards Capability Level Score Interoperability Level Score
2.2.1 Data Standards Managed 2 Peer-to-peer 2
2.2.2 Information content Managed 2 Distributed 3
2.2.3 Data protection, privacy, and security standards Managed 2 Peer-to-peer 2
2.2.4 Information exchange and interoperability standards Initial 1 System as silo 1
Subdomain Score: 1,75 Subdomain Score: 2,00
Domain Score: 2,25 Domain Score: 2,25
Subdomain 1: IT Infrastructure Capability Level Score Interoperability Level Score
3.1.1 ICT Hardware Managed 2 System as silo 1
3.1.2 Network Defined 3 Peer-to-peer 2
3.1.3 Development and Maintenance Managed 2 System as silo 1
Subdomain Score: 2,33 Subdomain Score: 1,33
Domain Score: 2,33 Domain Score: 1,33
Maturity Assessment Results
Domain 1: Organisational
Domain 2: Informational (Syntax and Semantics)
Domain 3: Technical





9.4 Case study results and practical recommendations
To identify the dimensions for which to provide practical recommendations, the criteria stated
above will be used. It is important to note that the recommendations included in this report
were formulated with the inputs and experiences gained via the maturity assessment which
was conducted with the regulatory authority. Ideally, the organisation conducting the maturity
assessment recognises the fact that the work does not come to an end once the maturity
assessment has been conducted. Rather, the PVR-CMM maturity assessment would be con-
ducted on a regular basis by the organisation, where the organisation recognises the cyclical
nature of assess, analyse, improve. Following each maturity assessment, a set of improvement
initiatives would be developed by the organisation with the help of the PVR-CMM. Even if the
organisation considers the improvement initiatives not worth the associated implementation
costs, the PVR-CMM can still be used to monitor and manage the maturity of its processes.
Given that this maturity assessment was conducted as a part of a case study, the following
recommendations have been developed by someone external to the regulatory authority, there-
fore the recommendations are limited to the extent that the author of the PVR-CMM does
not have the necessary understanding of the organisation. However, the best effort was made
to offer recommendations for improvement. It is envisioned that if the organisation was to
use the PVR-CMM as it is intended to be used, the organisation would be sufficiently guided















Capability maturity Interoperability maturity
Figure 9.7: Radar chart showing the domain maturity levels from the case study.
At the domain level, shown in Figure 9.7, it is evident that in general the interoperability
maturity of the RA is lagging behind the capability maturity. The only exception to this, at a
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Capability maturity Interoperability maturity
Figure 9.8: Radar chart showing the subdomain maturity levels from the case study.
domain level, is the interoperability maturity of the informational domain. The reason for this
can most likely be attributed to the RA’s reliance on the VigiFlow software to send and receive
ICSRs. As the regulatory authority currently uses VigiFlow, one could argue that their capability
and interoperability maturity in terms of the informational domain is high. A perspective that
was adopted during the assessment, however, is that if the RA were to stop their VigiFlow
subscription, the capability and interoperability maturity would be considerably lower. With
the exception of the data presentation/transmission dimension, all of the dimensions in the
informational domain were assessed under the context of the RA not having an active VigiFlow
subscription. The logic here was to assume that without VigiFlow, the PVR-CMM V2 could
help to improve the informational domain to the extent that the RA would no longer rely on
VigiFlow as the primary ICSR gateway, much like the case of Eudravigilance software in EU
and FAERS software in US. These are ICSR gateways that comply with VigiFlow standards
but offer significantly more functionality tailored to the region’s needs and priorities.
At the subdomain level, shown in Figure 9.8, observations with respect to sixth criterion are
highlighted. The subdomains with the greatest absolute difference between average capability
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maturity and average interoperability maturity are:
1. D1.2: Finance and economics, with an absolute difference of 2.0; and,
2. D1.4: Human resources, with an absolute difference of 2.33.
An additional observation is the interoperability maturity of subdomain D2.2: IT standards,
this is the only subdomain in the entire maturity assessment which scored a greater level
of interoperability maturity than capability maturity. The subdomains with below average
maturity levels for capability maturity and interoperability maturity, respectively, include:
1. D1.1: Leadership and governance;
2. D2.1: Business procedures;
3. D2.2: IT standards; and,
4. D3.1: IT infrastructure.
And for interoperability maturity, the subdomains which scored the lowest include:
1. D1.1: Leadership and governance;
2. D1.2: Finance and economics;
3. D1.4: Human resources; and,
4. D3.1: IT infrastructure.
9.4.1 Domain 1 results and recommendations
Domain 1, shown in Figure 9.9, contains three of the overall weakest dimensions in terms of
their combined capability and interoperability maturity levels (criterion 2), these three dimen-
sions are:
1. D1.1.1: Law, regulation, and policy;
2. D1.1.3: Business continuity and responsiveness; and,
3. D1.2.2: Financial resource mobilisation.
The dimensions in domain 1 with the greatest difference between their capability maturity level
and their interoperability maturity level (criterion 3), include:
1. D1.2.1: Financial management;
2. D1.4.1: Human resources policy; and,
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3. D1.4.3: Human resources capacity development.
Additional dimensions in domain 1 which scored below the average capability or interoperability
maturity level (criterion 1), include:
1. D1.1.6: Transparency and accountability;
2. D1.1.7: Partnerships;
3. D1.1.8: Stakeholder communication; and,
4. D1.1.9: Organisational strategy alignment.
Subdomain D1.1 scored the lowest average capability maturity level (criterion 4). In terms
of interoperability maturity, subdomains D1.1, D1.2, and D1.4, scored below the average
subdomain interoperability maturity across all domains (criterion 5).
Domain 1: Organisational
Subdomain 1: Leadership and Governance
1.1.1 Law, Regulation, and Policy
1.1.2 Governance structures and commitment
1.1.3 Business Continuity and Responsiveness
1.1.4 Data ethics/Ownership
1.1.5 Monitoring of performance and effectiveness
1.1.6 Transparency and accountability
1.1.7 Partnerships
1.1.8 Stakeholder communication
1.1.9 Organisational Strategy alignment
1.1.10 Building a culture of Safety
1.1.11 Organisational change management
Subdomain 2: Finance and Economics
1.2.1 Financial management
1.2.2 Financial resource mobilisation
Subdomain 3: Business Objectives
1.3.1 Regulatory Compliance
1.3.2 Resource efficiency and business sustainability
1.3.3 Data management
Subdomain 4: Human Resources
1.4.1 Human resources policy
1.4.2 Human resources capacity
1.4.3 Human resources capacity development
1.4.2 Human resources capacity


























Capability maturity Interoperability maturity
Figure 9.9: Radar chart showing the dimension level of domain 1 maturity levels from the case
study.




9.4 Case study results and practical recommendations
Dimension 1.1.1 Law, regulation and policy
The term vigilance was only recently added to the legal framework of the national regulator,
through an amendment Act made in 2015. This implies that pharmacovigilance has not been
addressed with a high degree of specificity. Recommendations would be to follow the example
of the European Medicines Agency and develop a more comprehensive pharmacovigilance legal
framework. The aim of such a framework would be to reduce the number of ADRs in a country,
this would be achieved through (European Medicines Agency, 2012):
 the collection of better data on medicines and their safety;
 rapid and robust assessment of issues related to the safety of medicines;
 effective regulatory action to deliver safe and effective use of medicines;
 empowerment of patients through reporting and participation; and
 increased levels of transparency and better communication.
The pharmacovigilance legal framework should also seek to impact marketing authorisation
applicants and holders, by (European Medicines Agency, 2012):
 making their roles and responsibilities clear;
 minimising duplication of effort;
 freeing up resources by rationalising and simplifying reporting on safety issues; and
 establishing a clear legal framework for post-authorisation monitoring.
Practical measures to facilitate the performance of pharmacovigilance in accordance with the
legislation should be developed and implemented, as is the case with the good pharmacovigi-
lance practice guidelines of the EMA.
Dimension 1.1.3 Business continuity and responsiveness
The recommendation here would be to develop a business continuity plan to enable the reg-
ulatory authority to continue to deliver its services through a major disruption. To do this,
the regulatory authority would need to determine a range of threat scenarios, then plan and
document how the organisation would continue to function through those incidents. The busi-
ness continuity plan can also include a disaster recovery plan, which would describe how the
organisation recovers from a significant disruption. The following six steps can be taken to
develop a business continuity plan (Adapted from (Cerullo & Cerullo, 2004)):
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1. Business Impact Analysis, to identify the critical business operations and processes, as
well as the resources which support them.
2. Identify principle classes of threat and the impact that they may have on the organisation.
These can be collated into a small number of archetypal scenarios, to assist with later
training and testing of the business continuity plan.
3. Take action to mitigate those risks. This is not strictly part of business continuity
planning, but it is recommended to carry it out at this stage of the process.
4. To create readiness plans to maintain continuity in the face of the threat that has
been identified. Typically, these are threats to people, to physical infrastructure, and to
technology and data.
5. To identify a core team of business continuity leaders. Conduct training, tests and
exercises to allow the organisation to evaluate the plans and to increase preparedness.
6. Maintain the plan and keep it under review, as part of a continuous business continuity
planning cycle.
Dimension 1.1.6 Transparency and accountability
Transparency and accountability should be understood by all members of the organisation. The
organisation should have strong policies in place to address the transparency of their business
practices and to understand the value of maintaining a positive sentiment by the external
environment. Upon completing the PVR-CMM maturity assessment, it was evident that the
organisation had recognised the need to make information publicly available. In addition to
current methods such as “Dear HCP1” letters and newsletters, it is recommended that the
following three categories of information be made available in the public domain to enable
accountability:
1. Standards and commitments: These include legislation, regulations, policies and SOPs.
2. Decisions and results: Decisions made by committees, declarations of interest, current
projects, package amendment details, progress reports on policy commitments, audit
reports, KPIs.
3. Consequences and responsive actions: These include follow ups of investigated com-
plaints and a list of corrective actions taken.
1SAHPRA defines a “Dear HCP” letter as “a letter distributed by an applicant or a holder of a certificate
of registration for a medicine to medical practitioners and other health care professionals to convey important
information about medicines. Such letters can be requested by the regulator or initiated by the applicant (South
African Health Products Regulatory Authority, 2015).
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A further recommendation would be to make use of the Pharmaceutical System Transparency
and Accountability Assessment Tool published by the World Health Organisation in 2018.
Dimension 1.1.7 Partnerships
Pharmacovigilance is a collaborative endeavour; therefore the organisation should seek to form
partnerships which provide complementary expertise. Currently the organisation takes part
in Industry Task Group (ITG) meetings to discuss pharmacovigilance. The organisation has
identified potential partnerships with the national Medicines Information Centre (MIC) as well
as the national poison centre. These partnerships should be managed so as to establish trust
between the partnering organisations. Partnerships between PV collaborating centres are also
important for sharing of information and the development and adoption of best practices.
The organisation should actively seek out partnerships which can bring together the necessary
diversity of expertise to strengthen the pharmaceutical system.
Dimension 1.1.8 Stakeholder communication
Currently the organisation has strong communication with industry but is still in the process of
establishing formal communication channels with its provincial constituents. Stakeholder com-
munication consists of three components. The recommendation here is to identify stakehold-
ers, perform a stakeholder analysis, and finally, manage the stakeholder relationships. Regular
communication with key stakeholders helps to create positive and long-standing relationships,
which inevitably result in a range of benefits for an organisation. Formal communication chan-
nels must be established between key stakeholders, whether internal or external, such as the
regulator, health authority, clinicians, MAHs and patients.
Active stakeholder engagement with stakeholders from various system perspectives such as
end-users, IT, or business management, would contribute to the success of health information
technology solutions in achieving interoperability. Adoption mechanisms such as awareness
campaigns, financial incentive programmes, and professional development and accreditation
programmes should also be considered.
Dimension 1.1.9 Organisational strategy alignment
Organisational alignment is important as there can be departmental boundaries within the
organisation which may impede interactions relating to PV. A further recommendation would
be that organisations create a multidisciplinary PV team to foster collaboration between the
various departments of the organisation. Clearly defined roles and responsibilities within the
organisation should be created for the entire drug development and post-marketing stages of
the product life cycle. In doing so, a clear chain of communication and command is established,
which contributes to accountability and assists with decision-making. Based on the results of
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the PVR-CMM assessment, it is evident that a siloed mentality exists within the organisation.
The organisation should seek to share a common understanding of vigilance, and its role in
various working groups such as pharmaceutical regulation, veterinary science, and medical
devices.
Dimension 1.2.1 Financial management
The interoperability of this dimension was difficult to interpret in this case. The main challenge
that was identified was the lack of communication and visibility of financial management
activities between different provinces, due to the differences in provincial government. In the
case of VigiFlow, the organisation encourages provinces to adopt the technology and is able to
provide requirement specifications to each province for the adoption of VigiFlow. However, the
organisation has no influence over budgets and the acquisition of finances at a provincial level.
Given that financial management strategies of various provinces are isolated, the dimension
was scored as level 1 for interoperability.
Dimension 1.2.2 Financial resource mobilisation
Financial resource mobilisation includes all activities relating to securing new and additional
financial resources for an organisation. The organisation is currently working on a project with
a top global management consulting firm, this project was made possible via a grant from the
Bill and Melinda Gates Foundation. Strategies to acquire additional financial grants similar
to the Bill and Melinda Gates Foundation grant should be investigated. Additionally, the
organisation should attempt to engage with national government to formalise regular financial
provisions. It is also potentially worthwhile to assist provincial partners in managing their
financial resources so as to facilitate the implementation of hardware and software upgrades,
such as making use of the VigiFlow system.
To initiate a financial resource mobilisation strategy, the organisation should identify potential
sources of funds, actively solicit pledges from donors and funders, follow up on pledges to obtain
the funds, deposit the funds and maintain records detailing the transactions and restrictions
of the usage of the funds.
Dimension 1.4.1 Human resources policy
The results of the PVR-CMM maturity assessment indicate that the organisation does not have
an internal human resources department. The HR policies are developed by the department
of health. The recommendation for this dimension is for the organisation to develop a human
resources policy which addresses the specific needs and goals of the organisation and includes
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Dimension 1.4.3 Human resources capacity development
Organisations should seek to acquire and retain PV personnel with varied and diverse expertise
and skill sets. Human resource managers should adapt their talent management approach so
as to identify, acquire, and develop talent which can continually meet the ever-changing ex-
pectations of PV. In addition to improving collaboration between departments, it is envisioned
that the PV teams of the future will consist of medical and science professionals, statisticians,
computer scientists, and IT developers.
Currently the organisation has no influence over the medical curricula in the country, but is
investigating ways to grow its involvement in this regard. The organisation has been involved
in training of HCPs in a number of provinces, to assist with the adoption of the VigiFlow
system. It was noted during the maturity assessment that the organisation is reluctant to offer
training in public health programs due to concerns of confusing HCPs who are receiving parallel
training from different stakeholders. An additional need which was identified was the need to
create awareness of the organisation among HCPs across the country. The recommendation
for this dimension is to incorporate patient safety outcomes in the curriculum of HCPs, which
must be supported by continuous evaluation and assessment during their professional careers.
In addition to education and training, medical training institutions should seek to address the
blame culture that is present in PV.
9.4.2 Domain 2 results and recommendations
Domain 2, shown in Figure 9.10, contains one of the overall weakest dimensions in terms of
their combined capability and interoperability maturity levels (criterion 2), D2.2.4: Information
exchange and interoperability standards. The dimension in domain 2 with the greatest differ-
ence between it’s capability maturity level and their interoperability maturity level (criterion
3), is D2.1.3: Workflows.
Additional dimension in domain 2 which scored below the average capability or interoperability
maturity level (criterion 1), include:
1. D2.1.1: Data capture;
2. D2.1.2: Data storage and aggregation;
3. D2.2.1: Data standards;
4. D2.2.2: Information content; and,
5. D2.2.3: Data protection, privacy, and security standards.
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Both subdomains D2.1 and D2.2 scored amongst the lowest average capability maturity levels
(criterion 4).
Domain 2: Informational
Subdomain 1: Business Procedures
2.1.1 Data Capture
2.1.2 Data Storage and Aggregation
2.1.3 Workflows
2.1.4 Data Presentation/Transmission
Subdomain 2: IT Standards
2.2.1 Data Standards
2.2.2 Information content
2.2.3 Data protection, privacy, and security standards
















Capability maturity Interoperability maturity
Figure 9.10: Radar chart showing the dimension level of domain 2 maturity levels from the
case study.
The practical recommendations with regard to the dimensions in domain two, identified here,
are as follows:
Dimension 2.1.1 Data capture
Currently there is a mixed approach when it comes to data capture in the country. There is
a mobile application which was developed for primary healthcare which includes the national
standard ADR reporting form. This mobile application is primarily used by HCPs to support
other work functions, not necessarily to report ADRs. The ADRs that are reported via this
method still need to be re-captured for entry into the VigiFlow system. The organisation
has identified the need for a mobile application exclusively for ADR reporting, but there are
challenges associated with adaptation for local implementation settings. In addition to paper
forms received from HCPs, the organisation also receives ADR reports in various formats from
MAHs, such as E2B compliant forms and CIOMS forms. Often these reports are sent as
email attachments, which can sometimes present a challenge to the organisation in terms of
readability. The recommendation for this dimension is to establish a standardised electronic
form for capturing data, one which is compliant with the E2B (R3) standard and therefore the
VigiFlow system too.
Dimension 2.1.2 Data storage and aggregation
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The storage of paper files is currently being outsourced to a third-party organisation. The
organisation does make use of the Vigibase database, for cost saving purposes. However,
currently there is no existing internal database for ICSRs and the organisation has identified a
need for a cloud-based storage system.
Dimension 2.1.3 Workflows
Workflows which were not organised to be interoperable was identified as one of the most
prominent challenges for the organisation. Workflows typically involve the use of Standard
Operating Procedures (SOPs). In the context of a spontaneous reporting system this includes
receiving the information, case entry, duplicate checking, case registration, case triage, data
entry and narrative write up, review, case closure and the transmission of the ICSR.
Dimension 2.2.1 Data standards
The recommendation for this dimension is that the organisation adopts a comprehensive port-
folio of data standards which relate to the exchange of electronic healthcare data. However,
it is important to be aware of the fact that due to the complex interactions of business pro-
cesses, international legislation, and varying system requirements in the global PV landscape,
the notion of ‘plug and play’ standards for interoperability is not as straightforward as it would
appear. For this reason, the HIT implementation teams need to adapt their approach to fit
their system requirements, while remaining mindful of the goal of interoperability. In general,
standardisation through the implementation of HITs requires adaptation that varies from one
context to the next. This adaptation can be guided and informed via the identification of
use cases. Use cases are commonly used in software and systems engineering to define the
interactions between an actor and a system to achieve a goal.
Dimension 2.2.2 Information content
For this dimension the organisation was scored a level 2, which is characterised by the existence
of an ICSR form with a simple but complete set of basic data elements which constitute the
minimum acceptable information. A level 3 in this dimension assumes the adoption of an
electronic reporting form, which the organisation does not comply with currently. However,
once the organisation has progressed to the wide scale adoption of electronic reporting, a level
3 will be attained if the electronic reporting form complies with standards such as E2B (R3)
and the Minimal Information Model for Patient Safety (MIM PS) standard.
Dimension 2.2.3 Data protection, privacy, and security standards
Documents containing sensitive PV data should not be left unattended. It is recommended that
the organisation adopt a clear desk policy for PV documents. A clean desk policy is one which
ensures all sensitive and confidential data is stored and protected from unauthorised viewing.
175
Stellenbosch University https://scholar.sun.ac.za
9. CASE STUDY IMPLEMENTATION AND EXTERNAL VALIDATION
Individuals that work with documents containing sensitive PV data should take appropriate
measures against unauthorised access to the data. The organisation must identify and adhere
to a specific set of data protection, privacy, and security standards. Currently, some standards
are incidentally and unpredictably adhered to. The organisation makes use of a secrecy clause
and has simple agreements with third party companies that store the ADR paper files for long
term storage. Discarded ADR reports are shredded via a shredding company. If the organisation
makes use of a cloud-based storage system for electronic ICSR information, it must be fully
protected so as to ensure access to the data can be restricted to named individuals. Sensitive
data should be encrypted to ensure the integrity of data transmissions. Currently, information
is aggregated so as to anonymise the data for inclusion in quarterly reports.
Dimension 2.2.4 Information exchange and interoperability standards
It was noted during the PVR-CMM maturity assessment that this dimension assumes the organ-
isation has a sufficient capability for electronic reporting. For this reason, there is no practical
recommendation that is justified in this instance. However, with repeated use of the PVR-
CMM and by conducting regular maturity assessments in between improvement initiatives, it
is envisioned that this dimension will become relevant to the organisation.
9.4.3 Domain 3 results and recommendations
Domain 3: Technical
Subdomain 1: IT Infrastructure
3.1.1 ICT Hardware
3.1.2 Network










Capability maturity Interoperability maturity
Figure 9.11: Radar chart showing the dimension level of domain 3 maturity levels from the
case study.
Domain 3, shown in Figure 9.11, contains two of the overall weakest dimensions in terms of their
combined capability and interoperability maturity levels (criterion 2), D3.1.1: ICT hardware,
and D3.1.3: Development and maintenance. With domain 3 consisting of only one subdomain,
the subdomain scored amongst the lowest average capability maturity level (criterion 4), as
well as below the average subdomain interoperability maturity across all domains (criterion 5).
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The practical recommendations with regard to the dimensions in domain three, identified here,
are as follows:
Dimension 3.1.1 ICT hardware
The recommendation for this dimension is for the organisation to identify the specific hardware
components needed to directly support the processes linked to patient safety. In this case, the
organisation has identified cloud-based storage of information as a desirable mechanism to
achieve a centralised storage of patient safety information. It was noted that the organisation
is dependent on national government to provide a national healthcare technology infrastructure,
which is costly. Investment in technological infrastructure may be considered difficult to justify
within the healthcare sector because of the perceived lack of tangible benefits on patient health
outcomes. However, given the undeniable increase in digital and mobile technology adoption
across all industries, these investments should be seen as paramount to ensure digital inclusion
of the healthcare sector. It is also important to note that improvements in the healthcare
technology infrastructure will not only benefit pharmacovigilance activities, but many other
healthcare activities too.
The interoperability of Health Information Technology solutions can only be realised if the HIT
solutions are implemented within a core infrastructure of hardware and network connectivity.
Hardware infrastructure on an operational level might consist of PCs and mobile devices but the
organisation also needs to develop and maintain their data warehousing and storage capabilities.
Findings from the PVR-CMM maturity assessment suggest that this would require significant
involvement from the government, as the organisation itself has no control over technology
capacity at the facility level across the various provinces.
Dimension 3.1.3 Development and maintenance
The successful creation, implementation and acceptance of HIT solutions is largely depen-
dent on workforce engagement and education. Education and training of the end-users is
paramount, particularly when it comes to HCPs, it would be advantageous to communicate
the benefits of the HIT solution by demonstrating how the HIT directly supports their work
practices. Successful use of the HIT solution is dependent on the capabilities of the end-users.
Performance capacity is improved with the improvement of personal capacity or skills that
enable the effective use of tools, in this case the HIT solution.
It is important to consider the roles of HCPs which use the HIT solutions, as well as the
IT workforce who are tasked with designing and developing the HIT solutions. By forming
direct linkages between IT and system developers and the end-users, improved functionality
and adherence can be achieved. Educating end-users on interoperability and its associated
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impacts and benefits through the use of training and educational material, will improve end-
user acceptance of newly implemented HIT initiatives. End-users on the operational level of the
health system are more likely to accept new HIT initiatives when there is a demonstrable benefit
in terms of how the HIT can support their direct needs and work activities. Furthermore, given
the continuous advancement of technology, the necessary change management plans must be in
place so as to facilitate the inevitable changes that improved technology will bring to the system
over time. As technologies and standards evolve over time, interoperability specifications may
need to be adapted.
9.5 Validation of PVR-CMM V2
Upon completion of the case study, the final step in determining the applicability, usefulness,
and value of the PVR-CMM, is to validate the outcomes of the case study. Recalling from
Chapter 8, De Bruin et al. (2005) state that the issue of generalisability of maturity models
can only be addressed if the maturity model in question is deployed to an entity that is external
to the development and verification of the maturity model. In order to formally validate the
PVR-CMM, several questions were asked to the national regulatory authority in the case study,
as to whether or not the model and its associated methodology could appropriately be used
to characterise the organisation’s maturity, to the extent that the results and recommended
actions are intelligible, and the resulting conclusions from the model’s implementation had
some degree of utility.
9.5.1 Validation questions
To validate the PVR-CMM V2, a questionnaire was sent to the three case study participants,
described in Section 9.3.2. To uphold the integrity of the validation outcomes, the validation
questionnaire was sent only to the three participants who were exposed to the entirety of the
PVR-CMM V2. The questions included in the validation questionnaire were divided into three
groups. The first group of questions refer to the accuracy of the model’s ability to charac-
terise the organisation’s capability and interoperability maturity levels. These 14 questions,
are addressed at a subdomain level (two questions per subdomain, one addressing capabil-
ity maturity, and the other addressing interoperability maturity), this is because presenting
these questions at a dimension level would essentially equate to conducting another maturity
assessment altogether. The results of the first group of questions are discussed in Section
9.5.2.
The second group of questions refer to the ability of the PVR-CMM V2 to achieve it’s stated
aims, as described in Section 7.3. The third and final group of questions refer to the strengths
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and weaknesses of the PVR-CMM V2, as well as it’s uniqueness and utility. These two groups
of questions, together with determining the validity of the PVR-CMM V2, also provide an
indication as to whether the PVR-CMM V2 is accepted or rejected by the intended target
audience. This refers to the eighth and final phase of Becker et al.’s (2009) eight phase
procedural model as well as the PVR-CMM phases of development in Table 7.2. The results
of the second and third groups of questions are discussed in Section 9.5.2.1.
9.5.2 Validation results
The results of the validation questionnaire are presented here in three groups. Table 9.2, sum-
marises the responses to the 14 questions referring to the ability of the model to accurately
reflect the organisation’s capability and interoperability maturity levels. Similarly to the ques-
tionnaires used in the verification activities in Chapter 8, this validation questionnaire made
use of a 5 point Likert scale.
As is evident in Table 9.2, the results of the first 14 questions are overwhelmingly positive.
While a response of “unsure” is not necessarily a negative response, the four instances where
P1 and P2 answered “unsure” are considered, from a limitations perspective, to be possibly
attributable to the effects of response bias. It could be, that due to the participant’s roles
within the regulatory authority, the participants might have felt as though they were being
scrutinised when confronted with a description of their organisation’s maturity that they did
not consider desirable, similarly to how individuals might feel when being audited, or during
performance reviews.
The results in Table 9.2, indicate that the PVR-CMM V2 can accurately characterise the




9. CASE STUDY IMPLEMENTATION AND EXTERNAL VALIDATION
Table 9.2: Summary of case study participant responses in the validation of the PVR-CMM
V2 outcomes.
Validation Questions P1 P2 P3 Average:
1.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 1: Leadership and Governance?
3 4 5 80,0%
1.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 1: Leadership and Governance?
4 3 4 73,3%
2.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 2: Finance and Economics?
4 3 4 73,3%
2.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 2: Finance and Economics?
4 3 4 73,3%
3.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 3: Business Objectives?
4 4 4 80,0%
3.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 3: Business Objectives?
4 4 4 80,0%
4.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 4: Human Resources?
4 4 5 86,7%
4.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 4: Human Resources?
4 4 5 86,7%
5.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 5: Business Procedures?
4 4 4 80,0%
5.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 5: Business Procedures?
4 4 4 80,0%
6.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 6: IT Standards?
4 5 4 86,7%
6.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 6: IT Standards?
4 5 4 86,7%
7.1
To what extent do you agree that the results accurately reflect the capability 
maturity of Subdomain 7: IT Infrastructure?
4 5 4 86,7%
7.2
To what extent do you agree that the results accurately reflect the 
interoperability maturity of Subdomain 7: IT Infrastructure?
4 5 4 86,7%
Average: 78,6% 81,4% 84,3%
9.5.2.1 Acceptance/Rejection of the PVR-CMM V2
In order to determine whether the maturity model has been successfully accepted by the target
audience, the stated aims of the maturity model must be achieved, from the perspective of the
target audience and the context within which the maturity assessment was conducted. This is
the eighth and final phase of the PVR-CMM phases of development shown in Table 7.1.
To support the validity of the PVR-CMM V2, as well as to substantiate the overall acceptance
of the model, the following questions were directed at the three primary case study participants,
the responses from the participants follow each question:
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Table 9.3: Summary of case study participant responses in the validation of the PVR-CMM
V2 aims.
Validation Questions P1 P2 P3
8












Do you believe the PVR-CMM can promote and improve interoperability by addressing 
the degree of integration of systems involved in spontaneous reporting?
Yes Yes Yes
12




Do you believe the PVR-CMM can provide a means for measuring interoperability 
progress across the community of spontaneous reporting systems in the global 
pharmacovigilance landscape?
Yes Yes Yes
Question 14: Are you aware of any other approach that has been proposed which is better
suited to address the interoperability of spontaneous reporting systems?
In response to question 14, all three of the participants answered no.
Question 15: What do you view as the key strengths of the PVR-CMM?
“Ability to show progress and feasibility of achieving goals. Ability to relate unit
goals to organizational goals.”
“Accuracy.”
“It is user friendly and easily accessible.”
Question 16: What do you view as the key weaknesses of the PVR-CMM?
“It is more suitable for use at management level as some information the junior
staff may not know.”
“Lacks flexibility.”
“It is time consuming.”
The suitability of the PVR-CMM for use at a management level is to be expected, as the
model is intended to be used by management and requires information from individuals who
have a good understanding of the entire SRS. In terms of the length of time associated with
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the maturity assessment, this is also to be expected, as the aim of the tool is to address the
maturity of a comprehensive set of dimensions.
Question 17: If the PVR-CMM was to fail in achieving it’s stated aim, what would be the
reason for this failure?
“Failure to use it (probably due to ignorance).”
“undefined processes.”
“Non implementation of the recommendations.”
In response to the case study participant who cited “undefined processes” of the PVR-CMM
as the potential reason for failure. This is likely in response to the level of generality in the
PVR-CMM and the need to make minor adaptations and refinements to the tool in order
to fit the organisation’s individual needs. This aspect of the PVR-CMM is addressed in the
disclaimer that is included in the introduction to the PVR-CMM V2, as seen in Figure 9.1.
Question 18: Would you recommend the PVR-CMM as a tool to help improve spontaneous
reporting systems?
All three of the case study participants indicated that they would recommend the use of the
PVR-CMM as a tool to help improve spontaneous reporting systems.
9.5.3 Validation conclusion
Overall, positive feedback was received from all three case study participants. The PVR-CMM
V2’s ability to achieve its stated aims has been shown to be valid. The strengths of the PVR-
CMM V2 reflect the development and design considerations. The case study participants are
in agreement that no other tool exists for the purpose of addressing the interoperability of
spontaneous reporting systems. The feedback presented in Sections 9.5.2 and 9.5.2.1, suggest
the unquestionable acceptance of the PVR-CMM V2.
9.6 Chapter 8: Conclusion
In this chapter the final version of the PVR-CMM was presented. A case study involving the
assessment of a SRS operated by an African RA was designed and executed. The results of
the assessment were analysed and practical recommendations for improvement were developed.
The RA was then asked a series of questions relating to the maturity assessment, to ascertain





The final chapter contains an overview of the research presented in this dissertation, as well
as confirmation that the research objectives, as stated in Section 1.4.2, have been achieved.
The limitations of the research are addressed, the contributions of the research are described,
and the opportunities and recommendations for further research are discussed.
10.1 Overview of research
The outcome of this research study is a proposed model based on the concept of a CMM,
which can be used by MAHs, RAs, or any entity that owns or operates an SRS to measure and
assess their PV capabilities in various organisational, informational, and technical, domains
and dimensions.
In Chapter 1 the context within which the research problem exists, as well as the aims and
objectives of the research were summarised. The research scope and document structure was
also described. Chapters 3, 4, 5, and 6, made up the literature review which together informed
the development of the PVR-CMM in Chapter 7.
The research methodology of this study was described in Chapter 2. In this chapter, the
research philosophy was discussed, as well as the research approach and strategy. The chapter
concluded with a discussion on the relevant research tools and techniques which were employed
in this dissertation.
The focus of Chapter 3 was to gain an understanding of: the global PV landscape; what is
meant by a standardised and interoperable SRS; and the challenges and barriers which affect
the spontaneous reporting of ADRs. Furthermore, an analysis of the effects of the lack of an
interoperable global PV reporting system was presented. From this step, the extent to which




Chapter 4 involved characterising the global PV system by identifying the role players, their
responsibilities, and the communication channels between them. This stage of the research
also identified and elaborated on best practices for the reporting of ADRs (the ICH E2B(R3)
standard for electronic ICSR transmission), as well as the solutions and services offered by the
UMC. By understanding the roles and responsibilities of the various role players, the PVR-CMM
could be developed with the three perspectives described in Section 7.3 in mind.
In Chapter 5 the concept of an MM was explored and defined within the context of this study.
The history of MMs as well as their various types and purposes was explored. The concept of
interoperability was also discussed, with a particular focus on the interoperability of HITs in the
eHealth field. The chapter concluded with a discussion on the need to take a sociotechnical
approach to introducing MMs within an eHealth context.
Taking into consideration the difficulty associated with implementing standardised HITs into
large, complex systems, the notion of STSs was investigated in Chapter 6. The PV system
was described as a sociotechnical system to gain an improved understanding of how best to
design and implement HITs in these complex systems. Through the conceptualisation of the
PV system as an STS, the PVR-CMM development process was more cognisant of social,
cultural, and political factors, rather than focussing solely on the technological factors.
Drawing on the findings of the preceding literature review chapters, the focus of the dissertation
then turned to the development of the PVR-CMM. Chapter 7 detailed the development of the
model, based on the concept of a CMM. A procedural model for the development of MMs was
followed in this chapter, and the methodology of the PVR-CMM development was laid out.
A body of literature surrounding the interoperability of information systems, as well as health
information systems specifically, was studied. From this research, a collection of 18 maturity
models and frameworks were identified. A comparison of these 18 models and frameworks
assisted with the selection and characterization of the 30 dimensions included in the first
generation of the PVR-CMM, which is presented at the end of Chapter 7.
Following the population of the PVR-CMM V1, a verification and validation strategy is de-
scribed, with the goal of ensuring the PVR-CMM’s suitability for implementation in a real
world setting. The PVR-CMM V1 was subjected to two verification processes, by engaging
with subject matter experts and focussing on the design requirements and model components
that made up the PVR-CMM V1. The feedback of the SMEs was incorporated so as to present
the final iteration of the PVR-CMM in Chapter 9.
Upon determining the suitability of the PVR-CMM for real-world implementation, the con-
ception of transfer media was described and a case study was designed so as to determine
the extent of the PVR-CMM V2’s empirical validity. The case study presented in Chapter 9,
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involved conducting a maturity assessment of the SRS of an African national pharmaceutical
regulatory authority. The results of the assessment were analysed and practical recommenda-
tions for improvement were developed. The regulatory authority was then asked a series of
questions relating to the maturity assessment, to ascertain the extent of the model’s general-
isability.
This last chapter contains an overview of the research presented in this dissertation, as well
as confirmation that the research objectives, as stated in Section 1.4.2, have been achieved.
The limitations of the research are addressed, the contribution of the research is described,
and opportunities and recommendations for further research are discussed.
10.2 Achieving the research objectives
It was envisaged that the research objectives (ROs) which would collectively contribute towards
achieving the aim stated in Chapter 1 included:
RO1: To conduct a literature review on the structure of the PV landscape and to define
concepts and paradigms from this literature relevant to this study.
Chapters 1, 3, and 4, collectively contributed to achieving this research objective, with each
chapter progressively contributing more detail towards the understanding of the global PV
landscape.
RO2: To evaluate the value of interoperability in the global PV reporting system through a
comprehensive and system-based evaluation of the effects of the lack of such interoperability
on PV/health outcomes.
This research objective is achieved in Chapter 3 and served as the primary topic of the jour-
nal article titled “An investigation into the value of a standardised global pharmacovigilance
reporting system”. The effects of the lack of interoperability are discussed in Section 3.5 and
the potential impacts of interoperability are noted in Section 3.6.
RO3: To identify through a comparative analysis of PV systems, the main elements that such
a standardised system would need to comprise of.
Chapter 4 discussed the various role-players and their responsibilities, as well as the commu-
nication channels which exist between them. The minimum requirements for an effective PV
system, as well as the objectives of PV monitoring systems were described. Chapter 4 also
involved a comparison of PV systems in three different contexts, found in Section 4.5.




Chapters 3, 4, and 6 collectively contribute to the achievement of this research objective.
Chapter 3 describes the cultural and economic barriers to ADR reporting. Chapter 4 describes
the numerous mechanisms of reporting and the various communication channels between the
different role-players in the PV system. Chapter 6 discussed the sociotechnical implications of
the poor design and implementation of technology in healthcare systems. The sociotechnical
nature of healthcare work is discussed in Section 6.2.1, and a comparison is drawn between a
generic sociotechnical system and the PV system, in Section 6.3. Finally, the challenges in PV
are related to the failures of sociotechnical systems.
RO5: To conduct a literature review on maturity models with a specific focus on the scientific
and design considerations of maturity models; and define concepts and paradigms from this
literature that are relevant to this study.
This research objective is addressed in Chapter 5. The history, types, and purposes of MMs
was discussed. The concept of maturity models for interoperability was discussed in Section
5.6.2, with a particular focus on the interoperability of HITs in the eHealth field. The chapter
concludes with a discussion on the need to include a sociotechnical approach to introducing
MMs within an eHealth context, in Section 5.7.
RO6: To conduct a literature review on sociotechnical systems, with a specific focus on the
associated theory, and to characterise the PV system as a sociotechnical system.
Chapter 6 addresses this research objective and the PV system is characterised as an STS in
Section 6.3. The contents of this chapter contributed towards the international conference
proceedings output titled “Sociotechnical considerations for Health Information Technology
design and implementation in complex and adaptive health systems”. Challenges associated
with standardisation in sociotechnical systems are described in Section 6.4, and understanding
change in sociotechnical systems is addressed in Section 6.5.2.
RO7: To define the design requirements for a PV reporting capability maturity model.
The design requirements are defined in Section 7.4 of Chapter 7.
RO7.1: To verify the design requirements by engaging subject matter experts.
The design requirements were verified in Section 8.6 of Chapter 8, and additional design
requirements were added in Chapter 7 accordingly.
RO8: To search for an existing model which satisfies the design requirements.
Chapter 7 includes a literature review that results in the comparison of 18 MMs, found in
Section 7.5. Although none of the MMs from the literature review were able to satisfy all of




yielded valuable insights which would guide the development of the PVR-CMM; particularly
by informing the selection and classification of the 30 dimensions into the respective domains
and subdomains.
RO9: To develop a maturity model for PV reporting activities, rooted in sociotechnical system
theory, if such a model does not exist.
Chapter 7 documented the development of the PVR-CMM; which drew from the findings of
the four preceding literature review chapters. The inclusion and contents of the ‘organisational’
and ‘informational’ domains were influenced by the findings presented in Sections 6.3 and 6.5.
RO9.1: To streamline and refine the maturity model by engaging subject matter experts, with
a focus on including an industry perspective, so as to verify that the maturity model is suitable
for implementation in a real world setting.
The outcomes of the first and second verification processes described in Sections 8.1 and 8.6,
of Chapter 8, resulted in the development of the PVR-CMM V2. At this stage, the model was
considered ready for implementation in a real-world setting.
RO10: To design and execute a case study in which the maturity model will be implemented
by a key role player in the PV landscape.
The presentation of the PVR-CMM V2, as well as the design and execution of the case study
were described in Sections 9.2 and 9.3, of Chapter 9, respectively. The case study was executed
with a prominent national pharmaceutical regulatory authority of the SADC region.
RO10.1: To analyse the findings and results of the case study.
The results of the case study, as well as the development of practical recommendations in
response to the results, are included in Section 9.4, of Chapter 7.
RO11: To validate the model by determining whether the model can achieve its stated aims,
as well as the extent of the model’s generalisability.
The validation process was documented in Section 9.5 of Chapter 9. Overall, the results of the
validation process were positive and the generalisability of the PVR-CMM V2 was confirmed.
10.3 Limitations
The primary limitation of this study is the time required to take the PVR-CMM through
a complete cycle of implementation. This is a common limitation among doctoral studies
involving the development of maturity models. An additional limitation faced in this study was
the challenge associated with securing the “buy-in” from a national regulatory authority for the




cycles, in various contexts, to evaluate the extent to which the PVR-CMM contributes to the
improvement of SRSs, and the interoperability thereof.
A third limitation to this research was the availability of SMEs to engage with during the val-
idation process. It was challenging to find SMEs, involved in PV from a systems perspective,
with the required knowledge relating to the functioning of SRSs, the global PV landscape, as
well as concepts more often associated with the discipline of engineering, such as interoper-
ability and capability maturity models. During this research endeavour it became clear that
PV has received limited attention from the Engineering discipline, however, as stated by SME
number three “it is a good concept to apply the CMM to PV activities”, thereby alluding to
an opportunity for future research efforts.
10.4 Original contribution
This research offers a number of contributions, both practical and theoretical.
10.4.1 Theoretical contribution
During the completion of this dissertation it became clear that PV has received limited attention
from the Engineering discipline. As discussed in the research gap in Section 1.3, as well as
during the development of the PVR-CMM in Section 7.5; there is no existence of a maturity
model which allows for the assessment of spontaneous reporting systems in PV. Therefore,
the unique contribution of this research is the PVR-CMM itself. The development of the
PVR-CMM is directly relevant to the research gap presented in Section 1.3 of Chapter 1.
An additional theoretical contribution was made in drawing the comparison between pharma-
covigilance and a sociotechnical system, as discussed in Chapter 6. The comparison between
PV and sociotechnical systems had not been made in the literature. By matching and compar-
ing elements of the PV system with those of sociotechnical systems, a new contribution was
made. This contribution is, however, considered a relatively minor natural conclusion which
should be true for most systems of this nature.
10.4.2 Practical contribution
Tied to the unique contribution that is the PVR-CMM itself, a practical contribution of this
research is the proven practical applicability of the PVR-CMM. This contribution was identified
based on the opinions of subject matter experts which were involved in the validation strategy.
A significant amount of encouraging feedback was received from the SMEs involved in the
verification and validation processes, upon learning about the research in this dissertation. The




process, whereby they stated that “it is a good concept to apply a capability maturity model
to PV activities”, implying that they had not encountered a CMM for PV activities in practice.
It is evident that pharmacovigilance receives little to no attention from researchers with a
systems background. SME 12 stated that the PVR-CMM would be “the best possible starting
point in developing a global regulatory authority curriculum in partnership with the WHO”.
10.5 Future work
Exploratory research is effective in laying the groundwork that will lead to future studies
(Stebbins, 2001). This research endeavour is of value to future research efforts in that a
foundation upon which future work can build has been set, potentially saving time and other
resources. One of the outcomes of the verification process was the confirmation of value
in applying the concept of a CMM to PV activities. As mentioned in Section 10.4.2, the
PVR-CMM could potentially be used to assist with the development of a global standardised
regulatory authority curriculum, with the WHO.
In terms of the PVR-CMM specifically, improvements for further iterations of the model could
include the accompaniment of additional material. The material could include summaries of
the PVR-CMM tailored for more specific target audiences, e.g. HCPs, health IT workers, de-
partments and functional groups of MAHs and RAs. By expanding the accompanying material
for the PVR-CMM, it is envisioned that further improvements in the accessibility and usability
of the PVR-CMM could be achieved.
Longitudinal studies involving the repeated use of the PVR-CMM as well as the continuous
monitoring of assessment outcomes and improvement initiatives would contribute significantly
to the PVR-CMM’s overall validity. The development of key performance indicators for various
role players in the PV landscape would contribute to the assessment process.
At the time of this study, it was deemed that wide-spread interoperability in PV as a result of
EHR technology is not feasible in the short term, as it is dependent on the large-scale roll-out
of EHRs around the world. However, due to the contemporary nature of the research area
within which the problem exists, and the constant advancement of technology, EHRs should
be re-evaluated continually when conducting research into interoperability in PV.
10.6 Chapter 9: Conclusion
This chapter provided an overview of the research included in this dissertation and the achieve-




the limitations encountered during this research endeavour, as well as the contributions of the
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Röglinger, M., Pöppelbuß, J. & Becker, J. (2012). Maturity models in business
process management. Business Process Management Journal , 18, 328–346. 72
Safren, M.A. & Chapanis, A. (1960). A critical incident study of hospital medication
errors. Nursing Research, 9, 223. 97
Sale, J.E., Lohfeld, L.H. & Brazil, K. (2002). Revisiting the quantitative-qualitative
debate: Implications for mixed-methods research. Quality and quantity , 36, 43–53. 16
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Law, regulation, and policy
The existence of the appropriate legal provisions that mandate and guide all PV related activities. Legal requirements and guidelines applicable to all National Competent Authorities/Regulatory Authorities and 
Marketing Authorisation Holders, regarding the collection, data management and reporting of suspected adverse drug reactions associated with medicinal products for human use.
Governance structures and 
commitment
The existence of the appropriate technical, political, and administrative authoritative entities to manage all affairs relating to health information systems. These authoritative entities ensure the optimal 
functioning of the HIS as well as coordinate stakeholder engagement across all levels of the organisations HIS. Management is actively committed to managing and improving patient safety.
Business continuity and 
responsiveness
A business continuity plan seeks to ensure that the necessary business processes can continue to function so as to maintain reporting compliance during times of partial or total system failure. Business 
continuity is about devising plans and strategies that enable organisations to continue business operations, and enable quick and effective recovery from any type of disruption, whatever its size or cause. 
Interoperability will not function as intended if the HIS and all its components do not function correctly. Therefore, business continuity of the national HIS is imperative for continuity of strong interoperability 
services of HIS. This includes putting in place systems for data recovery, continuity of healthcare, continuous flow of funding, staff transition plans, etc. In terms of responsiveness, MAHs are typically legally 
obligated to submit any and all reported ADRs that they receive within 15 calendar days to the Regulatory Authority which awarded them marketing authorisation.
Data ethics/ownership
Data ethics addresses the moral dimension of data management. This includes ensuring adherence to ethical principles throughout data generation, recording, curation, processing, dissemination, sharing, and 
use. Ethical practices should strive to ensure respect for the people behind the data; use of data in accordance with the intentions of the disclosing party; matching privacy and security safeguards to the 
expectation of individuals and populations from whom data are drawn; and following the law regarding personal health data privacy and security. These practices are sometimes referred to as responsible data 
practices.
Monitoring of performance and 
effectiveness
Processes to monitor the performance and effectiveness of the PV system, including: reviews of the system by those responsible for management, audits, compliance monitoring, inspections, evaluation of the 
effectiveness of actions taken during improvement initiatives.  Attributes from the maturity model to facilitate tracking of inputs, processes, and outputs against desired results of HIS interoperability 
implementation, and using data to make decisions.
Transparency and accountability
Communication of patient safety information and safety issues should be coordinated with all stakeholders in PV, while maintaining patient confidentiality. National competent authorities should publicise 
regular reports on the performance of their PV systems as well as the results of regular system audits.  Information used in decision-making processes should be made openly available to ensure objective and 
collaborative decision-making. Transparency addresses how an organisation is observed by outsiders based on the quality of information that the organisation shares with the public.
Partnerships
Implementing regulations which detail public-private partnerships specifically for the development of patient safety systems. Regulatory Authorities should clearly communicate the responsibilities and legal 
requirements of the MAHs within their jurisdiction.
Stakeholder communication Establish internal and external communication plans to facilitate the communication within your authority and with external stakeholders at national level.
Organisational strategy alignment
A shared understanding of the PV operating model within each organisation as well as a clear understanding of each organisations role in the global patient safety system. Implementing best practices and the 
alignment of operational activities. Organisations must develop clearly defined roles and responsibilities.
Building a culture of safety
A system of shared actions, values, and beliefs that develop within an organisation and are transferred to new members as the way to perceive, think, and feel in the organisation. Attitudes and behaviours of 
organisational workforce towards patient safety. Moving from a culture of compliance to a culture of commitment. The key to developing a strong organisational PV culture is to support and manage the natural 
social and behavioural aspects of the individuals interactions, rather than attempt to force cultural change by decree.
Organisational change management Operational processes are clearly linked to performance outcomes and goals. Organisations should seek to embed a culture of continuous improvement.
Financial management
Dedicated budget available for PV relate activities. The legal and administrative systems and procedures put in place permitting a government ministry and its agencies and organizations to conduct activities 
that ensure the correct use of public funds, and which meet defined standards of probity and regularity.  Activities include management and control of public expenditures, financial accounting, reporting, and 
asset management.  Proactive investment in technologies which can be leveraged to improve patient safety.
Financial resource mobilisation
All activities involved in securing new and additional financial resources for an organization (in this case, the HIS). It also involves making better use of and maximising existing financial resources. The existence 
of any regular financial provisions. Provision of funding demonstrates government commitment to patient safety and can directly improve conditions in the workplace environment which ultimately improves 
HCPs attitudes towards patient safety.
Regulatory compliance
All organisations must comply with patient safety reporting requirements which are imposed by the relevant Regulatory Authority. Compliance monitoring policies and strategies. This includes reviews, 
inspections, and audits which can be conducted regularly internally or by an external actor. A good compliance strategy reduces the risk of business disruption, litigation costs, and reputational damage.
Resource efficiency and business 
sustainability
Efficient resource utilisation improves system outputs by maximising the supply of inputs and minimising wasted resource expenses. Resource efficiency means achieving the desired outcomes in a sustainable 
manner. Business sustainability deals with the ability of an organisation to meet the demands of the present without effecting its ability to meet the demands of the future. Business sustainability typically 
involves financial, social, and environmental components.
Data management
Data management consists of the development, execution, and supervision of plans, policies, programs, and practices that control, protect, deliver, and enhance the value of data and information assets for 
decision making. Data management includes procedures on how data are captured, stored, analysed, transmitted, and packaged for use across the data supply chain. 
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Initial System as silo Managed
Some regulations are policies have been developed and implemented, 
but in an unstructured manner, lacking consistency.
No formal legislation or policies. Any existing policies are localised 
to the individual system setting. No standardisation,
Legislation has been developed to address patient safety, with a simple but 
complete set of regulations to support the legislation.
No formal governance structures exist and management of HIS affairs 
occurs on an ad hoc basis.
No formal governance structures. Any existing governance structure 
is localised to the individual system setting. No standardisation.
Simple, but functional governance structures exist. Governance structures function 
reactively and unpredictably.
Initial attempt at developing a business continuity plan has been made, 
outlining some of the processes needed to ensure business continuity.
No formal business continuity plan is in place across the 
organisation and any existing business continuity activities are 
localised to the individual system setting. No standardisation.
Simple, but complete business continuity plan for patient safety activities has been 
developed.
The organisation does not have formal processes or structures in place 
which address the ethics associated with business processes.
No formal policies for data ethics and ownership. The organisation 
works without interaction and any arrangements are unplanned and 
unanticipated. No standardisation.
Simple, but comprehensive set of processes and policy structures in place which 
address the ethics associated with critical data,
The organisation is unaware of the performance indicators which it 
should be measuring. Performance measurement is ad-hoc or by means 
of external audits and assessments.
Performance monitoring is performed internally with no industry 
benchmark to make a comparison against. No standardisation.
Simple, but comprehensive set of performance objectives is established. 
Performance monitoring is performed in a reactive manner.
Transparency and accountability is not thoroughly understood within 
the organisation. No comprehensive policy documentation exists 
addressing transparency and accountability.
Localised understanding of transparency and accountability. No 
standardisation.
Simple policies addressing transparency and accountability exist. Simple risk 
management plans associated with accountability exist.
An initial attempt has been made to identify key partnerships which the 
organisation should develop.
Partnerships are unplanned and unanticipated, no strategy to 
manage partnerships exists. No standardisation.
The organisation has established simple partnerships with all organisations that 
affect its business operations and value creation. The organisation focusses on 
building confidence in the partnerships.
No formal communication channels exist within the organisation or 
between the organisation and its external stakeholders.
No stakeholder communication strategy. Organisation does not 
interact with any external stakeholders. No standardisation.
Simple communication channels exist  both internally and externally.  
Business objectives are not well understood by the various departments 
within the organisation.
Business objectives are developed within the confines of the 
localised system setting. No standardisation.
Business objectives are understood within departments. Gaps exist between 
business objectives and business processes.
Patient safety culture is inconsistently managed. Patient safety is not 
considered a goal of the organisation.
No formal approach to building a culture of patient safety. No 
standardisation.
Simple commitment from management to improving patient safety culture within 
the organisation.
Patient safety culture is a culture of compliance.
Initial attempt at change management is implemented inconsistently. 
Recognised need for change management.
Organisational change is not considered a priority as the system is 
isolated and therefore not influenced by changes in the external 
environment. No standardisation.
Simple, but effective change management is applied in isolated projects.
Initial attempt at financial management for patient safety related 
activities.
Recognised need for appropriate financial management.
Financial management strategy is isolated and localised within the 
confines of the system setting. No standardisation.
Simple, but complete financial management strategy. Finances are managed in an 
unpredictable and reactive manner.
Funding for patient safety activities is acquired  in an unstructured, 
inconsistent  manner.
Financial resource mobilisation strategy is isolated and localised 
within the confines of the system setting. No standardisation.
Simple, but complete financial resource mobilisation plan.
The organisation is unaware of the full extent of its compliance 
obligations. Compliance is assessed ad-hoc or by means of external 
audits and assessments.
Regulatory compliance is measured in isolation and is localised to 
the system setting. No standardisation.
The organisations understands the full extent of its compliance obligations. A 
catalogue of compliance requirements is created. Compliance is managed in an 
unpredictable and reactive manner.
Ad hoc sustainability policies and practices in place.  Resource efficiency 
not considered a priority.
Resource efficiency and business sustainability activities are isolated 
and localised to the system setting. No standardisation.
Simple resource efficiency and business sustainability policies and practices are in 
place. Implemented on a per project basis.
Data management is performed ad hoc and inconsistently. A recognised 
need for formal data management policies and actions.
Data management is confined to the local system setting. No 
standardisation.
Simple, but complete set of policies and practices addressing the management of 
data.
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Interoperability level 2 Capability level 3 Interoperability level 3
Peer-to-peer Defined Distributed
Simple agreements between two homogenous systems are agreed upon to 
address simple business processes which are shared. Peer-to-peer.
Regulations are tailored to support patient safety activities and policies are 
developed to ensure compliance.
Legislation is fully distributed across all organisations/role players within the 
jurisdiction of the National Regulatory Authority.
Linking of systems for a common objective.
Cooperation of authoritative figures between two systems, governed by 
simple agreements. Peer-to-peer.
The organisation has a dedicated and committed governance structure which 
functions proactively to improve patient safety.
Distributed governance structures in place throughout organisation, enabling the 
organisation to interact with similar organisations in a structured manner.
Business continuity plans are informally developed between two operating 
systems based on simple agreements. Peer-to-peer.
Business continuity plan has been implemented and functions in a proactive 
manner to ensure regulatory compliance.
Business continuity plans include information relating to the functioning of 
continuity plans across the entire organisation, to avoid disruption of continuity 
work processes.
Interoperability guidelines exist but specific arrangements are unplanned. 
Simple agreements relating to data ethics and ownership exist between 
organisations. Work processes linked.
The organisation has a code of ethics and conduct. Individuals are committed to 
good conduct and strong ethical behaviour. 
Interoperability framework in place to address data ethics and ownership. Roles 
and responsibilities are defined but heterogenous systems are still distinct.
Performance monitoring is measured against other homogenous systems.
Peer-to-peer. Guidelines exist which describe interoperability.
Performance objectives are communicated to the business process owners. 
Standard procedures for internal performance measurement are developed and 
conducted on a regular basis.
Streamlining of performance monitoring across the entire organisation according 
to an interoperability framework.
Knowledge is shared.
Common understanding of transparency and accountability exists between 
some homogenous organisations. Guidelines exist which describe 
interoperability.
Transparency and accountability is understood by individuals in the organisation. 
The organisation has strong policies in place addressing the transparency of their 
business practices and understands the value of maintaining a positive sentiment 
by the external environment.
Streamlining of organisational procedures resulting in a common understanding of 
transparency and accountability between all homogenous organisations exists.
Guidelines on partnership management are available but specific 
arrangements are unplanned.
The partnerships are managed and trust is established between partner 
organisations.
A common partnership management strategy is developed with the help of an 
organisational interoperability framework. Streamlining or organisational 
procedures for knowledge sharing.
Peer-to-peer stakeholder communication based on simple agreements 
between homogenous organisations. Guidelines exist which describe 
interoperability.
Well defined communication channels exist within the organisation as well as 
between the organisation and its external stakeholders.
Stakeholder communication is developed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Work processes and business objectives are linked based on simple 
agreements in a peer-to-peer manner.
Business objectives are explicitly linked to business processes
Organisational strategy alignment is guided by an organisational interoperability 
framework. Streamlining or organisational procedures for knowledge sharing.
Safety culture extends beyond the local setting and is aligned with and linked 
across homogenous organisations. Guidelines exist which describe 
interoperability.
Management considers individual societal culture, organisational culture and the 
interaction between the two.
Patient safety culture evolves from a culture of compliance to a culture of 
commitment.
A culture of patient safety is developed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Guidelines on how organisational change management must occur with 
respect to interoperability.  Guidelines exist which describe interoperability.
Comprehensive change management is applied simultaneously over multiple 
projects within the organisation.
Organisational change is managed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Financial management activities are linked between homogenous 
organisations through simple agreements. Guidelines exist which describe 
interoperability.
Proactive financial management for patient safety related activities. Dedicated 
budget developed by organisation government to support the achievement of 
project and organisational performance objectives.
Financial management is guided by an organisational interoperability framework. 
Streamlining or organisational procedures for knowledge sharing.
Financial resource mobilisation activities are linked between homogenous 
organisations through simple agreements. Guidelines exist which describe 
interoperability.
Financial resource mobilisation is tailored to address project and work 
characteristics.
Supports project and organisational performance objectives.
Financial resource mobilisation strategy is guided by an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Regulatory compliance work processes are linked  between homogenous 
organisations through simple agreements. Guidelines exist which describe 
interoperability.
Internal compliance capability development. SOPs and a record management 
system is in place to manage compliance. Compliance is proactively managed and 
sustainable.
Regulatory compliance is assessed across homogenous interoperating 
organisations with the help of an interoperability framework. Streamlining of 
organisational procedures.
Resource efficiency and business sustainability activities are linked across 
homogenous organisations through simple agreements. Guidelines exist 
which describe interoperability.
Proactive efforts across the organisation to improve resource efficiency and 
business sustainability in all business operations.
Shared knowledge regarding resource efficiency and business sustainability across 
homogenous organisations which serve a common goal, through streamlining of 
organisational procedures.
Simple agreements regarding data management are implemented allowing 
simple electronic exchange of data between homogenous systems. Guidelines 
exist which describe interoperability.
Standard operating procedures are in place for the management of data. A 
detailed plan of action is developed to migrate from a paper based system to an 
electronic data management system. The necessary privacy and security 
measures are included.
Data management is guided by an organisational interoperability framework. 
Streamlining or organisational procedures for knowledge sharing.
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Capability level 4 Interoperability level 4
Quantitatively managed Integrated
Policies are developed to understand performance variation and detect, refine, 
or predict the area of focus to achieve quality and process performance 
objectives associated with patient safety.
National legislation is fully integrated and aligned with international legislation.
Policies are harmonised between organisations to share benefits and achieve value interoperability.
The organisation has patient safety as a strategic priority which is implemented 
through a detailed action plan with measurable outcomes.
Governance structure complimentary to other organisations to allow for shared benefits when 
managing affairs relating to patient safety.
Business continuity plan is operational and subjected to audits and reviews to 
ensure the achievement of quality and performance objectives and regulatory 
compliance.
Business continuity plans include information relating to the interoperability and coexistence with 
other organisations continuity plans, to avoid disruption of continuity work processes.
Individuals within the organisation demonstrate their commitment to the code of 
ethics and conduct.
Integrated approach to data ethics and ownership across all organisations with shared value systems 
and goals in the interoperability community.
The performance and effectiveness of business processes is quantitatively 
measured both internally and by external audits and assessments.
Integrated performance monitoring.  Based on industry benchmarking and external 
review/assessments between organisations with shared value systems and goals..
Individuals take responsibility for their work functions and are held accountable 
for their actions. The organisation monitors the sentiment of outsiders towards 
their business practices and adapts the business practices accordingly. The 
organisation has sound risk management plans to assist with accountability.
Integrated understanding of transparency and accountability across heterogenous organisations with 
shared value systems and goals.
Service level agreements are agreed upon across partnerships and allow for 
quantitative measurement.
Partnership management strategies of heterogenous organisations encourage the discovery of new 
partnership opportunities for different organisations.
Communication channels are monitored and controlled.
Stakeholder communication activities are linked between heterogenous organisations  and 
interoperability standards are implemented, allowing for the sharing of benefits and value between 
organisations serving a common goal.
Business processes are adapted to support business objectives and a shared 
understanding of the linkage between business objectives and business 
processes is understood within and across organisational departments.
Organisational strategies are linked between heterogenous organisations  and interoperability 
standards are implemented, allowing for the sharing of benefits and value between organisations 
serving a common goal.
Leadership uses patient safety outcomes to promote patient safety culture and 
acts on patient safety improvement initiatives. Visible commitment to patient 
safety throughout organisation.
Patient safety culture extends and is shared between heterogenous organisations  and interoperability 
standards are implemented, allowing for the sharing of benefits and value between organisations 
serving a common goal.
Organisation makes use of standards and methods for broadly managing and 
leading change.
Organisational change management activities are linked between heterogenous organisations  and 
interoperability standards are implemented, allowing for the sharing of benefits and value between 
organisations serving a common goal.
Finances are quantitatively managed. Expenditures are monitored against budget 
and finances are subjected to regular audits. Proactive investment in innovation 
and technology.
Financial management activities are linked between heterogenous organisations  and interoperability 
standards are implemented, allowing for the sharing of benefits and value between organisations 
serving a common goal.
Financial resource mobilisation has matured to ensure continuous and secure 
funding for all business processes involved in patient safety.
Financial resource mobilisation activities are linked between heterogenous organisations  and 
interoperability standards are implemented, allowing for the sharing of benefits and value between 
organisations serving a common goal.
Internal compliance capabilities are aligned with external auditing and 
assessment guidelines. The organisation has the capability to predict potentially 
impactful regulatory changes.
Regulatory compliance activities are linked between heterogenous organisations  and interoperability 
standards are implemented, allowing for the sharing of benefits and value between organisations 
serving a common goal.
Organisation and business principles are aligned with resource efficiency and 
business sustainability. Increased profitability is directly associated with resource 
efficiency and business sustainability.
Resource efficiency and business sustainability activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing for the sharing of benefits and 
value between organisations serving a common goal.
Data management processes are disseminated throughout the organisation so as 
to inform all stakeholders on how their work processes are affected. Data storage 
and data exchanges are formalised and monitored. 
Data management activities are linked between heterogenous organisations  and interoperability 
standards are implemented, allowing for the sharing of benefits and value between organisations 
serving a common goal.
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Capability level 5 Interoperability level 5
Optimizing Universal
All legislation and policies relating to patient safety are well defined, implemented, and actively 
reviewed and updated by a wide range of stakeholders.
National legislation is fully integrated and aligned with international legislation. Legislation is continuously updated and improved upon and 
contributes to the development of the international legislative landscape.
Comprehensive and dedicated governance structures in place. Comprising stakeholders from 
various organisations. Regular reviews and performance measurement of governance structures 
ensures continuous improvement.
Governance structures are comprised of individuals representing international industry and governments. Continuously reviewed and 
improved, ultimately contributing to the evolution of the international landscape.
Regular audits and reviews ensure that the business continuity plan has been fully implemented 
and ensures the achievement of quality and performance objectives and regulatory compliance.
Business continuity plan is fully integrated with international guidelines, standards and best practices. Continuously reviewed and improved, 
ultimately contributing to the evolution of the international landscape.
The organisation has strong ethical behaviour and a code of ethics and conduct which is aligned 
with international guidelines and best practices.
A universal approach to data ethics and ownership. All organisations in the global healthcare interoperability community are continually 
interoperating.
Quantitative measurement of business performance and effectiveness allows for optimisation of 
key business processes which contribute significantly to business performance. Performance data 
provides the capacity to innovate and grow.
Unified performance monitoring. All organisations in the global healthcare interoperability community are continually interoperating.
The organisation considers transparency and accountability as a value. Communication of auditing 
and assessment outcomes is done in a transparent manner so as to maintain a positive sentiment 
by the external environment. Strategic level decision making is inclusive of transparency and 
accountability principles. The organisation has a robust and agile risk management strategy.
A universal understanding of transparency and accountability across all interoperating organisations in the interoperability community. All 
organisations in the global healthcare interoperability community are continually interoperating.
Strong partnerships with partners sharing in value creation,  Partnerships are built on a solid 
foundation of trust and performance with partners seeking mutual benefit across the partnership.
Goal interoperability between among partnerships. Partnerships support the adaptation of work procedures.
Communication channels are well established. Communication channels within the organisation as 
well as between the organisation and its external stakeholders are continuously improved.
A universal approach to stakeholder communication. All organisations in the global healthcare interoperability community are continually 
interoperating. Supporting adaptation and continuous improvement of work procedures.
Strategy development is inclusive of all relevant departments, each of which contributing to 
support strategy development.
Goal interoperability between all organisations in the global healthcare interoperability community.
Universal alignment of organisational strategies regarding patent safety. All organisations in the global healthcare interoperability 
community are continually interoperating.
Patient safety culture is firmly rooted in the organisation across all levels and decision making 
across the health system is patient safety centred. Patient safety is considered an organisational 
value. Patient safety culture follows a culture of commitment and development.
Patient safety culture is a universal goal of all  organisations in the global healthcare interoperability community. All organisations in the 
global healthcare interoperability community are continually interoperating. Supporting adaptation and continuous improvement of work 
procedures.
Change management is evident across all levels of the organisation and contributes actively to the 
success of the organisation in meeting its business objectives.
Goal interoperability between all organisations in the global healthcare interoperability community.
 All organisations in the global healthcare interoperability community are continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
Financial management system is owned, reviewed and  actively updated by a wide range of 
stakeholders.
Goal interoperability between all organisations in the global healthcare interoperability community.
 All organisations in the global healthcare interoperability community are continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
Financial resource mobilisation strategy is owned, reviewed and actively updated by a wide range 
of stakeholders.
Goal interoperability between all organisations in the global healthcare interoperability community.
Universal financial resource mobilisation strategy regarding patent safety. All organisations in the global healthcare interoperability 
community are continually interoperating. Supporting adaptation and continuous improvement of work procedures.
Compliance and the associated risks are well  understood throughout the organisation and 
outcomes from compliance processes are used to inform strategic level decision making.
Goal interoperability between all organisations in the global healthcare interoperability community.
Universal regulatory compliance regarding patent safety. All organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous improvement of work procedures.
Strategic level decision making includes resource efficiency and business sustainability.
Goal interoperability between all organisations in the global healthcare interoperability community.
Universal alignment of resource efficiency and business sustainability strategies regarding patent safety. All organisations in the global 
healthcare interoperability community are continually interoperating.
The data management system allows for continuous monitoring of access and use. Electronic data 
exchange is considered the default method of transferring data both internally and externally. The 
data management system is continuously improved upon.
Goal interoperability between all organisations in the global healthcare interoperability community.
Universal alignment of data management strategies regarding patent safety. All organisations in the global healthcare interoperability 
community are continually interoperating.






























The existence of policy documents that specify the roles and responsibilities of the relevant PV staff. Including the designation of a Qualified Person for Pharmacovigilance (QPPV). A set of principles, guidelines, and 
norms that an organisation adopts to help manage its employees.
Human resources capacity
Availability of adequate personnel with relevant characteristics, attributes, and capabilities to perform the tasks or sets of tasks outlined by the organisations  PV operations and policy documents. This includes 
people across all stages of the system life cycle, from aspects such as design, development, implementation, and use of the system. (e.g. system architect designers, software developers, implementation and 
training personnel, as well as HCPs.)
Human resources capacity 
development
Awareness, education, and training initiatives aimed at the development of a strong PV culture within the organisation. An organised activity with clear learning outcomes that aims to impart knowledge and skills, 
shape attitudes, and develop specific competencies and capabilities in personnel. Provision of guidance on the importance of safe practices and procedures for patient safety. Increased sensitisation of healthcare 
workers on the causes and prevention of adverse events should form part of the continuous professional development of all HCPs. Patient safety training should form part of the curricula of healthcare training 
institutions.
Data capture Methods of capturing data associated with the suspected adverse drug reaction. Structured forms, electronic vs paper based, etc.
Data storage and aggregation Databases and database management. How data is aggregated for statistical analysis, as well as how duplication errors are avoided.
Workflows
Workflows describe the necessary sequential steps which need to be taken when performing the business processes. Workflows typically involve the use of Standard Operating Procedures (SOPs). In the context of 




The format in which data is presented to the subsequent entity in the chain of PV communication.
Data standards
Data standards is inclusive of knowledge representation and terminology standards.  Provisions for the inclusion of all relevant structured data useful to assess an individual case.  Knowledge representation refers 
to how medical knowledge is represented within an information system/application context. Collaboration among system users and developers is critical when managing inconsistent knowledge bases.  
Terminology standards provide specific codes for terminologies and classifications for clinical concepts such as diseases and medications. The terminology systems assign a unique code to a specific disease or 
entity. An appropriate MedDRA term should be provided in the lowest level term for the drug characterisation along with the resulting suspected adverse reaction.  Compliance with standardised medical data 
content standards such as WHO-ART and MedDRA.  
Information content
The information that is encoded in the ICSR for an ADR report. Standard data elements, provisions for free text narratives. Minimal Information Model for Patient Safety Incident Reporting and Learning Systems. 
The ICH ICSR E2B (R3) standard, current best practice.
Data protection, privacy, and 
security standards
Data protection, privacy and security standards associated with the exchange of patient safety information. Measures to disable unauthorised access of information, manipulation, modification or deletion of 
information. E.g. The EU General Data Protection Regulation (GDPR).
Information exchange and 
interoperability  standards
Standards which govern the transmission, organisation and interpretation of electronic data. This includes messaging standards, document standards, application standards, conceptual standards, and architecture 
standards. These standards are developed by SDOs such as International Standards Organisation (ISO), European Committee for Standardisation (CEN), Health Level Seven (HL7), and OpenEHR.  
ICT hardware
The physical hardware needed to support the operation of a spontaneous reporting system. This hardware includes computers, monitors, data input devices/peripherals (mouse, keyboard, etc.), as well as the 
appropriate cabling and availability of power.
Network
The existence of the appropriate IT infrastructure to enable the efficient and effective transmission of ICSRs whether it be over local area network (LAN) within a facility or wide area network (WAN) across facilities 
or organisation in different geographical locations.
Development and maintenance Proactive efforts to ensure that the technologies and standards used are maintained and evolved to continually meet the ever changing needs of the system.
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Initial System as silo Managed
Roles and responsibilities undefined with work processes being completed 
inconsistently, on an ad-hoc basis.
No formal interoperability framework addressing human resources policy.
HR policy is developed within the confines of the localised system setting.
No standardisation.
Simple, but complete set of defined roles and responsibilities with 
dedicated staff.
Patient safety work processes are performed ad hoc, in an inconsistent 
manner by unqualified individuals.
HR capacity is managed within the confines of the localised system setting.
No standardisation.
Patient safety work processes are identified and assigned to individuals in a 
structured manner.
Emerging need for professional development of patient safety workforce. 
Ad hoc and incidental training occurs by means of mentoring and 
apprenticeships.
No formal HR capacity development framework in place. HR capacity is 
developed on an ad hoc basis, unpredictably.
Simple HR capacity development plan in place which targets core 
competencies. 
Paper-based system for capturing patient safety information. 
Single technology used for data capture. Data capture occurs in an 
unstructured way and requires manual data integration.
No standardisation.
Simple electronic form to capture patient safety information.
No electronic database, paper based ADR reports.
Database is designed and  developed within the confines of the localised 
system setting. Data is stored manually.
No standardisation.
Simple electronic storage of ADR reports,  Microsoft Excel spreadsheet.
Initial attempt at defining workflows has been made but are not 
comprehensive in nature.
Workflows are developed within the confines of the localised system 
setting.
No standardisation.
Simple, but complete set of patient safety related workflows has been 
defined.
Paper-based ADR reports mailed via a postal service.
Data transmission is performed manually due to isolated use of 
technology. 
No standardisation.
ICSR sent as attachment via e-mail, but not E2B compliant.
No formal standards are adhered to, any standards that are adhered to are 
incidental and on an ad hoc basis.
Data standards are specific to a proprietary system. No interaction 
between systems negates the need for data standards.
No standardisation.
The need for data standards is recognised by the organisation and simple 
data standards governing the encoding of electronic data are adhered to.
No set of minimum information/data elements adhered to. A recognised 
need for a minimum set of information/data elements.
System as silo means no interaction with other systems and therefore no 
standard in place for the information content of the ICSR.
No standardisation.
The ICSR form has a simple but complete set of basic data elements which 
constitute the minimum acceptable information.
Identified need for data protection,  privacy and security standards. No 
standards are implemented or adhered to consistently.
System as silo, therefore no data protection, privacy, and security 
standards are in place.
No standardisation.
Some data protection, privacy and security standards are incidentally and 
unpredictably adhered to.
No formal standards are adhered to, any standards that are adhered to are 
incidental and on an ad hoc basis.
Information exchange and interoperability standards not implemented or 
adhered to because the system works without interaction with other 
systems.
No standardisation.
The need for interoperability is recognised and simple initiatives are 
employed to manage interoperability.
The organisation has inadequate hardware to support patient safety, but is 
aware of the need for appropriate ICT infrastructure.
Hardware across different operating locations of the organisation is not 
standardised and does not allow for the exchange of patient safety 
information.
No standardisation.
Simple, but complete assessment of ICT infrastructure needs for supporting 
patient safety, and a simple but complete infrastructure.
The organisation has an inadequate network to support the optimal 
functioning of an information system.
System as silo means that no networking ability is in place and no 
interaction with other systems in performed.
No standardisation.
Simple, but effective IT communications network is operational.
Maintenance and development of the organisations technology 
infrastructure is performed on an ad hoc basis.
Development and maintenance  is localised to the individual system 
setting.
No standardisation.
Simple, but complete set of practices defined to support the development 
and maintenance of the organisations IT infrastructure.
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Interoperability level 2 Capability level 3 Interoperability level 3
Peer-to-peer Defined Distributed
Guidelines on interoperability exist but specific arrangements relating to 
human resources policy are unplanned.
Well defined roles and responsibilities with dedicated staff of adequate 
competency.
Human resources policy is developed according to an organisational 
interoperability framework, based on organisations with shared goals and 
common roles and responsibilities.
HR capacity processes of homogenous systems linked and guided by 
interoperability guidelines.
Standardised roles and responsibilities are entrusted to qualified and 
capable personnel.
HR capacity is developed with the help of an organisational interoperability 
framework. Streamlining or organisational procedures for knowledge 
sharing.
HR capacity development processes  of homogenous organisations linked 
and guided by interoperability guidelines.
Formal, future-focussed, talent development programs implemented.
HR capacity development strategy is developed with the help of an 
organisational interoperability framework. Streamlining or organisational 
procedures for knowledge sharing.
Data capture is performed electronically and adheres to standards agreed 
upon by homogenous systems.
Guidelines exist which describe interoperability.
Web-based data capture via a "smart"/interactive form with standard data 
elements.
Distributed data capture standard.  Guided by an interoperability 
framework. Streamlining of data capture over a central server linking 
shared logical data models.
Database receives and stores data from more than one IT system via 
simple agreements for simple electronic data exchange,
Guidelines exist which describe interoperability.
Dedicated electronic ICSR database is established.
Functional linking of databases which share logical data models across 
organisations.
Standardised safety, security and privacy protocols.
Workflows are partially interoperable with other homogenous systems 
based on simple agreements for simple data exchange.
Guidelines exist which describe interoperability.
Workflows are well defined and standard operating procedures have been 
developed.
Workflows are linked across facilities of an organisations in the same 
country and are aligned to achieve a common objective.
Simple electronic data exchange between homogenous systems with 
discretional pre- and post-exchange data handling.
Guidelines exist which describe interoperability.
E2B compliant ICSR sent via e-mail.
Distributed data transmission standard. Streamlining of transmission over a 
central server linking shared logical data models.
Simple data standards are implemented allowing the electronic exchange 
of data between homogenous systems.
A comprehensive portfolio of data standards is adopted by the 
organisation. These data standards specifically address all the relevant 
topics relating to the exchange of electronic healthcare data. Knowledge 
representation and terminology standards are adhered to.
Distributed portfolio of data standards throughout the organisation. 
Linking of systems for a common objective. Standardised data protection, 
security, and privacy protocols in place.
Simple agreements between two homogenous systems regarding 
information content of the ICSR.
Electronic ICSR form with a standard set of data elements. E.g. the Minimal 
Information Model for Patient Safety (MIM PS).  No provision for free text 
narrative.
Standard information content model developed for the transmission of 
ICSRs between homogenous systems.
Data protection, privacy, and security standards are based on simple 
agreements for the simple exchange of electronic data between 
homogenous organisations.
Specific data protection, privacy and security standards are identified and 
adhered to.
Data protection, privacy, and security standards are selected and 
implemented based on an interoperability framework.
Information exchange and interoperability standards are implemented 
allowing the electronic exchange of data between homogenous systems.
Interoperability is understood as a business goal and competitive 
advantage. Formal interoperability standards are selected and adhered to. 
Organisational structures are in place to guide interoperability.
Information exchange and interoperability standards are selected and 
implemented according to an interoperability framework for organisations 
with shared goals, and aligned roles and responsibilities.
Hardware at different operating locations of the organisation allows for 
simple data exchange and the linking of business processes. 
The organisation has identified the specific hardware components that 
directly support the business processes related to patient safety.
Hardware at different operating locations of the organisation allows for 
linking of business processes which support the common goal of improved 
patient safety.
Safety, security, and privacy standards are implemented.
Simple agreements regarding LAN capabilities for simple peer-to-peer 
exchange of electronic data within an organisation.
The organisation has assessed its networking requirements.
An implementation plan is in place to improve the efficiency of the IT 
communications network.
Distributed WAN capability to allow network communication between 
homogenous systems. Streamlining of organisational procedures. 
Communication over a central server,
Guidelines for the development and maintenance of the organisations 
technical infrastructure are available, but are not followed consistently.
Standard operating procedures are in place to manage IT infrastructure 
development and maintenance to support patient safety business 
processes.
Development and maintenance of the organisations technical 
infrastructure is guided by a technology interoperability framework. 
Streamlining or organisational procedures for knowledge sharing.
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Capability level 4 Interoperability level 4 Capability level 5
Quantitatively managed Integrated Optimizing
Well defined roles and responsibilities with dedicated, fully competent staff, 
whose performance is measurable with performance indicators/metrics.
Integrated approach to human resources policy development across all 
heterogenous organisations with shared value systems and goals in the 
interoperability community.
Performance of human resources is optimal and consistent.
Outcomes of quality and process performance objectives are used when reviewing 
and developing new roles and responsibilities.
Designated staff across all levels of the organisation with the appropriate 
responsibilities, accountability, and authority for conducting patient safety 
activities. Patient safety staff are motivated to perform and have a high level 
of engagement.
HR capacity is sufficient that all heterogenous organisations with shared 
value systems and goals in the interoperability community are able to 
share benefits and value.
Patient safety staff take full control over the development of their career and the 
improvement of their work. Patient safety staff are self-motivating and assist HR 
with attracting world-class talent.
A culture of learning and professional development becomes embedded in the 
organisation. Performance support is available to assist with learning.
HR capacity development is linked across various heterogenous 
organisations serving a common goal for the sharing of benefits and value.
Continuous professional development. HR capacity development strategy is aligned 
with business strategy, resulting in an agile and future focussed workforce.
Electronic data capture via computer, web portal or mobile application. 
Data capture according to international standards to allow interoperability 
between various heterogenous systems which serve a common goal.
Automated data capture from other information systems (EHRs, pharmacy, labs etc.)
ICSR database compatible with medical terminology directories (e.g. 
MedDRA), access and usage monitoring, validity and duplication detection 
capability. 
Database receives and stores data from multiple heterogenous IT systems.
Standardised safety, security and privacy protocols.
ICSR database with backwards and forewords compatibility for the ICH ICSR E2B 
(R2/R3) standard reporting format.
Quantitative methods are employed to understand performance variation by 
focussing on process performance objectives.
Workflows from heterogenous organisations which serve a common goal 
are linked together for shared benefits and value interoperability.
The use of quantitative techniques allow for optimisation and continuous 
improvement of workflow management and developing and implementing SOPs.
ICSR sent to the UMC via the  web-based VigiFlow reporting tool.
Data transmission is according to industry standards, allowing the 
exchange of data between independent heterogenous systems.
E2B compliant ICSR transmitted via a proprietary gateway application, adhering to 
the ICH ICSR E2B (R3) business rules for the electronic transmission of ICSRs.
The portfolio of data standards has been disseminated throughout the 
organisation. Compliance is measured by an external auditing body and 
certification is awarded accordingly.
International standards and best practices adhered to by the organisation, 
allowing for the integration of heterogenous systems which serve a 
common goal.
Data standards are regularly reviewed and updated to be consistent with best 
practices and to ensure interoperability with other health information systems.
Electronic ICSR form compliant with the ICH E2B (R3) standard, with a 
comprehensive set of data elements and the provision for a free text 
narrative.
Shared information model across various heterogenous systems to allow 
for transmission of ICSRs within the interoperable community.
A system wherein the sought after information is pulled through on an as requested 
basis. Through correct harmonisation of systems and standards, information can be 
requested as opposed to reported or "pushed" to the entity requesting the 
information. Thus allowing for the inclusion of any and all information available.
Auditing and compliance monitoring of the data protection, privacy and 
security standards allows for quantitative feedback.
Common data protection, privacy, and security standards are adhered to 
by various heterogenous organisations which serve a common goal.
Management monitors compliance with data protection, privacy and security 
standards. Any issues of non-compliance are identified and remedial action is taken 
to ensure compliance in a timely manner
The organisation conducts interoperability  compliance assessments to gain 
insight into which aspects of interoperability require attention.  The 
organisation implements and adheres to a framework for interoperability 
compliance.
Common information exchange and interoperability standards are 
implemented across various heterogenous systems, allowing for the 
sharing of benefits and value between organisations serving a common 
goal.
The advantages of interoperability are widely understood throughout the 
organisation and are linked to specific business practices. The organisation leverages 
these advantages to improve overall efficiency and the bottom line. Information 
exchange and interoperability standards are regularly reviewed and updated to be 
consistent with best practices.
The organisation conducts regular reviews of hardware capabilities and 
performance to ensure that  performance objectives are met.
Hardware across different operating locations of different organisations 
allows for linking of systems.
Integration of heterogenous systems which serve a common goal.
The organisations ICT hardware infrastructure meets international standards. 
Policies are in place to ensure optimal functioning and maintenance of ICT hardware, 
allowing for continuous improvement.
The performance of the organisations IT communication network is measured 
against performance objectives.
Integrated WAN capabilities enable the integration of heterogenous 
systems which serve a common goal. Safety, security, and privacy 
standards are monitored closely.
The organisations IT communications networking capabilities are in line with 
international standards.
Functioning optimally and reliably, and subjected to regular testing and performance 
reviews.
A dedicated support team takes ownership of the development and 
maintenance of the organisations IT infrastructure.
Proactive development of infrastructure ensures optimal functioning and up-
to-date IT infrastructure.
Development and maintenance of technical infrastructure is shared across 
various heterogenous systems which serve a common goal.
IT infrastructure development and maintenance is focussed on continuous 
improvement and is performed so as to enable the system to respond to opportunity 
and change in the future.
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A universal approach to human resources policy development. All organisations in 
the global healthcare interoperability community are continually interoperating. 
Supporting adaptation and continuous improvement of work procedures.
Continuous improvement in HR capacity ensure continuous interoperation between 
all organisation in the global healthcare interoperability community. Supporting 
adaptation and continuous improvement of work procedures.
HR capacity development is universal and ensures continuous interoperation 
between all organisation in the global healthcare interoperability community. 
Supporting adaptation and continuous improvement of work procedures.
Data capture standards and applications are fully shared and distributed. All 
organisations in the global healthcare interoperability community are continually 
interoperating. Supporting adaptation and continuous improvement of work 
procedures.
Database is fully integrated with international guidelines, standards and best 
practices. 
Continuously reviewed and improved, ultimately contributing to the evolution of the 
global healthcare interoperability community.  Supporting adaptation and 
continuous improvement of work procedures.
Universally agreed upon workflows which support the adaptation and continuous 
improvement of work procedures. All organisations in the global healthcare 
interoperability community are continually interoperating.
Data transmission is according to universally agreed upon standards, and can be 
between any systems in the global healthcare interoperability community. 
Supporting adaptation and continuous improvement of work procedures.
Universally agreed upon and implemented standards which support the adaptation 
and continuous improvement of work procedures. All organisations in the global 
healthcare interoperability community are continually interoperating. 
A common information model is universally distributed allowing  the transmission of 
ICSRs between any organisations in the interoperable community. All organisations 
in the global healthcare interoperability community are continually interoperating. 
Supporting adaptation and continuous improvement of work procedures.
Universally agreed upon and implemented data protection, privacy, and security 
standards which support the adaptation and continuous improvement of work 
procedures.
Universally adopted information exchange and interoperability standards across all 
organisations participating in the global healthcare interoperability community. All 
organisations in the global healthcare interoperability community are continually 
interoperating.
Hardware allows for complete integration with international guidelines, standards 
and best practices. 
Continuously reviewed and improved, ultimately contributing to the evolution of the 
international landscape. Supporting adaptation and continuous improvement of 
work procedures.
Universal communications network established for the exchange of electronic 
healthcare data. Systems and applications can connect freely and exchange data 
where permissible, without necessarily serving a common goal. Supporting 
adaptation and continuous improvement of work procedures.
Universal interoperability of the global health information exchange supports 





Chapter 8 supporting content
This appendix provides the supporting content of Chapter 8. The content of this Appendix is
as follows:
 Section B.1: PVR-CMM V1 Verification pre-reading document,
 Section B.2: PVR-CMM V1 Verification questionnaire, and
 Section B.3: Responses from subject matter experts.
Section B.3.1: Response from SME number one.
Section B.3.2: Response from SME number two.
Section B.3.3: Response from SME number three.
Section B.3.4: Response from SME number four.
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ADR Adverse drug reaction 
EHR Electronic health record 
HCP Healthcare professional 
Heterogenous systems 
Two ICT systems which are owned and operated by distinct parent organisations 
(marketing authorisation holders, or regulatory authorities). 
HIT Health information technology 
Homogenous systems 
Two ICT systems, potentially in different locations, however, owned and 
operated by the same parent organisation or regulatory authority. 
ICSR Individual case safety report 
ICT Information and communication technology 
Interoperability 
The ability of information and communication technology (ICT) systems and the 
business processes they support to exchange data and to enable the sharing of 
information and knowledge. 
Interoperability 
community 
All organisations or role-players which seek to interoperate in order to receive or 
give value to and from one another. In this context the interoperability 
community includes, but is not limited to, regulatory authorities, MAHs, and 
academia. 
MAH Marketing authorisation holder 
PASS Post authorisation safety study 
PSUR Periodic safety update report 
PV Pharmacovigilance. 
PVR-CMM Pharmacovigilance Reporting Capability Maturity Model 
RA Regulatory authority 
Semantic 
Interoperability 
The ability of ICT systems to automatically interpret information exchanged, in a 
meaningful and accurate manner, to produce useful results as defined by the 
end user of both systems. 
SOP Standard operating procedure 
STS Sociotechnical system 
Syntactic 
Interoperability 
When two or more ICT systems are capable of communicating and exchanging 
data, through the use of specified data formats and communication protocols. 
UMC Uppsala Monitoring Centre 
WHO World Health Organisation 







Pharmacovigilance (PV) is based on the medical assessment of adverse medical events or drug-related 
problems, collected within organised health programmes. The large number of different PV systems, the 
equally large number of stakeholders within such systems (i.e. pharmaceutical companies, government 
regulatory bodies, national and international clinical regulatory bodies, healthcare workers, etc.), as well 
as the significant number of dimensions along which the effectiveness and efficiency could be measured, 
adds to this complexity. Furthermore, the lack of a standardised reporting protocol across the various PV 
systems hinders efforts to coherently manage PV on a global scale. 
 
1.1 PROBLEM DEFINITION 
The primary obstacle to standardising and achieving interoperability between spontaneous reporting 
systems globally is the fundamental difference in purpose of the existing spontaneous reporting systems. 
The 3 main role-players at the global level of pharmacovigilance are the Uppsala Monitoring Centre (the 
pharmacovigilance working group of the World Health Organisation), the various Marketing 
Authorisation Holders (MAHs), and the Regulatory Authorities (RAs) representing governments around 
the world. Each of these three role-players has its own goals and perspectives when conducting PV. 
1. The UMC:  To successfully integrate PV data from all WHO member countries and to perform 
statistical analysis and continuous monitoring of the global PV landscape. 
2. MAHs:  To achieve and maintain regulatory compliance, mitigation of financial and market risks, 
as well as being able to make informed marketing decisions. 
3. RAs:  To protect and promote patient safety within their public health programs and thus 
alleviate pressure on their health system. 
With this in mind, it is important to note that the strength of the global pharmacovigilance system lies in 
the integration of various national and industry PV systems. While the UMC offers substantial support to 
the WHO member countries, many of the developing member countries lack the capacity and capability 
to take full advantage of the services offered by the UMC. 
 
1.2 AIM OF THIS STUDY 
The aim of this study is to contribute towards the harmonization and interoperability of spontaneous 
reporting systems in the pharmacovigilance landscape. The development of a maturity model with a 
sociotechnical system focus will contribute towards this aim – the PVR-CMM (Pharmacovigilance 
Reporting Capability Maturity Model). 








The PVR-CMM should be useful and of value to MAHs and RAs conducting PV activities by providing 
guidance on how to reach ICH E2B (R3) compliance and thereby contribute maximally to PV on a global 
scale, while also receiving maximum value from the services offered by the UMC. Figure 1 shows a 
summary of the expected contribution of the PVR-CMM when used by MAHs or RAs. 
 
1.3 METHODOLOGY OF STUDY 
This validation pre-reading document will focus primarily on the PVR-CMM itself, however, key 
supporting research outcomes and findings will be included in the relevant appendices and referred to 
where necessary. 
The first step in this research was to gain an understanding into the global PV landscape, what is meant 
by a standardised spontaneous reporting system, the challenges and barriers which affect the 
spontaneous reporting of adverse drug reactions (ADRs), and an analysis of the effects of the lack of a 
standardised global PV reporting system. From this step, the extent to which standardisation could 
alleviate these PV challenges was established. 
The next step involved characterising the global PV system by identifying the role-players, their 
responsibilities, and the communication channels between them. This stage of the research also 
identifies and elaborates on best practices for the reporting of ADRs (the ICH E2B (R3) standard for 
electronic Individual Case Safety Report (ICSR) transmission) as well as the solutions and services offered 
Improved global PV goals
Leveraging technology to improve patient safety
Spontaneous reporting system interoperability
Through the harmonisation of standards and processes
Adoption of the ICH E2B (R3) standard
Current best practise for the electronic transmission of ICSRs
Capacity building
With the aid of a capability maturity model
FIGURE 1 SUMMARY OF THE EXPECTED CONTRIBUTION OF THE PVR-CMM. 






by the UMC. By understanding the roles and responsibilities of the various role-players, the PVR-CMM 
could be developed with the three perspectives described in section 1.1 in mind. 
The use of maturity models as assessment and improvement guidance tools was investigated in the 
following step in the research. One application of maturity models is to provide guidance towards 
interoperability. By comparing various maturity models and maturity assessment frameworks in an 
eHealth context, it was determined that maturity models can also feasibly be used for this purpose within 
the PV landscape. 
Taking into consideration the difficulty associated with implementing standardised health information 
technologies (HITs) into large, complex systems, the notion of sociotechnical systems was investigated. 
The pharmacovigilance system was described as a sociotechnical system to gain an improved 
understanding of how best to design and implement HITs in these complex systems. Further discussion 
relating to this can be found in Appendix A. Through the conceptualisation of the PV system as a 
sociotechnical system, the PVR-CMM development process was more cognizant of social, cultural, and 
political factors, rather than focussing solely on the technological factors. 
The concept of the PVR-CMM was then introduced and would be developed using all of the preceding 
theory and literature findings, from a sociotechnical system perspective. 
A body of literature surrounding the interoperability of information systems as well as health information 
systems specifically was studied. From this research, a collection of 18 maturity models and frameworks 
were identified. A comparison of these 18 models and frameworks assisted with the selection and 
characterization of the 30 dimensions included in the PVR-CMM (Appendix B). 
 
1.4 AIM OF VALIDATION PROCESS 
The aim of validation process is to engage subject matter experts in the pharmaceutical industry as well 
as in the regulatory space in order to determine the accuracy, applicability, validity, and value of the PVR-
CMM developed in this study. This is achieved by providing each subject matter expert with a brief 
summary of the research methodology leading up to the development of the PVR-CMM before 
conducting an interview, guided by a questionnaire. 
 
  






2. THE PVR-CMM 
The PVR-CMM was developed with the intention of being used in conjunction with other PV related 
statutes, guidelines and documents. The contents of the PVR-CMM should be considered as general 
guidelines which can be adapted to suit the individual needs of any country or organisation managing a 
spontaneous reporting system for pharmacovigilance, while incorporating current best practices and 
achieving and maintaining regulatory compliance. 
2.1 STRUCTURE OF THE MODEL 
The PVR-CMM is comprised of 3 domains which include 7 subdomains and 30 dimensions. Research 
suggests that interoperability results as a product of standardisation in four domains: technology, syntax1, 
semantics2, and pragmatics3. 
The PVR-CMM was structured with sociotechnical system engineering principles in mind, that is to say, 
placing equal importance on the social, political and environmental (workplace) factors. The domains 
were organised accordingly into three categories: Organisational (pragmatic), Informational (syntax and 
semantic), and Technical. These three domains lend themselves to the discussion of capability maturity 
as well as interoperability, and are consistent with the findings of the literature review (Appendix B). 
The PVR-CMM further breaks down these three domains and provides subdomains. The subdomains 
within the organisational domain characterise the pragmatic aspects of interoperability in PV. The 
informational subdomains characterise the semantics of interoperability, and the technical subdomains 
emphasise the syntax or format of the information being exchanged between systems. 
PV systems involve complex interactions between healthcare professionals, computer hardware and 
software, as well as the physical work environment within which they operate, all the while being 
exposed to external pressures from ever changing political, technological, cultural and social factors.  
2.2 DIMENSIONS 
The 30 dimensions included in the PVR-CMM will be listed below and motivation for their inclusion in 
the model will be provided. The contextual definition for each of these dimensions is included in the 
PVR-CMM itself, in the fourth column.  
1. Organisational (Pragmatics) 
 
1.1. Leadership & governance 
 
                                                          
 
1 Syntax standardisation refers to the agreement on the structure and language of the message exchanged by 
heterogenous applications across a network. 
2 Semantic standardisation refers to the extension of syntactic standardisation, that is to say the meaning of the 
messages are mutually understood. 
3 Pragmatic standardisation refers to agreements on protocols and practices which are prompted by specific 
messages. 






1.1.1. Law, regulation and policy 
This dimension serves as acknowledgement of the existence of the appropriate legal 
provisions that mandate and guide all PV related activities. From an interoperability 
perspective it is necessary to have a common understanding of legislation relating to the 
exchange of information and the associated security and privacy issues. Legislation and 
regulatory guidelines must be compatible and define the boundaries of interoperability 
between two ICT systems. 
1.1.2. Governance structures and commitment 
Governance structures are those consisting of the highest executive management of the 
organisation. The governance structure should enable management to ensure the 
organisation’s compliance with the relevant legislation. Governance impacts change 
management, regulatory compliance, and also directs the progress of evolving policies 
and procedures towards interoperability.   
1.1.3. Business continuity and responsiveness 
Certain pharmacovigilance processes are critical and the appropriate business continuity 
plans should be developed in a risk-based manner. These processes include collection, 
processing, management, and timely transmission of ICSRs. Back-up systems allowing 
exchange of critical information within an organisation, between organisations, or 
between the MAH and the RA. 
1.1.4. Data ethics/ownership 
Data ethics addresses the moral dimension of data management. This includes ensuring 
adherence to ethical principles throughout data generation, recording, curation, 
processing, dissemination, sharing, and use. With the aim of interoperability being the 
sharing of data, it is important to stipulate the ownership of the data and to protect and 
uphold the interests of the owner. 
1.1.5. Monitoring of performance and effectiveness 
The organisation should clearly define performance indicators which can be used to 
continuously monitor the performance of PV activities. Monitoring of performance will 
include activities such as reviews, audits, compliance monitoring, and inspections. Good 
pharmacovigilance practices have been defined by the European Medicines Agency and 
can serve as a set of quality requirements for the various PV activities. Corrective and 
preventative measures can be implemented as a means of addressing performance 
shortcomings. 
1.1.6. Transparency and accountability 






Transparency instils trust confidence in the organisation and their system by the public. 
Accountability refers to the organisation taking responsibility for its actions. Both 
transparency and accountability are exercised in a PV context through the clear 
communication of post authorisation safety studies (PASSs) and patient safety update 
reports (PSURs) by the MAH.  
1.1.7. Partnerships 
Patient safety and PV activities must be considered when forming and managing 
partnerships. In the case where multiple partner organisations make use of the same PV 
system, each partner must ensure that the PV system functions to meet their individual 
regulatory compliance needs.  
1.1.8. Stakeholder communication 
Provisions for timely and effective communication of patient safety information or safety 
concerns to the relevant stakeholders (consumers, HCPs, MAH, RAs, etc.), be it within an 
organisation or between organisations. This also applies to communication between 
MAHs and their respective RAs. Coordination and cooperation between the various 
parties involved in communicating patient safety information, as well as the management 
of communication tools and channels should seek to improve access to information by 
those in need of the information. 
1.1.9. Organisational strategy alignment 
It is important that the organisation has a shared understanding of the PV operating 
model across all levels of the organisation as well as a common understanding of the role 
of the organisation within the global patient safety system. Different functional units of 
an organisation, such as manufacturing, sales and marketing, and quality control, may 
have contradicting goals and incentive structures, which do not focus on patient safety. 
1.1.10.  Building a culture of safety 
By developing and maintaining a system of shared actions, values, and beliefs, the safety 
culture will permeate throughout the organisation. A strong culture of safety can help 
shape the way in which the organisation views PV, from that of a collection of compliance 
and risk mitigation activities, to a means of developing a set of standard business 
procedures which yield a competitive advantage. 
1.1.11. Organisational change management 
Change management processes need to be established to guide the adoption of newly 
identified best practices and updated work procedures. Change management is critical 






when dealing with an ever-changing business environment and the constant introduction 
of new technologies. 
1.2. Finance and Economics 
 
1.2.1. Financial management 
A dedicated budget for PV-related activities is crucial. Procedures must be in place to 
ensure correct spending of funds in the public sector. A proactive approach to investing 
in innovative technologies must be adopted, e.g. the case of the electronic health record 
(EHR). 
1.2.2. Financial resource mobilisation 
Activities relating to the acquisition of new financial resources for the organisation, are 
vital to guarantee the continued availability of financial resources. These financial 
resources could include grants, investments from the private sector, or monetary 
donations from international aid organisations.  
1.3. Business Objectives 
 
1.3.1. Regulatory compliance 
Organisational policies and processes must always be cognizant of, and remain compliant 
with, regulatory compliance policies. In order to maintain regulatory compliance, 
awareness of the applicable legislation and regulations is critical across all stakeholders 
in the PV system. 
1.3.2. Resource efficiency and business sustainability 
Business sustainability in this context refers to the organisation’s ability to continually 
control the costs and benefits of interoperability while sustaining the overall quality and 
performance of their spontaneous reporting system. Achieving efficient utilisation of 
resources is to exploit system inputs to maximise system outputs, while minimising 
wasted resources. 
1.3.3. Data management 
Data management refers to the set of procedures and policies which govern the 
management of data within the spontaneous reporting system. This includes how data 
are captured, collected, stored, transmitted and processed.  
1.4. Human Resources 
 






1.4.1. Human resources policy 
This dimension serves as acknowledgement of the existence of the necessary policies 
which specify roles and responsibilities for PV in the organisation. Every organisation is 
legally required to designate a qualified person for pharmacovigilance, this person is 
tasked with overseeing all PV related activities within the organisation. 
1.4.2. Human resources capacity 
This refers to the availability of personnel with the relevant and required characteristics, 
attributes, and capabilities to perform the specified PV roles. PV is a responsibility that is 
shared across functional business units within an organisation and therefore requires 
personnel across all stages of the system life cycle. 
1.4.3. Human resources capacity development 
Awareness, education, and training initiatives aimed at the development of a strong PV 
culture within the organisation. An organised activity with clear learning outcomes that 
aims to impart knowledge and skills, shape attitudes, and develop specific competencies 
and capabilities in personnel. 
2. Informational (Syntax and Semantics) 
 
2.1. Business Procedures 
 
2.1.1. Data capture 
Methods of capturing data associated with suspected adverse drug reactions and the 
technologies involved. The WHO states that an ADR reporting form is one of the minimum 
requirements for a functioning spontaneous reporting system. 
2.1.2. Data storage and aggregation 
The WHO states that an ADR report database is one of the minimum requirements for a 
functioning spontaneous reporting system. The methods of aggregating data for statistical 
analysis, as well as methods for duplicate detection are important when considering the 
spontaneous reporting system. 
2.1.3. Workflows 
Workflows detail the sequential steps taken when performing business processes and 
typically involve standard operating procedures (SOPs). 
2.1.4. Data presentation/transmission 






The format in which the ICSR is transmitted from the sender to the receiver. Currently the 
best practice is the ICH E2B (R3) standard for the electronic transmission of ICSRs with 
backwards/forwards compatibility. 
2.2. IT Standards 
 
2.2.1. Data standards 
To achieve syntactic interoperability the ICT systems which seek to interoperate must 
make use of specified data formats and communication protocols. 
2.2.2. Information content 
The data encoded in an ICSR must collectively represent information that is interpreted 
in the same way by the ICSR sender and receiver. 
2.2.3. Data protection, privacy, and security standards 
Information shared by consumers and HCPs has associated rights attributed to the 
consumers and HCPs, these rights must be protected and respected.  
2.2.4. Information exchange and interoperability standards 
For interoperability to occur, the interacting ICT systems must agree on the use of 
standard messaging formats.  
3. Technical 
 
3.1. IT Infrastructure 
 
3.1.1. ICT hardware 
ICT hardware refers to the physical hardware necessary for the effective and efficient 
operation of a spontaneous reporting system. 
3.1.2. Network 
The network refers to the existence of the appropriate IT infrastructure to enable the 
transmission of ICSRs over a local area network (LAN) or a wide area network (WAN). 
3.1.3. Development and maintenance 
This dimension refers to the development and maintenance of technologies and 
standards to ensure optimal performance of the spontaneous reporting system. It is 






important to note that maintenance involves different activities at the local and global 
levels. 
 
2.3 THE TWO MATURITY SCALES 
The PVR-CMM makes use of two maturity scales, relating to capability maturity and interoperability 
maturity respectively. It is believed that by providing two scales according to which maturity can be 
measured, the PVR-CMM user will better understand how the two perspectives interact with each other. 
The capability levels follow the method of the original Capability Maturity Model, developed by the 
Capability Maturity Model Integration (CMMI) Institute. The term capability is associated with specific 
business processes or a practice area within an organisation. Maturity is described as the degree to which 
an organisation has explicitly and consistently deployed processes, according to their business objectives.  
According to the CMMI Institute, the maturity level or capability level of an organisation provides a way 
to characterise its capability and performance. Organisations should focus their improvement efforts on 
a prioritised and manageable number of practice areas at a time. Continuous improvement is something 
which all organisations should seek to embed in their culture. Maturity models assist organisations with 
linking their business objectives to the improvement goals they seek to achieve. By placing the focus of 
the organisation on achieving its business objectives with the help of a MM, performance results typically 
occur naturally and endure for longer. 
The CMMI capability levels are as follows (CMMI Institute, 2018): 
Level 0: Incomplete Incomplete approach to meeting the intent of the practice area. 
Level 1: Initial Initial approach to meeting the intent of the practice area. 
Level 2: Managed 
Subsumes level 1. A simple, but complete set of practices that address 
the full intent of the practice area. 
Level 3: Defined 
Builds on level 2. Uses organisational standards and tailoring to address 
project and work characteristics. 
Level 4: Quantitatively 
Managed 
Builds on level 3. Uses statistical and other quantitative techniques to 
understand performance variation and detect, refine, or predict the area 
of focus to achieve quality and performance objectives. 
Level 5: Optimising 
Builds on level 4. Uses statistical and other quantitative techniques to 
optimise performance and improvement to achieve quality and process 
performance objectives. 
 
A maturity model which aims to promote and improve interoperability should seek to address the degree 
of integration of systems involved, provide guidance on which system components need to be improved, 
as well as provide a means for measuring interoperability progress in a community. Interoperability can 
be complex when dealing with multiple large systems, it can also be difficult to define because while 






interoperability can be measured to some extent, it is not an entity in and of itself. Interoperability can 
be measured by assessing how diverse entities interact and work together across technical, social, 
political, and organisational boundaries. 
In terms of organisational interoperability, the PVR-CMM was developed with the following levels: 
Level 1: System as silo 
Single technology. No standardisation. 
Technical and semantic issues are solved. 
Level 2: Peer-to-peer 
Two systems linked for simple exchange of data. 
Work processes are linked. 
Level 3: Distributed 
(Organisation bound; 
Interorganisational) 
Linking of homogenous systems for a common objective. 
Knowledge is shared. 
Level 4: Integrated 
(National; 
International) 
Linking of heterogenous systems for a common goal. 
Benefits are shared. 
Level 5: Universal 
Systems can connect and disconnect freely and exchange data without 
serving a common goal. 
 
2.4 CONCLUSION: 
This document, in combination with the accompanying questionnaire (document 2 of 2), serves to 
validate the development of the PVR-CMM. The approach that was followed during the research and 
development of the PVR-CMM was summarised in this document. Once the validation process is 
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Pharmacovigilance monitoring systems are examples of Health Information Technologies (HITs), a subset 
of ICTs (Information and communications technologies) which exist within health systems specifically. 
These PV systems involve complex interactions between healthcare professionals, computer hardware 
and software, as well as the physical work environment within which they are implemented. Traditional 
approaches to introduce ICTs into complex systems have been plagued with multiple shortcomings. This 
has highlighted the need to change the approach to introducing ICTs into such complex healthcare 
systems. 
A sociotechnical system (STS) is one which includes technical systems but also operational processes and 
people who use and interact with the technical system. 
STS engineering places more importance on a user-centred approach; one which focusses more so on job 
satisfaction and the needs of the end user. The use and value of sociotechnical systems design methods 
is discussed in more detail in the sociotechnical systems design section of this paper. As with systems 
engineering and its focus on the end user, the activities related to PV are patient centred. 
Pharmacovigilance can be classified as an open sociotechnical system, healthcare professionals interact 
with hardware and software infrastructure, recording, storing, and sharing data through the use of a 
human computer interface. These actions coupled with the multidisciplinary nature of communication 
and workflows in healthcare, influence internal organisational policies and culture, while adapting to ever 
changing external environments such as rules and regulations (Sittig and Singh, 2010). 
The aim of this chapter was to provide an argument for the adoption of sociotechnical systems design 
approaches to improve the design, implementation, and adoption of health information systems which 
seek to assist in promoting safer, better healthcare. The need to incorporate the social sciences in the 
improvement of health information systems has been widely acknowledged in literature (Braithwaite et 
al., 2009)., however, it has not yet been realised through the application of conventional system design 
methods in the context of pharmacovigilance. 
Large complex systems fail not because of technical inadequacy, but rather because they do not recognise 
the social and organisational complexity of the environment in which they are implemented. 
PV systems involve complex interactions between healthcare professionals, computer hardware and 
software, as well as the physical work environment within which they operate, all the while being exposed 
to external pressures from ever changing political, technological, cultural and social factors.    
From the findings presented in this research we show that HIT innovations can never be fully achieved 
with technological advances alone. Problems regarding HIT implementations cannot be solved simply with 
more or better HIT, improved training of HCPs and better technical support.  
The scope of this research revolves around the first stage of the PV system, that is, the reporting of ADRs, 
and the subsequent propagation of the generated signal to the VigiBase monitoring system of the World 
Health Organisation. With this in mind, the four levels in Figure 2 will be explained briefly below: 







FIGURE 2: A CONCEPTUAL DIAGRAM OF A FOUR-LEVEL HEALTH SYSTEM. (ADAPTED FROM: FERLIE ET AL., 2001) 
i. Operational Level: From an engineering perspective, the operational level of a system is the level 
at which decisions relating to the day to day activities of an organisation are made. Spontaneous 
reporting of suspected ADRs is the cornerstone of pharmacovigilance in that it generates the 
largest amount of data. It is at the operational level where the HCPs and patients have a direct 
interaction with the HIT system. At this level the nature of healthcare work and the individual 
characteristics of the HCPs, such as the knowledge base, skill level, training and education, 
attitudes, beliefs, and physical capabilities have the largest influence on the success or failure of 
the system. 
ii. Facility Level: The facility level encompasses the operational level. The facility within which the 
HCP works will have a number of intrinsic characteristics, such as the physical environment and 
layout, the organisational structure, embedded human-system interfaces, communication and 
coordination practices, as well as local work procedures. 
iii. National Level: All facility level activities are governed and coordinated at the national level. Each 
country conducting PV activities will do so according to different healthcare policies, laws and 
regulations. Decisions made at this level have a trickle-down effect on the facility and operational 
levels, affecting the overall safety, quality, and efficiency of these parts of the larger system. The 
PV data generated at the preceding levels is collated and analysed internally by National 
Competent Authorities before transmitting the signals to the VigiBase system. 






iv. Global Level: At a global level there are a number of external environmental forces influencing 
the system, such as technological innovations, economic pressures, political climate, and public 
awareness. The global level is unique in the context of a PV system in that participatory countries 
submit their domestic PV data to the World Health Organisation for the benefit of the entire 
world’s population. 
Based on these descriptions of the levels of the healthcare system, it becomes clear that the outcome of 
patient care is produced through the interaction of multiple intricate and fragmented subsystems.  This 
view of a health system highlights the need to educate healthcare providers across all levels and make 
them aware of their functioning in the greater system that is the healthcare system (Hartman et al., 2017). 
The successful design and implementation of HITs would therefore be of demonstrable value in terms of 
improving the delivery of patient care and, in the context of PV, improving patient safety.  
To assist with the successful design and implementation of HITs, the notion of a sociotechnical transition 
must be considered. One must delve into the operational level of the system and consider relationships 
amongst and between technology and its users across multiple system boundaries. The change process 
must consider how people work in situ rather than merely accept what they ‘say they do’, as well as how 
these people translate their beliefs into actions in the workplace and how they make choices in the 
workplace when executing their power. 
 
  








A body of literature surrounding the interoperability of information systems as well as health information 
systems specifically was studied. From this research, a collection of 18 maturity models and frameworks 
were identified. A comparison of these 18 models and frameworks assisted with the selection and 
characterization of the 30 dimensions included in the PVR-CMM.   
 
See the table below:

























ADR IT system functionality: Collect, Record, 
Report in E2B, Received ADR data analysis 
ADR system maturity level: Basic, Well 
developed, Advanced 
n/a n/a 
SCOPE team of 























Jurisdictional, Collaborative, Organisational, 
Informational, Managerial, Cost, 
Technological, Performance.  
Maturity levels: Computer interoperability, 
Process interoperability, Knowledge 



















Interoperability Categories:  Organisational 
(Economic/Regulatory Policy, Business 
Objectives, Business Procedures), 
Informational (Business Context, Semantic 
Understanding), Technical (Syntactic 
Interoperability, Network Interoperability, 
Basic Connectivity).  
Cross-cutting Issues: Configuration and 
Evolution, Operation and Performance, 
Security and Safety.   
Maturity levels: 0 None, 1 Initial, 2 
Managed, 3 Defined, 4 Quantitatively 
















New Data Sources, Complexity, Data 











Health Catalyst \citep{HAAM} 


































Domains: Leadership and Governance, 
Human Resources, Technology.  
Subdomains  
Maturity levels: 1 Nascent, 2 Emerging, 3 

















Maturity Influencing Factors: Data analysis, 
Strategy, People, Electronic medical record, 


















Components: (Policy, Law, and Regulation), 
(Systems, Structures, and Stakeholder 
Coordination), (Signal Generation and Data 
Management), (Risk Assessment and 
















Domains: Infrastructure Management, 
Knowledge, Infrastructure Provisioning, 
Service Management, Solution Driver, 
Ecosystem Relationship, Management 
Focus, Organisation, Agility, Pricing Scheme, 
Business Interface, Utilisation, Automation 
and Process Management.  
Maturity levels: 1 Basic, 2 Controlled, 3 












Governance: Leadership and Governance, 
Strategy and Value Management.  
Solutions: IEHI, Healthcare Service Delivery, 
Healthcare Information and Knowledge, 
Public Health and Healthcare Management 
and Administration.  
Foundations and Enablers: Infrastructure, 
Standards and Interoperability, IT Process 
Management, (Legislation, Policy and 
Compliance), Workforce, Adoption 
Mechanism, Technological and Innovation 
Yes CMM 



























Maturity levels: 1 Initial, 2 Ad-hoc, 3 
Defined, 4 Managed, 5 Optimised. 
Pharmacogovernance 





Policy, Law, Regulation (Governing 
structures, Norms, Policy Instruments, 
Practices, Institutional authority), 
Accountability and Transparency, 
Participation and Representation, Equity and 
Inclusiveness (Distribution of resources for 
PV), Ethics (Policy), Effectiveness and 
Efficiency (System integration and 
communication), Responsiveness (Risk 
communication), Intelligence and 
Information (e-Reporting technology, Risk 
communication), Stakeholder 
communication (Pooled resources, Network 

















Organisational, Informational, Technical.  
















Key Capabilities: Common Applications and 
Services, Infrastructure Hardware Platforms, 
Network Devices and Services, IT Security 
and Information Governance, Infrastructure 
Patterns and Practices, End User Devices, 
Infrastructure Governance, Business 
Alignment, Procurement, People and Skills, 
Value Management; Principles, Standards, 
Procedures and Guidelines.  
Maturity levels: 1 Basic, 2 Controlled, 3 

































n/a Case studies 
Layers of Interoperability: Legal and 
Regulatory (legal and regulatory 
constraints), Policy (collaboration 
agreements), Care Process (alignment of 
care processes), Information (defining of 
coding of information), Applications 
(integrated healthcare systems), IT 
Infrastructure (communication protocols).  
Implementation levels: Strategic, Tactical, 
Operational.   
Cross-cutting issues: (Standards and Profiles, 
Certification), (Security, Privacy, 
Governance). 
n/a n/a 














Man, Machine, Material, Method, Money. Yes CMM 










Elements: Focus on Users, Management, 
Process and Infrastructure, Resources, 
Education.  
Maturity phases: 1 Unrecognised, 2 






















Perspectives: Technical, Procedures, 
Standardisation.  
Maturity levels: Level 0 (System as silo), 
Level 1 (Peer-to-peer), Level 2 (Distributed 
Organisation-bound/Distributed Inter-
organisational), Level 3 (Integrated 















WHO Data Collection 
Tool - Module 11: 
Pharmacovigilance 
PV n/a n/a 
Legal Underpinnings, Directives, 
Organisation and Structure, Internal 
Procedures, Human and Other Resources, 
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Participant name*: ___________________________________ 
Email address*:  ___________________________________ 
Occupation:  ___________________________________ 
Industry:  ___________________________________ 
*Kindly note that the participant’s personal information is required for reference purposes but will not appear in the thesis 

















1. ABOUT THE PARTICIPANT (Please indicate your response with ‘ X ’) YES NO 
1.1. Are you currently working for an organization which plays a role in the PV system?   
1.2. Are you familiar with the activities relating to Pharmacovigilance?   
1.3. Are you familiar with the national legislation surrounding ADR reporting?   
1.4. Having read the pre-read document, are you familiar with the concept of a capability 
maturity model? 
  

























QUESTION 2: THE METHODOLOGY 
 
   
 


















2.1. To what extent do you agree that the PVR-CMM has the potential to achieve the stated aim of 
the study? 
















QUESTION 3: THE LITERATURE REVIEW 
 
   
 


















3.1. To what extent do you agree with the finding that the ICH E2B standard is the current best 
practice for reporting ADRs? 
     
3.2. To what extent do you agree that the ICH E2B (R3) standard would support harmonization and 
interoperability of spontaneous reporting systems? 




















QUESTION 4: THE PVR-CMM FRAMEWORK 
 
   
 


















4.1. The model represents a comprehensive set of dimensions which characterize the management 
of a spontaneous reporting system. 
     
4.2. The PVR-CMM enables the assessment of the maturity of an organization’s spontaneous 
reporting capability. 
     
4.3. The PVR-CMM can be used to guide improvement initiatives.      
4.4. The PVR-CMM is not bound by application and can be used by a Marketing Authorization 
Holder as well as a National Regulatory Authority. 
     
4.5. The PVR-CMM could be used for educational purposes to explain the various aspects of 
spontaneous reporting to anyone with little or no background in pharmacovigilance. 
     
4.6. The layout of the PVR-CMM is easy to understand.      
4.7. To what extent do you agree with the domain and subdomain layout of the model?      
4.8. The PVR-CMM achieved its aim of not focusing solely on the technical components of a 
spontaneous reporting system. 
     
4.9. The capability and interoperability statements are mutually exclusive.      






QUESTION 4: THE PVR-CMM FRAMEWORK 
 
   
 


















4.10. The capability and interoperability statements are collectively exhaustive.      
4.11. The capability statements and maturity levels accumulate while encompassing the 
preceding statements and maturity levels. 
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1. ABOUT THE PARTICIPANT (Please indicate your response with ‘ X ’) YES NO 
1.1. Are you currently working for an organization which plays a role in the PV system? X  
1.2. Are you familiar with the activities relating to Pharmacovigilance? X  
1.3. Are you familiar with the national legislation surrounding ADR reporting?  X 
1.4. Having read the pre-read document, are you familiar with the concept of a capability 
maturity model? 
X  
1.5. Having read the pre-read document, are you familiar with the concept of interoperability? X  
Additional comments: 























QUESTION 2: THE METHODOLOGY 
 
   
 


















2.1. To what extent do you agree that the PVR-CMM has the potential to achieve the stated aim of 
the study? 










QUESTION 3: THE LITERATURE REVIEW 
 
   
 
























QUESTION 3: THE LITERATURE REVIEW 
 
   
 


















3.1. To what extent do you agree with the finding that the ICH E2B standard is the current best 
practice for reporting ADRs? 
 X    
3.2. To what extent do you agree that the ICH E2B (R3) standard would support harmonization and 
interoperability of spontaneous reporting systems? 




















QUESTION 4: THE PVR-CMM FRAMEWORK 
 
   
 


















4.1. The model represents a comprehensive set of dimensions which characterize the management 
of a spontaneous reporting system. 
 X    
4.2. The PVR-CMM enables the assessment of the maturity of an organization’s spontaneous 
reporting capability. 
X     
4.3. The PVR-CMM can be used to guide improvement initiatives. X     
4.4. The PVR-CMM is not bound by application and can be used by a Marketing Authorization 
Holder as well as a National Regulatory Authority. 
 X    
4.5. The PVR-CMM could be used for educational purposes to explain the various aspects of 
spontaneous reporting to anyone with little or no background in pharmacovigilance. 
  X   
4.6. The layout of the PVR-CMM is easy to understand.  X    
4.7. To what extent do you agree with the domain and subdomain layout of the model?  X    
4.8. The PVR-CMM achieved its aim of not focusing solely on the technical components of a 
spontaneous reporting system. 
 X    
4.9. The capability and interoperability statements are mutually exclusive.   X   






QUESTION 4: THE PVR-CMM FRAMEWORK 
 
   
 


















4.10. The capability and interoperability statements are collectively exhaustive.   X   
4.11. The capability statements and maturity levels accumulate while encompassing the 
preceding statements and maturity levels. 
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Chapter 9 supporting content
This appendix provides the supporting content of Chapter 9. The content of this Appendix is
as follows:
 Section C.1: Appendix 1 of the PVR-CMM,
 Section C.2: PVR-CMM Version 2, and
 Section C.3: Letter of request for case study.
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1 PVR-CMM: Appendix 1 
Spontaneous Reporting Systems 
Spontaneous reporting systems 
 
Spontaneous reporting of adverse drug reactions (ADRs) involves the unsolicited generation 
of a signal by a health care professional (HCP) or a patient relating to the suspicion of an ADR. 
Spontaneous reporting is the cornerstone of data generation in post-marketing drug safety 
and surveillance. This method is advantageous over active surveillance methods in that it 
covers a large population of potential reporters, as well as a large profile of drugs, and it 
allows for the monitoring of a medicine throughout its entire life cycle. Spontaneous reporting 
during the post-marketing phase generates the majority of drug safety data, even more so 
than the clinical trials during the drug development process. 
What is meant by an interoperable spontaneous reporting system? 
An interoperable reporting system is envisioned to comprise of the following characteristics: 
• A global system wherein an ADR is reported once, with data of high quality to facilitate 
causality analysis; 
• A transparent system where data is accessible by all stakeholders, this includes public 
health programs (PHPs), regulatory authorities (RAs), manufacturers, HCPs, patients, 
and the public at large; 
• A system which ensures the confidentiality of patients; 
• A system which reduces fragmentation and duplication of data and resources;  
• A system which improves resource utilization in resource limited contexts; 
• A system which reduces administrative pressure, allowing HCPs to direct their 
attention to other priorities and give them more time to report ADRs; and   
• A system which enables HCPs to make more informed therapeutic decisions and 
improve patient safety. 
What are the objectives of such an interoperable spontaneous reporting system? 
• To reduce the frequency and severity of ADRs by widening the scope of 
pharmacovigilance on a global level; 
• To improve causality analysis and risk assessment, allowing HCPs to make more 
informed therapeutic decisions; 
• Enabling quantitative conclusions to be made regarding the safety of medicines over 
long term use; and 
• To improve the communication of drug safety information between HCPs and 
patients. 
  





2 PVR-CMM: Appendix 1 
Spontaneous Reporting Systems 
The successful operation of a spontaneous reporting system is dependent on the successful 
communication of relevant ADR information from the patient experiencing the ADR to the 
relevant PV authority, so that the necessary action can be taken so as to prevent medicine 
related problems and reduce morbidity and mortality associated with ADRs. Reporting or the 
detection of ADRs and subsequent generation of ADR data is therefore a critical function in 
the PV system. There exist a multitude of communication channels which are involved during 
the reporting of ADRs. 
In the event of a patient experiencing an ADR from the consumption of a medicine, the 
reporting process can be initiated in one of two ways, by consulting with a relevant HCP 
(typically a doctor, a pharmacist or a nurse) or, depending on where the patient lives and the 
severity of the ADR, direct patient reporting to a regional or national PV centre. The patient 
and their HCP discuss the ADR and investigate possible causes of the ADR.  These causes can 
include a misdiagnosis, an interaction between the prescribed medicine and another 
medicine or food substance, an error relating to the administration of the medicine or failure 
to adhere to the dosing and scheduling instructions of the medicine, or the possibility of the 
medicine being counterfeit or of sub-standard quality. A decision is reached by the patient 
and the HCP in terms of how to proceed with the treatment of the ADR, this could include a 
change in medication, a change in dosage or a change in frequency. This decision is often 
reached through the collaborative decision-making efforts of multiple healthcare 
professionals, each with unique knowledge bases, across multiple healthcare disciplines. At 
this point, in an ideal situation, regardless of the severity, duration or outcome of the ADR, 
the HCP would initiate a spontaneous report of the ADR to the relevant PV authority such as 
a regional or national PV centre. The PV authority then compiles an individual case safety 
report (ICSR) containing all of the relevant information regarding the patient, the ADR, and 
the suspected drug. 
The electronic transmission of ICSRs is outlined by the newly developed ICH E2B(R3) message 
standard. The standard was developed for the expedited exchange of safety information 
between systems subjected to various national and international rules and regulations. As the 
ever-increasing demand for world-wide data exchange continues, there has been a shift from 
paper-based systems to the electronic transmission of ICSRs using the ICH E2B(R3) standard.  
Adding to the complexities already faced in the PV landscape, patient safety messages must 
be transmitted throughout the product life-cycle. Interoperability is of vital importance when 
it comes to avoiding difficulties in reconciling ICSRs on a global level, which the World Health 
Organisation seeks to achieve. The ICH standard is the culmination of efforts to standardise 
reporting in PV. The recently developed ICSR standard, is a testament that standardised 
solutions do exist in practice but the challenge standing in the way of worldwide system 
interoperability lies not in developing these standards, but rather in the adoption and 
implementation of these standards. 
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Research suggests that interoperability results as a product of standardisation in four domains: technology, syntax, semantics, and pragmatics.
The PVR-CMM is structured with sociotechnical system engineering principles in mind, that is to say, placing equal importance on the social,
political, and environmental (workplace) factors. For these reasons, the 30 dimensions of the PVR-CMM (as seen below) are catagorised into 3
domains: Organisational (pragmatic), Informational (syntax and semantic), and Technical; as well as several subdomains.
The 30 dimensions which make up the PVR-CMM were selected from literature and have been subjected to multiple validation processes
whereby subject matter experts from various pharmacovigilance organisations judged their inclusion in the model as critical to the success of a
spontaneous reporting system in the global pharmacovigilance landscape. Explicitly, the 30 dimensions are:
The Pharmacovigilance Reporting Capability Maturity Model (PVR-CMM) is a maturity assessment tool which was developed to assist
organisations which own or operate a spontaneous reporting system for pharmacovigilance. The aim of the model is to promote and improve
interoperability by addressing the degree of integration of systems involved, providing guidance on which system components need to be
improved, as well as providing a means for measuring interoperability progress accross the community of spontaneous reporting systems in the
global pharmacovigilance landscape.
The PVR-CMM is developed in such a way that it aims to be easily understood at a high level, with the details of capability maturity and
interoperability maturity of the dimensions being addressed as the user delves deeper into the model.
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
OVERVIEW
INTRODUCTION
Spontaneous reporting of adverse drug reactions is widely considered to be the cornerstone of data generation in pharmacovigilance.
Pharmacovigilance systems, by nature, are complex. Spontaneous reporting systems are faced with problems such as under-reporting and the
communication of incomplete, unrepresentative, and uncontrolled data. The lack of standardisation and interoperability among these systems
results in a reduced capability to detect and characterise new adverse drug interactions and reactions. 
Maturity models assist organisations with linking their business objectives to the improvement goals they seek to achieve. By using this
maturity assessment tool, an organisation can:
  -  Identify their current maturity level
  -  Identify a desired maturity level
  -  Benchmark and/or compare their capability maturity against a community of similar organisations 
  -  Identify specific dimensions where potential improvement can be made
  -  Develop a roadmap or plan to grow the organisations maturity to the desired level
The development of the PVR-CMM was the culmination of an extensive multidisciplinary literature review covering aspects of
pharmacovigilance, sociotechnical systems, interoperability, and maturity models. Through multiple validation processes with subject matter
experts, the PVR-CMM has demonstrated value to organisations which own or operate a spontaneous reporting system.
Disclaimer: The PVR-CMM was developed with the intention of being used in conjunction with other PV related statutes, guidelines and
documents. The contents of the PVR-CMM should be considered as general guidelines which can be adapted to suit the individual needs of any
country or organisation managing a spontaneous reporting system for pharmacovigilance, while incorporating current best practices and
achieving and maintaining regulatory compliance. The PVR-CMM lends support to other pharmacovigilance tools such as the WHO Global
Benchmarking Tool and the Indicatior Based Pharmacovigilance Assessment Tool.
It is intended that the user of the PVR-CMM has a sufficient understanding of their organisations pharmacovigilance system so that the
necessary adaptations and refinements to the tool can be made to fit the organisation's individual needs. The PVR-CMM has been developed to
allow for enough generality to be widely applicable to organisations in pharmacovigilance, but also with enough specificity that it is possible to
identify potential areas of weakness and strength. It was deemed necessary to simplify certain complex realities, at the sacrifice of accuracy in
some cases, however, the best effort was made to avoid a too generic, vague, or too detailed and too complex approach. Although the covered
topics are necessarily complex, simplicity in order to improve readability and applicability was paramount, with the intention of developing a
tool which can be used to better understand the situation and define focused, specific strategies for improvement.
Finally, the PVR-CMM should by no means be considered perfect or even complete, it is expected that with feedback from users the model can
be continuously improved, making it a better, more accurate tool. To send feedback, please see the note at the bottom of this page.
C. CHAPTER 9 SUPPORTING CONTENT
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Domain 1: Organisational Domain 2: Informational
Subdomain 1: Leadership and Governance Subdomain 1: Business Procedures
1.1.1 Law, Regulation, and Policy 2.1.1 Data Capture
1.1.2 Governance structures and commitment 2.1.2 Data Storage and Aggregation
1.1.3 Business Continuity and Responsiveness 2.1.3 Workflows
1.1.4 Data ethics/Ownership 2.1.4 Data Presentation/Transmission
1.1.5 Monitoring of performance and effectiveness
1.1.6 Transparency and accountability Subdomain 2: IT Standards
1.1.7 Partnerships 2.2.1 Data Standards
1.1.8 Stakeholder communication 2.2.2 Information content
1.1.9 Organisational Strategy alignment 2.2.3 Data protection, privacy, and security standards
1.1.10 Building a culture of Safety 2.2.4 Information exchange and interoperability standards
1.1.11 Organisational change management
Subdomain 2: Finance and Economics Domain 3: Technical
1.2.1 Financial management
1.2.2 Financial resource mobilisation Subdomain 1: IT Infrastructure
3.1.1 ICT Hardware
Subdomain 3: Business Objectives 3.1.2 Network
1.3.1 Regulatory Compliance 3.1.3 Development and Maintenance
1.3.2 Resource efficiency and business sustainability
1.3.3 Data management
Subdomain 4: Human Resources
1.4.1 Human resources policy
1.4.2 Human resources capacity
1.4.3 Human resources capacity development
Please direct any feedback regarding this tool to: Results
16497457@sun.ac.za
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The overall maturity level of the system being assessed is
represented by the collective maturity levels of these 30
dimensions. The results section of this tool will provide an
overview of the maturity levels, as well as some graphical
representations of the maturity levels across the various domains
and subdomains.
MATURITY LEVELS



























Builds on level 3. Uses statistical and other quantitative techniques to understand performance 
variation and detect, refine, or predict the area of focus to achieve quality and performance 
objectives.
Single technology. No standardisation.
Technical and semantic issues are solved.
Two systems linked for simple exchange of data.
Work processes are linked.
Linking of homogenous systems for a common objective.
Knowledge is shared.
Linking of heterogenous systems for a common goal.
Benefits shared.
Systems can connect and disconnect freely and exchange data without serving a common goal.
DESCRIPTION
The interoperability maturity scale used in the PVR-CMM is based on the work of Gottschalk (2009) and van Velsen et al.  (2016):
Builds on level 4. Uses statistical and other quantitative techniques to optimise performance and 
improvement to achieve quality and process performance objectives.
CAPABILITY MATURITY
DESCRIPTION
Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
Initial approach to meeting the intent of the practice area.
Subsumes level 1. A simple, but complete set of practices that address the full intent of the practice 
area.
The PVR-CMM makes use of two maturity scales, relating to capability maturity and interoperability maturity respectively. Capability is 
associated with specific business processes or a practice area within an organisation. Whereas, maturity is the degree to which an organisation
has explicitly and consistently deployed processes, according to the business objectives. Interoperability can be defined as "the ability of
different information technology systems and software applications to communicate, exchange data, and use information that has been
exchanged".
Builds on level 2. Uses organisational standards and tailoring to address project and work 
characteristics.
The capability maturity levels that are used in the PVR-CMM are exactly the same as those originally developed by the well known CMMI
Institute (2018):
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Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
Imke de Kock; Department of Industrial Engineering, Stellenbosch University (Stellenbosch, South Africa).
PROFILE
INSTRUCTIONS
9)  When all of the dimensions have been assessed the top right corner of the screen will display "RESULTS", click here.
5)  Click the drop-down list in the red outlined cell to select the level which you have identified
6)  The number of the level and the description of the level will update accordingly
4)  Identify which level description most accurately describes the maturity of the dimension in question
10)  The results will be summarised and graphical representation of the results can be found using the appropriate links on the results page
(Please note that the level descriptions are based on generic situations, so “perfect matches” to your specific reality will be rare. )
7)  Click on the green arrow in the top right corner of the window to navigate to the next dimension
8)  Repeat steps 3 - 7 until all of the dimensions have been assessed
1)  Complete the user profile form by clicking the link at the bottom of this page labelled "PROFILE"
2)  When the profile form is complete, click the link at the bottom labelled "BEGIN ASSESSMENT"
3)  Read the dimension definition and the maturity statements for both the capability maturity and the interoperability maturity  scales
C.2 PVR-CMM Version 2
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Respondent details:       (All fields marked * MUST be completed)
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Note:  This document forms part of a larger project about pharmacovigilance, namely a PhD dissertation titled "Towards the interoperability of spontaneous 
reporting systems in pharmacovigilance: a maturity model approach with a sociotechnical system focus". © Maximillian Schurer, Louis Louw, Louzanne Bam, 
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D1.1.1 Law, Regulation, and Policy
The existence of the appropriate legal provisions that mandate and guide all PV related activities. Legal requirements and guidelines applicable to all National Competent Authorities/Regulatory Authorities and Marketing 
Authorisation Holders, regarding the collection, data management and reporting of suspected adverse drug reactions associated with medicinal products for human use. From an interoperability perspective it is necessary 
to have a common understanding of legislation relating to the exchange of information and the associated security and privacy issues. Legislation and regulatory guidelines must be compatible and define the boundaries of 
interoperability between two ICT systems.
SYSTEM AS SILO
All legislation and policies relating to patient safety are well defined, 
implemented, and actively reviewed and updated by a wide range of 
stakeholders.
Regulations are tailored to support patient safety activities and policies 
are developed to ensure compliance.
Policies are developed to understand performance variation and detect, 
refine, or predict the area of focus to achieve quality and process 
performance objectives associated with patient safety.
Simple agreements between two homogenous systems are agreed upon to 
address simple business processes which are shared.
Peer-to-peer.
Legislation is fully distributed across all organisations/role players within 
the jurisdiction of the National Regulatory Authority.
Linking of systems for a common objective.
National legislation is fully integrated and aligned with international 
legislation.
Policies are harmonised between organisations to share benefits and 
achieve value interoperability.
National legislation is fully integrated and aligned with international 
legislation. Legislation is continuously updated and improved upon and 
contributes to the development of the international legislative landscape.
CAPABILITY MATURITY LEVEL
Select the level with the most accurate 
description
DESCRIPTION
Some regulations are policies have been developed and implemented, but 
in an unstructured manner, lacking consistency.
Legislation has been developed to address patient safety, with a simple 
but complete set of regulations to support the legislation.
INTEROPERABILITY MATURITY 
LEVEL
Select the level with the most accurate 
description
DESCRIPTION


















LEVEL NAME LEVEL NAME
1 Initial 1 System as silo
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The organisation has a dedicated and committed governance structure 
which functions proactively to improve patient safety.
Distributed governance structures in place throughout organisation, 
enabling the organisation to interact with similar organisations in a 
structured manner.
The organisation has patient safety as a strategic priority which is 
implemented through a detailed action plan with measurable outcomes.
Governance structure complimentary to other organisations to allow for 
shared benefits when managing affairs relating to patient safety.
Comprehensive and dedicated governance structures in place. 
Comprising stakeholders from various organisations. Regular reviews and 
performance measurement of governance structures ensures continuous 
improvement.
Governance structures are comprised of individuals representing 
international industry and governments. 
Continuously reviewed and improved, ultimately contributing to the 
evolution of the international landscape.
DESCRIPTION DESCRIPTION
No formal governance structures exist and management of HIS affairs 
occurs on an ad hoc basis.
No formal legislation or policies. Any existing policies are localised to the 
individual system setting.
No standardisation.
Simple, but functional governance structures exist. Governance 
structures function reactively and unpredictably.
Cooperation of authoritative figures between two systems, governed by 
simple agreements.
Peer-to-peer.
D1.1.2 Governance structures and commitment
The existence of the appropriate technical, political, and administrative authoritative entities to manage all affairs relating to health information systems. These authoritative entities ensure the optimal functioning of the 
HIS as well as coordinate stakeholder engagement across all levels of the organisations HIS. Management is actively committed to managing and improving patient safety. The governance structure should enable 
management to ensure the organisation’s compliance with the relevant legislation. Governance impacts change management, regulatory compliance, and also directs the progress of evolving policies and procedures 
towards interoperability.
CAPABILITY MATURITY LEVEL
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Business continuity plan has been implemented and functions in a 
proactive manner to ensure regulatory compliance.
Business continuity plans include information relating to the functioning of 
continuity plans across the entire organisation, to avoid disruption of 
continuity work processes.
Business continuity plan is operational and subjected to audits and 
reviews to ensure the achievement of quality and performance objectives 
and regulatory compliance.
Business continuity plans include information relating to the 
interoperability and coexistence with other organisations continuity plans, 
to avoid disruption of continuity work processes.
Regular audits and reviews ensure that the business continuity plan has 
been fully implemented and ensures the achievement of quality and 
performance objectives and regulatory compliance.
Business continuity plan is fully integrated with international guidelines, 
standards and best practices. 
Continuously reviewed and improved, ultimately contributing to the 
evolution of the international landscape.
DESCRIPTION DESCRIPTION
Initial attempt at developing a business continuity plan has been made, 
outlining some of the processes needed to ensure business continuity.
No formal business continuity plan is in place across the organisation and 
any existing business continuity activities are localised to the individual 
system setting.
No standardisation.
Simple, but complete business continuity plan for patient safety activities 
has been developed.
Business continuity plans are informally developed between two operating 
systems based on simple agreements. 
Peer-to-peer.
D1.1.3 Business Continuity and Responsiveness
A business continuity plan seeks to ensure that the necessary business processes can continue to function so as to maintain reporting compliance during times of partial or total system failure. Business continuity is about 
devising plans and strategies that enable organisations to continue business operations, and enable quick and effective recovery from any type of disruption, whatever its size or cause. Certain PV processes are critical and 
the appropriate business continuity plans should be developed in a risk-based manner. These processes include collection, processing, management, and timely transmission of ICSRs. Back-up systems allowing exchange of 
critical information within an organisation, between organisations, or between the MAH and the RA. Interoperability will not function as intended if the HIS and all its components do not function correctly. Therefore, 
business continuity of the national HIS is imperative for continuity of strong interoperability services of HIS. This includes putting in place systems for data recovery, continuity of healthcare, continuous flow of funding, staff 
transition plans, etc. In terms of responsiveness, MAHs are typically legally obligated to submit any and all reported ADRs that they receive within 15 calendar days to the Regulatory Authority which awarded them 
marketing authorisation. 
CAPABILITY MATURITY LEVEL
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The organisation has a code of ethics and conduct. Individuals are 
committed to good conduct and strong ethical behaviour. 
Interoperability framework in place to address data ethics and ownership. 
Roles and responsibilities are defined but heterogenous systems are still 
distinct.
Individuals within the organisation demonstrate their commitment to the 
code of ethics and conduct.
Integrated approach to data ethics and ownership across all organisations 
with shared value systems and goals in the interoperability community.
The organisation has strong ethical behaviour and a code of ethics and 
conduct which is aligned with international guidelines and best practices.
A universal approach to data ethics and ownership. All organisations in the 
global healthcare interoperability community are continually 
interoperating.
DESCRIPTION DESCRIPTION
The organisation does not have formal processes or structures in place 
which address the ethics associated with business processes.
No formal policies for data ethics and ownership. The organisation works 
without interaction and any arrangements are unplanned and 
unanticipated.
No standardisation.
Simple, but comprehensive set of processes and policy structures in place 
which address the ethics associated with critical data,
Interoperability guidelines exist but specific arrangements are unplanned. 




Data ethics addresses the moral dimension of data management. This includes ensuring adherence to ethical principles throughout data generation, recording, curation, processing, dissemination, sharing, and use. Ethical 
practices should strive to ensure respect for the people behind the data; use of data in accordance with the intentions of the disclosing party; matching privacy and security safeguards to the expectation of individuals and 
populations from whom data are drawn; and following the law regarding personal health data privacy and security. These practices are sometimes referred to as responsible data practices.
CAPABILITY MATURITY LEVEL
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Performance objectives are communicated to the business process 
owners. Standard procedures for internal performance measurement are 
developed and conducted on a regular basis.
Streamlining of performance monitoring across the entire organisation 
according to an interoperability framework.
Knowledge is shared.
The performance and effectiveness of business processes is 
quantitatively measured both internally and by external audits and 
assessments.
Integrated performance monitoring.  Based on industry benchmarking and 
external review/assessments between organisations with shared value 
systems and goals.
Quantitative measurement of business performance and effectiveness 
allows for optimisation of key business processes which contribute 
significantly to business performance. Performance data provides the 
capacity to innovate and grow.
Unified performance monitoring. All organisations in the global healthcare 
interoperability community are continually interoperating.
DESCRIPTION DESCRIPTION
The organisation is unaware of the performance indicators which it 
should be measuring. Performance measurement is ad-hoc or by means 
of external audits and assessments.
Performance monitoring is performed internally with no industry 
benchmark to make a comparison against.
No standardisation.
Simple, but comprehensive set of performance objectives is established. 
Performance monitoring is performed in a reactive manner.
Performance monitoring is measured against other homogenous systems.
Peer-to-peer. 
Guidelines exist which describe interoperability.
D1.1.5 Monitoring of performance and effectiveness
Processes to monitor the performance and effectiveness of the PV system, including: reviews of the system by those responsible for management, audits, compliance monitoring, inspections, evaluation of the effectiveness 
of actions taken during improvement initiatives.  Attributes from the maturity model to facilitate tracking of inputs, processes, and outputs against desired results of HIS (Health Information System) interoperability 
implementation, and using data to make decisions. Good PV practices have been defined by the European Medicines Agency and can serve as a set of quality requirements for the various PV activities. Corrective and 
preventative measures can be implemented as a means of addressing performance shortcomings. 
CAPABILITY MATURITY LEVEL
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Transparency and accountability is understood by individuals in the 
organisation. The organisation has strong policies in place addressing the 
transparency of their business practices and understands the value of 
maintaining a positive sentiment by the external environment.
Streamlining of organisational procedures resulting in a common 
understanding of transparency and accountability between all 
homogenous organisations exists.
Individuals take responsibility for their work functions and are held 
accountable for their actions. The organisation monitors the sentiment of 
outsiders towards their business practices and adapts the business 
practices accordingly. The organisation has sound risk management plans 
to assist with accountability.
Integrated understanding of transparency and accountability across 
heterogenous organisations with shared value systems and goals.
The organisation considers transparency and accountability as a value. 
Communication of auditing and assessment outcomes is done in a 
transparent manner so as to maintain a positive sentiment by the 
external environment. Strategic level decision making is inclusive of 
transparency and accountability principles. The organisation has a robust 
and agile risk management strategy.
A universal understanding of transparency and accountability across all 
interoperating organisations in the interoperability community. All 
organisations in the global healthcare interoperability community are 
continually interoperating.
DESCRIPTION DESCRIPTION
Transparency and accountability is not thoroughly understood within the 
organisation. No comprehensive policy documentation exists addressing 
transparency and accountability.
Localised understanding of transparency and accountability.
No standardisation.
Simple policies addressing transparency and accountability exist. Simple 
risk management plans associated with accountability exist.
Common understanding of transparency and accountability exists 
between some homogenous organisations. 
Guidelines exist which describe interoperability.
D1.1.6 Transparency and accountability
Transparency instils trust confidence in the organisation and their system by the public. Accountability refers to the organisation taking responsibility for its actions. Both transparency and accountability are exercised in a 
PV context through the clear communication of post authorisation safety studies (PASSs) and patient safety update reports (PSURs) by the MAH. Communication of patient safety information and safety issues should be 
coordinated with all stakeholders in PV, while maintaining patient confidentiality. National competent authorities should publicise regular reports on the performance of their PV systems as well as the results of regular 
system audits.  Information used in decision-making processes should be made openly available to ensure objective and collaborative decision-making. Transparency addresses how an organisation is observed by outsiders 
based on the quality of information that the organisation shares with the public.
CAPABILITY MATURITY LEVEL
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The partnerships are managed and trust is established between partner 
organisations.
A common partnership management strategy is developed with the help 
of an organisational interoperability framework. Streamlining or 
organisational procedures for knowledge sharing.
Service level agreements are agreed upon across partnerships and allow 
for quantitative measurement.
Partnership management strategies of heterogenous organisations 
encourage the discovery of new partnership opportunities for different 
organisations.
Strong partnerships with partners sharing in value creation,  Partnerships 
are built on a solid foundation of trust and performance with partners 
seeking mutual benefit across the partnership.
Goal interoperability between among partnerships.
Partnerships support the adaptation of work procedures.
DESCRIPTION DESCRIPTION
An initial attempt has been made to identify key partnerships which the 
organisation should develop.
Partnerships are unplanned and unanticipated, no strategy to manage 
partnerships exists.
No standardisation.
The organisation has established simple partnerships with all 
organisations that affect its business operations and value creation. The 
organisation focusses on building confidence in the partnerships.
Guidelines on partnership management are available but specific 
arrangements are unplanned.
D1.1.7 Partnerships
Patient safety and PV activities must be considered when forming and managing partnerships. In the case where multiple partner organisations make use of the same PV system, each partner must ensure that the PV 
system functions to meet their individual regulatory compliance needs.  Implementing regulations which detail public-private partnerships specifically for the development of patient safety systems. Regulatory Authorities 
should clearly communicate the responsibilities and legal requirements of the MAHs within their jurisdiction.
CAPABILITY MATURITY LEVEL
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Well defined communication channels exist within the organisation as 
well as between the organisation and its external stakeholders.
Stakeholder communication is developed with the help of an 
organisational interoperability framework. Streamlining or organisational 
procedures for knowledge sharing.
Communication channels are monitored and controlled.
Stakeholder communication activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
Communication channels are well established. Communication channels 
within the organisation as well as between the organisation and its 
external stakeholders are continuously improved.
A universal approach to stakeholder communication. All organisations in 
the global healthcare interoperability community are continually 
interoperating. Supporting adaptation and continuous improvement of 
work procedures.
DESCRIPTION DESCRIPTION
No formal communication channels exist within the organisation or 
between the organisation and its external stakeholders.
No stakeholder communication strategy. Organisation does not interact 
with any external stakeholders.
No standardisation.
Simple communication channels exist  both internally and externally.  
Peer-to-peer stakeholder communication based on simple agreements 
between homogenous organisations. 
Guidelines exist which describe interoperability.
D1.1.8 Stakeholder communication
Provisions for timely and effective communication of patient safety information or safety concerns to the relevant stakeholders (consumers, HCPs, MAH, RAs, etc.), be it within an organisation or between organisations. This 
also applies to communication between MAHs and their respective RAs. Coordination and cooperation between the various parties involved in communicating patient safety information, as well as the management of 
communication tools and channels should seek to improve access to information by those in need of the information.  Establish internal and external communication plans to facilitate the communication within your 
authority and with external stakeholders at national level.
CAPABILITY MATURITY LEVEL
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Business objectives are explicitly linked to business processes
Organisational strategy alignment is guided by an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Business processes are adapted to support business objectives and a 
shared understanding of the linkage between business objectives and 
business processes is understood within and across organisational 
departments.
Organisational strategies are linked between heterogenous organisations  
and interoperability standards are implemented, allowing for the sharing 
of benefits and value between organisations serving a common goal.
Strategy development is inclusive of all relevant departments, each of 
which contributing to support strategy development.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
Universal alignment of organisational strategies regarding patent safety. 
All organisations in the global healthcare interoperability community are 
continually interoperating.
DESCRIPTION DESCRIPTION
Business objectives are not well understood by the various departments 
within the organisation.
Business objectives are developed within the confines of the localised 
system setting.
No standardisation.
Business objectives are understood within departments. Gaps exist 
between business objectives and business processes.
Work processes and business objectives are linked based on simple 
agreements in a peer-to-peer manner.
D1.1.9 Organisational strategy alignment
It is important that the organisation has a shared understanding of the PV operating model across all levels of the organisation as well as a common understanding of the role of the organisation within the global patient 
safety system. Different functional units of an organisation, such as manufacturing, sales and marketing, and quality control, may have contradicting goals and incentive structures, which do not focus on patient safety. 
Implementing best practices and the alignment of operational activities. Organisations must develop clearly defined roles and responsibilities.
CAPABILITY MATURITY LEVEL
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Management considers individual societal culture, organisational culture 
and the interaction between the two.
Patient safety culture evolves from a culture of compliance to a culture of 
commitment.
A culture of patient safety is developed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Leadership uses patient safety outcomes to promote patient safety 
culture and acts on patient safety improvement initiatives. Visible 
commitment to patient safety throughout organisation.
Patient safety culture extends and is shared between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
Patient safety culture is firmly rooted in the organisation across all levels 
and decision making across the health system is patient safety centred. 
Patient safety is considered an organisational value. Patient safety 
culture follows a culture of commitment and development.
Patient safety culture is a universal goal of all  organisations in the global 
healthcare interoperability community. All organisations in the global 
healthcare interoperability community are continually interoperating. 
Supporting adaptation and continuous improvement of work procedures.
DESCRIPTION DESCRIPTION
Patient safety culture is inconsistently managed. Patient safety is not 
considered a goal of the organisation.
No formal approach to building a culture of patient safety.
No standardisation.
Simple commitment from management to improving patient safety 
culture within the organisation.
Patient safety culture is a culture of compliance.
Safety culture extends beyond the local setting and is aligned with and 
linked across homogenous organisations.
Guidelines exist which describe interoperability.
D1.1.10 Building a culture of Safety
A system of shared actions, values, and beliefs that develop within an organisation and are transferred to new members as the way to perceive, think, and feel in the organisation. Attitudes and behaviors of organisational 
workforce towards patient safety. Moving from a culture of compliance to a culture of commitment. The key to developing a strong organisational PV culture is to support and manage the natural social and behavioral 
aspects of the individuals interactions, rather than attempt to force cultural change by decree. A strong culture of safety can help shape the way in which the organisation views PV, from that of a collection of compliance 
and risk mitigation activities, to a means of developing a set of standard business procedures which yield a competitive advantage. 
CAPABILITY MATURITY LEVEL




































LEVEL NAME LEVEL NAME
1 Initial 1 System as silo
2 Managed 2 Peer-to-peer





5 Optimizing 5 Universal
©Stellenbosch University, 2018
MJ Schurer, L Louw, L Bam, IH de Kock Results
Comprehensive change management is applied simultaneously over 
multiple projects within the organisation.
Organisational change is managed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Organisation makes use of standards and methods for broadly managing 
and leading change.
Organisational change management activities are linked between 
heterogenous organisations  and interoperability standards are 
implemented, allowing for the sharing of benefits and value between 
organisations serving a common goal.
Change management is evident across all levels of the organisation and 
contributes actively to the success of the organisation in meeting its 
business objectives.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
 All organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Initial attempt at change management is implemented inconsistently.
Recognised need for change management.
Organisational change is not considered a priority as the system is isolated 
and therefore not influenced by changes in the external environment.
No standardisation.
Simple, but effective change management is applied in isolated projects.
Guidelines on how organisational change management must occur with 
respect to interoperability. 
Guidelines exist which describe interoperability.
D1.1.11 Organisational change management
Operational processes are clearly linked to performance outcomes and goals. Organisations should seek to embed a culture of continuous improvement. Change management processes need to be established to guide the 
adoption of newly identified best practices and updated work procedures. 
Change management is critical when dealing with an ever-changing business environment and the constant introduction of new technologies.
CAPABILITY MATURITY LEVEL
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Proactive financial management for patient safety related activities. 
Dedicated budget developed by organisation government to support the 
achievement of project and organisational performance objectives.
Financial management is guided by an organisational interoperability 
framework. Streamlining or organisational procedures for knowledge 
sharing.
Finances are quantitatively managed. Expenditures are monitored against 
budget and finances are subjected to regular audits. Proactive investment 
in innovation and technology.
Financial management activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
Financial management system is owned, reviewed and  actively updated 
by a wide range of stakeholders.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
 All organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Initial attempt at financial management for patient safety related 
activities.
Recognised need for appropriate financial management.
Financial management strategy is isolated and localised within the 
confines of the system setting.
No standardisation.
Simple, but complete financial management strategy. Finances are 
managed in an unpredictable and reactive manner.
Financial management activities are linked between homogenous 
organisations through simple agreements. Guidelines exist which describe 
interoperability.
D1.2.1 Financial management
Dedicated budget available for PV relate activities. The legal and administrative systems and procedures put in place permitting a government ministry and its agencies and organizations to conduct activities that ensure 
the correct use of public funds, and which meet defined standards of probity and regularity.  Activities include management and control of public expenditures, financial accounting, reporting, and asset management.  
Proactive investment in technologies which can be leveraged to improve patient safety.
CAPABILITY MATURITY LEVEL
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Financial resource mobilisation is tailored to address project and work 
characteristics.
Supports project and organisational performance objectives.
Financial resource mobilisation strategy is guided by an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Financial resource mobilisation has matured to ensure continuous and 
secure funding for all business processes involved in patient safety.
Financial resource mobilisation activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
Financial resource mobilisation strategy is owned, reviewed and actively 
updated by a wide range of stakeholders.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
Universal financial resource mobilisation strategy regarding patent safety. 
All organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Funding for patient safety activities is acquired  in an unstructured, 
inconsistent  manner.
Financial resource mobilisation strategy is isolated and localised within the 
confines of the system setting.
No standardisation.
Simple, but complete financial resource mobilisation plan.
Financial resource mobilisation activities are linked between homogenous 
organisations through simple agreements.
Guidelines exist which describe interoperability.
D1.2.2 Financial resource mobilisation
All activities involved in securing new and additional financial resources for an organization (in this case, the HIS). It also involves making better use of and maximising existing financial resources. The existence of any 
regular financial provisions. Provision of funding demonstrates government commitment to patient safety and can directly improve conditions in the workplace environment which ultimately improves HCPs attitudes 
towards patient safety.
CAPABILITY MATURITY LEVEL
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Internal compliance capability development. SOPs and a record 
management system is in place to manage compliance. Compliance is 
proactively managed and sustainable.
Regulatory compliance is assessed across homogenous interoperating 
organisations with the help of an interoperability framework. Streamlining 
of organisational procedures.
Internal compliance capabilities are aligned with external auditing and 
assessment guidelines. The organisation has the capability to predict 
potentially impactful regulatory changes.
Regulatory compliance activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
Compliance and the associated risks are well  understood throughout the 
organisation and outcomes from compliance processes are used to 
inform strategic level decision making.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
Universal regulatory compliance regarding patent safety. All organisations 
in the global healthcare interoperability community are continually 
interoperating. Supporting adaptation and continuous improvement of 
work procedures.
DESCRIPTION DESCRIPTION
The organisation is unaware of the full extent of its compliance 
obligations. Compliance is assessed ad-hoc or by means of external audits 
and assessments.
Regulatory compliance is measured in isolation and is localised to the 
system setting.
No standardisation.
The organisations understands the full extent of its compliance 
obligations. A catalogue of compliance requirements is created. 
Compliance is managed in an unpredictable and reactive manner.
Regulatory compliance work processes are linked  between homogenous 
organisations through simple agreements. Guidelines exist which describe 
interoperability.
D1.3.1 Regulatory Compliance
All organisations must comply with patient safety reporting requirements which are imposed by the relevant Regulatory Authority. Compliance monitoring policies and strategies. This includes reviews, inspections, and 
audits which can be conducted regularly internally or by an external actor. 
A good compliance strategy reduces the risk of business disruption, litigation costs, and reputational damage.
CAPABILITY MATURITY LEVEL
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Proactive efforts across the organisation to improve resource efficiency 
and business sustainability in all business operations.
Shared knowledge regarding resource efficiency and business 
sustainability across homogenous organisations which serve a common 
goal, through streamlining of organisational procedures.
Organisation and business principles are aligned with resource efficiency 
and business sustainability. Increased profitability is directly associated 
with resource efficiency and business sustainability.
Resource efficiency and business sustainability activities are linked 
between heterogenous organisations  and interoperability standards are 
implemented, allowing for the sharing of benefits and value between 
organisations serving a common goal.
Strategic level decision making includes resource efficiency and business 
sustainability.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
Universal alignment of resource efficiency and business sustainability 
strategies regarding patent safety. All organisations in the global 
healthcare interoperability community are continually interoperating.
DESCRIPTION DESCRIPTION
Ad hoc sustainability policies and practices in place.  Resource efficiency 
not considered a priority.
Resource efficiency and business sustainability activities are isolated and 
localised to the system setting.
No standardisation.
Simple resource efficiency and business sustainability policies and 
practices are in place. Implemented on a per project basis.
Resource efficiency and business sustainability activities are linked across 
homogenous organisations through simple agreements.
Guidelines exist which describe interoperability.
D1.3.2 Resource efficiency and business sustainability
Efficient resource utilisation improves system outputs by maximising the supply of inputs and minimising wasted resource expenses. Resource efficiency means achieving the desired outcomes in a sustainable manner. 
Business sustainability deals with the ability of an organisation to meet the demands of the present without effecting its ability to meet the demands of the future. Business sustainability typically involves financial, social, 
and environmental components.
CAPABILITY MATURITY LEVEL
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Standard operating procedures are in place for the management of data. 
A detailed plan of action is developed to migrate from a paper based 
system to an electronic data management system. The necessary privacy 
and security measures are included.
Data management is guided by an organisational interoperability 
framework. Streamlining or organisational procedures for knowledge 
sharing.
Data management processes are disseminated throughout the 
organisation so as to inform all stakeholders on how their work processes 
are affected. Data storage and data exchanges are formalised and 
monitored. 
Data management activities are linked between heterogenous 
organisations  and interoperability standards are implemented, allowing 
for the sharing of benefits and value between organisations serving a 
common goal.
The data management system allows for continuous monitoring of access 
and use. Electronic data exchange is considered the default method of 
transferring data both internally and externally. The data management 
system is continuously improved upon.
Goal interoperability between all organisations in the global healthcare 
interoperability community.
Universal alignment of data management strategies regarding patent 
safety. All organisations in the global healthcare interoperability 
community are continually interoperating.
DESCRIPTION DESCRIPTION
Data management is performed ad hoc and inconsistently. A recognised 
need for formal data management policies and actions.
Data management is confined to the local system setting.
No standardisation.
Simple, but complete set of policies and practices addressing the 
management of data.
Simple agreements regarding data management are implemented allowing 
simple electronic exchange of data between homogenous systems.
Guidelines exist which describe interoperability.
D1.3.3 Data management
Data management consists of the development, execution, and supervision of plans, policies, programs, and practices that control, protect, deliver, and enhance the value of data and information assets for decision 
making. 
Data management includes procedures on how data are captured, stored, analysed, transmitted, and packaged for use across the data supply chain. 
CAPABILITY MATURITY LEVEL
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Well defined roles and responsibilities with dedicated staff of adequate 
competency.
Human resources policy is developed according to an organisational 
interoperability framework, based on organisations with shared goals and 
common roles and responsibilities.
Well defined roles and responsibilities with dedicated, fully competent 
staff, whose performance is measurable with performance 
indicators/metrics.
Integrated approach to human resources policy development across all 
heterogenous organisations with shared value systems and goals in the 
interoperability community.
Performance of human resources is optimal and consistent.
Outcomes of quality and process performance objectives are used when 
reviewing and developing new roles and responsibilities.
A universal approach to human resources policy development. All 
organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Roles and responsibilities undefined with work processes being 
completed inconsistently, on an ad-hoc basis.
No formal interoperability framework addressing human resources policy. 
HR policy is developed within the confines of the localised system setting.
No standardisation.
Simple, but complete set of defined roles and responsibilities with 
dedicated staff.
Guidelines on interoperability exist but specific arrangements relating to 
human resources policy are unplanned.
D1.4.1 Human resources policy
The existence of policy documents that specify the roles and responsibilities of the relevant PV staff. Including the designation of a Qualified Person for Pharmacovigilance (QPPV). A set of principles, guidelines, and norms 
that an organisation adopts to help manage its employees.
CAPABILITY MATURITY LEVEL
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Standardised roles and responsibilities are entrusted to qualified and 
capable personnel.
HR capacity is developed with the help of an organisational 
interoperability framework. Streamlining or organisational procedures for 
knowledge sharing.
Designated staff across all levels of the organisation with the appropriate 
responsibilities, accountability, and authority for conducting patient 
safety activities. Patient safety staff are motivated to perform and have a 
high level of engagement.
HR capacity is sufficient that all heterogenous organisations with shared 
value systems and goals in the interoperability community are able to 
share benefits and value.
Patient safety staff take full control over the development of their career 
and the improvement of their work. Patient safety staff are self-
motivating and assist HR with attracting world-class talent.
Continuous improvement in HR capacity ensure continuous interoperation 
between all organisation in the global healthcare interoperability 
community. Supporting adaptation and continuous improvement of work 
procedures.
DESCRIPTION DESCRIPTION
Patient safety work processes are performed ad hoc, in an inconsistent 
manner by unqualified individuals.
HR capacity is managed within the confines of the localised system 
setting.
No standardisation.
Patient safety work processes are identified and assigned to individuals in 
a structured manner.
HR capacity processes of homogenous systems linked and guided by 
interoperability guidelines.
D1.4.2 Human resources capacity
Availability of adequate personnel with relevant characteristics, attributes, and capabilities to perform the tasks or sets of tasks outlined by the organisations  PV operations and policy documents. 
This includes people across all stages of the system life cycle, from aspects such as design, development, implementation, and use of the system. (e.g. system architect designers, software developers, implementation and 
training personnel, as well as HCPs.)
CAPABILITY MATURITY LEVEL
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Formal, future-focussed, talent development programs implemented.
HR capacity development strategy is developed with the help of an 
organisational interoperability framework. Streamlining or organisational 
procedures for knowledge sharing.
A culture of learning and professional development becomes embedded 
in the organisation. Performance support is available to assist with 
learning.
HR capacity development is linked across various heterogenous 
organisations serving a common goal for the sharing of benefits and value.
Continuous professional development. HR capacity development strategy 
is aligned with business strategy, resulting in an agile and future focussed 
workforce.
HR capacity development is universal and ensures continuous 
interoperation between all organisation in the global healthcare 
interoperability community. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Emerging need for professional development of patient safety workforce. 
Ad hoc and incidental training occurs by means of mentoring and 
apprenticeships.
No formal HR capacity development framework in place. HR capacity is 
developed on an ad hoc basis, unpredictably.
Simple HR capacity development plan in place which targets core 
competencies. 
HR capacity development processes  of homogenous organisations linked 
and guided by interoperability guidelines.
D1.4.3 Human resources capacity development
Awareness, education, and training initiatives aimed at the development of a strong PV culture within the organisation. An organised activity with clear learning outcomes that aims to impart knowledge and skills, shape 
attitudes, and develop specific competencies and capabilities in personnel. Provision of guidance on the importance of safe practices and procedures for patient safety. Increased sensitisation of healthcare workers on the 
causes and prevention of adverse events should form part of the continuous professional development of all HCPs. Patient safety training should form part of the curricula of healthcare training institutions.
CAPABILITY MATURITY LEVEL
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Web-based data capture via a "smart"/interactive form with standard 
data elements.
Distributed data capture standard.  Guided by an interoperability 
framework. Streamlining of data capture over a central server linking 
shared logical data models.
Electronic data capture via computer, web portal or mobile application. 
Data capture according to international standards to allow interoperability 
between various heterogenous systems which serve a common goal.
Automated data capture from other information systems (EHRs, 
pharmacy, labs etc.)
Data capture standards and applications are fully shared and distributed. 
All organisations in the global healthcare interoperability community are 
continually interoperating. Supporting adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Paper-based system for capturing patient safety information. 
Single technology used for data capture. Data capture occurs in an 
unstructured way and requires manual data integration.
No standardisation.
Simple electronic form to capture patient safety information.
Data capture is performed electronically and adheres to standards agreed 
upon by homogenous systems.
Guidelines exist which describe interoperability.
D2.1.1 Data Capture
Methods of capturing data associated with the suspected adverse drug reaction and the technologies involved. The WHO states that an ADR reporting form is one of the minimum requirements for a functioning 
spontaneous reporting system. Structured forms, electronic vs paper based, etc.
CAPABILITY MATURITY LEVEL
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Dedicated electronic ICSR database is established.
Functional linking of databases which share logical data models across 
organisations.
Standardised safety, security and privacy protocols.
ICSR database compatible with medical terminology directories (e.g. 
MedDRA), access and usage monitoring, validity and duplication 
detection capability. 
Database receives and stores data from multiple heterogenous IT systems.
Standardised safety, security and privacy protocols.
ICSR database with backwards and forewords compatibility for the ICH 
ICSR E2B (R2/R3) standard reporting format.
Database is fully integrated with international guidelines, standards and 
best practices. 
Continuously reviewed and improved, ultimately contributing to the 
evolution of the global healthcare interoperability community.  Supporting 
adaptation and continuous improvement of work procedures.
DESCRIPTION DESCRIPTION
No electronic database, paper based ADR reports.
Database is designed and  developed within the confines of the localised 
system setting. Data is stored manually.
No standardisation.
Simple electronic storage of ADR reports,  Microsoft Excel spreadsheet.
Database receives and stores data from more than one IT system via 
simple agreements for simple electronic data exchange,
Guidelines exist which describe interoperability.
D2.1.2 Data Storage and Aggregation
Databases and database management. How data is aggregated for statistical analysis, as well as how duplication errors are avoided. The WHO states that an ADR report database is one of the minimum requirements for a 
functioning spontaneous reporting system. 
The methods of aggregating data for statistical analysis, as well as methods for duplicate detection are important when considering the spontaneous reporting system.
CAPABILITY MATURITY LEVEL
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Workflows are well defined and standard operating procedures have 
been developed.
Workflows are linked across facilities of an organisations in the same 
country and are aligned to achieve a common objective.
Quantitative methods are employed to understand performance 
variation by focussing on process performance objectives.
Workflows from heterogenous organisations which serve a common goal 
are linked together for shared benefits and value interoperability.
The use of quantitative techniques allow for optimisation and continuous 
improvement of workflow management and developing and 
implementing SOPs.
Universally agreed upon workflows which support the adaptation and 
continuous improvement of work procedures. All organisations in the 
global healthcare interoperability community are continually 
interoperating.
DESCRIPTION DESCRIPTION
Initial attempt at defining workflows has been made but are not 
comprehensive in nature.
Workflows are developed within the confines of the localised system 
setting.
No standardisation.
Simple, but complete set of patient safety related workflows has been 
defined.
Workflows are partially interoperable with other homogenous systems 
based on simple agreements for simple data exchange.
Guidelines exist which describe interoperability.
D2.1.3 Workflows
Workflows describe the necessary sequential steps which need to be taken when performing the business processes. Workflows typically involve the use of Standard Operating Procedures (SOPs). In the context of a 
spontaneous reporting system this includes receiving the information, case entry, duplicate checking, case registration, case triage, data entry and narrative write up, review, case closure and the transmission of the ICSR.
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E2B compliant ICSR sent via e-mail.
Distributed data transmission standard. Streamlining of transmission over 
a central server linking shared logical data models.
ICSR sent to the UMC via the  web-based VigiFlow reporting tool.
Data transmission is according to industry standards, allowing the 
exchange of data between independent heterogenous systems.
E2B compliant ICSR transmitted via a proprietary gateway application, 
adhering to the ICH ICSR E2B (R3) business rules for the electronic 
transmission of ICSRs.
Data transmission is according to universally agreed upon standards, and 
can be between any systems in the global healthcare interoperability 
community. Supporting adaptation and continuous improvement of work 
procedures.
DESCRIPTION DESCRIPTION
Paper-based ADR reports mailed via a postal service.
Data transmission is performed manually due to isolated use of 
technology. 
No standardisation.
ICSR sent as attachment via e-mail, but not E2B compliant.
Simple electronic data exchange between homogenous systems with 
discretional pre- and post-exchange data handling.
Guidelines exist which describe interoperability.
D2.1.4 Data Presentation/Transmission
The format in which data is presented to the subsequent entity in the chain of PV communication. Currently the best practice is the ICH E2B(R3) standard for the electronic transmission of ICSRs with backwards/forwards 
compatibility.
CAPABILITY MATURITY LEVEL
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A comprehensive portfolio of data standards is adopted by the 
organisation. These data standards specifically address all the relevant 
topics relating to the exchange of electronic healthcare data. Knowledge 
representation and terminology standards are adhered to.
Distributed portfolio of data standards throughout the organisation. 
Linking of systems for a common objective. Standardised data protection, 
security, and privacy protocols in place.
The portfolio of data standards has been disseminated throughout the 
organisation. Compliance is measured by an external auditing body and 
certification is awarded accordingly.
International standards and best practices adhered to by the organisation, 
allowing for the integration of heterogenous systems which serve a 
common goal.
Data standards are regularly reviewed and updated to be consistent with 
best practices and to ensure interoperability with other health 
information systems.
Universally agreed upon and implemented standards which support the 
adaptation and continuous improvement of work procedures. All 
organisations in the global healthcare interoperability community are 
continually interoperating. 
DESCRIPTION DESCRIPTION
No formal standards are adhered to, any standards that are adhered to 
are incidental and on an ad hoc basis.
Data standards are specific to a proprietary system. No interaction 
between systems negates the need for data standards.
No standardisation.
The need for data standards is recognised by the organisation and simple 
data standards governing the encoding of electronic data are adhered to.
Simple data standards are implemented allowing the electronic exchange 
of data between homogenous systems.
D2.2.1 Data Standards
Data standards is inclusive of knowledge representation and terminology standards.  Provisions for the inclusion of all relevant structured data useful to assess an individual case.  Knowledge representation refers to how 
medical knowledge is represented within an information system/application context. Collaboration among system users and developers is critical when managing inconsistent knowledge bases.  Terminology standards 
provide specific codes for terminologies and classifications for clinical concepts such as diseases and medications. The terminology systems assign a unique code to a specific disease or entity. An appropriate MedDRA term 
should be provided in the lowest level term for the drug characterisation along with the resulting suspected adverse reaction.  Compliance with standardised medical data content standards such as WHO-ART and MedDRA.  
CAPABILITY MATURITY LEVEL
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Electronic ICSR form with a standard set of data elements. E.g. the 
Minimal Information Model for Patient Safety (MIM PS).  No provision for 
free text narrative.
Standard information content model developed for the transmission of 
ICSRs between homogenous systems.
Electronic ICSR form compliant with the ICH E2B (R3) standard, with a 
comprehensive set of data elements and the provision for a free text 
narrative.
Shared information model across various heterogenous systems to allow 
for transmission of ICSRs within the interoperable community.
A system wherein the sought after information is pulled through on an as 
requested basis. Through correct harmonisation of systems and 
standards, information can be requested as opposed to reported or 
"pushed" to the entity requesting the information. Thus allowing for the 
inclusion of any and all information available.
A common information model is universally distributed allowing  the 
transmission of ICSRs between any organisations in the interoperable 
community. All organisations in the global healthcare interoperability 
community are continually interoperating. Supporting adaptation and 
continuous improvement of work procedures.
DESCRIPTION DESCRIPTION
No set of minimum information/data elements adhered to. A recognised 
need for a minimum set of information/data elements.
System as silo means no interaction with other systems and therefore no 
standard in place for the information content of the ICSR.
No standardisation.
The ICSR form has a simple but complete set of basic data elements 
which constitute the minimum acceptable information.
Simple agreements between two homogenous systems regarding 
information content of the ICSR.
D2.2.2 Information content
The data encoded in an ICSR must collectively represent information that is interpreted in the same way by the ICSR sender and receiver. The information that is encoded in the ICSR for an ADR report. Standard data 
elements, provisions for free text narratives. 
Minimal Information Model for Patient Safety Incident Reporting and Learning Systems. The ICH ICSR E2B (R3) standard, current best practice.
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Specific data protection, privacy and security standards are identified and 
adhered to.
Data protection, privacy, and security standards are selected and 
implemented based on an interoperability framework.
Auditing and compliance monitoring of the data protection, privacy and 
security standards allows for quantitative feedback.
Common data protection, privacy, and security standards are adhered to 
by various heterogenous organisations which serve a common goal.
Management monitors compliance with data protection, privacy and 
security standards. Any issues of non-compliance are identified and 
remedial action is taken to ensure compliance in a timely manner
Universally agreed upon and implemented data protection, privacy, and 
security standards which support the adaptation and continuous 
improvement of work procedures.
DESCRIPTION DESCRIPTION
Identified need for data protection,  privacy and security standards. No 
standards are implemented or adhered to consistently.
System as silo, therefore no data protection, privacy, and security 
standards are in place.
No standardisation.
Some data protection, privacy and security standards are incidentally and 
unpredictably adhered to.
Data protection, privacy, and security standards are based on simple 
agreements for the simple exchange of electronic data between 
homogenous organisations.
D2.2.3 Data protection, privacy, and security standards
Data protection, privacy and security standards associated with the exchange of patient safety information. Measures to disable unauthorised access of information, manipulation, modification or deletion of information. 
E.g. The EU General Data Protection Regulation (GDPR).
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Interoperability is understood as a business goal and competitive 
advantage. Formal interoperability standards are selected and adhered 
to. Organisational structures are in place to guide interoperability.
Information exchange and interoperability standards are selected and 
implemented according to an interoperability framework for organisations 
with shared goals, and aligned roles and responsibilities.
The organisation conducts interoperability  compliance assessments to 
gain insight into which aspects of interoperability require attention.  The 
organisation implements and adheres to a framework for interoperability 
compliance.
Common information exchange and interoperability standards are 
implemented across various heterogenous systems, allowing for the 
sharing of benefits and value between organisations serving a common 
goal.
The advantages of interoperability are widely understood throughout the 
organisation and are linked to specific business practices. The 
organisation leverages these advantages to improve overall efficiency 
and the bottom line. Information exchange and interoperability standards 
are regularly reviewed and updated to be consistent with best practices.
Universally adopted information exchange and interoperability standards 
across all organisations participating in the global healthcare 
interoperability community. All organisations in the global healthcare 
interoperability community are continually interoperating.
DESCRIPTION DESCRIPTION
No formal standards are adhered to, any standards that are adhered to 
are incidental and on an ad hoc basis.
Information exchange and interoperability standards not implemented or 
adhered to because the system works without interaction with other 
systems.
No standardisation.
The need for interoperability is recognised and simple initiatives are 
employed to manage interoperability.
Information exchange and interoperability standards are implemented 
allowing the electronic exchange of data between homogenous systems.
D2.2.4 Information exchange and interoperability standards
Standards which govern the transmission, organisation and interpretation of electronic data. This includes messaging standards, document standards, application standards, conceptual standards, and architecture 
standards. 
These standards are developed by SDOs such as International Standards Organisation (ISO), European Committee for Standardisation (CEN), Health Level Seven (HL7), and OpenEHR.  
For interoperability to occur, the interacting ICT systems must agree on the use of standard messaging formats.
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The organisation has identified the specific hardware components that 
directly support the business processes related to patient safety.
Hardware at different operating locations of the organisation allows for 
linking of business processes which support the common goal of improved 
patient safety.
Safety, security, and privacy standards are implemented.
The organisation conducts regular reviews of hardware capabilities and 
performance to ensure that  performance objectives are met.
Hardware across different operating locations of different organisations 
allows for linking of systems.
Integration of heterogenous systems which serve a common goal.
The organisations ICT hardware infrastructure meets international 
standards. Policies are in place to ensure optimal functioning and 
maintenance of ICT hardware, allowing for continuous improvement.
Hardware allows for complete integration with international guidelines, 
standards and best practices. 
Continuously reviewed and improved, ultimately contributing to the 
evolution of the international landscape. Supporting adaptation and 
continuous improvement of work procedures.
DESCRIPTION DESCRIPTION
The organisation has inadequate hardware to support patient safety, but 
is aware of the need for appropriate ICT infrastructure.
Hardware across different operating locations of the organisation is not 
standardised and does not allow for the exchange of patient safety 
information.
No standardisation.
Simple, but complete assessment of ICT infrastructure needs for 
supporting patient safety, and a simple but complete infrastructure.
Hardware at different operating locations of the organisation allows for 
simple data exchange and the linking of business processes. 
D3.1.1 ICT Hardware
The physical hardware needed to support the operation of a spontaneous reporting system. This hardware includes computers, monitors, data input devices/peripherals (mouse, keyboard, etc.), as well as the appropriate 
cabling and availability of power.
CAPABILITY MATURITY LEVEL




































LEVEL NAME LEVEL NAME
1 Initial 1 System as silo
2 Managed 2 Peer-to-peer
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The organisation has assessed its networking requirements.
An implementation plan is in place to improve the efficiency of the IT 
communications network.
Distributed WAN capability to allow network communication between 
homogenous systems. Streamlining of organisational procedures. 
Communication over a central server,
The performance of the organisations IT communication network is 
measured against performance objectives.
Integrated WAN capabilities enable the integration of heterogenous 
systems which serve a common goal. Safety, security, and privacy 
standards are monitored closely.
The organisations IT communications networking capabilities are in line 
with international standards.
Functioning optimally and reliably, and subjected to regular testing and 
performance reviews.
Universal communications network established for the exchange of 
electronic healthcare data. Systems and applications can connect freely 
and exchange data where permissible, without necessarily serving a 
common goal. Supporting adaptation and continuous improvement of 
work procedures.
DESCRIPTION DESCRIPTION
The organisation has an inadequate network to support the optimal 
functioning of an information system.
System as silo means that no networking ability is in place and no 
interaction with other systems in performed.
No standardisation.
Simple, but effective IT communications network is operational.
Simple agreements regarding LAN capabilities for simple peer-to-peer 
exchange of electronic data within an organisation.
D3.1.2 Network
The existence of the appropriate IT infrastructure to enable the efficient and effective transmission of ICSRs whether it be over local area network (LAN) within a facility or wide area network (WAN) across facilities or 
organisation in different geographical locations.
CAPABILITY MATURITY LEVEL























LEVEL NAME LEVEL NAME
1 Initial 1 System as silo
2 Managed 2 Peer-to-peer
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Standard operating procedures are in place to manage IT infrastructure 
development and maintenance to support patient safety business 
processes.
Development and maintenance of the organisations technical 
infrastructure is guided by a technology interoperability framework. 
Streamlining or organisational procedures for knowledge sharing.
A dedicated support team takes ownership of the development and 
maintenance of the organisations IT infrastructure.
Proactive development of infrastructure ensures optimal functioning and 
up-to-date IT infrastructure.
Development and maintenance of technical infrastructure is shared across 
various heterogenous systems which serve a common goal.
IT infrastructure development and maintenance is focussed on 
continuous improvement and is performed so as to enable the system to 
respond to opportunity and change in the future.
Universal interoperability of the global health information exchange 
supports adaptation of work processes relating to the development and 
maintenance of technical infrastructure.
DESCRIPTION DESCRIPTION
Maintenance and development of the organisations technology 
infrastructure is performed on an ad hoc basis.
Development and maintenance  is localised to the individual system 
setting.
No standardisation.
Simple, but complete set of practices defined to support the 
development and maintenance of the organisations IT infrastructure.
Guidelines for the development and maintenance of the organisations 
technical infrastructure are available, but are not followed consistently.
D3.1.3 Development and Maintenance
Proactive efforts to ensure that the technologies and standards used are maintained and evolved to continually meet the ever-changing needs of the system. This dimension refers to the development and maintenance of 
technologies and standards to ensure optimal performance of the spontaneous reporting system. It is important to note that maintenance involves different activities at the local and global levels.
CAPABILITY MATURITY LEVEL





































Subdomain 1: Leadership and Governance Capability Level Score Interoperability Level Score
1.1.1 Law, Regulation, and Policy Initial 1 System as silo 1
1.1.2 Governance structures and commitment Initial 1 System as silo 1
1.1.3 Business Continuity and Responsiveness Initial 1 System as silo 1
1.1.4 Data ethics/Ownership Initial 1 System as silo 1
1.1.5 Monitoring of performance and effectiveness Initial 1 System as silo 1
1.1.6 Transparency and accountability Initial 1 System as silo 1
1.1.7 Partnerships Initial 1 System as silo 1
1.1.8 Stakeholder communication Initial 1 System as silo 1
1.1.9 Organisational Strategy alignment Initial 1 System as silo 1
1.1.10 Building a culture of Safety Initial 1 System as silo 1
1.1.11 Organisational change management Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 2: Finance and Economics Capability Level Score Interoperability Level Score
1.2.1 Financial management Initial 1 System as silo 1
1.2.2 Financial resource mobilisation Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 3: Business Objectives Capability Level Score Interoperability Level Score
1.3.1 Regulatory Compliance Initial 1 System as silo 1
1.3.2 Resource efficiency and business sustainability Initial 1 System as silo 1
1.3.3 Data management Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 4: Human Resources Capability Level Score Interoperability Level Score
1.4.1 Human resources policy Initial 1 System as silo 1
1.4.2 Human resources capacity Initial 1 System as silo 1
1.4.3 Human resources capacity development Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Subdomain 1: Business Procedures Capability Level Score Interoperability Level Score
2.1.1 Data Capture Initial 1 System as silo 1
2.1.2 Data Storage and Aggregation Initial 1 System as silo 1
2.1.3 Workflows Initial 1 System as silo 1
2.1.4 Data Presentation/Transmission Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Subdomain 2: IT Standards Capability Level Score Interoperability Level Score
2.2.1 Data Standards Initial 1 System as silo 1
2.2.2 Information content Initial 1 System as silo 1
2.2.3 Data protection, privacy, and security standards Initial 1 System as silo 1
2.2.4 Information exchange and interoperability standards Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Subdomain 1: IT Infrastructure Capability Level Score Interoperability Level Score
3.1.1 ICT Hardware Initial 1 System as silo 1
3.1.2 Network Initial 1 System as silo 1
3.1.3 Development and Maintenance Initial 1 System as silo 1
Subdomain Score: 1,00 Subdomain Score: 1,00
Domain Score: 1,00 Domain Score: 1,00
Maturity Assessment Results
Domain 1: Organisational
Domain 2: Informational (Syntax and Semantics)
Domain 3: Technical
The following results pertain to:
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Domain 3 detailed
Results as radar charts
Domains and subdomains summary
Domain 1 detailed
Domain 2 detailed
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D1.1: Leadership and Governance
D1.2: Finance and Economics
D1.3: Business Objectives




Capability maturity Interoperability maturity




Subdomain 1: Leadership and Governance
1.1.1 Law, Regulation, and Policy
1.1.2 Governance structures and commitment
1.1.3 Business Continuity and Responsiveness
1.1.4 Data ethics/Ownership
1.1.5 Monitoring of performance and effectiveness
1.1.6 Transparency and accountability
1.1.7 Partnerships
1.1.8 Stakeholder communication
1.1.9 Organisational Strategy alignment
1.1.10 Building a culture of Safety
1.1.11 Organisational change management
Subdomain 2: Finance and Economics
1.2.1 Financial management
1.2.2 Financial resource mobilisation
Subdomain 3: Business Objectives
1.3.1 Regulatory Compliance
1.3.2 Resource efficiency and business sustainability
1.3.3 Data management
Subdomain 4: Human Resources
1.4.1 Human resources policy
1.4.2 Human resources capacity
1.4.3 Human resources capacity development
























































Subdomain 1: Business Procedures
2.1.1 Data Capture
2.1.2 Data Storage and Aggregation
2.1.3 Workflows
2.1.4 Data Presentation/Transmission
Subdomain 2: IT Standards
2.2.1 Data Standards
2.2.2 Information content
2.2.3 Data protection, privacy, and security standards
2.2.4 Information exchange and interoperability standards
































Subdomain 1: IT Infrastructure
3.1.1 ICT Hardware
3.1.2 Network
3.1.3 Development and Maintenance
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Meiring Naude Road, Pretoria 
 
Letter of Request for Case Study 
 
Dear Sir/Ma’am, 
My name is Max Schurer, I am completing a PhD in Industrial Engineering at the University of Stellenbosch. My 
research focus is the interoperability of ICSR collection tools and spontaneous reporting systems in 
pharmacovigilance. My PhD supervisor is Dr Louis Louw. I am writing to kindly request your help with a case study 
of your organisation to verify part of my research. 
Spontaneous reporting is considered the cornerstone of data generation in pharmacovigilance (PV). The aim of the 
Pharmacovigilance Reporting Capability Maturity Model (PVR-CMM) is to promote and improve interoperability in 
PV by addressing the degree of integration of systems involved, provide guidance on which system components 
need to be improved, as well as provide a means for measuring interoperability progress across the community of 
spontaneous reporting systems in the global PV landscape. 
The case study would involve performing a maturity assessment of your organisation’s spontaneous reporting 
system. It is envisioned that this will require a number of 30-45 minute sessions/interviews with 2-3 relevant 
members of your organisation at each session, spanning over a period of up to 2 weeks in the month of August 
2019. These sessions will not necessarily involve the same people on each occasion. The question of who will need 
to be present at each session is one which will be best answered by a member of SAHPRA who can assist me with 
identifying the most appropriate SAHPRA member/s for each session depending on the topic of the session. The 
session topics will be based on the seven subdomains of the PVR-CMM, namely: Leadership and governance, Finance 
and economics, Business objectives, Human resources, Business procedures, IT standards, and IT infrastructure. 
The intention behind the multiple brief sessions is to avoid causing any disruption to your organisation. The sessions 
will be held subject to the availability of the contributors. 
The materials involved in the case study are the PVR-CMM and a document which will provide some more context 
regarding the model’s development and intended use. Please note that this case study will result in no cost being 
incurred by SAHPRA. The university of Stellenbosch will facilitate and finance all travel and accommodation 
requirements. Accompanying this letter is a preview of the PVR-CMM in .pdf format. The complete PVR-CMM will 
be presented during the case study and is an easy to use Excel document. 
The findings of this case study will form part of my PhD thesis, however, all information provided during the case 
study sessions/interviews will be held anonymously and will not allow for traceability back to the original 
contributor. No personal information will be included in the thesis whatsoever. 
In summary, I kindly request the following: 
• Confirmation of your willingness to participate in this case study, 
• Assistance with identifying the appropriate contact person from SAHPRA who I can meet with in Pretoria, 
to plan the sessions (identify relevant SAHPRA contributors) and the timelines associated with the 
information sessions. 






Department of Industrial Engineering | Stellenbosch University 
Private Bag X1, Matieland, 7602 
Tel: +27 72 903 9791 | E-mail: 16497457@sun.ac.za | www.sun.ac.za 
• A proposed date for the above-mentioned meeting (In person would be preferable), or a proposed starting 
date. 
In return for your cooperation with this case study your organisation will receive a formal maturity assessment via 
the PVR-CMM, as well as several recommendations for continuous improvement initiatives once the feedback has 
been appropriately analysed. If you require any additional information, or have any questions please don’t hesitate 
to contact me (details below). 
Thank you very much for your time and I look forward to working with your organisation, 
Kind regards, 
Maximillian J. Schurer 
PhD Industrial Engineering candidate (Full time) 
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